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General introduction
INTRODUCTION TO THE THESIS
The antitumor effects of chemotherapeutics in vitro are often not matched by antitumor effects 
in vivo after systemic administration of these agents in animal models or in patients. Achieving an 
adequate drug concentration at the tumor site is a major challenge as drugs are dilated after sys-
temic administration and rapidly cleared by liver and kidney. Dose-escalation is limited by toxicity 
to normal tissues, such as bone marrow, liver, kidney, hart, gastrointestinal track and the neural 
system. Pathophysiologic properties of tumor and the tumor-associated vasculature provide a 
number of barriers to adequate drug uptake at the tumor site. High interstitial fluid pressure (IFP), 
functional and non-functional tumor vessels and inadequate blood supply makes the intratumor-
al drug distribution and drug uptake very heterogeneous [1]. The amount of drug reaching the 
tumor cell is therefore insufficient to eradicate the tumor. There are however additional important 
targets for antitumor agents. Tumors consist of tumor cells and tumor stroma; endothelial cells 
(ECs), pericytes, immune cells and matrix composition These components are just as important in 
tumor biology and provide important targets for anticancer therapy.
The organization of normal blood vessels. Blood vessels consist of an endothelial cell lining 
surrounded by vascular mural cells (smooth muscle cells or pericytes), and a basal membrane 
enveloping both cells. ECs form the inner lining of a blood vessel providing a dynamic barrier 
between the underlying tissue and the blood. They regulate blood flow, thrombosis, thrombolysis 
and platelet adherence and play a key role in immune and inflammatory reactions by interacting 
with leucocytes. ECs can vary between organs and between arteries and veins not only expressing 
different markers but also responding differently to the same stimuli [2-4]. In established vessels 
adhesion between neighboring ECs is made by three types of junctional adhesions: adherens 
junctions, tight junctions and gap junctions [5]. Vascular endothelial (VE) cadherin, the primary 
component of the adherens junctions, is a member of the cadherin membrane receptor family 
involved in the calcium-dependent homophilic cell-cell interactions of its extracellular domain 
and is strictly located at the intercellular junctions of ECs. Intracellularly VE-cadherin is connected 
to the actin cytoskeleton via several catenin proteins, like α-catenin, β-catenin, γ-catenin (also 
referred to as plakoglobin) and p120. Mice were generated that lack VE-cadherin expression or 
express a mutant VE-cadherin lacking the beta-catenin cytoplasmic binding site to define the role 
of VE-cadherin in vivo. Both mutations lead to embryonic lethality within the early days of devel-
opment due to lack of vessel development suggesting that VE-cadherin and its association with 
beta-catenin is requires for sprouting and adherens of ECs during early angiogenesis [6,7].
Smooth muscle cells and pericytes are assumed to belong to the same lineage. However, a 
good distinction is often difficult because some vessels, like arterioles and venules, have mural 
cells with properties between smooth muscle cells and pericytes. Also, there is no single common 
marker available to define a pericyte. Desmin, alpha smooth muscle actin and the high-molecular-
weight melanoma-associated antigen (the mouse derivate is called NG2) are proteins used to 
identify pericytes but the expression varies between species, organs and pathological conditions 
[8,9]. The smooth muscle cells can be distinguished from the pericytes through their position in 
relation to the vessels. Vascular smooth muscle cells are not in direct contact with the ECs but are 
separated from the endothelium by the basal membrane. Pericytes are embedded in the basal 
lamina and make direct contact with the ECs by peg-socket contact and junctions [10-14]. There 
is still a lot controversy about the exact role of the pericytes. They have been suggested to sup-
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press endothelial proliferation without having a role during the initial steps in angiogenesis. How-
ever reports have been published of pericytes lying in front of a sprouting endothelial cell [15].
Surrounding the vascular cells is the basal membrane, a self-assembled complex sheet-like 
structure providing structural support and regulating cell behavior. It consists of about 50 proteins 
although type IV collagen, laminin, heparan-sulphate proteoglycans and nidogen/entactin are 
the dominant components. Different isoforms of these proteins, quantity and assembly provides 
specificity making the composition of the basal membrane unique in each tissue [16-19]. ECs 
adhere to the underlying extracellular matrix (ECM) by a diverse family of integrins. Integrins are 
glycoproteins, consisting of an α- and a β-subunit, which forms heterodimeric receptors for the 
extracellular matrix. There are 18 α- and 8 β-units and each formed integrin has a unique set of 
ECM ligands. αVβ3, one of the most important integrins in ECs adhesion binds to fibronectin, 
collagen, vitronectin, and fibrinogen whereas αVβ5 binds predominantly to vitronectin [20]. The 
αV integrins are important in the formation of new blood vessels. They appear to be de-novo 
induced and activated on tumor angiogenic endothelia [21] and promote endothelial cell attach-
ment, spreading, survival, proliferation and locomotion [22-25]. αV integrins, in particular αVβ3 
and αVβ5, have been considered as therapeutic targets to inhibit angiogenesis [21].
The organization of tumor blood vessels. Tumor-associated vasculature (TAV) is “abnormal” 
in many aspects in comparison to normal vessels. The TAV display a lack of hierarchical branching 
organization in which the recognizable features of arterioles, capillaries and venules is lost. Ves-
sels are tortuous and unevenly dilated. As a result, tumor blood flow is chaotic, can be stationary 
and even change direction. This leads to hypoperfusion, hypoxia and acidosis in solid tumors. Tu-
mor-associated ECs are disorganized with irregular shape, sometime even overlapping each other 
or displaying fenestrae [26]. These intracellular openings make the vessel highly permeable and 
allow passage of macromolecules across the vasculature. Also, vesicles can form at the luminal 
side of the ECs fusing with the abluminal membrane releasing the content in the subendothelial 
space. The transcellular pathway is also mediated by vesiculo-vacuolar organelles (VVOs) [27-29]. 
These are clusters of interconnecting vacuoles in the cytoplasm of an EC transporting molecules 
form the luminal plasma membrane to the abluminal side. Permeability increase subsequently 
results in an increased IFP. This overall rise in IFP is further enhanced by the absence of functional 
lymphatics, typical in the tumor environment. Pericytes have long been neglected as important 
in angiogenesis and even believed to be absent in the tumor vasculature. However, pericytes are 
present in the tumor microenvironment and like the ECs, they have bizarre features not found in 
other conditions. In general, tumor-associated pericytes are irregularly scattered, sometimes over-
lapping other pericytes and loosely associated with the vessel endothelium. They display several 
extensions along the endothelium or into the tumor stroma occasionally contacting other vessels 
[30]. Also, the basal membrane has a loose association with ECs and pericytes, irregular thickness 
and extensions into the stroma [31]. The TAV varies greatly among tumor types. Eberhard quanti-
fied maturation in glioblastoma and 5 different carcinoma’s and found that microvessel pericyte 
coverage ranges form 10 to 20 % in glioblastoma and renal cell carcinoma to approximately 65 
% in mammary and colon carcinomas [32]
The antiangiogenic and antivascular approach. In 1971 Folkman proposed that inhibition of 
the development of newly formed tumor blood vessels would be an attractive new approach in 
cancer treatment [33]. Starving the tumor to death by depriving it from the inflow of nutrients 
with the use of vascular targeting agents was in theory a strait forward approach. Putting the 
theory in practice proved not so simple, but this idea leads to several strategies focusing on the 
specific pathway or characteristics of the TAV. First, the antiangiogenesis strategies interfere with 
the formation of new tumor blood vessel formation. Growth factors are important in this process 
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and vascular endothelial growth factor (VEGF) is believed to be the most important factor. It is an 
important mitogen for vascular ECs, mediates secretion and activation of enzymes that contrib-
utes to the degradation of the extracellular matrix and increases vascular permeability [34-37]. 
One prominent success in antiangiogenic cancer therapy is bevacizumab (Avastin), an antibody 
that neutralizes the activity of all isoforms of the VEGF-A molecule. [38]. Pre-clinical studies have 
shown that anti-VEGF therapy besides prohibiting vessel growth, also improve the integrity of 
remaining vessels bringing them to a more “normalized” structure. Pericytes are recruited espe-
cially to the tumor vessels and not to the normal vasculature. Alongside reinforcing the vessels 
with pericytes, matrix metalloproteinases are produced reducing the abnormal thick multilayer 
basal membrane. This is then followed by a reduction in IFP and an increase in oxygenation that 
leads to a better penetration of co-administered chemo- or radiotherapy [39,40]. Evidence for this 
normalization strategy has also been demonstrated recently in glioblastoma patients treated with 
AZD2171 (cediranab), a tyrosine kinase inhibitor of VEGF receptors. Daily administration of the 
inhibitor induced vascular normalization within 24 hours and lasted at least 28 days [41].
A second approach is to cause direct damage of the established tumor vasculature by vascular 
disrupting agents (VDAs). Although the VDAs have often been grouped with the antiangiogenic 
agents their working mechanism is quite different. In contrast to the antiangiogenic agents that 
prevent formation of new blood vessels, the VDAs target the already established TAV by destroy-
ing the endothelial lining. This causes shutdown of blood flow, deprivation of oxygen and nutri-
ents resulting in massive tumor necrosis. This concept was formally proposed when Denekamp 
et al. suggested that the high proliferation rate of the tumor-associated ECs could be a potential 
target [42]. They demonstrated that occlusion of the blood supply in a subcutaneously implanted 
tumor resulted in tumor regression and long-term tumor control. VDAs can be divided in ligand 
bound and small molecules agents. Ligand bound VDAs are usually antibodies or peptides di-
rected against a marker selectively upregulated on tumor-associated ECs and requires an intensive 
knowledge and identification of suitable targets on the (human) tumor endothelium [43]. In con-
tradiction, small molecule VDAs subdivided in tubulin-binding agents and flavonoids have no spe-
cific selectivity. Because of the high turnover in the tumor endothelium, these dividing immature 
ECs rely on their tubulin cytoskeleton network to maintain shape and integrity. Tubulin-binding 
VDAs inhibit tubulin polymerization and change the shape of the ECs. These changes dramatically 
alters vascular permeability and blood flow inducing hemorrhage and coagulation [44,45]. The 
antivascular effects of flavoids are mediated via the release of vasoactive components like TNF, 
serotonin and nitric oxide leading to apotosis of ECs, increased permeability and IFP resulting in 
vascular collapse and tumor necrosis [46-49]
The provascular approach. In contrast to the other strategies that both attack the vasculature 
this approach is rather counter-intuitive. In this strategy the choice of a chemotherapeutic agent 
depends on its efficacy in killing the tumor cells. However, as mentioned above reaching the ap-
propriate toxic levels at the site of the tumor cells is a major problem. For successful treatment 
the chemotherapeutic drug has to be accompanied by an agent that does not necessarily have a 
toxic effect but serves as a facilitator to improve the bioavalability of the drug. Agents such as TNF, 
histamine and interleukin-2 have been demonstrated to increase the intratumoral concentration 
of chemotherapy [50-55]. Especially the use of TNF has been very successful and many studies 
have been performed to elucidate its mechanism. The isolated limb perfusion (ILP) is a treatment 
for malignancies of the extremities in which the tumor-bearing extremity is isolated form the pa-
tient’s circulatory system, connected to a heart-lung machine and perfused with cytotoxic agents. 
This achieves very high loco-regional drug levels with minimal systemic exposure to the drug and 
thus no systemic toxicity. The combination of TNF and melphalan in the ILP results in an increased 
tumor response in patients with in-transit melanoma metastases or locally advanced soft-tissue 
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sarcomas compared to ILP with melphalan alone without the toxic side effects. [56]. These results 
led to the approval of TNF by the European Medicine Evaluation Agency and TNF-based ILP has 
become the standard treatment for patients with in-transit melanoma and non-resectable sarco-
mas of the extremities. The majority of the patients can thus be spared an amputation [57,58]. 
We observed that with the administration of TNF there is an increased accumulation of the cyto-
toxic drug in the tumor [59,60]. Histopathologically, hemorrhagic necrosis was found after perfu-
sion with both drugs. Almost directly after perfusion, platelet aggregation and damage to the 
ECs was found. It has also been showed previously that leucocytes play an important roll in the 
tumor response [61]. Systemic treatment with low-dose TNF in combination with liposomal en-
capsulated doxorubicin (Doxil) in tumor-bearing animals resulted in an improved tumor response 
compared to treatment with Doxil alone [50,62]. In this setting low-dose TNF administration lead 
to enhanced extravasation of liposomes in the tumor microenvironment, based on an increase 
in the leakiness of the TAV. TNF-induced enhanced accumulation of the liposomes in the tumor 
appears to be crucial for the observed response.
AIM OF THE THESIS
The aim of this thesis is to improve the delivery of cytotoxic agents to the tumor cells and to 
explain the mechanism behind this process. For this we use two agents with different targets; 
vasoactive agents that target the tumor-associated vasculature and chemotherapy that kills the 
tumor cells. Two vasoactive agents, TNF and Cilengitide are investigated in combination with the 
cytotoxic agents, melphalan, doxorubicin or Doxil. We studied the effects on ECs, pericytes and 
extracellular matrix as well as the interactions between the blood components, peripheral blood 
mononuclear cells and endothelial cells en the 4D kinetics of the uptake of the chemotherapeutic 
agents at the tumor site. A better insight in these processes will lead to the design of improved 
treatment regimens and more effective therapies for cancer patients.
OUTLINE OF THE THESIS
In the first part, the tumor response of two vasoactive agents, TNF and Cilengitde is investigated. 
In chapter 2 we study the antitumor activity after systemic treatment with TNF and Doxil in 
osteosarcoma-bearing rats. Previous experiments in soft tissue sarcoma-bearing rats showed im-
pressive tumor response with this combination accompanied by augmented accumulation of the 
chemotherapeutic drug. Therefore, this treatment needs to be evaluated in tumor types with a 
different origin and structure. Chapter 3 describes the antitumor activity of Cilengitide, a cyclic 
inhibitor of αV integrins in clinical development as an antiangiogenic agent, in the melphalan-
based ILP setting in soft tissue sarcoma-bearing rats. We investigate the effect of this inhibitor of 
ECs in vitro as well as in vivo and evaluate the capacity of Cilengitide to augment the intratumoral 
drug concentrations as we have observed after administration of TNF.
In the second part of this thesis the effect of TNF on endothelial cells is studied in vitro. In 
Chapter 4 we investigate the ECs integrity and measure cell growth, cell morphology, perme-
ability. We combine TNF with other important factors as interferon-gamma and peripheral blood 
mononuclear cells (PBMC) and look at endogenous produced factors that could be responsible 
for the observed effects. In the following two chapters, based on the changes in vascular integrity 
as observed in the experiments described in the previous chapter, we focus in more detail on the 
cell to matrix (chapter 5) and cell to cell adhesion (chapter 6). In chapter 5 endogenous pro-
duced matrix metalloproteinase-2 and -9 that contribute to the degradation of the endothelial 
layer is studied and in chapter 6 we study the effect of TNF on the increased permeability and the 
presence of the adherent junction protein VE-cadherin.
Chapter 1 17
In the third part, we focus on the mechanism and action of TNF in the locoregional and sys-
temic treatment in combination with conventional chemotherapy in vivo. Chapter 7 describes 
the early changes in the tumor microenvironment during and directly after TNF-based ILP, which 
could explain the improved tumor response. We investigate the effect of TNF on the vasculature 
and immune cell infiltration using histology and also evaluate the expression of several cytokines 
in the tumor tissue. In chapter 8 we use the dorsal skin-fold chamber with a B16BL6 tumor to 
elucidate the systemic effect of TNF and tumor distribution of free and liposomal chemotherapy 
in more detail. As observed in previous experiments TNF increased the intratumoral Doxil concen-
tration. However, the exact location of the drug was still unknown. Using intravital microscopy 
we study the liposomal distribution inside the tumor in more detail. In chapter 9 we investigate 
whether or not addition of systemic low-dose TNF in combination with Doxil would have similar 
effects on different tumors. For this we use four tumors with differences in their vascular proper-
ties. Besides the evaluation of tumor response we also investigate the correlation between these 
vascular differences and the observed response.
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ABSTRACT
Improved efficacy of Doxil (Stealth liposomal doxorubicin) com-
pared to free doxorubicin has been demonstrated in the treat-
ment of several tumor types. We have shown that addition of 
a low-dose tumor necrosis factor-alpha (TNF) to systemic Doxil 
administration dramatically improved tumor response in the high-
ly vascularized rat soft tissue sarcoma BN175. Whether a similar 
enhanced efficacy can be achieved in less vascularized tumors is 
uncertain. We therefore examined the effect of systemic adminis-
tration of Doxil in combination with low-dose TNF in intermediate 
vascularized osteosarcoma-bearing rats (ROS-1). Small fragments 
of the osteosarcoma were implanted subcutaneously in the lower 
limb. Treatment was started when the tumors reached an average 
diameter of 1 cm. Rats were treated with 5 intravenous injec-
tions at 4 day interval with Doxil or doxorubicin and TNF. Systemic 
treatment with Doxil resulted in a better tumor growth delay than 
free doxorubicin, but with progressive diseases in all animals. The 
3.5-fold augmented accumulation of Doxil compared to free 
doxorubicin presumably explains the enhanced tumor regression. 
Addition of low-dose TNF augmented the antitumor activity of 
Doxil, although no increased drug uptake was found compared 
to Doxil alone. In vitro studies showed that ROS-1 is sensitive to 
TNF, but systemic treatment with TNF alone did not result in a 
tumor growth delay. Furthermore we demonstrated that treat-
ment with Doxil alone or with TNF resulted in massive coagula-
tive necrosis of tumor tissue. In conclusion, combination therapy 
of Doxil and low-dose TNF seems attractive for the treatment of 
highly vascularized tumors but also of intermediate vascularized 
tumors like the osteosarcoma.
INTRODUCTION
Encapsulation of anticancer agents in liposomes 
offers a potential means of manipulating drug 
distribution to improve antitumor efficacy and 
reduce toxicity. Stealth liposomes are sterically 
stabilized liposomes that contain methoxy-
polyethylene glycol (MPEG). Because of their 
small size, long circulation time, and reduced 
interaction with formed elements of the blood, 
these liposomes tend to accumulate in tumors, 
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presumably due to leakage through the often-
compromised tumor vasculature [1-8]. Doxil 
(Stealth liposomal doxorubicin) is effective in 
the treatment of several -tumor types, includ-
ing advanced or metastatic soft tissue sarcoma 
[9], AIDS-related Kaposi’s sarcoma [10], meta-
static breast cancer [11] and epithelial ovarian 
cancer [12].
Pre-clinical and clinical studies have shown 
impressive improvement of the antitumor activ-
ity of melphalan and doxorubicin in local treat-
ment of different tumor types when TNF was 
co-administered [13-18]. We demonstrated 
that the basis for the synergy is, on one hand 
a significant enhancement of tumor selective 
melphalan and doxorubicin uptake and on the 
other hand the subsequent destruction of tu-
mor vasculature caused by TNF [19,20].
Successful application of TNF for systemic 
treatment of tumors however is seriously ham-
pered by its severe toxicity and therefore only 
low dosages can be administered [21,22]. In 
previous studies we showed that systemic co-
administration of Doxil and low-dose TNF re-
sulted in a pronounced tumor response in both 
rat and mice tumor models. In soft tissue sarco-
ma-bearing rats systemic treatment with Doxil 
in combination with low-dose TNF improved 
the antitumor activity dramatically resulting in 
a tumor response (complete or partial regres-
sion) in most of the animals. Repeated injec-
tion of Doxil combined with TNF resulted in 
augmented accumulation of the drug in tumor 
tissue, which could explain the observed syner-
gistic antitumor effect [23]. When B16BL6 mel-
anoma-bearing mice were injected with Doxil 
combined with TNF, also an increased drug ac-
cumulation was found compared to liposomes 
alone [24]. TNF increases the leakiness of the 
vasculature by increasing the gaps between 
the endothelial lining in the tumor, possibly 
explaining the augmented accumulation after 
extravasation of liposomes [25,26].
We evaluate in the experiments described 
here whether the use of TNF in combination 
with Doxil not only results in synergistic anti-
tumor response in the highly vascularized soft 
tissue sarcoma but also in the less vascularized 
osteosarcoma.
EXPERIMENTAL PROCEDURES
Agents. Human recombinant tumor necrosis 
factor-alpha with a specific activity of 5x107 IU/
mg was kindly provided by Dr. G. Adolf (Bender 
Wien GmbH) and stored at a concentration of 2 
mg/ml at -80°C or under liquid nitrogen. Endo-
toxin levels (LAL) were below 0.6 EU/mg. Pegy-
lated liposomal doxorubicin (Doxil) was kindly 
provided by Dr. P. Working (ALZA Corporation). 
Doxorubicin hydrochloride (adriblastina) was 
purchased from Pharmachemie BV.
Animals and tumor model. Male inbred 
WAG/RIJ rats were used for the osteosarcoma 
model (ROS-1). This tumor originated sponta-
neously in the tibia of a rat. Rats were obtained 
from Harlan-CPB and weighing 250-300 gram. 
Rats were fed a standard laboratory diet ad li-
bitum. Small fragments (3 mm) of the synge-
neic ROS-1 sarcoma or the soft tissue sarcoma 
BN175 were implanted subcutaneously in the 
right hind leg as previously described [27]. Tu-
mor growth was recorded by caliper measure-
ment and tumor volume calculated using the 
formula 0.4 x (A2 x B) (where B represents the 
largest diameter and A the diameter perpen-
dicular to B). Rats were sacrificed if tumor di-
ameter exceeded 25 mm or at the end of the 
experiments. Animal studies were done in ac-
cordance with protocols approved by the com-
mittee on Animal Research of the Erasmus MC, 
Rotterdam, the Netherlands.
Treatment protocol. Treatment was started 
when the ROS-1 tumors reached an average di-
ameter of 9-11 mm. The rats were randomized 
into the following 6 groups: placebo liposomes 
(sham), TNF, doxorubicin, Doxil, doxorubicin 
plus TNF and Doxil plus TNF. Rats were injected 
5 times i.v. with an interval of 4 days between 
the injections; first dose of 4.5 mg/kg Doxil or 
doxorubicin and 1.0 mg/kg for consecutive 
doses. TNF was given at a concentration of 15 
µg/kg for all 5 doses. When rats were treated 
with doxorubicin or Doxil combined with TNF, 
these agents were injected separately, shortly 
after each other. The classification of tumor re-
sponse was: progressive disease (PD) = increase 
of tumor volume (> 25%) over a 20 day period; 
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no change (NC) = tumor volume equal to vol-
ume as start of treatment (in a range of - 25% 
and + 25%); partial remission (PR) = decrease 
of tumor volume (- 25 and -90 %); complete 
remission (CR) = tumor volume less than 10% 
of initial volume.
Measurement of doxorubicin accumulation 
in tumor tissue. The effect of TNF on Doxil ac-
cumulation in ROS-1 tumors was investigated. 
After 3 injections the tumor size of rats treated 
with Doxil in combination with TNF started to 
differ from the tumor size of rats in the other 
groups and for this reason we decided to com-
pare doxorubicin tumor uptake not later than 
this time point. Rats received 3 injections of 
doxorubicin or Doxil with or without TNF with 
an interval of 4 days between the injections as 
described in the treatment protocol. Tumors 
were excised 24 hours after the last injection 
and tissues were analyzed for doxorubicin and 
its fluorescent metabolites as previously de-
scribed [28]. Briefly, tumors were incubated 
in acidified isopropanol (0.075 N HCl in 90% 
isopropanol) for 24 hours at 4°C and after 
that the tumors were homogenized (PRO200 
homogenizer with 10 mm generator, Pro Sci-
entific), centrifuged for 30 min at 2500 rpm 
and supernatants were harvested. A Hitachi 
F4500 fluorescence spectrometer (excitation 
472 nm and emission 590 nm) was used for 
measurement of the samples. A standard curve 
was prepared with known concentrations of 
doxorubicin diluted in acidified isopropanol. All 
measurements were repeated after addition of 
an internal doxorubicin standard.
Histology. Rats were treated with placebo li-
posomes, TNF, Doxil or Doxil plus TNF. When 
the tumors reached an average diameter of 17 
± 1 mm, they were excised and fixed in 4% 
formaldehyde and embedded in paraffin. Tis-
sue sections of 4 µm were cut and stained 
with hematoxylin and eosin, examined on a 
Leica DM-RXA and photographed using a Sony 
DXC950 camera. At least 3 different tumors 
in each experimental group were subjected to 
blind evaluation.
Immunohistochemistry. Untreated BN175 
and ROS-1 tumors with a diameter of 9-11 
mm were excised and immediately frozen in 
liquid nitrogen. Immunohistochemical studies 
were performed on acetone-fixed 7 µm cry-
ostat sections. The tumor sections were fixed 
for 30 min with 4% formaldehyde and after 
rinsing with PBS, the endogenous peroxidase 
activity was blocked by incubation for 5 min in 
methanol/3% H2O2. The slides were incubated 
for 1 hour with mouse anti rat CD31 (1:50; 
Becton Dickinson) diluted in 5% rat serum/PBS. 
Thereafter, sections were washed with PBS and 
incubated for 1 hour with goat anti mouse 
peroxidase-labeled antibody (1:100; DAKO) di-
luted in 5% rat serum/PBS. After rinsing with 
PBS, positive cells were revealed by immu-
noperoxidase reaction with DAB solution (DAB-
kit, DAKO) and counterstained lightly with hae-
matoxylin (Sigma). The sections were examined 
on a Leica DM-RXA and photographed using a 
Sony 3CCD DXC 950 camera. The number of 
vessels and the area of vessels per field of inter-
est were measured in calibrated digital images 
(Research Assistant 3.0, RVC). For quantifica-
tion of the microvessel density (MVD) 6 repre-
sentative fields of interest per slide, 3 sections 
of 4 individual tumors were examined.
In vitro cytotoxicity assay. The rat osteo-
sarcoma ROS-1 cells were maintained in MEM 
supplemented with 10% FCS and 0.1% peni-
cilline-streptomycine. Media and supplements 
were obtained from Life Technologies. ROS-1 
cells were plated in 96-well plates (Costar BV) 
at a final concentration of 1x104 cells per well 
and allowed to grow for 24 hours. Cells were 
incubated at 37ºC in 5% CO2 for 72 hours 
in the presence of various concentrations of 
TNF, doxorubicin and Doxil. The range of final 
drug concentrations was 0.1 - 10 µg/ml for 
TNF, 0.001 - 100 µg/ml doxorubicin and 0.05 
- 1000 µg/ml Doxil. Growth of tumor cells was 
measured using the sulphorhodamine-B as-
say (SRB, Sigma) according to the method of 
Skehan [29]. In short, cells were washed twice 
with phosphate buffered saline, incubated with 
10% trichloric acetic acid (1 hour, 4ºC) and 
washed again. Cells were stained with 0.4% 
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SRB (15-30 min), washed with 1% acetic acid 
and were allowed to dry. Protein bound SRB 
was dissolved in TRIS (10 mM, pH 9.4). The op-
tical density (O.D.) was read at 540 nm. Tumor 
cell growth was calculated using the formula: 
cell growth = (O.D. test well/O.D. control) x 
100 percent.
In vitro assessment of doxorubicin uptake 
in tumor cells. Intracellular doxorubicin levels 
in osteosarcoma ROS-1 cells were measured 
by flowcytometry to determine whether the 
observed in vitro toxicity correlated with cel-
lular uptake of doxorubicin. ROS-1 cells were 
plated in 24-well plates at a final concentration 
of 5x104 cells per well and allowed to growth 
for 24 hours. Doxorubicin, Doxil and TNF, dilut-
ed in MEM supplement with 10 % FCS, were 
added to the wells, after which cells were in-
cubated for 10, 30, 60 and 120 min. The final 
drug concentration in the wells for all 3 drugs 
was 0, 0.1, 1.0 and 10 µg/ml. After incubation, 
cells were washed to discard non-incorporated 
drug and treated with trypsin-EDTA for 2 min. 
The cell suspensions were washed twice in me-
dium and resuspended in PBS. Cellular uptake 
was measured on a Becton Dickinson FACScan 
using Cell Quest software on Apple Macintosh 
computer. Excitation was set at 488 nm and 
emission at 530 nm.
Statistical analysis. Results were evaluated for 
statistical significance with the Mann Whitney 
U test. P-values below 0.05 were considered 
statistically significant. Calculations were per-
formed on a personal computer using Graph-
Pad Prism v3.0 and SPSS v10.0 for Windows 
2000.
RESULTS
The combination of low-dose TNF and 
Doxil results in strong antitumor response. 
To evaluate the antitumor activity of Doxil in 
combination with low-dose TNF, osteosarcoma-
bearing rats were treated with a total of 5 in-
jections of doxorubicin or Doxil with or without 
TNF. Treatment with doxorubicin resulted in a 
slight delay in tumor growth, with progressive 
diseases in all animals (Fig. 1). Progressive dis-
ease was also seen in all animals treated with 
Doxil, but with a better tumor growth delay 
than doxorubicin. Addition of TNF to the Doxil 
treatment enhanced the antitumor response, 
resulting in a response rate of 50% (partial plus 
complete response). In contrast, addition of TNF 
to doxorubicin treatment did not improve the 
antitumor response. Treatment with TNF alone 
had no antitumor effect. No obvious systemic 
toxicity was observed in any of the treatments.
Necrosis is observed after treatment with 
TNF and Doxil. Histopathological examination 
was performed on tumors with the same size, 
shortly after regrowth occurred. Treatment of 
the rats with Doxil and Doxil in combination 
with TNF resulted in severe tumor necrosis and 
extensive cell death (Fig. 2). Massive coagula-
tive necrosis of 68% of the tumor area was 
seen in Doxil treated tumors and 40% in the 
Doxil plus TNF treated tumors. Less necrosis was 
seen in rats treated with placebo liposomes or 
TNF (10 and 17%, respectively). In all 4 groups 
infiltrated polymorph nuclear cells (PMN) were 
detected.
Addition of TNF did not increase intratu-
moral drug concentration. To investigate 
whether the observed beneficial effect of TNF 
on the Doxil treatment was due to an increased 
liposome extravasation into tumor tissue, dox-
orubicin concentrations in tumors after 3 treat-
ments were determined. Doxorubicin levels in 
tumors were 3.5-fold higher when Doxil was 
injected compared to doxorubicin, although 
not significantly (Fig. 3). Addition of TNF did 
not induce a further accumulation of Doxil and 
TNF had also no effect on the tumor uptake of 
free doxorubicin.
ROS-1 tumors contain fewer vessels com-
pared to BN175. Quantification of the micro-
vessel density (MVD) was performed by immu-
nohistochemical staining of endothelial cells in 
frozen BN175 and ROS-1 tumor sections. The 
number of vessels as well as the total tumor 
vessel area was measured. The area per vessel 
was computed by dividing the total vessel area 
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Figure 1. Addition of TNF improves the antitumor effect of Doxil in ROS-1 osteosarcoma-bearing rats. Rats were 
injected 5 times i.v. with an interval of 4 days between the injections (arrows). Chemotherapy or TNF alone had hardly 
any effect on the tumor growth. Combination of doxorubicin with TNF reduced tumor growth but the most impressive 
results were obtained with the treatment of Doxil in combination with TNF. Data points represent tumor volumes  ± SD 
of 6 to 8 individual animals.
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Figure 2. Massive necrosis is observed after Doxil treatment. Paraffin sections of the osteosarcoma after systemic 
treatment were stained with haematoxylin-eosin. Sham and TNF-treated tumors hardly showed any necrosis when the 
tumors reached a size of 17 mm. Necrosis was observed in Doxil treated tumors that was further enhanced with the ad-
dition of TNF. Scale bar apply for upper pictures, 500 µm. Scale bar apply for lower pictures, 100 µm. (See color section 
for a full-color version.)
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by the number of vessels. The number of ves-
sels in the BN175 tumor was 2.9 times higher 
than in the ROS-1 tumor (Fig. 4a), although 
the vessels had the same size (Fig. 4b and Fig. 
4c).
Addition of TNF did not increase cytotox-
icity on ROS-1 cells in vitro. In vitro experi-
ments were performed to define whether di-
rect cytotoxicity contributed to the improved 
tumor response of Doxil in combination with 
TNF. Figure 5 shows that exposure of ROS-1 
tumor cells to doxorubicin resulted in a dose 
dependent cell growth inhibition, with an IC50 
of 3.8 µg/ml. Doxil appeared to be less cyto-
toxic to osteosarcoma cells with an IC50 of 25.7 
µg/ml. ROS-1 cells were moderately sensitive to 
TNF with a maximum growth inhibition of 32% 
at 10 µg/ml TNF. Addition of TNF to doxorubi-
cin or Doxil had no effect on the cytotoxicity of 
the antitumor agents; comparable IC50 values 
were found (Fig. 5a and Fig. 5b).
Addition of TNF did not change uptake of 
Doxil or doxorubicin in tumor cells in vitro. 
We examined if TNF augmented the intracel-
lular accumulation of doxorubicin or Doxil, 
which could explain the improved tumor re-
sponse. Increased intracellular concentrations 
of doxorubicin or Doxil were observed when 
incubated with increasing concentrations of 
doxorubicin or Doxil (ranging 0.1 to 10 µg/ml) 
and increasing time (ranging 10 to 120 min). 
Addition of TNF up to 10 µg/ml did not result 
in an increased uptake of doxorubicin or Doxil 
(data not shown).
DISCUSSION
In the present study we demonstrated that 
Stealth liposomal doxorubicin (Doxil) resulted 
in a better tumor growth delay than free doxo-
rubicin in osteosarcoma-bearing rats. However, 
tumor control was not achieved as progressive 
disease was observed in all animals. Addition of 
low-dose TNF augmented the antitumor activ-
ity of Doxil resulting in a response rate of 50%. 
These experiments are in agreement with ear-
lier studies where we demonstrated that TNF 
improved the antitumor activity of Doxil in a 
rat soft tissue sarcoma and a mouse melanoma 
model [23,30].
Transport of small drugs across the blood 
vessel wall involves diffusion whereas transport 
of macromolecules involves convection. Diffu-
sion is the random motion of small molecules. 
Convection is mediated by the movement of 
fluid [31-34]. In highly vascularized tumors 
more tumor cells will be reached by the che-
motherapeutics. In general, tumor vessels are 
more permeable than normal vessels and the 
maximum size of particles that can cross the 
tumor vessel wall is called the pore cutoff size. 
There is a large variance in cutoff sizes in dif-
ferent tumor types. Vessels of some, but not 
all, primary brain tumors are nearly imperme-
able, while in other tumors cutoff pore sizes 
between 100 nm and 1.2 µm are found. Vas-
cular permeability may depend on tumor type 
and microenvironment and increases with tu-
mor size. It is believed that not the microvessel 
density is the limiting factor of macromolecule 
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Figure 3. Addition of TNF does not increase intratu-
moral doxorubicin levels. Doxorubicin levels in tumors 
after systemic administration of 3 injection of doxorubicin 
or Doxil with or without TNF were measured. Significant 
more doxorubicin was observed intratumoral when admin-
istered in liposomal formulation compared to free drug. 
However addition of TNF did not increase the accumulation 
of doxorubicin or Doxil. Columns represent µg doxorubicin 
per g tumor tissue ± SD of 3 to 6 individual animals.
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Figure 4. Structural differences between ROS-1 osteosarcoma and BN175 soft tissue sarcoma. (a) The microvessel 
density (MVD, number of vessels per field of interest at magnification 40x) of untreated ROS-1 and BN175 tumors of 9-11 
mm in diameter was assessed by immunohistochemical staining for CD31. The BN175 tumor had 2.9 times more vessels 
than the ROS-1 tumor. Columns represent MVD ± SEM of 3 sections of 4 individual tumors; *, P < 0.05. (b) The vessels 
of the BN175 and ROS-1 tumors had the same size. Columns represent area endothelium per vessel per field of interest ± 
SEM of 3 sections of 4 individual tumors. (c) Untreated tumor sections of ROS-1 and BN175 of 8-10 mm in diameter were 
stained for CD31. BN175 showed much more tumor vessels compared to ROS-1. Scale bar apply for all images, 100 µm.
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Figure 5. No synergistic effect of TNF is observed in vitro. (a) In vitro growth of ROS-1 tumor cells with Doxil with 
varies concentrations of TNF showed that cells were moderate sensitive to TNF alone. Exposure to Doxil resulted in a 
dose dependent cell growth reduction but addition of TNF had no effect of the antitumor activity of Doxil. (b) The same 
observations with doxorubicin were observed. Addition of TNF did not increase the cytotoxic effect of doxorubicin. Doxo-
rubicin was found more cytotoxic to ROS-1 tumor cells compared to Doxil. Data points represent percentage cell growth 
compared to control treated cells ± SEM of 2 treatments in 3 individual experiments.
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drug delivery to solid tumors, but the perme-
ability of the tumor vessels [35,36].
Several studies have shown that encapsula-
tion of anticancer agents in liposomes can re-
duce systemic toxicity while retaining or even 
improving in vivo efficacy [1,4,7,37]. Doxil is ef-
fective in the treatment of several tumor types, 
including advanced or metastatic soft tissue 
sarcoma [38], AIDS-related Kaposi’s sarcoma 
[39], metastatic breast cancer [40] and epitheli-
al ovarian cancer [41]. Stealth liposomes have a 
long circulation time and tend to accumulate in 
tumors, presumably due to leakage through the 
tumor vasculature [1,3,4,6-8,42]. In the pres-
ent study we showed that systemic treatment 
with Doxil resulted in a better tumor growth 
delay than free doxorubicin and that the 3.5-
fold increased drug accumulation could explain 
the observed enhanced antitumor effect. The 
antitumor activity of Doxil in the osteosarcoma 
model is comparable to the antitumor activity 
in the soft tissue sarcoma BN175, although in 
vitro studies showed a clear difference. BN175 
cells are 10 times more sensitive to Doxil than 
ROS-1 cells [23]. Four times more Doxil is found 
in ROS-1 tumor tissue than in the BN175 tu-
mor after 3 i.v. injections of Doxil alone. Most 
likely this indicates that the tumor vessels of 
the ROS-1 tumor are more permeable than the 
vessels of the BN175 tumor.
Previously we reported on the improved an-
titumor activity of systemically injected Doxil 
when combined with low-dose TNF in soft tis-
sue sarcoma-bearing rats. Repeated injections 
of Doxil plus TNF resulted in augmented tumor 
uptake of doxorubicin, which could explain 
the observed enhanced antitumor effect [23]. 
Also in the B16BL6 melanoma-bearing mice 
an augmented accumulation of Doxil is seen 
when combined with TNF. TNF likely increases 
the leakiness of the vasculature by increasing 
the gaps between the endothelial lining in the 
tumor, possibly explaining the augmented ac-
cumulation after extravasation of liposomes 
[25,43].
In the present study we did not observe an 
increased drug accumulation when Doxil was 
combined with TNF in the osteosarcoma ROS-1 
model. TNF has an effect on tumor endothelial 
cells and the ROS-1 tumor is less vascularized 
than the BN175 tumor. Although in TNF-based 
isolated hepatic perfusions a highly vascular-
ized tumor results in a good tumor response 
and vice versa, no such effect was found in the 
TNF-based ILP. Both the BN175 and the ROS-1 
tumor showed a synergistic antitumor response 
when TNF is added to the ILP [18,44].
In vitro studies demonstrated a higher sensi-
tivity of the osteosarcoma cells for TNF as com-
pared to the BN175 cells. The dose of TNF used 
in the systemic treatment is probably too low 
to have an effect on its own, but may switch 
the balance to a better response when com-
bined with Doxil. Also, administration of TNF 
may trigger local production of TNF and oth-
er cytokines improving tumor response when 
combined with Doxil.
We found less coagulative necrosis in tu-
mor tissue after treatment with Doxil and TNF 
than with Doxil alone. We think this is due to 
the fact that the tumors were excised at the 
same size. As the tumors from Doxil plus TNF 
treated rats regressed more they also regrew 
more to gain the same size as the Doxil alone 
treated tumors. We demonstrated for the first 
time that TNF augments the antitumor activity 
of Doxil not only in highly vascularized tumors 
like the soft tissue sarcoma BN175, but also 
in the intermediate vascularized ROS-1. These 
findings confirm the promising role for TNF as 
enhancer of systemic therapy of solid tumors 
with Stealth liposomes.
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INTRODUCTION
Growth of solid tumors depends strongly on 
tumor angiogenesis, the formation of new 
blood vessels in the tumor microenvironment 
[1]. Adhesion receptors of the integrin family 
are the main endothelial cell adhesion mol-
ecules binding to the underlying extracellular 
matrix (ECM). The αV integrins are important in 
the formation of new blood vessels. They ap-
pear to be de-novo induced and activated on 
tumor angiogenic endothelia [2] and promote 
endothelial cell attachment, spreading, survival, 
proliferation and locomotion [3-10]. αV integ-
rins, in particular αVβ3 and αVβ5, have been 
considered as therapeutic targets to inhibit 
angiogenesis [2]. Cilengitide is a cyclic penta-
peptide inhibitor of αVβ3 and αVβ5 integrins, 
and blocks growth factors- and tumor-driven 
angiogenesis [11]. The isolated limb perfusion 
(ILP) is a surgical procedure used in the clinic for 
rescue therapy of distributed malignant mela-
noma and soft tissue sarcoma and has a high 
success rate [12,13]. In this model, the tumor 
response depends on the combination of the 
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ABSTRACT
Isolated limb perfusion (ILP) with tumor necrosis factor-alpha 
(TNF) and the antitumor drug melphalan, is successfully used to 
treat patients with advanced bulky melanoma and sarcoma of 
the limbs. However, the intrinsic toxicity of TNF led us to explore 
alternative drugs that might synergize with chemotherapy in this 
setting. Cilengitide (EMD 121974) is a cyclic inhibitor of αV inte-
grins in clinical development as an antiangiogenic agent. In this 
study, we show that Cilengitide strongly enhances the antitumor 
effects of melphalan in soft tissue sarcoma-bearing rats treated 
by ILP. Interestingly, and in notable contrast to previous in vivo an-
titumor studies with αV inhibitors, Cilengitide acts in a time frame 
in the hours immediately bordering the ILP. Cilengitide triggers 
a strong increase in the concentration of melphalan within the 
tumor and increased death of tumor associated endothelial cell, 
but did not affect non-tumoral tissues. As Cilengitide has a low 
toxicity these data indicate its possible use in combination with 
chemotherapy in more demanding settings, such as organ perfu-
sion and systemic administration, for the treatment of advanced 
solid tumors.
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alkylating reagent melphalan with the anti-neo-
vascular activity of tumor necrosis factor-alpha 
(TNF). We have shown that TNF augments the 
influx of the cytotoxic agents into the tumor 
compartment, likely due to increased vascular 
permeability and reduction of the intratumoral 
pressure [14-16]. Also, in animal isolated organ 
perfusions we showed a beneficial effect of TNF 
in combination with chemotherapy [17,18]. 
However, the severe local toxicity prevents the 
effective use of TNF either during organ perfu-
sion or for systemic administration in humans. 
Since Cilengitide can disrupt the endothelial 
cell layer of angiogenic vessels, we hypothe-
sized that at early time point’s disruption of the 
endothelial cells could result in an increased 
vascular permeability and enhanced melphalan 
accumulation in the tumor, as we showed for 
TNF. Therefore we investigated whether pertur-
bation of the tumor-vascular compartment by 
Cilengitide could affect melphalan-based ILP 
and improve antitumor response.
EXPERIMENTAL METHODS
Agents. Cilengitide (EMD 121974; cyclic(Arg-
Gly-Asp-D-Phe-(N-Methyl)-Valine) in physi-
ological saline (15 mg/ml; 25.5 mM) and 
EMD 66203 (cyclic(Arg-Gly-Asp-D-Phe-Valine; 
c(RGDfV)) in physiological saline (15 mg/ml; 
26 mM) were kindly provided by Merck KGaA, 
Darmstadt, FRG, and further diluted in saline or 
appropriate culture medium. Melphalan (Alk-
eran) was purchased from GlaxoSmithKline BV 
and diluted in PBS to a concentration of 2 mg/
ml. Recombinant human tumor necrosis factor-
alpha (TNF; 2 mg/ml; specific activity 6x107 U/
mg; endotoxin < 1 units (EU) per mg protein) 
was kindly provided by Boehringer Ingelheim.
Animals and tumor model. Male inbred 
Brown Norway rats (Harlan-CPB, the Nether-
lands) were used at a weight of 250-300 g, 
and were fed a standard laboratory diet ad libi-
tum. Small fragments (1 mm3) of the syngeneic 
BN175 soft tissue sarcoma were implanted sub-
cutaneously in the right hind leg just above the 
ankle as previously described [19]. Rats were 
sacrificed when tumor diameter exceeded 25 
mm or at the end of the experiment. All ani-
mal studies were done in accordance with pro-
tocols approved by the committee on Animal 
Research of the Erasmus MC, Rotterdam, the 
Netherlands.
Treatment protocol. After implantation tu-
mors were allowed to grow to a diameter of 
12-14 mm and rats were randomly assigned 
to the different treatment groups as listed in 
table 1. The treatment schedules for the dif-
ferent groups are depicted in figure 1 (Fig. 1). 
Rats were injected i.p. with Cilengitide (50 mg/
kg) or saline 2 hours before and 3 hours after 
ILP. During ILP Cilengitide (500 µg, 170 µM), 
melphalan (40 µg, 8 µg/ml) and/or TNF (50 µg, 
10 µg/ml) were added to the circuit contain-
ing a total volume of 5 ml Haemaccel (Behring 
Pharma).
Isolated limb perfusion. The perfusion tech-
nique was performed as described previously 
[19]. Isoflurane (Pharmachemie) was used as 
inhalation anesthesia during the operation. The 
femoral vessels were approached through an 
incision parallel to the inguinal ligament after 
systemic heparin administration of 50 IU (Leo 
Pharmaceutical Products) to prevent coagula-
tion. The femoral artery and vein were cannu-
lated with silastic tubing (0.30 mm inner diam-
eter, 0.64 mm outer diameter; 0.64 mm inner 
diameter, 1.19 mm outer diameter, respectively; 
Dow Corning, Ann Arbor, MI). Applying a tour-
niquet around the groin temporarily occluded 
the collaterals. An oxygenation reservoir filled 
with 5 ml Haemaccel and a low-flow roller 
pump (Watson Marlow type 505 U, Falmouth) 
were included into the circuit. Cilengitide, mel-
phalan and TNF were added as bolus to the 
circuit reservoir. The roller pump circulated the 
perfusate at a flow of 2.4 ml/min for 30 min. 
It is important to note that in this study the ILP 
with melphalan and/or TNF lasted only 20 min, 
as a pre-perfusion with Cilengitide or sham of 
10 min was given. This was in contrast to previ-
ous studies in which we performed perfusion 
with TNF and melphalan for the full 30 min. A 
washout with 5 ml oxygenated Haemaccel was 
performed at the end of the perfusion. During 
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ILP and washout, the hind leg was kept at a 
constant temperature of 38-39°C by a warm-
water mattress applied around the leg. Limb 
function was subsequently monitored daily to 
assess treatment and drug related local toxic-
ity.
Assessment of tumor response. Tumor 
growth was recorded daily by caliper measure-
ment and tumor volume calculated using the 
formula 0.4 x (A2 x B) (where B represents the 
largest diameter and A the diameter perpendic-
ular to B). The classification of tumor response 
was: progressive disease (PD) = increase of tu-
mor volume (>25%); no change (NC) = tumor 
volume equal to volume during perfusion (in a 
range of -25% and + 25%); partial remission 
(PR) = decrease of tumor volume (-25% and 
-90%); complete remission (CR) = tumor vol-
ume less than 10% of initial volume. Response 
rate (RR) is partial remission and complete re-
mission.
Histopathology staining. Directly after ILP, 
tumors were excised, stored in formalin, and 
embedded in paraffin. Four µm sections were 
cut and stained with hematoxylin and eosin us-
ing standard procedures. Three or four different 
tumors in each experimental group were sub-
jected to blinded evaluation. At least 6 slides 
were examined from each tumor. The sections 
were examined on a Leica DM-RXA light micro-
scope and photographed using a Sony 3CCD 
DXC 950 camera.
Drug pharmacokinetics. During the treat-
ment protocol depicted in figure 1 serum 
and perfusate samples were collected from at 
least 3 rats as indicated. At the end of perfu-
sion directly after washout, tumor and part of 
the hind limb muscle were excised. Samples 
were immediately frozen in liquid nitrogen to 
stop metabolism of melphalan, and stored at 
-80°C.
Tissue and perfusate concentrations of 
melphalan. Tumor and muscle tissues were 
homogenized in 2 ml acetonitrile (Pro 200 
homogenizer, Pro Scientific) and centrifuged 
at 2500 g. Melphalan was measured in these 
supernatants, serum and perfusate samples by 
gas chromatography-mass spectrometry (GC-
MS) as described earlier by Tjaden and de Bruijn 
[20]. p-(Bis(2-chloroethyl)amino)-phenylacetic 
methyl ester was used as internal standard.
Cilengitide pharmacokinetics. The levels of 
Cilengitide in serum were measured using liq-
uid chromatography with tandem mass spec-
trometric detection (LC-MS/MS) as described 
elsewhere [21]. The cyclic peptide c(RGDfV) 
was used as an internal standard. Stocks solu-
tions of c(RGDfV) were prepared in acetonitrile/
methanol/water (1:1:1, v/v/v) and further di-
luted with methanol/water (2:98, v/v). Sample 
aliquots were mixed with internal standard so-
lution (1:80, v/v), extracted over an Oasis HLB 
column (50x1 mm; Waters), and resolved on a 
reversed phase column (LiChroCart 30-2 Puro-
i.p. Cilengitide
Start ILP Cilengitide
Start ILP TNF + melphalan at t=10 min
End of ILP, tissue sample
Serum sample Cilengitide measurment
Perfusate sample melphalan measurment
End of experiment
4 weeks
Treatment
Sampling
Cil i.p.
50 mg/kg
Cil ILP
100 µg/mL
Cil i.p.
50 mg/kg
t=
t=
t=
-2h 0h 0.5h 3h
-1.9h -1h -0.1h 0.6h 2h 3.6h 4.5h 10.5h 24h
-0.01h 0.25h 0.5/0.6h
Figure 1. Time-line of Cilengitide treatment and sample collection. (See color section for a full-color version.)
Cilengitide augments tumor response to melphalan40
spher, RP8e; Merck KGaA) on a gradient from 
100% (0.1%) formic acid to 10% (0.1%) for-
mic acid/90% acetonitrile (v/v). Detection was 
carried out by multiple reaction monitoring in 
the positive ion mode using an API-3000 mass 
spectrometer (Applied Biosystems). Mass tran-
sitions of M+H+ m/z 589 to 312 and m/z 575 
to 312 (precursor and product ions) were used 
for Cilengitide and internal standard c(RGDfV), 
respectively.
Endothelial apoptosis. Apoptotic cell death 
was detected by TUNEL staining with a com-
mercially available DNA end-labeling kit (In Situ 
Cell Death-detection Kit, Fluorescein labeled, 
Roche). Tumor tissues were also stained for 
the presence of endothelial cells to differenti-
ate between apoptosis of the endothelium and 
apoptosis of tumor cells. Acetone-fixed frozen 
sections were post-fixed in 4% paraformalde-
hyde for 30 min and incubated for 1 hour with 
mouse anti rat CD31PE (1:50; Becton Dickin-
son). After washing with PBS the sections were 
again fixed in 4% paraformaldehyde for 10 
min and permeabilized with 0.1% Triton X-100 
in 0.1% sodium citrate for 2 min on ice. The 
slides were then incubated with the TUNEL 
mixture for 1 hour at 37°C, mounted with 
mounting medium containing polyvinyl alcohol 
(Mowiol 4-88, Fluka) and 2.5% (w/v) DABCO 
(Sigma), examined on a Leica DM-RXA micro-
scope and photographed using a Sony 3CCD 
DXC 950 camera.
Culture conditions. Cells isolated from the 
BN175 tumor cells were maintained in culture 
in RPMI-1640 (Lonza) supplemented with 10% 
fetal calf serum (Lonza). Human umbilical vein 
endothelial cells (HUVEC) were isolated by col-
lagenase digestion using the method described 
by Jaffe [22] and cultured in HUVEC medium 
containing human endothelial-SFM (Invitro-
gen), 20% heat-inactivated newborn calf se-
rum (Lonza), 10% heat-inactivated human 
serum (Lonza), 20 ng/ml human recombinant 
basic Fibroblast Growth Factor (Peprotech EC 
Ltd), 100 ng/ml human recombinant Epidermal 
Growth Factor (Peprotech EC Ltd). Each isolate 
was derived from an individual umbilical vein 
and used for experiments at passage 5 or 6. For 
all experiments, unless mentioned otherwise, 
HUVEC were cultured on plates coated with 
vitronectin (1 µg/ml; Promega), fibronectin (10 
µg/ml; Roche Diagnostics) or gelatin (10 mg/
ml; Sigma) in a concentration of 6x103 cells in 
100 µl per well for a 96 well-plate (Corning BV) 
and 3x104 cells in 500 µl per well for a 24 well-
plate (Corning BV) and allowed to adhere for 
24 hours. BN175 cells were cultured in similar 
concentrations on untreated plates. Cells were 
incubated at 37ºC in 5% CO2.
Integrin expression and inhibition of ad-
hesion by Cilengitide. To identify the in-
tegrin usage and sensitivity to Cilengitide of 
rat integrins on the BN175 tumor cells, cell-
attachment and attachment-inhibition assays 
were performed as described before [23]. In 
brief, 2.5x104 BN175 cells per well in RPMI-
1640 medium supplemented with 0.5% bo-
vine serum albumin were allowed to adhere 
for 1 hour at 37°C on plates coated with the 
ECM molecules human plasma fibronectin, 
vitronectin, fibrinogen, collagen type I (Serva), 
collagen type IV (Sigma), or laminin I (Sigma), 
before washing and quantification by assay for 
lysozomal hexosaminidase against an external 
standard curve. The assays were performed in 
the presence or absence of 1 mM Mn2+ ions to 
reveal the presence of expressed but non-acti-
vated integrins. For adhesion inhibition assays, 
plates were coated with vitronectin (2 µg/ml) 
and 2.5x104 cells per well suspended in culture 
medium were allowed to adhere for 1 hour in 
the presence of serially diluted Cilengitide and 
c(RGDfV), before washing and quantification 
of attached cells.
In vitro response of endothelial cells and 
tumor cells to Cilengitide. HUVEC and 
BN175 cells were cultured in a 96 well-plate 
for 72 hours in the continuous presence of 
various concentrations of Cilengitide and mel-
phalan. Cell growth was measured using the 
sulphorhodamine-B (SRB) assay according to 
the method of Skehan [24]. In short, cells were 
washed twice with PBS, fixed with 10% trichlo-
ric acetic acid (1 hour, 4ºC) and washed again. 
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Cells were stained with 0.4% SRB (Sigma) for 
15-30 min, washed with 1% acetic acid and 
were allowed to dry. Protein bound SRB was 
dissolved in TRIS (10 mM, pH 9.4). The optical 
density (O.D.) was read at 540 nm. Cell growth 
was calculated using the formula: cell growth = 
(O.D. test well/O.D. control) x 100 percent. The 
drug concentration reducing the absorbance 
to 50% of the control (IC50) was determined 
from the growth curves. The experiments were 
repeated at least 5 times.
In vitro apoptosis assay. HUVEC in a 24 well-
plate were incubated with 50, 5, 0.5 or 0 µg/
ml Cilengitide for 5 and 60 min. Detached cells 
were collected from the supernatant and at-
tached cells were harvested by mild trypsiniza-
tion. Early apoptosis was detected by annexin 
V and necrosis/late apoptosis with propidium 
iodide staining, according to the manufactur-
er’s instructions (Vybrant Apoptosis Assay kit 
#3, Molecular Probes). Cells were immediately 
analyzed by flow-cytometry (FACScan, Becton 
Dickinson) and data analysis was performed 
using WinMDI 2.7 (Freeware, Joseph Trotter, 
Scripps Research Institute). Alternatively, apop-
tosis was also detected using YO-PRO-1 (Mo-
lecular Probes). At the end of the incubation 
period, detached cells were removed, HUVEC 
medium containing YO-PRO-1 (0.5 µM) was 
added to the well with the remaining adherent 
cells, and incubated for 15 min at 37°C. Fluo-
rescence was then visualized using an inverted 
Zeiss Axiovert 100M microscope and captured 
with an Axiocam HRc digital camera, using Ax-
ioVision v4.0 software.
Morphology and permeability changes in 
vitro. HUVEC in a 24 well-plate were incubated 
with 50, 5, 0.5 or 0 µg/ml Cilengitide and after 
0.5, 1, 2, 4, 8 and 24 hours morphological cell 
changes were examined with a 10x N.A. 0.30 
Plan-Neofluar objective lens using an inverted 
Zeiss Axiovert 100M microscope equipped with 
an Axiocam HRc digital camera using AxioVision 
v4.0 software (Carl Zeiss). Alternatively, HUVEC 
were plated in 500 µL Cilengitide containing 
HUVEC medium at a concentration of 3x104 
cells per well in a coated 24 well-plate. After 
0.5, 1, 2, 4, 8 and 24 hours the adherence of 
the cells was examined microscopically.
To evaluate the transendothelial monolayer-
permeability, HUVEC were plated in a coated 
transwell (Corning BV; 0.4 µm pore size, 6.5 
mm diameter, polyester filters) at a density of 
1.2x104 cells per well. In the lower compart-
ment, 1 ml of HUVEC medium was added. Two 
days after seeding a confluent monolayer had 
formed, non-adhering cells were removed and 
the medium was replaced with 200 µl of 50, 5, 
0.5 or 0 µg/ml Cilengitide together with 50 µl 
fluorescein (0.5 mg/ml, Sigma). At 0.25, 0.5, 1, 
2, 4, 8 and 24 hours, 50 µl medium of the low-
er chamber was taken and fluorescence was 
measured at excitation 490 nm and emission 
530 nm, in a Victor2 1410 multilabel counter 
(Wallac). Induction of permeability was indicat-
ed by a higher concentration of fluorescein in 
the lower chamber of the transwell relative to 
untreated controls.
Statistical analysis. In vitro results were 
evaluated for statistical significance with the 
Mann-Whitney U-test. Synergy of Cilengitide, 
melphalan and TNF was tested as described be-
fore [25]. Briefly, the tumor-response-ratio was 
calculated by dividing the tumor volume at day 
5 and 8 with the volume at day 0. The ratio 
of Cilengitide alone plus melphalan alone was 
compared with the ratio of Cilengitide plus mel-
phalan (Mann-Whitney U-test). Response rates 
were subjected to analysis-of-variance and post 
hoc to the least significant difference multiple 
comparison test. All statistical tests were two-
sided and P values less than 0.05 were con-
sidered as statistically significant. Calculations 
were performed on a personal computer using 
GraphPad Prism v3.0 and SPSS v11.0 for Win-
dows 2000.
RESULTS
The combination of Cilengitide and mel-
phalan results in a strong tumor response. 
The anti-vascular agent TNF is applied only dur-
ing the brief period of perfusion during ILP, and 
yet, it strongly enhances the antitumor activ-
ity of melphalan [14,26]. Based on this experi-
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ence, we investigated whether the antiangio-
genic agent Cilengitide might also work in such 
a short time scale. To test the activity of Cilen-
gitide in a combination with chemotherapy 
for the treatment of tumors in ILP, rats bearing 
established and rapidly growing syngeneic soft 
tissue sarcoma in the hind limb were perfused 
with Cilengitide combined with melphalan and 
TNF under different regimens (Table 1 and Fig. 
2). In the first set of experiments Cilengitide 
was administered to animals pre- and post-ILP 
by i.p injection and during ILP with melphalan, 
to maximally saturate available αV integrins. 
This protocol gave a response rate (RR) of 77%, 
with 8/13 complete and 2/13 partial respond-
ers (group 13), with a response on tumor vol-
ume for at least 12 days. This treatment was 
much more effective than ILP with melphalan 
plus TNF (group 14, RR of 25%) and ILP with 
melphalan (group 10, RR of 8%) without any 
addition of Cilengitide. ILP and i.p. treatment 
with Cilengitide alone (group 4, RR of 0%) had 
no effect (statistics are presented in Supple-
mentary Table 1 and Supplementary Table 
2). We could show a statistically significant syn-
ergy between Cilengitide (when injected i.p. 
and given during ILP) and melphalan (P < 0.05; 
Table 1. Treatment groups and tumor response of BN175 soft tissue sarcoma bearing rats after ILP with Ci-
lengitide, TNF and melphalan.
Groupa Therapy regimen Tumor responsed
i.p injectionsb in perfusatec PD SD PR CR RR n
1 Sham Sham 9 1 0 10
2 Sham Cilengitide 4 0 4
3 Cilengitide Sham 7 0 7
4 Cilengitide Cilengitide 14 0 14
5 Sham TNF 9 1 1 1 17% 12
6 Cilengitide TNF 5 0 5
7 Sham Cilengitide+TNF 6 0 6
8 Cilengitide Cilengitide+TNF* 5 0 5
9 Cilengitide Cilengitide+TNF 10 2 16% 12
10 Sham melphalan 9 2 1 8% 12
11 Cilengitide melphalan 5 1 17% 6
12 Sham Cilengitide+melphalan 3 0 3
13 Cilengitide Cilengitide+melphalan 2 1 2 8 77% 13
14 Sham TNF+melphalan 7 2 1 2 25% 12
15 Cilengitide TNF+melphalan 3 3 100% 6
16 Sham Cilengitide+TNF+melphalan 2 1 2 1 50% 6
17 Cilengitide Cilengitide+TNF+melphalan 2 0 3 8 85% 13
18 Cilengitide before ILP Cilengitide+TNF+melphalan 3** 1 1 20% 5
19 Cilengitide after ILP TNF+melphalan 3 1 1 40% 5
Note: animals were treated as depicted in the time line in figure 1.
a Group numbers refer to table 1.
b Rats were injected i.p. 2 hours before and 3 hours after ILP with Cilengitide as described in the experimental proce-
dures.
c ILP was started with sham or Cilengitide and after 10 min melphalan or TNF was added.
d Tumor response is classified as described in the experimental procedures: PD, progressive disease; SD, stable disease; 
PR, partial response; CR, complete response in absolute numbers; RR, response rate (PR plus CR) in percentage.
* In this group TNF was added directly with Cilengitide at the beginning of the perfusion. In contrast with the other 
groups, in which TNF and/or melphalan was present for 20 min, TNF was present in this group for the full 30 min in the 
perfusate.
** Although initially a response was observed rapid regrowth occurred showing PD at day 10.
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Figure 2. Tumor response in rats treated with Cilengitide in combination with melphalan-based isolated limb 
perfusion. (a) BN175 tumor growth was measured daily after treatment as depicted in figure 1. In the left graphs all rats 
received Cilengitide (Cil) as i.p. injection and as bolus in the perfusate. In right graphs different regiments of Cilengitide 
with melphalan were used. Tumor volumes of individual animals at 5 days (b) and 8 days (c) after i.p. with Cilengitide and 
ILP with Cilengitide, melphalan (M or Mel) and TNF (T). These results show that Cilengitide-melphalan combination results 
in a strong tumor response. Data points represent tumor volume ± SD; number of rats is indicated in table 1.
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Cilengitide or melphalan given alone versus Ci-
lengitide plus melphalan treatment).
In a second set of experiments Cilengitide 
was only administered during ILP or as an i.p. 
injection before and after the ILP only. Injection 
of Cilengitide i.p. improved tumor response in a 
melphalan-based ILP (group 11) to 17%, while 
administration only during ILP with melphalan 
(group 12) did not affect tumor-response. In a 
third set of experiments Cilengitide was given in 
combination with a melphalan plus TNF-based 
ILP. Addition of Cilengitide to a TNF-plus-mel-
phalan ILP resulted in a very good response rate 
of 85% (group 17). To obtain the best response 
Cilengitide had to be given i.p. before and after 
ILP and in the perfusate during the perfusion. 
In contrast to the combination with melphalan, 
Cilengitide had a much weaker impact on TNF-
based perfusion (groups 7-9), suggesting that 
Cilengitide and TNF may both affect the same 
target, namely tumor endothelial cells, each to 
an already maximal extend. Treatment of the 
rats with Cilengitide alone (i.e. i.p. or during 
ILP, group 2, 3 and 4) had no effect on tumor 
progression. Importantly, a perfusion with mel-
phalan plus TNF for the full 30 minutes as pre-
viously routinely conducted, results in a tumor 
response of around 75%, indicating that the 
time frame of exposure affects response rate. 
No gross toxicity related to the applied high 
systemic and local doses of Cilengitide was 
seen (data not shown).
Supplementary Table 1. Statistical analysis of tumor response
Groupa Therapy regimen Groupa
i.p injectionb in perfusatec 4 9 13 17
1 Sham Sham 0.237 0.633 0.000 0.000
4 Cilengitide Cilengitide 0.134 0.000 0.000
9 Cilengitide Cilengitide +TNF 0.002 0.002
13 Cilengitide Cilengitide + melphalan 0.930
17 Cilengitide Cilengitide + TNF + melphalan
Note: animals were treated as depicted in the time line in figure 1.
a Group numbers refer to table 1.
b Rats were injected i.p. 2 hours before and 3 hours after ILP with Cilengitide as described in the experimental proce-
dures
c ILP was started with sham or Cilengitide and after 10 min melphalan or TNF was added
Supplementary Table 2. Statistical analysis of tumor volumes
Groupa Therapy regimen Groupd
i.p injectionb in perfusatec 4 9 10 11 12 13 17
4 Cilengitide Cilengitide X 0.198 0.005 0.058 0.078 0.000 0.000
9 Cilengitide Cilengitide+TNF 0.504 X 0.204 0.512 0.564 0.000 0.014
10 Sham melphalan 0.002 0.049 X 0.925 1.000 0.002 0.004
11 Cilengitide melphalan 0.039 0.190 0.615 X 0.796 0.007 0.022
12 Sham Cilengitide+melphalan 0.059 0.312 0.815 1.00 X 0.042 0.069
13 Cilengitide Cilengitide+melphalan 0.000 0.012 0.060 0.188 0.251 X 0.939
17 Cilengitide Cilengitide + TNF + mel-
phalan
0.000 0.000 0.073 0.114 0.122 0.398 X
Note: animals were treated as depicted in the time line in figure 1.
a Group numbers refer to table 1.
b Rats were injected i.p. 2 hours before and 3 hours after ILP with Cilengitide as described in the experimental proce-
dures
c ILP was started with sham or Cilengitide and after 10 min melphalan or TNF was added.
d Upper right corner statistical analysis at day 5 and lower left corner at day 8.
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The combination of Cilengitide and mel-
phalan results in loss of endothelial integ-
rity and hemorrhage. While administration 
of melphalan alone during the ILP had mini-
mal effect on the tumor-associated vascula-
ture, combined administration of Cilengitide 
and melphalan dramatically affected the en-
dothelial integrity of tumor blood vessels. Im-
munohistological analysis of perfused tumors, 
removed immediately after ILP, revealed a clear 
disruption of the endothelial layer. Endothelial 
cells detached from the vessel wall in tumors 
treated with Cilengitide in combination with 
melphalan, while administration of melphalan 
alone had no such effect (Fig. 3a and Fig 3b). 
These results were confirmed by TUNEL stain-
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Figure 3. Histopathology of BN175 tumor after Cilengitide treatment in combination with a melphalan-based 
ILP. (a) Tumors were excised immediately after treatment for histological evaluation. Left panel, H&E staining was per-
formed on tumors of all groups and showed no effect on tumor cells and tumor vasculature (open arrow) when animals 
were treated with sham, melphalan or TNF alone. Confirming previous results, ILP with melphalan plus TNF resulted in 
marked vascular damage (arrow head), which was accompanied by hemorrhage and edema (asterisk). Right panel, ad-
ministration of Cilengitide alone had no noticeable effect on tumor histology or on tumor-associated vasculature (open 
arrow). However, when Cilengitide was combined with melphalan, TNF or melphalan plus TNF massive vascular destruc-
tion (open arrow) and hemorrhage (asterik) were observed. (b) Damage to the tumor-associated vasculature is visualized 
by CD31 staining. Tumors were removed at the end of the treatment, frozen and processed for immunohistochemistry as 
described in the experimental procedures. Perfusion with Cilengitide alone had marginal effect on tumor vessel integrity 
or diameter (closed arrow), while treatment with a combination of Cilengitide with melphalan, TNF or melphalan plus TNF 
resulted in profound loss of vascular integrity (open arrow) and widening of the vascular lumen (arrow head). Endothelial 
cell apoptosis is shown after treatment with Cilengitide plus melphalan and TNF by TUNEL staining. The photograph 
(lower right panel) demonstrates apoptotic tumor cells (green), endothelial cells (red) and apoptotic endothelial cells (yel-
low, arrow). Scale bar apply for all images, 100 µm. (See color section for a full-color version.)
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ing showing apoptosis of intratumoral en-
dothelial cells when Cilengitide was adminis-
tered (Fig. 3b, lower right panel). Large areas 
of tumor necrosis were observed in all combi-
nation protocols involving Cilengitide; Cilengit-
ide with melphalan, Cilengitide with TNF and 
Cilengitide with melphalan plus TNF. Although 
ILP with TNF plus Cilengitide resulted in abun-
dant tumor necrosis there was no translation in 
a clinical tumor response. These observations 
show that combination with a chemotherapeu-
tic agent is crucial for achieving clinical tumor 
regression in this model. Minimal apoptosis or 
hemorrhage was found in non-tumor tissue 
(data not shown).
The addition of Cilengitide increases in-
tratumoral melphalan concentrations. To 
investigate whether improved tumor response 
to melphalan in combination with Cilengitide 
involved enhanced drug delivery in the tumor, 
we measured intratumoral levels of melphalan. 
After ILP with melphalan alone on average 0.6 
µg ± 0.2 melphalan per g tumor tissue was 
found, which was augmented 3.2 (1.9 ± 0.1 
µg/g; P < 0.01) to 7-fold (4.2 ± 2.0 µg/g; P < 
0.05) by the addition of Cilengitide, depending 
on dosing schedule (Fig. 4a). Cilengitide did 
not affect the accumulation of melphalan in the 
muscle tissue of the perfused leg. These results 
are consistent with our previous observations 
in TNF-based ILP, whereby TNF increased mel-
phalan accumulation in tumor tissue through 
an effect on vascular permeability, while leav-
ing permeability in normal tissue unaffected 
[27].
The combination with melphalan has no 
influence on the systemic pharmacokinet-
ics of Cilengitide. To evaluate the systemic 
Cilengitide levels, Cilengitide was administered 
i.p. before ILP and in the perfusate during ILP in 
combination with melphalan and/or TNF. Blood 
samples were collected during treatment as 
depicted in figure 1. Systemic Cilengitide lev-
els reached around 20 µg/ml (35 µM) within 
10 min after i.p. administration and continued 
to rise to approximately 40 µg/ml (70 µM) in 
the first hour (Fig. 4b). Thereafter systemic 
Cilengitide levels in serum dropped with an 
elimination half-life of 2.1 hours. The adminis-
tration of Cilengitide during ILP did not affect 
systemic levels as a relatively low concentration 
was used and a thorough washout was applied 
at the end of the perfusion. Data fitted a one-
phase exponential decay with a goodness of 
fit of 0.93. The ILP, whether with Cilengitide, 
TNF, melphalan or combinations thereof, did 
not influence the systemic pharmacokinetics of 
Cilengitide.
Cilengitide disrupts cell adhesion mediated 
by αVβ3 and αVβ5 integrins and increases 
cell death and permeability in vitro. In con-
trast to the well-characterized integrin profiles 
of endothelial cells, BN175 rat sarcoma have yet 
to be characterized for their adhesion proper-
ties. We investigated the interaction of BN175 
cells with αV ligands vitronectin, fibronectin 
and fibrinogen, and with non-αV ligands col-
lagens type I and IV and laminin, and the sensi-
tivity of this attachment to Cilengitide. BN175 
cells attached and spread strongly on vitronec-
tin, fibronectin and laminin I, but poorly on col-
lagens and fibrinogen. Even when the integrin 
activator Mn2+ was added, collagen adhesion 
remained on background and adhesion to vit-
ronectin increased strongly. Addition of Mn2+ 
caused only a weak increase of adhesion to fi-
brinogen (Fig. 5a). This profile indicates that 
αVβ5 is the principal vitronectin receptor, and 
that low amounts of αVβ3 in a weakly activat-
ed state are also present on BN175 cells. Adhe-
sion to vitronectin was strongly inhibited by Ci-
lengitide with an IC50 of approximately 2 µg/ml 
(4 µM), and by the related analogue c(RGDfV) 
with an IC50 of 9 µg/ml (16 µM) (Fig. 5b). These 
data are consistent with αVβ5 dependent ad-
hesion to vitronectin [23,28]. Adhesion on fi-
bronectin was likely principally mediated by 
α5β1. Laminin I adhesion was likely mediated 
by α6β1. Lack of adhesion to collagen reveals 
no active α1β1 or α2β1 receptors.
To test whether the observed synergy be-
tween melphalan and Cilengitide was a direct 
effect on endothelial cells or tumor cells, cul-
tured endothelial cells (i.e. HUVEC) and BN175 
cells were exposed to Cilengitide and melphalan 
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or TNF, and combinations thereof. The addition 
of melphalan to Cilengitide increased cell death 
of both BN175 cells and HUVEC (Fig. 5c), but 
addition of TNF had no effect (Supplementary 
Fig. 1a). Endothelial cells on vitronectin were 
more sensitive to Cilengitide than cells cultured 
on fibronectin. αV integrins, which mediate at-
tachment to vitronectin, and especially αVβ3, 
provide a survival signal to endothelial cells 
which, when disrupted, may stimulate their 
apoptosis [2]. Endothelial cells grown on the 
matrix components vitronectin and fibronectin 
and exposed to Cilengitide underwent apopto-
sis and necrosis, especially when grown on the 
obligate αV ligand vitronectin, closely correlat-
ing with the above-described assay (P < 0.01; 
Supplementary Fig. 1b and Supplementary 
Fig. 1c). This cell death was secondary to cell 
detachment, since cells that remained adher-
ent during Cilengitide treatment stained nega-
tive for apoptosis (YO-PRO-1), and YO-PRO-1 
positive cells were only observed among al-
ready detached cells, indicating that cell-death 
followed rather then preceded Cilengitide-in-
duced detachment (data not shown). As a dis-
ruption of the vascular lining was observed in 
vivo following Cilengitide-ILP by histology we 
speculated that the increase in melphalan in 
the tumor was a result of an improved intratu-
moral delivery.
To test whether Cilengitide affected en-
dothelial permeability directly, HUVEC mono-
layers were exposed to Cilengitide. Within 30 
min, a time frame relevant for the ILP, endothe-
lial permeability increased 3.5-fold when cul-
tures were exposed to 50 µg/ml Cilengitide, 
which is below the maximum theoretical level 
reached during the ILP (100 µg/ml) (P < 0.05; 
no i.p. Cil; ILP Mel (group 10)
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Figure 4. Tumor accumulation and phamacokinetics (a) Tumoral accumulation of melphalan after treatment with 
Cilengitide and melphalan-based isolated limb perfusion. Immediately after the end of the ILP and washout, tumor and 
muscle of the perfused limb (right) and non-perfused limb (left) were excised, weighted and snap-frozen. Melphalan 
content was measured as described in the experimental procedures. Both addition of Cilengitide to the perfusion as well 
as i.p. pre-treatment augmented accumulation of melphalan in the tumor. Accumulation in adjacent skin was not signifi-
cantly affected. Columns represent µg melphalan per gram tissue ± SD of 6 individual animals; *, P < 0.05 versus group 
10; **, P < 0.001 versus group 10. (b) Pharmacokinetics of Cilengitide in serum of rats during treatment as depicted in 
figure 1. Blood samples were collected and Cilengitide concentration determined as described in the experimental proce-
dures. Cilengitide was injected 2 hours before and 3 hours after the ILP. Hexed region indicate perfusion period. Serum 
concentrations increase sharply after i.p. injection followed by a single phase clearance with a half life of 2.1 hours. Perfu-
sion with Cilengitide did not affect Cilengitide levels in the blood due to the isolated procedure and thorough washout. 
Also addition of TNF, melphalan or TNF plus melphalan did not affect Cilengitide pharmacokinetics. Data points represent 
µg Cilengitide per ml ± SD of 3 individual animals.
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Figure 5. In vitro effects of Cilengitide on BN175 tumor cells and HUVEC. (a) Attachment characteristics of BN175 
cells. BN175 cells were allowed to attach for 1 hour to surfaces coated with the indicated concentrations of ECM mole-
cules vitronectin, fibronectin, fibrinogen, laminin, collagen type I or collagen type IV in RPMI or RPMI with supplemented 1 
mM Mn2+. (b) BN175 cells were allowed to attach for 1 hour to vitronectin in the presence of the indicated concentrations 
of Cilengitide or c(RGDfV). Data points represent cell attachment (100% cell attachment was equivalent to OD 1.5) ± SEM 
of 3 individual experiments in duplicate. (c) BN175 tumor cells and HUVEC were exposed to Cilengitide alone or combined 
with melphalan for a period of 72 hours and cell content was evaluated. A dose response of Cilengitide on BN175 cells 
was observed which appeared to interact with melphalan, showing higher toxicity of melphalan when Cilengitide was 
added. Comparable activity was observed when HUVEC were exposed to Cilengitide combined with melphalan. HUVEC 
appeared more sensitive to Cilengitide when grown on vitronectin compared to fibronectin. Data points represent cell 
growth ± SEM of at least 3 individual experiments in duplicate. (d) HUVEC were cultured as a confluent monolayer in a 
transwell chamber and exposed to Cilengitide. Permeability of the endothelial layer was determined by measuring the 
trans-endothelial diffusion of fluorescein over time. Exposure of endothelial cells to Cilengitide augmented vascular per-
meability within 30 min especially when cells were cultured on vitronectin. Columns represent percentage permeability 
compared to control treated cells ± SEM of at least 3 individual experiments in duplicate; *, P < 0.05 versus control. (e) 
HUVEC seeded on vitronectin, were exposed to Cilengitide directly (non-adherent) or after 24 hours of culturing (adher-
ent) and morphology was studied 1 hour after Cilengitide exposure. Cilengitide caused HUVEC detachment in adherent 
cells and also inhibited adhesion. Scale bar apply for all images, 100 µm.
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Supplementary Figure 1. Effect of Cilengitide on BN175 tumor cells and HUVEC. (a) BN175 tumor cells and HUVEC 
were exposed to Cilengitide combined with TNF for a period of 72 hours and cell content was evaluated. TNF appeared to 
have no direct effect on the BN175 cells and HUVEC or the toxicity profile of Cilengitide. Data points represent cell growth 
± SEM of at least 3 individual experiments in duplicate. (b) Representative FACS data of Cilengitide-induced apoptosis 
in HUVEC grown on vitronectin or fibronectin in a time frame of 5 and 60 min. The number in each quadrant represent 
percentage cells. (c) Quantification of apoptosis (Annexin V positive cells) and necrosis (Annexin V and PI positive cells) 
is depicted. More apoptosis and necrosis after addition of Cilengitide (Cil) was observed when HUVEC were grown on 
vitronectin. Columns represent cell population ± SEM of 3 individual experiments in duplicate; *, P < 0.01 versus 0 µg/ml 
Cilengitide of the same time period.
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Fig. 5d). Permeability continued to increase to 
a maximum of 5-fold in 1 hour. At a Cilengit-
ide concentration of 0.5 µg/ml we found that 
the endothelial cell morphology was already 
changed, and that cells detached when grown 
on vitronectin (Fig. 5e). HUVEC that were ex-
posed to Cilengitide directly did not adhere to 
vitronectin, confirming that vitronectin recep-
tors on HUVEC were fully inhibited by Cilen-
gitide (Fig 5e, Supplementary Fig. 2 and 
Supplementary Table 3).
DISCUSSION
The tumor vasculature is considered as an ex-
cellent target in cancer treatment. Tumor en-
dothelial cells have a distinctive phenotype that 
allows their targeting to achieve antitumor 
effects directly or in combination with che-
motherapy. Integrin αVβ3 and αVβ5 are highly 
expressed on activated endothelial cells of the 
tumor neovasculature, while their expression is 
low on quiescent endothelia. Therefore, these 
integrins have been proposed as an attractive 
therapeutic target [3,29-31]. Prevention of the 
binding of the integrins αVβ3 and αVβ5 to ECM 
ligands can result in endothelial cell apoptosis 
[32,33]. Further support for the importance of 
αV-integrin on tumor endothelia comes from 
studies employing specific antibodies. The anti-
αV-integrin antibody 17E6 inhibits melanoma 
development [23], while the αVβ3-antibody 
LM609 inhibits growth and invasion of tu-
mors and inhibits angiogenesis in a CAM as-
say [3,4,29]. Animal studies demonstrated that 
addition of Cilengitide to radioimmunotherapy 
improved treatment efficacy in an experimental 
breast cancer model, apparently by targeting 
Adherent cells - gelatin Adherent cells - gelatin Non adherent cells - gelatin Non adherent cells - gelatin
0.5 µg/ml Cilengitide 0 µg/ml Cilengitide 0.5 µg/ml Cilengitide 0 µg/ml Cilengitide
Adherent cells - fIbronectin Adherent cells - fIbronectin Non adherent cells - fibronectin Non adherent cells - fibronectin
0.5 µg/ml Cilengitide 0 µg/ml Cilengitide 0.5 µg/ml Cilengitide 0 µg/ml Cilengitide
Supplementary Figure 2. Effect of Cilengitide on the adherence of HUVEC. HUVEC seeded on fibronectin and 
gelatin, were exposed to Cilengitide directly (non-adherent) or after 24 hours of culturing (adherent) and morphology 
was studied 1 hour after Cilengitide exposure. Cilengitide caused some HUVEC detachment in adherent cells and also 
inhibited adhesion on fibronectin coating but had no effect on the adherence on gelatin. Scale bar apply for all images, 
100 µm.
Supplementary table 3. Percentage non-adherent cells on different coatings.
Coating Cilengitide (µg/ml)
50 5 0.5 0
Vitronectin 99.5 ± 0.9* 85.5 ± 9.2* 77.0 ± 29* 11.2 ± 0.5
Fibronectin 55.3 ± 13.9* 36.7 ± 20.1 30.7 ± 7.4 17.1 ± 4.0
Gelatin 28.0 ± 0.5 21.4 ± 2.7 16.6 ± 4.0 20.4 ± 3.1
Note: HUVEC were plated in Cilengitide containing HUVEC medium in wells coated with different ECM. One hour after 
plating cells photographs were taken and adherent and non-adherent cells were counted. Data represent percentage 
non-adherent cells ± SD of 3 individual experiments. *, P < 0.05 versus 0 µg/ml Cilengitide.
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both tumor cells and endothelia, since apop-
tosis of both populations was increased in the 
combination groups [34,35]. Furthermore, 
treatment with a related αVβ3 antagonist di-
minished the severity of arthritis, in associa-
tion with increased endothelial cell apoptosis 
in angiogenic blood vessels [36], and blocked 
neo-angiogenesis in ophthalmological models 
[37,38]. Cilengitide is currently being evaluated 
in clinical phase I/II trials for glioblastoma acute 
myeloid leukaemia, metastatic melanoma and 
prostate cancer [39-41].
As Cilengitide can interfere with endothelial 
cell adhesion and trigger endothelial cell apop-
tosis in neovasculature, we tested whether its 
addition to a melphalan-based ILP treatment 
of established solid tumors could improve tu-
mor response. Here we demonstrate that a 
Cilengitide-melphalan combination treatment 
results in a strong antitumor response with a 
77% overall response rate (partial plus com-
plete responders) while treatment with Cilen-
gitide or melphalan alone resulted respectively 
in a very limited response rate of 0 and 8%. 
Many other studies have shown that blockade 
of αV-integrins can slow tumor growth, usu-
ally in immune-suppressed xenograft models, 
and typically in multiple repeat doses, usually 
daily [42-44]. In marked contrast, in this study, 
large, well established, syngeneic, orthotopic 
tumors were exposed only briefly to Cilengitide 
in combination with melphalan. The synergistic 
effect of Cilengitide on the classical alkylating 
agent melphalan in this short term, and argu-
ably highly realistic model were notable. Our 
results show that pre-loading the animals with 
Cilengitide is crucial for synergy, suggesting 
that saturation of the integrins may pre-sensi-
tize target cells to the cytotoxic activity of mel-
phalan. Our parallel histological studies show 
that Cilengitide rapidly disrupts the endothe-
lia of the tumor vasculature, while leaving the 
normal vasculature intact, resulting in massive 
intratumoral hemorrhage. In vitro we observed 
Cilengitide-induced anchorage-dependent 
cells death (anoikis), in line with previous re-
sults [42]. These observations are consistent 
with our previous results using TNF-based iso-
lated perfusions [26]. Moreover, as seen when 
TNF was used in ILP, addition of Cilengitide also 
augmented the accumulation of melphalan 
within the tumor [14,15]. At least two mecha-
nisms induced by Cilengitide can be considered 
for this effect: a) an increased leakiness of the 
tumor vasculature or b) an improved perfusion 
of the tumor. The first hypothesis is supported 
by the intratumoral hemorrhage observed in 
vivo in Cilengitide-treated animals, and by the 
increased permeability of an endothelial mono-
layer that is induced by Cilengitide in vitro. For 
the second hypothesis there is to date no ex-
perimental support.
The in vitro experiments described here indi-
cate that a direct effect of Cilengitide on tumor 
cells may also contribute to its antitumor ef-
fect Tumor cell kill is observed in vitro at a rela-
tive low Cilengitide concentration. As single 
agent Cilengitide inhibits brain-tumor growth 
[44] and has been reported to stabilize disease 
progression in advanced head and neck cancer 
[45]. Effects on endothelial cells may also affect 
local tumor progression. Cilengitide can inhibit 
endothelial cell invasion in 3D ECM gels, and 
vascular endothelial growth factor and basic fi-
broblast growth factor-induced differentiation 
[28]. However, in our study we do not observe 
a direct effect of Cilengitide on tumor growth. 
This might be due to the unique and short ex-
posure of the tumor to Cilengitide in our ex-
perimental model, in contrast to the repeated/
prolonged exposure in other studies. The his-
tology clearly shows that treatment with Ci-
lengitide alone had no effect on tumor cells or 
endothelial cells. These results are in contrast 
with the in vitro observation showing detach-
ment of endothelial cells by Cilengitide. We 
hypothesize that either the effect of Cilengit-
ide is milder in vivo due to reduced dose level 
and duration of exposure, or due to the en-
gagement by endothelial cells and tumor cells 
of integrins other than αVβ3 and αVβ5. Our 
in vitro data shows, however, that Cilengitide 
enhances the cytotoxic activity of melphalan, 
which may very well explain the observed tu-
mor response in vivo.
In conclusion, our results show that addi-
tion of Cilengitide augments the activity of 
co-administered melphalan in the local treat-
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ment of established experimental sarcoma. 
This increased antitumor effect may involve at 
least three Cilengitide-dependent effects: a) 
increased accumulation of melphalan in the 
tumor, b) sensitization of tumor cells to the an-
titumor effect of melphalan, c) sensitization of 
endothelial cells to the cytotoxic activity of mel-
phalan. These results also corroborate a critical 
role of integrin αVβ3 and αVβ5 for the integrity 
and survival or angiogenic tumor vessels. Previ-
ously we reported comparable results with the 
cytokine TNF in combination with melphalan. 
Thus the present data indicate that Cilengitide 
may substitute for the biological activity of TNF 
in this therapy. Since Cilengitide, in contrast to 
TNF, has no dose limiting toxicity in patients 
[21] the strong sensitizing effect combined 
with low toxicity indicates a great potential for 
Cilengitide, in systemic treatment settings in 
combination with chemotherapy.
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ABSTRACT
Tumor response is strongly enhanced by addition of tumor necro-
sis factor-alpha (TNF) to chemotherapy in local-regional perfusion. 
TNF primarily targets the endothelial lining of the tumor-associated 
vasculature, thereby improving permeability of the vascular bed. 
This augments uptake of the co-administered chemotherapeutic 
drug in the tumor. In vitro, however the high-dose TNF used had 
no direct effect on endothelial cells, indicating that other factors, 
most likely TNF-induced, are involved in the antivascular activi-
ties observed in vivo. This is supported by in vivo studies in our 
laboratory in which depletion of leukocytes resulted in loss of 
the antivascular activity of TNF. The present study examined the 
role of peripheral blood mononuclear cells (PBMC) on endothe-
lial cells by exposing them to TNF, interferon-gamma (IFN) and 
PBMC. We observed morphological changes of the endothelial 
cells when exposed to TNF in combination with IFN. Endothelial 
cells became elongated and gaps between the cells appeared. 
Addition of PBMC enhanced these alterations even further. The 
endothelial layer became disrupted with highly irregularly shaped 
cells displaying large gap formations. PBMC also contributed to 
an increased permeability of the endothelial layer without aug-
menting apoptosis. Replacing PBMC by interleukin-1beta (IL-1ß) 
produced similar effect with regard to inhibition of cell growth, 
morphological changes and induction of apoptosis. Blocking IL-
1ß with a neutralizing antibody diminished the effects inflicted of 
PBMC. These observations indicate that endogenously produced 
IL-1ß by primed PBMC plays an important role in the antivascular 
effect of TNF.
INTRODUCTION
The success of the clinical isolated limb per-
fusion programs to treat in-transit melanoma 
metastases and limb threatening soft tissue 
sarcomas with a combination of tumor necrosis 
factor-alpha (TNF) and chemotherapeutic drugs 
has launched investigations into the mecha-
nisms behind the synergistic antitumor ef-
fects observed [1-3]. In our laboratory we have 
demonstrated that addition of TNF leads to an 
enhanced accumulation of melphalan or dox-
orubicin in the tumor in various isolated limb 
perfusion (ILP) models [4,5]. In the systemic 
setting, TNF enhances the tumor accumulation 
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of long circulating liposomal drugs, resulting in 
synergistic antitumor effects [6,7].
Clinical and experimental studies demon-
strate that TNF primarily targets the endothelial 
lining of the tumor-associated vasculature (TAV) 
[8,9]. Angiograms of patients receiving a TNF-
based ILP demonstrated complete disruption of 
the TAV. Histological studies after ILP showed 
extravasation of erythrocytes and hemorrhagic 
necrosis, resulting from endothelial cell degen-
eration and loss of endothelial integrity, which 
could be linked to high-dose TNF that is used 
in the ILP [10]. Strikingly, also in low-dose sys-
temic treatment TNF dramatically improved tu-
mor response without obvious damage to the 
endothelial lining. Taken together, these results 
indicate that TNF-induced vascular permeability 
was critical for the tumor response observed.
The response of endothelial cells to TNF and 
another important cytokine; interferon-gamma 
(IFN) has been extensively studied. These cytok-
ines are known to inhibit the proliferation of 
endothelial cells [11,12], to increase the per-
meability of the endothelial layer [13], to inhibit 
the αVß3 mediated endothelial cell adhesion to 
the extracellular matrix [14], to augment neu-
trophil transmigration [15,16] and to induce 
morphological changes [17] in vitro. However, 
in vitro TNF inflicts only minor changes in en-
dothelial cells, and tumor cells appear quite in-
sensitive to TNF. Also, in vivo, TNF alone in high 
concentrations does not induce tumor regres-
sion after an ILP.
An important in vivo observation is the ne-
cessity of leukocytes during TNF-based ILP to 
obtain the typical synergistic tumor response. 
This could also explain the lack of response 
of endothelial cells to TNF alone in vitro [18]. 
These observations place interaction of TNF 
with leukocytes at the center of the synergistic 
tumor response observed. In this study, we in-
vestigate the interaction of TNF and peripheral 
blood mononuclear cells (PBMC) in mediating 
endothelial cell morphology changes, which 
could explain the synergy observed. In particu-
lar we focus on PBMC-produced factors, which 
contribute to the increased permeability of the 
endothelial cell lining.
EXPERIMENTAL PROCEDURES
Agents. Recombinant human Tumor necrosis 
factor-alpha (TNF) and recombinant human 
Interferon-gamma (IFN) were kindly provided 
by Dr. G. Adolf (Boehringer Ingelheim GmbH). 
TNF had a specific activity of 5x107 U/mg as 
determined in the murine LM cell assay [19]. 
Endotoxin levels were < 1.25 units (EU) per mg 
protein. IFN had a specific activity of 2.5x107 
U/mg as determined in an HLA-DR assay. Re-
combinant human interleukin-1beta (IL-1ß) 
was purchased from Peprotech EC Ltd. As de-
termined by stimulation of thymidine uptake 
by murine C3H/HeJ thymocytes, the ED50 was 
≤ 0.1 ng/ml, corresponding to a specific activ-
ity of ≥ 1x107 U/mg. Endotoxin levels were less 
than 1 EU per µg protein. Goat anti human 
interleukin-1beta (anti IL-1ß) was purchased 
from R&D systems. As determined by the LAL 
method, endotoxin levels were less than < 0.01 
EU per µg. Melphalan (Alkeran, 50 mg per vial) 
was purchased from GlaxoSmithKline BV and 
diluted in phosphate buffered saline to a con-
centration of 2 mg/ml. Doxorubicin (Adriablas-
tina) was purchased from Pharmachemie BV in 
a concentration of 2 mg/ml.
Cells and cultured conditions. Human um-
bilical vein endothelial cells (HUVEC) were 
isolated by collagenase digestion using the 
method described by Jaffe et al [20]. Each iso-
late was derived from an individual umbilical 
vein and used for experiments at passage 5. 
HUVEC were cultured in HUVEC medium con-
taining human endothelial-serum free medium 
(Invitrogen), 20% heat inactivated newborn 
calf serum (Cambrex), 10% heat inactivated 
human serum (Cambrex), 20 ng/ml human re-
combinant basic fibroblast growth factor (Pep-
rotech EC Ltd), 100 ng/ml human recombinant 
epidermal growth factor (Peprotech EC Ltd) in 
fibronectin (Roche Diagnostics) coated flasks. 
HUVEC had the characteristic cobblestone mor-
phology and tested positive for CD31. Human 
peripheral blood mononuclear cells (PBMC) 
were isolated from healthy donors using the 
Vacutainer CPT Mononuclear Cell Preparation 
Tubes with sodium heparin (Becton Dickinson). 
PBMC were washed with phosphate buffered 
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saline and counted with trypan blue to deter-
mine the viable cell concentration. PBMC, at a 
final concentration of 120x104 PBMC/ml, were 
used in all experiments.
Assessment of toxicity towards endothe-
lial cells. HUVEC were plated to 96 well mul-
tiplates (Corning BV), coated with fibronectin, 
at a final concentration of 6x103 cells per well 
and allowed to grow for 24 hours. TNF, IFN, 
doxorubicin and melphalan were added to the 
wells and incubated for 72 hours. The range 
of final drug concentration was 0.6 ng/ml - 15 
µg/ml. The endothelial cells were also incu-
bated for 72 hours with combinations of cy-
tokines and cytotoxic agents. As a control, cells 
were incubated with HUVEC medium alone. 
Growth of endothelial cells was measured us-
ing the sulphorhodamine B protein stain assay 
(SRB) according to the method of Skehan [21]. 
Briefly, cells were washed with PBS, incubated 
with 10% trichloric acetic acid (1 hour, 4ºC) 
and washed in distilled water. Cells were then 
stained for 15 min with SRB (Sigma), washed 
with 1% acetic acid and allowed to dry. Protein 
bound SRB was dissolved in 10 mM Tris buf-
fer and optical density (O.D.) was measured at 
540 nm. Cell growth was calculated using the 
formula: percentage cell growth = (O.D. test 
well/O.D. control well) x 100 percent. HUVEC 
exposed to the concentrations of TNF and IFN 
indicated in the results section were co-incu-
bated with PBMC. Prior to addition of the drug, 
a plate (0 hour) was washed, fixated and used 
as 100% growth. Every 24 hours after addi-
tion of the agents, up to 144 hours, a plate 
was washed carefully 3 times to remove PBMC, 
fixated and stained using the SRB method. In 
order to test the necessity of cell-cell interac-
tion between endothelial cells and PBMC, a 
transwell system was used. HUVEC were plated 
in fibronectin coated 24 well multiplates (Corn-
ing BV) at a final concentration of 3x104 cells 
per well and allowed to grow for 24 hours. A 
transwell with pores of 0.4 µm (Millipore) was 
placed into 600 µl HUVEC medium contain-
ing TNF with or without IFN. In the transwell, 
PBMC in 300 µl were added. To establish the 
role of IL-1ß, HUVEC were incubated with TNF, 
IFN and IL-1ß or exposed to TNF, IFN, PBMC in 
the presence of a neutralizing antibody against 
IL-1ß for 144 hours. After 144 hours the plate 
was washed, fixated and stained using the SRB 
method. Cells incubated with only HUVEC me-
dium were used as 100% growth.
Morphological changes. HUVEC were plated 
in fibronectin coated 24 well multiplates at a 
final concentration of 3x104 cells per well and 
allowed to grow for 24 hours. The cells were 
incubated with TNF and IFN at dosage range 
mentioned in the results section, in combina-
tion with respectively PBMC, IL-1ß or PBMC in 
the presence of neutralizing antibodies to IL-1ß. 
After 24, 72 and 144 hours, morphological cell 
changes were examined with a 10x N.A. 0.30 
Plan-Neofluar objective lens using an inverted 
Zeiss Axiovert 100M microscope equipped 
with an Axiocam digital camera (Carl Zeiss). 
Cell elongation was measured and expressed 
as the ratio of the length of the major cell axis 
to the width perpendicular to the length. Ten 
cells and at least four independent incubations 
were determined. In addition, gap formation 
was determined for each treatment. The cell-
free area was outlined and the gap formation 
was calculated using the formula: percentage 
cell-free area = (cell-free area/total area) x 100 
percent. All measurements were done using 
the AxioVision 3.0 software.
Immunofluorescence. HUVEC were plated 
on to fibronectin coated cover glass at a final 
concentration of 3x104 cells per glass and al-
lowed to grow for 24 hours. The cells were in-
cubated with HUVEC medium, 10 µg/ml TNF 
in combination with 0.001 µg/ml IFN or 10 µg/
ml TNF in combination with 0.001 µg/ml IFN 
and PBMC. After 144 hours of incubation, cells 
were rinsed in PBS and fixed with 3.6% para-
formaldehyde for 10 min at room temperature. 
Cells were permeabilized with 0.1% Triton 
X-100 for 10 min at room temperature, and 
aspecific binding sites were blocked with 1% 
BSA in PBS for 10 min at room temperature. 
Cells were stained with Alexa Fluor 568 phal-
loidin (1:400; Molecular Probes) for the detec-
tion of F-actin (20 min, room temperature) and 
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mounted with vectashield (Vector laboratories) 
mixed with DAPI (Molecular Probes) in order to 
stain cell nuclei. Cells were examined using a 
Leica DMRX-A microscope and images taken 
with a Sony DXC 950 camera.
Western blot. HUVEC, PBMC and HUVEC co-
cultured with PBMC were stimulated with 10 
µg/ml TNF combined with 0.001 - 0.1 µg/ml 
IFN for 48 hours. After stimulation, superna-
tant was collected to determine the presence 
of endogenous IL-1ß. Reduced samples were 
separated by electrophoresis in a 15% SDS-
polyacrilamide gel and transferred to a PVDF 
membrane (BioRad). Following transfer, the 
membranes were blocked with MPBS (5% 
milk powder in PBS/0.05% tween-20) and in-
cubated overnight with goat anti human IL-1ß 
(1:1500; R&D systems) in MPBS. After wash-
ing, the membrane was incubated with rabbit 
anti goat biotin (1:1500; Southern Biotechnol-
ogy) in MPBS. Bound biotin was incubated with 
alkaline-phosphatase-streptavidin complex 
(BioRad), and this in turn stained with BCIP/
NBT liquid substrate (BioRad). The staining was 
stopped with 2 mM EDTA.
Apoptosis assay. Two methods were used for 
the detection of apoptosis: first, FACS analysis 
using annexin V (for apoptotic cells) and pro-
pidium iodide (PI, necrotic cells) to screen all 
cells (adherent and detached), and secondly, 
YO-PRO-1 for detection of apoptotic adherent 
cells. To avoid detection of apoptotic PBMC, 
these were added in a transwell system (Mil-
lipore). HUVEC were incubated with combina-
tions of 10 µg/ml TNF, 0.001 µg/ml IFN, 0.01 
µg/ml IL-1ß and PBMC. After incubation for 24, 
72 or 144 hours, detached cells were collect-
ed from the supernatant and living cells were 
harvested by mild trypsinization and washed 
with PBS. Early apoptosis was detected using 
the annexin V kit, according to the manufac-
turer’s instructions (Vybrant Apoptosis Assay kit 
#3, Molecular Probes). Cells were immediately 
analyzed by flowcytometry (FACScan, Becton 
Dickinson). Data analysis was performed using 
WinMDI 2.7 (Freeware, Joseph Trotter, Scripps 
Research Institute). Alternatively, apoptosis was 
also detected using the monomeric cyanine nu-
cleic acid stain YO-PRO-1 (Molecular probes). 
At the end of the incubation period of the 
HUVEC, detached cells were removed. HUVEC 
medium with YO-PRO-1, in a final concentra-
tion of 0.5 µM, was added to the well with the 
remaining adherent cells and incubated for 15 
min at 37°C. Fluorescence was visualized using 
an inverted Zeiss Axiovert 100M microscope 
and captured with an Axiocam digital camera, 
using AxioVision v3.0 software.
Endothelial cell permeability assay. HUVEC 
were plated in a transwell (0.4 µm pore size, 
6.5 mm diameter, polyester filters; Corning BV), 
coated with fibronectin, at a density of 2.5x104 
cells per well. After culture for 24 hours, the 
medium in the upper chamber was replaced 
with medium containing combinations of TNF, 
IFN, PBMC, IL-1ß, anti IL-1ß or HUVEC medium 
during 24, 72 and 144 hours. To measure per-
meability, FITC-BSA in a concentration of 50 
µg/well was added to the upper chamber. After 
the indicated incubation time the FITC fluores-
cence at the lower chamber was read using a 
fluorescence plate reader (Wallac Victor2, Per-
kin Elmer).
Statistical analysis. The Mann-Whitney U-
test was used in all statistical analysis. P values 
below 0.05 were considered statistically signifi-
cant.
RESULTS
Morphological changes in endothelial cells 
in relation to activated PBMC. A crucial ob-
servation raised the question how TNF affects 
the endothelial lining of tumor vessels. When 
leukocytes were depleted we observed im-
paired tumor response to TNF-based ILP [18]. 
Secondly, IFN has been added in several studies 
because of synergistic antitumor activity when 
combined with TNF, although its beneficial ef-
fect is still debated [22]. Therefore, we tested 
the effect of a combination of TNF and IFN 
on endothelial cells. HUVEC were incubated 
with TNF, IFN, melphalan or doxorubicin for 72 
hours. TNF or IFN alone had only a negligible 
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effect on the endothelial cells. Incubation of 
HUVEC with melphalan or doxorubicin result-
ed in a dose related cytotoxicity with an IC50 
of respectively 40 µg/ml and 0.2 µg/ml (data 
not shown). When HUVEC were exposed to 
TNF or IFN in combination with melphalan or 
doxorubicin the IC50 of these drugs were not al-
tered, indicating a lack of synergy between the 
cytokines and the cytotoxic agents (data not 
shown). Even when TNF, IFN and melphalan 
were combined no synergy could be observed 
(data not shown). These results demonstrate a 
clear lack of direct activity of TNF and IFN on 
endothelial cells. Therefore, we tried to estab-
lish the role of leukocytes in TNF-based tumor 
therapy. HUVEC were exposed to TNF, IFN and 
PBMC during 144 hours and effect on cell 
growth was determined. Addition of PBMC to 
TNF and IFN inflicted strong cell growth reduc-
tion of HUVEC and eventually cell death, which 
was not observed with TNF and IFN alone (Fig. 
1a). TNF levels between 10 and 0.1 µg/ml have 
been tested resulting in comparable but less 
pronounced effects for the lower concentra-
tions. Photographs were taken to examine the 
morphology of the cells after incubation (Fig. 
1b). Under normal culture conditions endothe-
lial cells form a monolayer of cobblestone-like 
cells. Exposure of HUVEC to TNF resulted in 
slight elongation of the cells, whereas incuba-
tion with 0.001 µg/ml IFN alone or PBMC alone 
had no effect on cell morphology. Combination 
of 10 µg/ml TNF with 0.001 µg/ml IFN resulted 
in more pronounced morphological changes. 
Cells became more elongated and gaps be-
tween the cells became visible. Dramatic dis-
ruption of the HUVEC monolayer resulted from 
exposure to 10 µg/ml TNF, 0.001 µg/ml IFN and 
PBMC. Exposure of HUVEC to 10 µg/ml TNF in 
combination with 0.1 µg/ml IFN resulted in the 
formation of elongated cells and even larger 
gaps, addition of PBMC further increased these 
observed effects. These differences in gap for-
mation and cell elongation were confirmed by 
measurements of cell-free area and the cell 
shape ratio (Table 1). Addition of PBMC to 10 
µg/ml TNF and IFN, 0.1 µg/ml as well as 0.001 
µg/ml, resulted in significant changes in length 
to width ratio and cell-free area compared to 
incubations in which PBMC were not added.
Cytoskeletal changes in HUVEC exposed 
to TNF, IFN and PBMC. Control endothelial 
cells treated with HUVEC medium showed ac-
tin fibers highly concentrated at the periphery 
of the cell, ending in dense points. When cells 
were treated with 10 µg/ml TNF in combination 
with 0.001 µg/ml IFN, cells became elongated 
and enlarged, which was not further enhanced 
with higher dose of IFN (0.1 µg/ml). The cellular 
alignment corresponded with alignment of ac-
tin fibers. More stretched actin fibers were seen 
in the center of the cell while actin was dimin-
ished at the periphery. The dense actin points, 
observed in cells treated with HUVEC medium, 
seemed lowered, although also the number of 
cells is decreased. Addition of 10 µg/ml TNF in 
combination with 0.001 µg/ml IFN and PBMC 
resulted in stretching of the actin fibers and 
bleb formation, which could possibly indicate 
loss of membrane integrity (Fig. 2).
Identification of IL-1ß as a crucial soluble 
factor for HUVEC morphology. To determine 
the role of PBMC in the above-observed en-
dothelial morphology changes we evaluated 
whether a cell-cell interaction was necessary for 
this process or if a soluble factor could be iden-
tify. Incubation of endothelial cells with TNF, 
IFN and PBMC was performed in a transwell 
system to avoid contact between endothe-
lial cells and PBMC by physical separation of 
the cells while soluble factors are not blocked. 
Comparable growth curve and morphological 
changes were obtained as when endothelial 
cells were in contact with the PBMC (data not 
shown). These results indicate that a soluble 
factor is responsible for the observed results. To 
determine possible soluble factors derived from 
PBMC, western blot analysis was performed. 
After analysis of the supernatant of PBMC and/
or HUVEC stimulated with above-mentioned 
cytokines, it was shown that both PBMC and 
HUVEC produced soluble IL-1ß in response to 
TNF irrespective of the IFN concentration (Fig. 
3). To test the hypothesis that IL-1ß is respon-
sible for the effects observed in cell growth 
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Figure 1. The morphology of HUVEC changes after incubation of primed-PBMC. (a) Cell growth of HUVEC, incu-
bated with 10 µg/ml TNF and PBMC (left graph), and 10 µg/ml TNF (right graph) in combination with 0.1 µg, 0.001 µg, 
and 0 µg IFN per ml was measured in course of time. Cells incubated with medium alone were used as a control. Cells in-
cubated with TNF and 0.1 µg/ml IFN showed cell growth stabilization whereas a concentration of 0.001 µg/ml IFN had no 
effect on cell growth. PBMC greatly enhanced the cell growth inhibitory effect of TNF and IFN, resulting even in cell death. 
Data points represent percentage cell growth compared to control treated cells at 0 hour ± SEM of at least 2 treatments of 
5 individual experiments; *, P < 0.05, cells incubated for 144 hours with PBMC versus cells incubated without PBMC. (b) 
Photographs of HUVEC taken 144 hours after incubation with 10 µg/ml TNF, 0.001 µg/ml IFN (indicated as IFN) or 0.1 µg/
ml IFN and PBMC. Typical cobblestone structure of the monolayer after incubated with only medium is shown. Incubation 
with TNF resulted in elongation and alignment of the cells. When IFN (0.001 µg/ml) or PBMC was administered no mor-
phological changes were observed. Treatment of cells with TNF and IFN (0.001 µg/ml), TNF and PBMC, or IFN (0.001 µg/
ml) and PBMC resulted in increased elongation of the HUVEC and slight gap formation. These changes further expanded 
when incubated with a combination of TNF, IFN (0.001 µg/ml) and PBMC. A higher dose of IFN (0.1 µg/ml) alone showed 
already elongation of the cells, which was not changed when PBMC were added. Further elongation and gap formation 
was seen when combined with TNF and, TNF and PBMC. Scale bar apply for all images, 100 µm.
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Table 1. Effect of PBMC on cell elongation and gap formation.
Incubation
Medium PBMC
Length to width ra-
tioa
Cell-free area (%)b Length to width ra-
tioa
Cell-free area (%)b
Medium 1.5 ± 0.2 0 2.3 ± 0.8 1 ± 1
TNF 5.4 ± 0.4 1 ± 1 10.5 ± 2.5* 14 ± 13#
0.001 µg/ml IFN 1.9 ± 0.2 0 2.9 ± 0.4 0
TNF + 0.001 µg/ml IFN 6.4 ± 0.4 10 ± 9 16.5 ± 2.3* 39 ± 21#
0.1 µg/ml IFN 4.3 ± 0.3 0 6.4 ± 0.4* 0
TNF + 0.1 µg/ml IFN 11.9 ± 2.2 38 ± 25 26.1 ± 2.8* 78 ± 14#
Note: HUVEC were incubated during 144 hours. Concentrations used were 10 µg/ml TNF and 0.1 µg/ml or 0.001 µg/
ml IFN.
a Ratio of major and minor axes was measured to determine the cell elongation. Data represent length to width ratio ± 
SEM of 10 cells per treatment of at least 4 individual experiments; *, P < 0.05, cells incubated without PBMC versus cells 
incubated with corresponding cytokines and PBMC
b Cell-free area, as a percent of the total area, was calculated to verify the gap formation. Data represent percentage 
cell free area ± SD of at least 4 individual experiments; #, P < 0.05, cells incubated without PBMC versus cells incubated 
with corresponding cytokines and PBMC.
Medium TNF + IFN TNF + IFN + PBMC
Figure 2. The cytoskeleton changes after incubation of primed PBMC. Staining for F-actin (red) and DAPI (blue) 
after incubation of HUVEC as described in the experimental procedures. Untreated cells revealed actin mainly localized at 
the periphery of the cell and clustering to form actin rich points (arrow). Cells treated with TNF (10 µg/ml) in combination 
with IFN (0.001 µg/ml) showed a decrease in peripheral actin and actin fibers oriented in the long axis of the cell. Cells 
treated with a combination of TNF, IFN and PBMC showed further elongation of actin fibers. Scale bar apply for all images, 
50 µm. (See color section for a full-color version.)
PBMC
HUVEC
TNF
IFN
Figure 3. Incubation with TNF leads to production of IL-1ß. Western blot analysis of endogenous IL-1ß production by 
HUVEC and PBMC as described in the experimental procedures. Cells, PBMC as well as HUVEC that were incubated with 
TNF produced endogenous IL-1ß. IFN had no effect on production of IL-1ß.
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and morphological changes two approaches 
were performed. First, endothelial cells were 
exposed to TNF and IFN in combination with 
IL-1ß. Second, production of IL-1ß by PBMC 
after stimulation with TNF, IFN and PBMC was 
blocked with a neutralizing antibody. After 144 
hours, cell growth was measured (Table 2). 
Replacement of PBMC with 0.01 µg/ml IL-1ß 
evoked comparable HUVEC growth reduction. 
Moreover, comparable morphological changes 
of HUVEC were observed, indicating IL-1ß as 
a critical PBMC-derived factor in TNF mediat-
ed endothelial disruption. Looking at cell-free 
area, 10 µg/ml TNF in combination with 0.001 
µg/ml IFN and PBMC showed comparable gap 
formation as TNF in combination with IFN and 
0.01 µg/ml IL-1ß, namely 39 ± 22% and 26 
± 9% (Fig. 4a). Combining TNF and IFN with 
PBMC or IL-1ß-induced comparable degree of 
cell elongation, respectively 16.5 ± 2.3 and 14.5 
± 2.3 (Fig. 4b). When endogenous IL-1ß was 
blocked in cells treated with 10 µg/ml TNF in 
combination with 0.001 µg/ml IFN and PBMC, 
cell-free area (5 ± 5%) as well as length to 
width ratio (7.9 ± 2.5) was strongly diminished 
and comparable to exposure with TNF and IFN 
alone (10 ± 9% for cell-free area and 6.4 ± 0.4 
for length to width ratio). When a concentra-
tion of 0.1 µg/ml IFN was used the same effects 
were observed. PBMC, in a combination with 
TNF and IFN, could be replaced by IL-1ß, with 
regard to induction of cell-free area (78 ± 14% 
for PBMC versus 71 ± 16% for IL-1ß) and cell 
elongation (26.1 ± 2.8 for PBMC versus 23.5 
± 3.3 for IL-1ß) (data not shown). Importantly, 
incubation of HUVEC with 0.001 µg/ml IFN 
and 0.01 µg/ml IL-1ß resulted in more elon-
gated and aligned cells than when incubated 
with 0.001 µg/ml IFN and PBMC (Fig 4c). This 
is in line with the results of the western blot 
showing that IFN does not induce production 
of IL-1ß. Secondly, especially the combination 
of IFN and IL-1ß seems responsible for the ob-
served morphological changes. This could also 
be confirmed by inhibition of endogenous IL-
1ß. Blocking endogenous IL-1ß, with 1 µg/ml 
anti IL-1ß, in cells that were incubated with 10 
µg/ml TNF, 0.001 µg/ml IFN and PBMC reversed 
the PBMC inflicted effects. Addition of anti IL-ß 
to TNF plus IFN did not change the response 
of HUVEC indicating that PBMC are the most 
likely source of IL-ß (data not shown). That TNF 
is the stimulator of the production of IL-1ß was 
confirmed by blocking endogenous IL-1ß. In 
cells incubated with 10 µg/ml TNF combined 
with PBMC and anti IL-1ß a reduction in cell 
elongation was observed.
TNF and IFN-induced apoptosis in HUVEC. 
To exclude the possibility that the observed ef-
fect on HUVEC were related to induction of 
apoptosis, we tested for cell death using an-
nexin V and YO-PRO-1. Exposure of HUVEC to 
TNF and IFN resulted in 24 ± 2% apoptosis in 72 
hours, which did not increase further over the 
next 72 hours. Addition of PBMC or IL-1ß had 
no further effect (apoptosis respectively 26 ± 
2% and 20 ± 3%) (Fig. 5a). YO-PRO-1 pictures 
revealed that adherent cells incubated with 10 
µg/ml TNF and 0.001 µg/ml IFN remained vi-
able (Fig. 5b, left photographs) Similar pictures 
were seen when cells were incubated with 10 
Table 2. Effect of IL-1ß on HUVEC growth.
Incubation Cell growth (% of control)a
Medium PBMC IL-1ß PBMC+IL-1ß
TNF 95 ± 2 72 ± 9 56 ± 6* 81 ± 9**
IFN 90 ± 3 58 ± 8* 58 ± 4* 83 ± 9**
TNF+IFN 78 ± 4 48 ± 7* 42 ± 3* 84 ± 5**
Note: HUVEC were incubated with 10 µg/ml TNF, 0.001 µg/ml IFN, 0.01 µg/ml IL-1ß and 1 µg/ml anti IL-1ß for 144 hours. 
HUVEC incubated with HUVEC medium only were used as controls and set as 100 percent cell growth.
a Percentage cell growth of HUVEC exposed to given factors as compared to HUVEC cultured in HUVEC medium only. 
Data represent percentage cell growth compared to HUVEC medium treated cells ± SEM of 2 treatments of at least 3 
individual experiments; *, P < 0.05, cells incubated with PBMC or IL-1ß versus medium; **, P < 0.05, cells incubated 
with anti IL-1ß versus cells incubated with IL-1ß or PBMC.
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µg/ml TNF in combination with 0.001 µg/ml IFN 
and PBMC (Fig. 5b, right photographs) or 0.01 
µg/ml IL-1ß (data not shown).
Augmentation of endothelial permeability 
by TNF and IFN. To assess the importance of 
our findings for the clinical setting, i.e. augmen-
tation of drug accumulation in tumor tissue by 
increasing permeability of the tumor vascular 
bed, we tested the effect of TNF, IFN and PBMC 
on the permeability of a HUVEC monolayer. Ex-
posure of the HUVEC monolayer to TNF and 
IFN for 24 hours until 72 hours had no effect 
on FITC-BSA transfers irrespective of the pres-
ence of PBMC (data not shown). However, at 
144 hours of incubation permeability increased 
2-fold for TNF in combination with IFN and a 
6-fold increase was observed for the combina-
tion of TNF, IFN and PBMC (Fig. 6). Replacing 
PBMC with IL-1ß resulted in similar permeabil-
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Figure 4. Endogenous produced IL-1ß is responsible for TNF-induced morphological changes. (a) Cell-free area, 
as function of gap formation and (b) length to width ratio, representative for cell elongation, after 144 hours incubated 
with 10 µg/ml TNF, 0.001 µg/ml IFN, PBMC, 0.01 µg/ml IL-1ß or anti IL-1ß, were calculated. Cell-free area and length to 
width ratio were significantly augmented when PBMC were added. Replacing PBMC by IL-1ß resulted in a similar increase. 
Blocking endogenous IL-1ß with the neutralizing antibody in cells reversed the effects. Columns represent percentage 
cell-free area ± SD of at least 4 individual experiments and length to width ratio ± SEM of 10 cells per treatment of at least 
4 individual experiments; *, P < 0.05, cell-free area or length to width ratio cells incubated with TNF in combination with 
IFN versus cells incubated with TNF in combination with IFN and PBMC or IL-1ß; **, not significant versus cells incubated 
with TNF in combination with IFN; #, not significant versus cells incubated with TNF in combination with IFN and PBMC. (c) 
Represented photographs were taken 144 hours after incubation. Exposure to HUVEC medium, TNF, IFN or IL-1ß resulted 
at most in some elongation of the cells. Exposure of HUVEC to TNF, IFN and IL-1ß combined inflicted strong morphology 
changes and gap formation comparable to the combination of TNF, IFN and PBMC. Likewise, addition of IL-1ß to TNF 
inflicted comparable results when TNF was combined with PBMC. However, whereas addition of IL-1ß to IFN inflicted a 
strong response this was not seen when IFN and PBMC were added. Blocking of endogenous IL-1ß with 1 µg/ml anti IL-1ß 
reversed the strong morphological changes inflicted by TNF, IFN and PBMC. This was also observed when anti IL-1ß was 
added to HUVEC incubated with 10 µg/ml TNF and PBMC. Scale bar apply for all images, 100 µm.
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Figure 5. No change in apoptosis is found after addition of PBMC. Apoptosis was detected using PI and annexin V 
or YO-PRO-1 after 144 hours of incubation. (a) Viable cells are negative for PI and annexin V, apoptotic cells are positive 
for annexin V and necrotic cells are double positive for PI and annexin V. Numbers in each quadrant represent percentage 
cells. No significance was observed between the different incubations. (b) YO-PRO-1 pictures revealed that adherent cells 
after incubation with TNF (10 µg/ml) in combination with IFN (0.001 µg/ml) showed no apoptosis. Addition of PBMC gave 
no increase in apoptosis of adherent cells. Scale bar apply for all images, 100 µm.
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Figure 6. Permeability of the endothelial layer increases after 144 hours of incubation. Permeability changes after 
144 hours with 10 µg/ml TNF, 0.001 µg/ml IFN, PBMC, 0.01 µg/ml IL-1ß or 1 µg/ml anti IL-1ß were detected. Addition of 
PBMC to TNF and IFN showed significant increase in permeability. Replacing PBMC with IL-1ß also resulted in increased 
permeability, whereas blocking endogenous IL-1ß reversed the effects. Columns represent percentage permeability in-
crease compared to medium treated cells ± SD of 3 individual experiments; *, P < 0.05, permeability in cells incubated 
with TNF in combination with IFN versus cells incubated with TNF in combination with IFN and PBMC or IL-1ß; **, not 
significant versus cells incubated with TNF in combination with IFN; #, not significant versus cells incubated with TNF in 
combination IFN and PBMC.
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ity increase. Addition of anti IL-1ß reduced the 
permeability increase by TNF in combination 
of IFN and PBMC back to the level of TNF in 
combination with IFN. These results indicate a 
striking indirect effect of TNF on the vascular 
permeability through induction of IFN and IL-
1ß production by PBMC.
DISCUSSION
Previously, we showed that both in local re-
gional setting as well as in systemic approaches 
addition of high-dose TNF to chemotherapy 
dramatically improves drug accumulation in 
the solid tumor resulting in profound tumor 
responses [4,5,7,23]. An important activity of 
this TNF-based therapy is an alteration of the 
pathophysiology of the solid tumor. Here, we 
report that high-dose TNF, especially in com-
bination with IFN, induces morphological 
changes of endothelial cells; the cells become 
elongated and gap formation between the 
cells occurs. Importantly, these morphologic 
changes are much more pronounced when 
PBMC are added. Cells become further elon-
gated, therefore intensifying gap formation 
that contributes to an increased permeability. 
The addition of PBMC turned the endothelial 
cells sensitive to lower concentrations of IFN. 
We demonstrate that PBMC-derived IL-1ß is re-
sponsible for this effect. It seems that IFN has 
a direct effect on endothelial cell growth but 
hardly on endothelial cell morphology, which 
is enhanced by IL-1ß. Beside that, we observe 
minimal changes in cell growth and percentage 
apoptosis. These observations indicate that the 
cascade initiated by high-dose TNF rather in-
duce a change in endothelial cell morphology, 
resulting in formation of gaps and augmented 
vascular permeability than apoptosis of the en-
dothelial cells. We observed that TNF has its 
effect on confluent endothelial cell monolayer 
and we speculate that the permeability change 
is not due to a decreased cell proliferation but 
to alterations in cell morphology.
It has been reported that stimulation of 
endothelial cells is associated with reduction 
and redistribution of extra- and intracellular 
proteins [14,24-28]. These proteins, like actin, 
are important in maintaining cell integrity and 
shape. Other proteins are crucial for contact 
of endothelial cells to the extracellular matrix. 
After stimulation of endothelial cells focal ad-
hesion points are disrupted and cells detach 
from the matrix. Disruption of anchorage of 
endothelial cells to matrix components through 
integrins initiates anoikis. Although we saw no 
major induction of cell death, cells have to de-
tach from the matrix in order to migrate and 
stretch. From our results we conclude that the 
TNF-induced cascade predominantly resulted in 
alteration of cell-cell and cell-matrix interaction 
and not a disruption of this contact.
Components of adherens and tight junctions, 
like occludin, cadherin and ZO-1, are down-
regulated within stimulated cells and contact 
between two neighboring cells is breached [29-
33]. Redistribution of the actin cytoskeleton, 
detachment of the cells, and loss of contact are 
associated with the increased permeability of 
an endothelial monolayer when it is stimulated 
with cytokines [34-36]. We show here that the 
addition of PBMC even further expands the 
morphological changes of the endothelial cells, 
which is associated with actin redistribution, 
and therefore further increasing permeability. 
The permeability increase is most likely associ-
ated with the altered morphology and gap for-
mation but may also result from the induction 
of vesiculo-vascuolar organelles (VVOs) [37]. 
As we recently showed that histamine also im-
proves tumor response by augmenting vascular 
leakage, this is currently under investigation, as 
histamine is known to induce VVOs [38].
Furthermore, TNF is a mediator for recruit-
ment of leukocytes and participates in the 
production of numerous endogenous factors, 
like IL-1ß, IL-2, IL-4, IL-6, IL-8 and IFNγ [39-42]. 
Moreover, we demonstrate that addition of 
IL-1ß to a combination of TNF and IFN could 
mimic the morphological changes observed 
when PBMC was added. We hypothesize that 
IL-1ß plays an important part in the process of 
TNF-induced morphological alterations of en-
dothelial cells. Western blot analysis showed 
that TNF is essential for the production on IL-
1ß, indicating an indirect effect of TNF towards 
the endothelial cells.
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It has been shown that within a few hours 
after perfusion infiltration of erythrocytes, poly-
morphnuclear cells and platelets start to aggre-
gate whereas macrophages invade the tumor 
later, after approximately 7 days. Lymphocytes 
start to infiltrate the tumor 6 to 7 days after 
perfusion [10,43]. Although after perfusion 
a wash out is performed, removing cytokines 
and cytotoxic agents, macrophages and lym-
phocytes are likely to produce a steady state 
of TNF, IFN and interleukins, which could have 
a continuous effect on the tumor vasculature. 
It has been described that tumor infiltrating 
lymphocytes are producing cytokines like TNF 
and IFN after treatment [44-46]. Angiograms 
of fast growing sarcomas revealed that a few 
weeks after perfusion the tumor-associated 
vasculature is eradicated [47], indicating that 
only one boost of high-dose exogenous TNF 
triggers mechanisms, which have an impact for 
extended periods of time. Further investigation 
is performed to understand the short-term ef-
fects of TNF on the endothelial cells.
Our data indicates that high-dose TNF in-
flicts endothelial damage through the induc-
tion of IFN and PBMC-derived IL-1ß. However, 
although we hypothesis IL-1ß as a major fac-
tor also other PBMC-derived factors are likely 
involved. Mainly inhibition of proliferation and 
severe alterations in morphology over longer 
periods are observed. The role of PBMC, in this 
model, is predominantly the intensification of 
PBMC
IFN
IL-1beta
Tumor tissue
Blood vessel
Endothelial cell
RBC
Stimulated
PBMC
TNF-alpha
Figure 7. Proposed mechanism of TNF-mediated changes in tumor vascular permeability leading to augmented 
local drug accumulation in high-dose TNF combination therapy. Here we show that TNF, added in combination 
with cytotoxic agents, activate PBMC to produce IL-1ß and IFN. Mainly IFN and IL-1ß are responsible for the induction of 
morphological changes of the endothelial lining of the tumor-associated vasculature, thereby increasing vascular perme-
ability. This enhances infiltration of blood cells and improves drug accumulation in the surrounding tumor tissue. (See 
color section for a full-color version.)
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the morphological changes and permeability 
of the endothelial barrier. Translated to the in 
vivo situation (Fig. 7) this increased permeabil-
ity participates on one side in an augmented 
leakage of co-administered chemotherapeutic 
in the tumor. On the other side recruitment 
of PBMC, provides continuous production of 
endogenous cytokines, contributing to the de-
struction of tumor vessels and necrosis of the 
tumor.
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ABSTRACT
The importance of combining chemotherapy and antivascular or 
antiangiogenic therapy has been underscored by a number of 
studies. We and others demonstrated the synergistic interaction 
between chemotherapy and tumor necrosis factor-alpha (TNF) in 
solid tumor treatment. TNF facilitates an augmented accumulation 
of the co-administered chemotherapeutic specifically in tumor tis-
sue. The factors involved in the TNF-mediated vascular response 
are largely unknown. Here we show that TNF-induced production 
of interleukin-1beta by peripheral blood mononuclear cells trig-
gers the endothelial cells to produce matrix metalloproteinase-9, 
which is responsible for changes in endothelial morphology and 
permeability. These data indicate that TNF indirectly affects en-
dothelial permeability through degradation of the matrix.
INTRODUCTION
Addition of tumor necrosis factor-alpha (TNF) 
to chemotherapy results in dramatic improve-
ment of tumor response in patients with in-
transit melanoma metastases and limb threat-
ening soft tissue sarcomas [1-4]. Two previous 
findings provided important information on 
the activity of TNF. First, when TNF is added an 
augmented accumulation of the co-adminis-
tered drug (e.g. melphalan or doxorubicin) is 
observed. Secondly, for TNF to be active leu-
kocytes are indispensable [8,9]. Within a few 
hours after TNF administration extravasation of 
erythrocytes, infiltration of polymorphonuclear 
cells and platelet aggregation occurs. Mac-
rophages and lymphocytes invaded the tumor 
6 to 7 days after perfusion. In vitro endothelial 
cells appeared quite insensitive to TNF, whereas 
in the presence of peripheral blood mononu-
clear cells (PBMC) disruption of the endothe-
lial monolayer was observed. Endothelial cells 
became elongated, intensifying gap formation 
that engenders increased permeability. Further 
investigations revealed that these observed ef-
fects were induced by PBMC-derived interleu-
kin-1beta (IL-1ß) [10]. Loss of endothelial integ-
rity could result from, first the disruption of the 
adhesive interaction between neighboring en-
dothelial cells and secondly from disruption of 
interaction between cell and extracellular ma-
trix. Degradation of the basal membrane and 
extracellular matrix involves the participation 
of proteolytic enzymes, like metalloproteinases 
(MMPs). MMP-2 and MMP-9 are produced by 
stromal cells and cleaves substrates, such as 
laminin and type IV collagen, which are over 
expressed in the basal lamina in tumors [11-
14].
In our system the interaction between two 
cell types, HUVEC and PBMC, is investigated. 
We looked at the production and the biological 
role of MMPs and tried to identify which cell 
type produces the necessary MMPs in this co-
culture. Here we show that TNF interacts with 
MMP-9 after TNF-induction causes loss of endothelial integrity78
peripheral blood mononuclear cells and en-
dothelial cells, in coalition with other cytokines, 
like interferon-gamma (IFN) and IL-1ß, mediat-
ing MMP production. From the enhanced MMP 
production matrix degradation results inflicting 
morphologic changes of the endothelial cell 
and increased endothelial permeability.
EXPERIMENTAL PROCEDURES
Agents. Recombinant human Tumor necrosis 
factor-alpha (TNF) and recombinant human In-
terferon-gamma (IFN) were kindly provided by 
Boehringer Ingelheim GmbH. TNF had a spe-
cific activity of 5x107 U/mg as determined in 
the murine LM cell assay. Endotoxin levels were 
< 1.25 units (EU) per mg protein. IFN had a spe-
cific activity of 2.5x107 U/mg as determined in 
an HLA-DR assay. Recombinant human inter-
leukin-1beta (IL-1ß) was purchased from Pep-
rotech EC Ltd. As determined by stimulation of 
thymidine uptake by murine C3H/HeJ thymo-
cytes, the ED50 was ≤ 0.1 ng/ml, corresponding 
to a specific activity of ≥ 1x107 U/mg. Endotoxin 
levels were less than 1 EU per µg protein. Goat 
anti human interleukin-1beta (anti IL-1ß) was 
purchased from R&D systems. As determined 
by the LAL method, endotoxin levels were less 
than 10 ng/ml. GM6001 (Ilomastat), a broad 
spectrum MMP inhibitor was purchased from 
Chemicon and N-actelylcysteine (NAC) from 
Pharmachemie BV. Active Human MMP-2 and 
MMP-9 enzymes were purchased from Calbio-
chem.
Cells and cultured conditions. Human um-
bilical vein endothelial cells (HUVEC) were iso-
lated by collagenase digestion using the meth-
od described by Jaffe et al [15]. Each isolate 
was derived from an individual umbilical vein 
and used for experiments at passage 5 or 6. 
HUVEC were cultured in HUVEC medium con-
taining human endothelial-serum free medium 
(Invitrogen), 20% heat inactivated newborn 
calf serum (Lonza), 10% heat inactivated hu-
man serum (Lonza), 20 ng/ml human recom-
binant basic fibroblast growth factor (Pepro-
tech EC Ltd), 100 ng/ml human recombinant 
epidermal growth factor (Peprotech EC Ltd) on 
fibronectin (Roche Diagnostics) coated flasks. 
HUVEC had the characteristic cobblestone 
morphology and tested positive for CD31. For 
all experiments, with the exception of west-
ern blot, cells were cultured, after plating, in 
serum-poor HUVEC medium (Human endothe-
lial-SFM, 5% heat inactivated human serum, 
20 ng/ml human recombinant basic fibroblast 
growth factor and 100 ng/ml human recom-
binant epidermal growth factor). For western 
blot experiments, cells were cultured in serum-
free HUVEC medium (human endothelial-SFM, 
20 ng/ml human recombinant basic fibroblast 
growth factor and 100 ng/ml human recom-
binant epidermal growth factor). Apart from 
a slower growth rate there were no changes 
in sensitivity towards the added drugs. Human 
peripheral blood mononuclear cells (PBMC) 
were isolated from healthy donors using the 
Vacutainer CPT Mononuclear Cell Preparation 
Tubes with sodium heparin (Becton Dickinson). 
PBMC were washed with phosphate buffered 
saline and counted with trypan blue to deter-
mine the viable cell concentration. PBMC, at a 
final concentration of 120x104 PBMC/ml, were 
used in all experiments.
Stimulation of endothelial cells. HUVEC 
were plated in 24 wells multiplate (Corning BV), 
coated with fibronectin, at a final concentra-
tion of 3x104 cells per well. After 24 hours, cells 
were washed and supernatant was replaced 
with serum-poor HUVEC medium containing 
10 µg/ml TNF, 0.1 µg/ml IFN, PBMC or 0.01 µg/
ml IL-1ß. To block production by endogenous 
IL-1ß, HUVEC were pretreated for 3 hours with 
a neutralizing antibody for IL-1ß and addition-
ally co-cultured with the cytokines and PBMC. 
GM6001, an inhibitor for MMP-1, 2, 3, 8 and 
9, was added in a concentration of 25 µM and 
N-acteylcysteine, which is known to inhibit par-
ticularly MMP-2 and 9, in a concentration of 
12.5 mM. For western blot analysis the same 
concentrations TNF, IFN and PBMC in serum-
free HUVEC medium were used. HUVEC were 
also incubated with active human MMP-2 and 
MMP-9 enzyme. Unless mentioned otherwise, 
incubation time was 144 hours in a humidified 
atmosphere at 37°C and 5% CO2.
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Assessment of growth and morphology 
changes of endothelial cells. Growth of en-
dothelial cells was measured using a Sulphor-
hodamine B protein stain assay (SRB, Sigma) 
according to the method of Skehan [16]. As a 
control, endothelial cells incubated with only 
HUVEC medium were used. Briefly, cells were 
incubated with 10% trichloric acetic acid (1 
hour, 4°C), stained for 15 min with SRB, washed 
with 1% acetic acid and allowed to dry. Protein 
bound SRB was dissolved in 10 mM Tris buffer, 
and the optical density (O.D.) was measured at 
540 nm. Cell growth was calculated using the 
formula: percentage cell growth = (O.D. test 
well/O.D. control well) x 100 percent. Mor-
phological cell changes were examined with a 
10x NA 0.30 plan-neofluar objective lens using 
an inverted Zeiss Axiovert 100M microscope 
equipped with an Axiocam digital camera (Carl 
Zeiss). Cell elongation was measured and ex-
pressed as the ratio of the length of the ma-
jor cell axis to the width perpendicular to the 
length. Ten cells and at least four independent 
incubations were determined. In addition, gap 
formation was determined. The cell-free area 
was outlined and gap formation was calculat-
ed using the formula: percentage cell-free area 
= (cell-free area/total area) x 100 percent. Al 
measurements were done using the AxioVision 
3.0 software.
Sample preparation. After HUVEC incuba-
tion, supernatant was collected and centrifuged 
to pellet detached cells and PBMC. To ensure 
that the supernatants were derived from equal 
cell numbers, for each experimental condition, 
DNA content was measured (CyQuant Cell Pro-
liferation Assay Kit, Molecular Probes). Bacte-
riophage λ DNA, included in the kit, was used 
as standard. In general, 5 to 20 µl of superna-
tant was loaded on the gel, corresponding to 
1000 ng/ml DNA.
Preparation of cell lysates. After indicated 
incubations, adherent cells were washed and 
harvested by scraping the cells into a small vol-
ume of lysis buffer (20 mM Tris-HCl (pH 8.8), 
125 mM NaCl, 1% triton X-100). Extracts were 
incubated on ice for 30 min and clarified by 
microcentrifuge at 20,000g for 10 min. Protein 
concentration of lysate was determined using 
the Advanced Protein Assay Reagent (Cytoskel-
eton).
Gelatin zymography. MMP-9 and MMP-2 
activity were analysed by zymography. Under 
non-reducing conditions, samples were elec-
trophoresed on a 10% polyacrilamide gel con-
taining 1% gelatin (Sigma). Following electro-
phoresis, gels were washed with 2.5% triton 
X-100 and incubated in MMP-development 
buffer (50 mM Tris-HCl (pH 8.8), 5 mM CaCl2) 
for 24 hours at 37°C. Gels were stained dur-
ing 5 hours with 0.5% Coomassie Blue R250 
(Sigma) and destained in 45% methanol:45% 
distilled H2O:10% acetic acid. Protein identity 
was confirmed using a MMP-9 and MMP-2 
standard (Chemicon). All zymographic MMP 
activities were inhibited by the metal chelator 
EDTA, confirming their identity as MMP. Com-
puterized densitometry was used to evaluate 
enzymatic activity (ImageJ 1.31v, Wayne Ras-
band).
Western blot analysis. Proteins in the super-
natant were precipitated using ice-cold aceton 
at –20°C for at least 1 hour and dried over-
night. The pelleted proteins were resuspended, 
electrophoresed under reducing conditions on 
a 10% polyacrilamide gel and transferred to a 
PVDF membrane (BioRad). Following transfer, 
the membranes were blocked with MPBS (5% 
milkpowder in PBS/0.05% tween-20) and in-
cubated overnight with mouse anti human 
MMP-1 or mouse anti human MMP-3 at 4°C 
(1:100; Calbiochem) in MPBS. After washing, 
the membrane was incubated with goat anti 
mouse biotin (1:1500; Southern Biotechnolo-
gy) in MPBS. Bound biotin was incubated with 
alkaline-phosphatase-streptavidin complex 
(BioRad) and this in turn stained with BCIP/NBT 
liquid substrate (Roche Diagnostics).
Enzyme-linked immunoabsorbant assay. 
Total MMP-1, MMP-2, MMP-3 and MMP-9 
content in the supernatant were determined 
using a commercial ELISA kit according to the 
manufacturer’s instruction. Quantikine Human 
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MMP-2 and MMP-9 were purchased from R&D 
systems and MMP-1 and MMP-3 Biotrak ELISA 
system from Amersham Biosciences.
RESULTS
Endothelial MMP-9 expression after stimu-
lation with TNF, IFN and PBMC. Exposure of 
HUVEC to TNF or IFN alone, as well as com-
bined failed to induce MMP-9. However, pro-
duction of MMP-9 was significantly enhanced 
when endothelial cells were stimulated with 
TNF (10 µg/ml) in combination of IFN (0.1 µg/
ml) and PBMC (Fig. 1a). These observations 
were confirmed by ELISA (Supplementary 
Fig. 1a). Lowering the IFN dose to 0.001 µg/
ml resulted in comparable MMP-9 expression 
(data not shown). MMP-2 was continuously 
expressed and responded poorly to stimula-
tors, which is known from the literature, and 
corresponded with ELISA (data not shown). In-
tracellular MMP-9 production, latent as well as 
active, was observed in cells exposed to TNF in 
combination with PBMC and increased further 
when IFN was added (Fig. 1b). To distinguish 
PBMC-derived MMPs from MMPs produced by 
endothelial cells, we removed the supernatant, 
including PBMC and cytokines after 72 hours 
of incubation. The endothelial cells were in-
cubated for an additional 72 hours with fresh 
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Figure 1. MMP-9 expression is increased after HUVEC stimulation with TNF, IFN and PBMC. (a) Supernatant of 
HUVEC incubated for 144 hours with TNF, IFN and PBMC were assessed by gelatin zymography. MMP-9 expression was 
significantly increased when HUVEC were exposed to TNF, IFN and PBMC. (b) Zymography of HUVEC lysate was also 
implemented and revealed that HUVEC incubated with TNF, IFN and PBMC produce a large amount of MMP-9. (c) Ad-
ditional zymographs were performed to identify that MMP are predominantly EC-derived. HUVEC were incubated with 
cytokines in combination with PBMC for 72 hours. After 72 hours supernatant was replaced with cytokines alone (left) 
or with cytokines in combination with PBMC (right) for an additional 72 hours. HUVEC initially incubated with TNF, IFN 
and PBMC continued to produce MMP-9 after PBMC were removed. (d) HUVEC were exposed to TNF, IFN and PBMC for 
24 hours. Supernatant was replaced with medium and every 24 hours a sample was taken and zymography performed. 
MMP-9 band densities were quantified by densitometry and showed that HUVEC continues to produce MMP-9. Columns 
represent percentage densitrometric increase ± SD of 3 individual experiments. The cell treated with TNF in combination 
with IFN and PBMC for the initial 24 hours was set at 0 hours.
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medium and respective cytokines but without 
PBMC. As a reference, cells were incubated 
with fresh medium with cytokines and PBMC 
(Fig. 1c). The endothelial cells appeared to pro-
duce equal amounts of MMP-9 irrespective of 
the incubation conditions or sequence. This in-
dicates that particularly endothelial cells are re-
sponsible for the production of MMP-9. Prim-
ing of HUVEC for 24 hours with TNF combined 
with IFN and PBMC resulted in continuous pro-
duction of MMP-9 (Fig. 1d) and MMP-2 (data 
not shown) till 144 hours. PBMC incubated 
with medium, TNF or IFN alone or TNF com-
bined with IFN produced an equivalent amount 
of MMP-9 and MMP-2 (data not shown). These 
experiments confirmed that, in a co-culture of 
HUVEC and PBMC, the endothelial cells are the 
main source of MMP-9. The zymography re-
vealed a constitutive band at approximately 45 
kDa possibly resulting from MMP-1 or MMP-3 
activity. We assayed the production of MMP-1 
with ELISA and western blot (Supplementary 
Fig. 1b). MMP-1 secretion was only increased 
with the addition of TNF. Stimulation of HU-
VEC with other combinations did not induce 
MMP-1 production. We could not detect any 
measurable levels of MMP-3 with western blot 
(data not shown). With ELISA, we detected lev-
els of MMP-3 in a range from 500 pg/ml to 
1000 pg/ml, however, these were not affected 
by the different stimuli (data not shown).
Identification of IL-1ß as a crucial factor 
for the production of MMP-2 and -9. Pre-
viously, we identified PMBC-derived IL-1ß as 
a crucial factor in TNF-mediated morphology 
and permeability changes of endothelial cells 
[10] (Fig. 2a). Therefore, we examined the role 
of endogenous produced IL-1ß in TNF-evoked 
MMP production in endothelial cells. First, en-
dothelial cells were exposed to TNF and IFN in 
combination with IL-1ß. Second, endogenous 
production of IL-1ß by PBMC was blocked with 
a neutralizing antibody. IL-1ß alone failed to 
induce MMP-9 production. However, similar 
MMP-9 levels were produced by endothelial 
cells when stimulated by TNF combined with 
PBMC as with TNF combined with IL-1ß. The 
results indicate that PBMC can be replaced by 
IL-1ß. Moreover, the MMP-9 production was 
further enhanced by IFN (Fig. 2b). The MMP-2 
production is not affected by IL-1ß (data not 
shown). Pre-incubation of endothelial cells for 
3 hours with anti IL-1ß and subsequently stim-
ulated with TNF combined with IFN and PBMC 
resulted in a prominent decline in MMP-9 pro-
duction (Fig. 2c). These data demonstrate the 
importance of IL-1ß in MMP-9 production. 
Next to that, the results indicate that endothe-
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Supplementary Figure 1. MMP-9 expression is increased, but MMP-1 is not after HUVEC stimulation with TNF, 
IFN and PBMC. (a) ELISA of supernatant of HUVEC incubated for 144 hours with TNF, IFN and PBMC revealed a increase 
in MMP-9 production. (b) ELISA and Western blot of these samples for MMP-1 showed no significant changes. Columns 
represent ng MMP per ml ± SEM of 2 treatments of 3 individual experiments.
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lial-derived MMP-9 is essential for the observed 
effects and not MMP-9 produced by PBMC.
Morphological changes and survival of 
HUVEC after MMP inhibition. We investigat-
ed the effect of MMPs on endothelial cell mor-
phology changes and growth. For this purpose, 
we used two different inhibitors, GM6001, a 
broad spectrum MMP-inhibitor and N-acetyl-
cysteine (NAC), an inhibitor for MMP-2 and 
MMP-9. Gelatin zymography (Fig. 3a) and 
densitrometric analysis (Supplementary Table 
1) revealed a decrease in MMP-9 and MMP-2 
production when inhibitors were added. The 
MMP-9 production of HUVEC treated with TNF 
in combination with IFN and PBMC decreased 
6-fold when N-acetylcysteine was added. Den-
sitrometric analysis of zymography showed a 
10-fold decrease in MMP-9 gelatinase activity 
by N-acetylcysteine in HUVEC incubated with 
TNF in combination with IFN and IL-1ß (Fig. 
3b). Under normal culture conditions endothe-
lial cells formed a typical cobblestone monolay-
er (Fig. 3c). Exposure to N-acetylcysteine had 
no effect on the cells, while GM6001 induced 
a slight stretching of the cells (data not shown). 
Endothelial cells cultured with TNF combined 
with IFN and PBMC showed a fibroblast-like 
resemblance and large gaps between the cells 
became visible. Also, the gap formation in the 
endothelial layer incubated with TNF combined 
with IFN and IL-1ß was markedly reduced when 
MMP production was inhibited with N-acetyl-
cysteine. Although, we observed no changes 
in cell elongation we found a significantly re-
duced gap formation when MMP activity was 
suppressed with either N-acetylcysteine (Table 
1) or GM6001 (data not shown). MMP inhibi-
tion causes survival in cells treated with TNF 
in combination with IFN and TNF in combina-
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Figure 2. Identification of IL-1ß as the mediator of EC-derived MMP-9 production. (a) Photographs of HUVEC were 
taken 144 hours after incubation with TNF, IFN and PBMC. Typical cobblestone structure of the monolayer after incubated 
with only medium is shown. Incubation with TNF, IFN and PBMC resulted in pronounced elongation of the cells and gap 
formation. When PBMC were replaced with IL-1ß the inflicted morphology changes were comparable. Scale bar apply 
for all images, 100 µm. (b) Gelatinase activity was determined in supernatant of HUVEC incubated with TNF, IFN, PBMC 
or IL-1ß. Representative zymographs are shown and revealed that HUVEC stimulated with IL-1ß in combination with TNF 
(left zymography) or with TNF and IFN (right zymography) produce large amounts of MMP-9. (c) Prior to treatment of the 
HUVEC with TNF (T) in combination with IFN (I) and PBMC (P), a neutralizing antibody against IL-1ß (1 µg/ml) was added 
to the culture. Blocking of endogenous produced IL-1ß strongly reduced the MMP-9 production.
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Figure 3. MMP-inhibitors reduces the TNF-induced effects on HUVEC growth and morphology. (a) Supernatant 
of HUVEC treated with MMP-inhibitor N-acetylcysteine (left zymography) or GM6001 (right zymography) were evaluated 
with zymography and showed a reduction in gelatinase activity when MMP-inhibitors were added. (b) Densitrometric 
analysis of the MMP-9 band in zymography of supernatant taken from HUVEC incubated with TNF, IFN and IL-1ß showed 
that MMP-9 production is also significantly decreased when N-acetylcysteine (NAC) was added. Colums represent arbi-
trary units ± SD of 3 individual experiments. (c) Photographs of HUVEC were taken 144 hours after incubation with TNF 
(T), IFN (I), PBMC (P) or IL-1ß and the MMP-inhibitor N-acetylcysteine. Cells incubated with TNF, IFN and PBMC showed 
again the morphological changes as before. Blocking MMP production with N-acetylcysteine decreased these changes, 
especially gap formation, significantly Scale bar apply for all images, 100 µm.
Supplementary table 1. Densitometric analysis of MMP-9 and MMP-2 activity in HUVEC conditioned me-
dium.
Incubation
MMP-9 activity
(fold-increase of control)
MMP-2 activity
(fold-increase of control)
Medium NAC Medium NAC
Medium 1 0.5 ± 0.4 1 0.6 ± 0.1*
TNF 1.3 ± 0.5 0.2 ± 0.1* 1 ± 0.1 0.7 ± 0.1
IFN 1.1 ± 0.6 0.35 ± 0.3 1.1 ± 0.2 0.9 ± 0.2
PBMC 5.5 ± 4.7 0.92 ± 0.5 1.0 ± 0.1 0.9 ± 0.1
TNF + PBMC 16.9 ± 10.4 3.0 ± 1.5 1.3 ± 0.2 1.0 ± 0.2
IFN + PBMC 1.3 ± 0.5 0.4 ± 0.3 1.1 ± 0.1 0.7 ± 0.1
TNF + IFN 1.7 ± 0.2 0.3 ± 0.3* 1.9 ± 0.2 1.5 ± 0.2
TNF + IFN + PBMC 40.0 ± 22.1 6.0 ± 2.0* 5.2 ± 1.5 4.0 ± 0.5
Note: Huvec were incubated with 10 µg/ml TNF, 0.1 µg/ml IFN, PBMC and N-acetylcysteine for 144 hours and zymog-
raphy of the supernatant was performed as described in the experimental procedures. Computerized densitometry 
were calculated to evaluate relative enzymatic activity using HUVEC medium as control. Data represent fold increase 
compared to HUVEC medium treated cells ± SD of at least 4 individual experiments; *, P < 0.05, cells incubated with 
medium versus N-acetylcysteine.
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tion with IFN and PBMC (Table 2). The data 
confirmed the observation that IL-1ß and en-
dothelial-derived MMPs are key players in TNF-
inflicted morphology and permeability changes 
of endothelial cells.
Effect of exogenous MMP on HUVEC mor-
phology. To further indicate that these specific 
EC-derived MMPs are needed we stimulated 
HUVEC with exogenous MMP, at levels mea-
sured in the MMP-9 and MMP-2 ELISA. HUVEC 
stimulated with only MMP-2 or MMP-9 showed 
no changes compared to cells incubated with 
medium. Incubation of HUVEC with TNF in 
combination with IFN showed cell elongation 
and gap formation that was further increased 
with the addition of PBMC. However, when 
PBMC were replaced with MMP-2 or MMP-9 
we noticed that the morphological changes 
were comparable to those seen in cells incu-
bated with TNF and IFN (Fig. 4a). Looking at 
cell elongation, TNF in combination with IFN 
showed no change in length to width ratio as 
TNF in combination with IFN and MMP-2 or 
MMP-9 enzyme, namely 6.0 ± 0.7 for TNF plus 
IFN, and 9.4 ± 0.8 for TNF in combination with 
IFN plus MMP-2, and 8.8 ± 1.7 for TNF in com-
bination with IFN plus MMP-9. Length to width 
ratio of HUVEC incubated with TNF in combi-
nation with IFN and PBMC (18.9 ± 1.3) or IL-
Table 1. Cell length to width ratio and cell-free area of HUVEC in the presence of MMP inhibitor N-acetyl-
cysteine.
Incubation Length to width ratioa Cell-free area (%)b
Medium NAC Medium NAC
Medium 1.3 ± 0.1 2.0 ± 0.4 0 ± 0.1 0 ± 0.1
TNF + IFN + PBMC 20.6 ± 2.1 13.5 ± 1.2 93.3 ± 3.8 9.9 ± 3.4*
TNF + IFN + IL-1ß 12.6 ± 1.8 11.0 ± 1.1 91.8 ± 2.1 21.1 ± 3.6*
Note: HUVEC were incubated with 10 µg/ml TNF, 0.1 µg/ml IFN and PBMC or 0.1 µg/ml IL-1ß. MMP activity was inhibited 
with N-acetylcysteine for 144 hours and morphological cell changes examined.
a Ratio of major and minor axes was measured to determine the cell elongation. Data represent length to width ratio ± 
SEM of 10 cells per treatment of at least 4 individual experiments.
b Cell-free area, as a percent of the total area, was calculated to verify the gap formation. Data represent percentage 
cell-free area ± SD of at least 4 individual experiments; *, P < 0.05, cells incubated with HUVEC medium versus N-
acetylcysteine.
Table 2. Percentage survival of HUVEC in the presence of TNF, IFN, PBMC and the MMP inhibitors GM6001 
and N-acetylcysteine.
Incubation % Mediuma % GM6001b λc % NAC b λc
TNF + PBMC 66.7 ± 1.9 59.2 ± 3.4 -7.5 88.3 ± 3.2* 21.6
TNF + 0,1 µg/ml IFN 28.4 ± 3.15 43.3 ± 5.5* 14.9 78.3 ± 7.2* 49.9
TNF + 0.001 µg/ml IFN 66.7 ± 3.7 73.9 ± 14.2 7.2 97.9 ± 8.9* 31.1
TNF + 0.1 µg/ml IFN + PBMC 20.7 ± 1.8 38.4 ± 7.3* 17.7 56.9 ± 4.3* 36.4
TNF + 0.001 µg/ml IFN + PBMC 37.2 ± 1.9 58.6 ± 9.3* 21.4 62.0 ± 4.0* 24.8
Note: HUVEC were incubated with 10 µg/ml TNF, IFN and PBMC. MMP activity was inhibited with GM6001 or N-
acetylcysteine for 144 hours. HUVEC incubated with HUVEC medium only were used as controls and set as 100 percent 
cell growth.
a Percentage cell growth of HUVEC exposed to given factors as compared to HUVEC cultured with HUVEC medium 
only.
b Percentage cell growth of HUVEC exposed to given factors and MMP inhibitor as compared to HUVEC cultured with 
HUVEC medium only.
Data represent percentage cell growth compared to HUVEC medium treated cells ± SEM of 2 experiments of at least 4 
individual experiments; *, P < 0.05, cells incubated with medium versus inhibitor.
c Survival gain or loss in the presence of GM6001 or N-acetylcysteine compared to cells treated without inhibitors.
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1ß (22.5 ± 1.8) was significantly enlarged as 
compared to the other combinations (Fig. 4b). 
Also, cell-free area, as an indication for gap for-
mation, in HUVEC incubated with TNF and IFN 
(14.3 ± 11.5%) was comparable with that of 
TNF in combination with IFN and MMP-2 (24.1 
± 19.3%) and TNF in combination with IFN and 
MMP-9 (11.0 ± 8.0%). Cell-free area was sig-
nificantly higher in HUVEC exposed to TNF in 
combination with IFN and PBMC (97.9 ± 0.6%) 
or IL-1ß (91.8 ± 2.1%) (Fig. 4c). Exogenous 
MMP did not inflict the same morphological 
effects as seen in HUVEC incubated with TNF 
in combination with IFN and PBMC or in HU-
VEC incubated with TNF in combination with 
IFN and IL-1ß.
DISCUSSION
We have previously shown that TNF-mediated 
changes of the endothelial lining of the tumor-
associated vasculature with TNF drastically im-
proved tumor response through an augmented 
accumulation of the co-administered chemo-
therapeutic drug [16-18]. We also demonstrat-
ed that exposure of HUVEC to TNF combined 
with IFN and PBMC induced cell elongation and 
gap formation. The main PBMC-derived factor 
responsible for the observed changes is IL-1ß 
[10]. The morphology and permeability changes 
implicate degradation of the extracellular ma-
trix (ECM) that is governed by activated MMPs. 
We found increased amounts of MMP-9 in su-
pernatant and cell lysate of HUVEC stimulated 
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Figure 4. Exogenous MMPs has no effect on HUVEC morphology. (a) Photographs were taken of HUVEC incubated 
with TNF (T) and IFN (I) combined with PBMC (P), IL-1ß, MMP-2 or MMP-9. HUVEC incubated with TNF and IFN showed 
some cell elongation and gap formation that was further increased when PBMC were added. Replacing PBMC with ac-
tive MMP-2 or MMP-9 enzyme did not induce these changes. Scale bar apply for all images, 100 µm. (b) Length to width 
ratio, representative for cell elongation, and (c) cell-free area, as function of gap formation, were calculated. Incubation 
with TNF and IFN increased cell elongation as well as gap formation compared to control. These effects were not further 
increased when MMP-2 or MMP-9 was added. However, addition of PBMC augmented cell elongation as well as gap 
formation. Columns represent length to width ratio ± SEM of 10 cells per treatment of at least 4 individual experiments 
and percentage cell-free area ± SD of at least 4 individual experiments; *, P < 0.05, cells incubated with medium, MMP-2 
or MMP-9 versus cells incubated with PBMC.
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with TNF, IFN and PBMC, whereas production 
of MMP-1, MMP-2 and MMP-3 was not affect-
ed. Adding IL-1ß validated the importance of 
IL-1ß in the production of MMPs and blocking 
endogenous produced IL-1ß with a neutralizing 
antibody. Thus we concluded that IL-1ß trig-
gers the endothelial cells to produce MMP-9. 
We established the biological relevance of in-
creased activity of MMP-9 with the aid of MMP 
inhibitors. Inhibition of MMPs reversed the ef-
fect of TNF, IFN and PBMC on HUVEC. Cells 
were rescued, gap formation was reduced and 
permeability decreased significantly, indicating 
that MMP-9 plays an important role in these 
processes.
Overproduction of MMP-2 and -9 has been 
long recognized as a major contribution to the 
degradation of extracellular matrix in the tumor 
environment. They are not only involved in the 
mechanical removal of the proteins in the ECM 
but are also able to participate in the regulation 
of cell growth, apoptosis, angiogenesis, inva-
sion and metastasis [19-21]. Elevated levels of 
gelatinases correlates with the aggressiveness 
of the tumor and is often associated with poor 
prognosis [22,23]. The current view is that ge-
latinases contribute positively in favor of tumor 
progression and therefore several MMP inhibi-
tors are studied in clinical trials, although re-
sults have been disappointing thus far [24-26]. 
However, it seems likely that the breakdown 
of the ECM and the basal membrane renders 
the underlying tumor tissue more accessible for 
chemotherapeutic drug.
Addition of high-dose TNF to an isolated 
limb perfusion (ILP) with melphalan results in 
high response rates in patients with in-transit 
melanoma metastases and limb threatening 
soft tissue sarcomas and in four out of five pa-
tients amputation could be avoided [27-31]. 
Angiograms of sarcoma-bearing patients af-
ter TNF-based ILP demonstrated complete de-
struction of the tumor vascular bed, whereas 
the normal vessels were not affected [32]. In 
our laboratory, we demonstrated that addi-
tion of TNF leads to an enhanced accumula-
tion of melphalan or doxorubicin specifically 
in the tumor in various ILP models [5,6]. This 
indicated that TNF primarily affects the tumor 
vasculature. Furthermore, systemic use of low-
dose TNF in combination with Stealth lipo-
somal doxorubicin (DOXIL) resulted as well in 
increased accumulation of cytotoxic drug in the 
tumor and therefore in significant improved tu-
mor response [7,33,34]. In conclusion, we hy-
pothesize that loss off endothelial cell integrity 
and increased permeability is of considerable 
importance in the treatment of solid tumors. 
MMPs have been reported to proteolyse cad-
herins, ß-catenin and occludin, which are im-
portant proteins in maintaining cell integrity 
[35-37]. Given that intercellular junctions rep-
resent a second significant target for MMPs, 
increased vascular permeability may also occur 
through destruction of the tight and adherens 
junctions that maintain the endothelial barrier. 
Cytokine-mediated induction of MMPs, leading 
to increased junctional reorganization, may be 
an important mechanism for increased perme-
ability observed in ILP and liposomal treatment. 
Effects of cytokines and PBMC on junctional 
proteins are currently under investigation by 
us. Strikingly, addition of exogenous MMP did 
not simulate the effects we observed with en-
dogenous produced MMPs. Also, MMP-9 ap-
peared only as a zymogen in the supernatant, 
whereas the active form could be detected in 
the cell lysate. This indicates that location of 
the MMP is of crucial importance. We specu-
late that endothelial cell-associated MMPs, 
which are in close proximity to the underlin-
ing matrix are the source of proteolytic activity. 
Docking of MMPs on the cell surface provides 
a direct mechanism by which cells utilize the 
proteolytic activity on the ECM. Additionally, 
cell surface localized MMPs are also protected 
against most inhibitors. Paradoxically, MMP-2 
in the cell lysate was decreased when IFN was 
added whereas in the supernatant MMP-2 was 
not affected. This could indicate that the role 
of MMP-2 is minimal in this setting.
As suggested in figure 5 (Fig.5) the pres-
ent work supports a model in which endog-
enously produced IL-1ß by TNF-primed PBMC, 
stimulates endothelial cells to produce MMP-9, 
hereby causing degradation of the underlying 
ECM, resulting in loss of the integrity of the 
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endothelial lining subsequently increasing per-
meability of the tumor vessels.
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ABSTRACT
Tumor necrosis factor-alpha (TNF) in combination with interferon-
gamma (IFN) changes the integrity of the endothelial cell mono-
layer and this is further enhanced with the addition of peripheral 
blood mononuclear cells (PBMC). The enhanced effect of PBMC 
was mostly induced by the endogenous production if interleukin-
1beta (IL-1ß) after TNF stimulation. VE-cadherin is an important 
protein in maintenance of the endothelial integrity. In this study 
we investigated the effect of TNF, IFN, PBMC and IL-1ß on the ex-
pression of VE-cadherin in human umbilical vein endothelial cells 
(HUVEC).
INTRODUCTION
Increased permeability of the tumor-associated 
vasculature is a feature observed when the 
proinflammatory cytokine TNF is used in the 
treatment of soft tissue sarcoma and mela-
noma. As a result of this enhance permeability 
more chemotherapeutic drug, like melphalan 
or doxorubicin, extravasate from the blood cir-
culation into the tumor tissue resulting in an 
improved antitumor effects [1-3]. Normally, the 
use of TNF is limited because of the severe side 
effect when administered at the dose needed 
for a tumor effect. Our laboratory is specialised 
in two techniques in which TNF can be safely 
administered. First, high doses can be reached 
using an isolated limb perfusion (ILP) in which 
the blood circulation of the tumor-bearing ex-
tremity is isolated form the rest of the body. 
Second, systemic low dose TNF in the margin 
of the maximal tolerated dose can repeatedly 
be administrated. TNF or the chemotherapeu-
tic agent as a single therapy gave poor results, 
the dual approach in which TNF changes the 
vascular permeability and the chemotherapeu-
tic agent that kills the tumor cells results in an 
improved tumor response [4,7].
TNF activates the endothelium resulting in 
altered cell morphology, changes in adhesion 
expression and loss in barrier function [8,9]. 
The response of endothelial cells to TNF and 
another important cytokine; interferon-gamma 
(IFN) has been extensively studied. In vitro, these 
cytokines inhibit proliferation of endothelial 
cells, inhibits αVβ3-mediated adhesion to the 
extracellular matrix and induce morphological 
and permeability changes. These changes in-
duced by TNF and IFN were further enhanced 
by the addition of peripheral blood mononu-
clear cells.
Adherens junctions act as important regula-
tors in the integrity of endothelial cells by con-
necting neighbouring cells and are formed by 
transmembrane proteins belonging to the cad-
herin superfamily [10]. Endothelial cells express 
a cell-specific cadherin, vascular endothelial (VE) 
cadherin, also known as CD144 or cadherin-5. 
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It mediates a homophilic, calcium dependent 
adhesion with the VE-cadherin of an adjacent 
endothelial cell and the cytoplasmic domain 
interact with ß-catenin and plakoglobin that 
associates in turn with α-catenin linking the 
entire complex to the actin cytoskeleton [11].
In this study we investigate the effects of 
TNF, IFN and PBMC on the effect of VE-cadher-
in in endothelial cells to further illustrated the 
changes in vascular permeability.
EXPERIMENTAL PROCEDURES
Agents. Recombinant human Tumor necrosis 
factor-alpha (TNF) and recombinant human IFN 
gamma (IFN) were kindly provided by Boehring-
er-Ingelheim GmbH. TNF had a specific activity 
of 5 x 107 U/mg and endotoxin levels were < 
1.25 U/mg protein. IFN had a specific activity 
of 2.5 x 107 U/mg and endotoxin levels were 
< 1 U/mg protein. Recombinant human inter-
leukin-1beta (IL-1ß) was purchased from Pep-
rotech EC Ltd with an activity of 1 x 107 U/mg 
and endotoxin levels were < 1U/µg protein.
Cells and cultured conditions. Human um-
bilical vein endothelial cells (HUVEC) were iso-
lated by collagenase digestion using the meth-
od described by Jaffe et al [12]. Each isolate 
was derived from an individual umbilical vein 
and used for experiments at passage 5. HUVEC 
were cultured in HUVEC medium containing 
human endothelial-serum free medium (Invit-
rogen), 20% heat inactivated newborn calf 
serum (Lonza), 10% heat inactivated human 
serum (Lonza) 20 ng/ml human recombinant 
Basic Fibroblast Growth Factor (Peprotech EC 
Ltd), 100 ng/ml human recombinant Epidermal 
Growth Factor (Peprotech EC Ltd) in fibronectin 
(Roche Diagnostics) coated flasks. HUVEC had 
the characteristic cobblestone morphology and 
tested positive for CD-31.
Human peripheral blood mononuclear cells 
(PBMC) were isolated from healthy donors 
using the Vacutainer CPT Mononuclear Cell 
Preparation Tubes with sodium heparin (Bec-
ton Dickinson). PBMC were washed with phos-
phate buffered saline and counted with trypan 
blue to determine the viable cell concentration. 
PBMC, at a final concentration of 120x104 
PBMC/ml, were used in all experiments.
Assessment of toxicity, apoptosis and per-
meability towards endothelial cells. HUVEC 
were plated in fibronectin-coated wells at a 
concentration of 6 x 104 cells per ml and al-
lowed to grow for 24 hours. Combinations of 
TNF, IFN, IL-1ß and PBMC were added to the 
well and incubated for 72 and 144 hours. As 
a control, cells were incubated with HUVEC 
medium alone. Growth of endothelial cells 
was measured using the sulphorhodamine B 
(SRB, Sigma) protein stain assay, according to 
the method of Skehan [13]. Briefly, cells were 
washed with PBS, incubated with 10% trichlo-
ric acetic acid (1 hour, 4ºC) and washed in dis-
tilled water. Cells were then stained for 15 min 
with SRB, washed with 1% acetic acid and al-
lowed to dry. Protein bound SRB was dissolved 
in 10 mM Tris buffer and optial density (O.D.) 
was measured at 540 nm. Cell growth was 
calculated using the formula: percentage cell 
growth = (O.D. test well/O.D. control well) x 
100 percent. For the apoptosis assay, detached 
cells in the supernatant were collected and 
living cells were harvested by mild trypsiniza-
tion and washed with PBS. Early apoptosis was 
detected using the annexin V kit and necro-
sis by propidium iodide (PI), according to the 
manufacturer’s instructions (Vybrant Apoptosis 
Assay kit #3, Molecular Probes). Cells were im-
mediately analyzed by flowcytometry (FACS-
can, Becton Dickinson). Data analysis was per-
formed using WinMDI 2.7 (Freeware, Joseph 
Trotter, Scripps Research Institute). To measure 
permeability, HUVEC were plated in the upper 
chamber of a transwell (0.4 µm pore size, 6.5 
mm diameter, polyester filters; Corning BV), 
coated with fibronectin, at a density of 2.5x104 
cells per transwell. When the cell established 
a rigid monolayer the medium in the upper 
chamber was replaced with medium contain-
ing combinations of TNF, IFN, IL-1ß and PBMC 
for 72 and 144 hours. To measure permeability, 
FITC-BSA in a concentration of 50 µg/well was 
added in the upper chamber. After the indicat-
ed incubation time, the upper chamber was re-
moved and the FITC fluorescence at the lower 
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chamber was read using a fluorescence plate 
reader (Wallac Victor2, Perkin Elmer).
Morphological changes. HUVEC were in-
cubated with combinations of TNF, IFN, IL-1ß 
and PBMC. After 72 and 144 hours, morpho-
logical cell changes were examined with a 10x 
N.A. 0.30 Plan-Neofluar objective lens using 
an inverted Zeiss Axiovert 100M microscope 
equipped with an Axiocam digital camera (Carl 
Zeiss). Cell elongation was measured and ex-
pressed as the ratio of the length of the ma-
jor cell axis to the width perpendicular to the 
length. Ten cells and at least four independent 
incubations were determined. In addition, gaps 
formation was determined for each treatment. 
The cell-free area was outlined and the gap 
formation was calculated using the formula: 
percentage cell-free area = (cell free area/total 
area) x 100 percent. Al measurements were 
done using the AxioVision 3.0 software.
Immunofluorescence. HUVEC were cultured 
in a final concentration of 6 x 104 cells per ml 
on a fibronectin coated cover glass and allowed 
to grow for 24 hours. The cells were incubated 
with HUVEC medium, 10 µg/ml TNF in combi-
nation with 0.001 µg/ml IFN or 10 µg/ml TNF in 
combination with 0.001 µg/ml IFN and PBMC. 
After 72 hours incubation, cells were rinsed in 
PBS and fixed with 3.6 % paraformaldehyde for 
10 min at room temperature. Cells were per-
meabilized with 0.1% Triton X-100 for 10 min, 
and a-specific binding sites were blocked with 
1% BSA in PBS for 10 min. Cells were stained 
with mouse anti human VE-cadherin (1:100; 
Chemicon) for 20 min followed by incubation 
with an Alexa Fluor conjugated goat anti mouse 
488 secondary antibody (Molecular Probes) for 
another 20 min. After washing the cells were 
mounted with vectashield (Vector laboratories) 
mixed with DAPI (Molecular Probes) in order to 
stain cell nuclei. Cells were examined using a 
Leica DMRX-A microscope and images taken 
with a Sony DXC 950 camera.
Analysis of VE-cadherin expression by 
western blotting. HUVEC were incubated 
with combinations of TNF, IFN, IL-1ß and PBMC 
for 72 hours, washed with PBS to removed 
PBMC, scraped off in PBS using a cell scraper 
and collected. After pelleting down the cells, 
the pellet was dissolved in ice cold lysis buf-
fer (20 mM Tris-HCl (pH 7.2), 100 mM NaCl, 
1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 2 µg/
ml pepstatin, 2 µg/ml leupeptin, 2 µg/ml apro-
tonin), incubated for 1 hour on ice and centri-
fuged at 200 rcf. Centrifuging the supernatant 
at 25,000 rcf for 30 min separated the cytosolic 
and membrane-bound proteins. The superna-
tant with the cytosolic proteins was collected 
en stored at -20°C until further analysis. To 
remove any contaminating cytosolic proteins 
the pellet was washed with ice-cold lysis buf-
fer and centrifuged at 25.000 rcf for 30 min. 
The pellet was resuspended in ice-cold extrac-
tion buffer (20 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 5 mM EDTA, 0.5% Igepal CA-630, 0.1% 
SDS, 1 mM PMSF, 2 µg/ml pepstatin, 2 µg/ml 
leupeptin, 2 µg/ml aprotonin), incubated for 1 
hour on ice and centrifuged at 25.000 rcf for 
30 min. The supernatant with the membrane-
bound proteins was collected and stored at 
-20°C until further analysis. Protein concentra-
tion in the cytosolic and membrane fractions 
was determined with Compassion Plus reagent 
(Pierce) and 7 µg of protein was separated by 
electrophoreses in a 10% SDS-PAGE gel un-
der reducing conditions and transferred to a 
polyvinylidene difluoride membrane (Bio-Rad). 
Membranes were blocked with MPBS (5% milk 
powder in PBS/0.05% tween-20) and incubat-
ed with mouse anti human VE-cadherin diluted 
in MPBS (1:200; Chemicon) overnight at 4°C. 
After washing, the membrane was incubated 
with goat anti mouse biotin diluted in MPBS 
(1:1500; Southern Biotechnology) for 1 hour 
at room temperature. Bound biotin was incu-
bated with alkaline-phosphatase-streptavidin 
complex (Bio-Rad), and this in turn stained with 
BCIP/NBT liquid substrate (Bio-Rad). The stain-
ing was stopped with 2 mM EDTA.
Semi-quantitative RT-PCR. Total RNA was 
extracted from HUVEC incubated with com-
binations of TNF, IFN, IL-1ß and PBMC for 72 
hours using TRIzol reagent as suggested by 
the manufacturer (Invitrogen). cDNA synthesis 
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was carried out by incubating 1.0 µg RNA with 
Omniscript Reverse Transcriptase (Qiagen) and 
oligo d(T)16 (Invitrogen) for 1 hour at 42°C fol-
lowing heating for 5 min at 93°C to terminate 
the reaction. PCR reaction was performed with 
a Biometra T-gradient PCR machine on a reac-
tion mix of 1.5 µl cDNA, 200 nM dNTP, 1,5 mM 
MgCl2, 50 pM of the sense and antisense prim-
ers and 0.5 U Titanium Taq DNA polymerase 
(Becton Dickinson) in PCR buffer to 50 µl final 
volume. The VE-cadherin primer (sense 5’-AC-
GACAACTGGCCTGTGTTCAC-3’ and antisense 
5’-TGCATCCACTGCTGTCACAGAG-3’) was 
purchased from Invitrogen. ß2-microglobulin 
(sense 5’-CTCACGTCATCCAGCAGAGA-3’ and 
antisense 5’-CGGCAGGCATACTCATCTTT-3’) 
was used as an internal standard. For PCR we 
used the following parameters: initial denatur-
ation at 94˚C for 5 min followed by a maxi-
mum of 40 cycles of 94˚C for 45 sec, annealing 
at 61.5 °C for 45 sec and extension 72˚C for 
1 min. To obtain results from the exponential 
phase of the reaction every 2 cycles, 5 µl of PCR 
product was collected and the samples were 
separated on a 1.5% agarose gel, stained with 
ethidium bromide and photographed under ul-
traviolet light box. A 100-bp ladder was used 
as the standard. The threshold cycle was deter-
mined as the cycle where the visible band of a 
specific PCR product first appeared on the gel. 
The results were expressed as the cycle of first 
appearance of the band normalized with the 
cycle of first appearance of ß2-micorglobulin.
Statistical analysis. The Mann-Whitney U-
test was used in all statistical analysis. P values 
below 0.05 were considered statistically signifi-
cant.
RESULTS
TNF and IFN increase endothelial perme-
ability that is further increased with the 
addition of PBMC. HUVEC were exposed to 
TNF, IFN, PBMC and IL-1ß during 72 and 144 
hours and changes in growth and permeability 
were determined. The cytokines TNF and IFN 
as a single treatment gave no effect on the 
endothelial monolayer and reduction in cell 
growth was not observed (data not shown). 
Even the combination TNF and IFN gave no re-
duction in cell growth (85 ± 12%) demonstrat-
ing a lack of direct activity of these cytokines 
on endothelial cells. When HUVEC were incu-
bated for 72 hours with TNF in combination 
with IFN and PBMC no significant difference 
in cell growth (90 ± 13%) could be observed. 
However, the additive effects of PBMC became 
apparent after 144 h of incubation resulting 
in a significant reduction in cell growth (47 ± 
8%). This effect could also be observed when 
PBMC was replaced by IL-1ß. Incubation for 72 
hours with TNF in combination with IFN and 
IL-1ß had no effect on cell growth (77 ± 15%) 
and significant induction of cell growth was 
observed 144 hours later (42 ± 3%) (Fig. 1a). 
There was a significant increase in endothelial 
permeability after exposure for 72 hours with 
TNF and IFN (152 ± 4%), TNF in combination 
with IFN and PBMC (163 ± 8%) or with IL-1ß 
(130 ± 4%). Further incubation of the endothe-
lial cells increased permeability to a 7-fold in-
crease after TNF in combination with IFN and 
PBMC and 6-fold increase in combination with 
IL-1ß (Fig. 1b). That endogenous produced IL-
1ß after priming the PBMC is responsible for 
the effects has been shown in previous experi-
ments. Neutralising the endogenous produced 
IL-1ß with an antibody brought the cell growth 
(84 ± 5 %) and permeability changes back to 
the level of TNF and IFN (data not shown). No 
significant changes in apoptosis was found af-
ter incubation with TNF and IFN compared to 
control and even addition of PBMC or IL-1ß 
had no influence on cell apoptosis indicating 
that morphological changes is the major effect 
for the increased permeability of the endothe-
lial layer (data not shown).
TNF and IFN induce morphological changes 
in the endothelial monolayer. HUVEC un-
der normal conditions form a cobblestone-like 
monolayer. Incubation with TNF alone resulted 
in a slight increase in cell elongation whereas 
IFN alone had no effect on the HUVEC (data not 
shown). The morphological phenotype of the 
HUVEC changed with the addition of TNF and 
IFN from this cobblestone monolayer to more 
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stretched cells that was even further enhanced 
with the addition of PBMC or IL-1ß. Also gaps 
between the cells became visible with the ad-
dition of PBMC after 144 hours of incubation. 
These gaps were also observed when replac-
ing PBMC with IL-1ß (Fig. 2a). Incubation af-
ter 72 hours with TNF in combination with IFN 
resulted in significant cell elongation compared 
to control treated HUVEC (7.5 ± 0.9 versus 1.4 
± 0.1). At this time point we observed no gap 
formation and the surface was for 96 ± 5% 
covered with endothelial cells. This cell elonga-
tion is apparently sufficient to induce moder-
ate increase in permeability. Longer incubation 
had no effect on cell elongation, but increased 
contact loss between the cells, increasing gap 
formation slightly. At 72 hours, the addition of 
PBMC or IL-1ß had no effect on cell elonga-
tion and gap formation compared to TNF and 
IFN. However, after 144 hours cell elongation 
was drastically increased and the cells obtained 
a fibroblast like morphology with a length to 
width ratio of 16.4 ± 2.2 after addition of 
PBMC or 14.5 ± 2.3 after IL-1ß (Fig. 2b). Also 
the gap formation was significant increased re-
sulting in a cell area of 61 ± 10% of the total 
area after incubation with TNF in combination 
with IFN and PBMC. Replacing PBMC with IL-
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Figure 1. TNF and IFN increase growth reduction and endothelial permeability. (a) Cell growth of HUVEC incu-
bated with 10 µg/ml TNF and 0.001 µg/ml IFN in combination with PBMC or IL-1ß after 72 or 144 hours. Seventy-two 
hours after incubation, no effect was observed. At 144 hours addition of PBMC or IL-1ß resulted in significant growth 
reduction. Columns represent percentage cell growth compared to control treated cells ± SEM of 5 individual experiments 
in duplicate; *, P < 0.05 versus control treated cells; #, P < 0.05 versus cells treated with TNF in combination with IFN. (b) 
Permeability changes of the endothelial layer were measured as described in the experimental procedures. Addition of 
TNF in combination with TNF increased permeability changes after 72 hours of incubation compared to control treated 
cells. At that time point PBMC or IL-1ß had no effect. The effect of PBMC or IL-1ß was observed 144 hours after incuba-
tion. Columns represent percentage permeability increase compared to control treated cells ± SEM of at least 3 individual 
experiments in duplicate; *, P < 0.05 versus control treated cells; #, P < 0.05 versus cells treated with TNF in combination 
with IFN.
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1ß reduced the cell area also significantly to 75 
± 4% (Fig. 2c).
TNF-primed PBMC and IL-1ß disrupts VE-
cadherin at the membrane. Increased per-
meability and leakage of the vasculature is of-
ten the result of a disruption in the junction 
proteins between neighbouring cells. VE-cad-
herin is the major transmembrane protein in 
maintaining the integrity of the endothelial cell 
monolayer. Therefore we investigated the pat-
tern of VE-cadherin in untreated HUVEC and 
HUVEC incubated with TNF, IFN in combination 
with PBMC or IL-1ß. Because the additional ef-
fects of PBMC or IL-1ß became apparent after 
72 hours we chose this time point for the anal-
ysis. Immunofluoresent staining of VE-cadherin 
in untreated cells shows a uniform VE-cadherin 
staining pattern localised at the membrane of 
the cells. When cells were exposed to TNF and 
IFN, the staining pattern changed with some 
loss of cell-cell contacts and slight reduction of 
VE-cadherin staining at the membrane. With 
the addition of PBMC or IL-1ß staining of VE-
cadherin was reduced drastically especially at 
sites with gap formation in with endothelial 
cells had lost contact with the neighbouring 
cell (Fig. 3a). Western blot analysis shows no 
significant change in overall expression of VE-
cadherin in endothelial cells after exposure to 
TNF or IFN alone (data not shown) and also 
after incubation with TNF in combination with 
IFN, no significant reduction could be found. 
However, with the addition of PBMC or IL-1ß 
VE-cadherin levels were markedly reduced in 
the membrane fraction of the cells (Fig. 3b). 
PCR analysis of HUVEC after incubation indi-
cates that the exposure to TNF and IFN does 
not reduce mRNA levels of VE-cadherin. Even 
with the addition of PBMC or IL-1ß no reduc-
tion is observed (Fig. 4). These data indicates 
that the production of VE-cadherin is not al-
tered by PBMC or IL-1ß, but that the protein 
is degraded at the membrane resulting in gap 
formation and increased permeability. Because 
we observed a reduction in staining pattern in 
de VE-cadherin after TNF and IFN incubation 
and no reduction in protein level we believe 
that VE-cadherin proteins relocalize within the 
membrane thereby stimulating permeability 
changes. Addition of PBMC or IL-1ß then de-
grades these proteins.
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Figure 2. TNF and IFN induce morphological changes. (a) Photographs taken from HUVEC incubated with TNF, IFN 
and PBMC or IL-1ß for 72 or 144 hours. Scale bar apply to all images, 100 µm. (b) Length to width ratio and (c) cell area 
were measured after incubation for 72 or 144 hours. TNF and IFN increased cell elongation after 72 hours and addition 
of PBMC or IL-1ß had no effect. The additive effects were observed after 144 hours. Columns represent percentage cell-
free area ± SD of at least 5 individual experiments and length to width ratio ± SEM of 10 cells per treatment of at least 4 
individual experiments; *, P < 0.05 versus control treated cells; #, P < 0.05 versus cells treated with TNF in combination 
with IFN.
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Figure 3. VE-cadherin is degraded at the cell membrane. (a) Staining for VE-cadherin and DAPI of HUVEC after in-
cubation for 72 hours as described in the experimental procedures. Control treated cells show that VE-cadherin localized 
at cell-cell junctions between two cells. Incubating the cells with TNF and IFN resulted in a more speckled pattern of VE-
cadherin. Addition of PBMC and IL-1ß further reduced VE-cadherin expression at the cell junctions. Scale bar apply for all 
images, 50 µm. (b) Western blotting show a significant decrease in the expression of VE-cadherin in the membrane frac-
tion of HUVEC after incubation of TNF in combination with IFN and PBMC. Replacing PBMC with IL-1ß also significantly 
decreased the amount of VE-cadherin. Columns represent percentage pixel density compared to control ± SD of at least 4 
individual experiments; *, P < 0.05 versus control treated cells. (See color section for a full-color version.)
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Figure 4. No change in the mRNA expression of VE-cadherin was observed. VE-cadherin mRNA expression in 
HUVEC incubated for 72 hours was investigated using semi-quantitative PCR. The mRNA expression did not change after 
incubation. The decrease protein expression at the membrane is not caused by an decrease in mRNA production. Col-
umns represent the cycle of first appearance of the VE-cadherin band minus the first appearance of the ß2-microglobulin 
housekeeping gene ± SEM of 2 treatments of 3 individual experiments.
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DISCUSSION
Previously we demonstrated that TNF in com-
bination with IFN and PBMC induced perme-
ability changes in endothelial cells and the ef-
fect of PBMC was mediated by endogenous 
produced IL-1ß after TNF-stimulation [9]. TNF 
alone has hardly any effect on endothelial 
cells and that has also been found by other 
researchers [14,15]. Other stimulators like IFN, 
PBMC, melanoma conditioned medium or hy-
perthermia, that mimic the tumor environment 
of conditions during ILP are required for TNF 
effects. Here we show that the additional ef-
fect of PBMC or IL-1ß starts after 3 days of in-
cubation. When endothelial cells were exposed 
to TNF in combination with IFN a significant 
increase in flux of the macromolecule FITC-BSA 
was found, indicating a change in endothelial 
integrity.
VE-cadherin, the primary component of the 
adherens junctions, is a member of the cadherin 
membrane receptor family involved in the calci-
um-dependent homophilic cell-cell interactions 
of its extracellular domain and is strictly locat-
ed at the intercellular junctions of endothelial 
cells. The extracellular binding between two 
VE-cadherin molecules mainly affects the initial 
cell-cell contacts during vessel development. 
The intracellular domain connects to the actin 
cytoskeleton through cytoplasmic interactions 
with catenin proteins, like α-catenin, β-catenin, 
γ-catenin (also referred to as plakoglobin) and 
p120. An increase in vascular permeability is 
in most occasions associated with a disruption 
if VE-cadherin [10, 16]. Furthermore, dynamic 
changes in membrane-associated VE-cadherin 
are also involved in the transmigration of leu-
cocytes. It seems that VE-cadherin relocate and 
cluster together at the site of diapedesis [17-
19]. Treatment of cells with TNF in combination 
with IFN results in degradation of VE-cadherin 
at the membrane that was further enhanced 
with the addition of PBMC. Replacing PBMC 
with IL-1ß also showed reduction of the pro-
tein.
However, these findings have little relevance 
to the ILP since TNF-induced effects in vitro re-
quires longer exposure then is clinical used. In 
contrast, priming of polymorfnuclear cells in-
stead of PBMC with TNF induced permeability 
changes within 30 min of incubation without 
no obvious gap-formation, cell elongation and 
cell number. However, degradation of VE-cad-
herin is observed within 30 min.
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ABSTRACT
Addition of high-dose TNF to melphalan-based isolated limb 
perfusion (ILP) enhances antitumor effects impressively. Unfortu-
nately, the mechanism of action of TNF is still not fully under-
stood. Here we investigated the effects of TNF on the tumor mi-
croenvironment and on secondary immunological events during 
and shortly after ILP in soft tissue sarcoma-bearing rats. Already 
during ILP softening of the tumor was observed. Co-adminis-
tration of TNF in the ILP with melphalan induced a 6-fold en-
hanced drug accumulation of melphalan in the tumor compared 
to ILP with melphalan alone. Also, directly after perfusion with 
TNF plus melphalan, so already in a time-frame of 30 minutes, 
vascular destruction, erythrocyte extravasation and hemorrhage 
was detected. However, interstitial fluid pressure (IFP) and pH in 
the tumor were not altered by TNF and no clear immune effects, 
cellular infiltration and cytokine expression were observed. Taken 
together, these results indicate that TNF-induces rapid damage to 
the tumor vascular endothelial lining resulting in augmented drug 
accumulation. As other important parameters were not changed, 
e.g. IFP and pH, we speculate that the tumor vascular changes 
and concurrent hemorrhage and drug accumulation are the key 
explanations for the observed synergistic antitumor response.
INTRODUCTION
Isolated limb perfusion (ILP) with tumor ne-
crosis factor-alpha (TNF) and melphalan, or in 
lesser extend with doxorubicin, is currently one 
of the therapies available for the treatment of 
patients with advanced bulky melanoma and 
sarcoma of the limbs and results in impressive 
enhancement of the response rates of over 
80% in a great variety of tumors [1,2]. Ef-
fective tumor therapy with TNF requires high 
concentrations, a prerequisite that is limited by 
the toxicity of the cytokine. The development 
of the ILP allows locoregional high doses with 
minimal risk for systemic toxicity. Investigations 
to the exact mechanism of the synergistic ef-
fect between TNF and chemotherapy in ILP are 
still ongoing. At the histopathological level it 
was shown that 3 hours after ILP the effects of 
TNF in a ILP starts with intratumoral endothe-
lial cell activation followed by over-expression 
of adhesion molecules, which in turn leads to 
polymorphonuclear leukocyte (PMN) homing, 
endothelium injury and finally coagulative and 
hemorrhagic necrosis [3,4].
We developed a TNF-based isolated limb 
perfusion models in rats, with similar results 
compared to the clinical setting, to gain further 
insight in the mechanisms underlying the ob-
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served synergy [5,6]. In this animal model we 
also observed hemorrhagic necrosis, edema, 
extravasation of erythrocytes, infiltration of 
polymorphonuclear neutrophils and destruc-
tion of tumor vasculature 24 hours after perfu-
sion [7]. The antitumor response is regulated 
by numerous factors, including cytokine pro-
duction by tumor cells and other cell source of 
the tumor microenvironment (endothelial cells, 
fibroblasts, tumor infiltrating lymphocytes) 
and other cytotoxic factors, like nitric oxide. 
Performing an ILP with TNF in combination of 
melphalan in leukopenic rats we found that the 
synergistic TNF-effect was lost, indicating the 
importance of leukocytes in this model [8]. TNF 
induces the production of other cytokines (e.g. 
IL-1, IL-6 and IL-8) as well as cytotoxic factors 
(e.g. nitric oxide) by T lymphocytes, granulo-
cytes and macrophages, which could mediate 
the tumor suppression. The complexity of the 
interaction of TNF with various immune modu-
lators within the tumor microenvironment is 
yet not well defined [9-11].
These histopathological effects of TNF de-
scribed thus far are relatively long after ILP. 
However, early vascular changes, i.e. directly at 
the end of the ILP procedure, are unknown. In 
this study we focus on the effects inflicted by 
TNF during and shortly after ILP.
EXPERIMENTAL PROCEDURES
Agents. Recombinant human tumor necrosis 
factor-alpha was provided by Boehringer In-
gelheim GmbH with a specific activity of 5.8 
x 107 U/mg as determined in the murine L-M 
cell assay [12]. Endotoxin levels were < 1.25 
units (EU) per mg protein. TNF concentrations 
used were 50 µg in 5 ml perfusate. Melphalan 
(Alkeran, GlaxoSmithKline BV) was diluted in 
phosphate buffered saline to a concentration 
of 2 mg/ml. Concentrations used were 40 µg 
in 5 ml perfusate.
Animals and tumor model. Male inbred BN 
rats, weighing 250-300 gram, obtained from 
Harlan-CPB were used for isolated limb per-
fusions. Rats were fed a standard laboratory 
diet ad libitum and were housed under stan-
dard conditions. The experimental protocols 
adhered to the rules outlined in the “Dutch 
Animal Experimentation Act” (1977) and the 
published “Guidelines of the UKCCCR for the 
welfare of animals in experimental Neoplasia 
[13]. The committee on Animal Research of 
the Erasmus University Rotterdam, the Neth-
erlands, approved the protocol. The rapidly 
growing and metastasizing BN175 soft tissue 
sarcoma, which is transplantable to the BN rat, 
was used. Fragments of 2-3 mm were implant-
ed subcutaneous in the right hind limb, just 
above the ankle. Perfusion was performed at a 
tumor diameter of 13 ± 2 mm, approximately 
7 days after implantation.
Isolated limb perfusion. The perfusion tech-
nique was performed as described previously 
[6]. Briefly, animals were anaesthetized with 
Ketalin (Apharmo) and Xylazin (Bayer B.V.). To 
prevent coagulation 50 IU of heparin was in-
jected intravenously. To keep the rat’s hind limb 
at a constant temperature of 38-39°C, a warm 
water mattress was applied. Temperature was 
measured with a temperature probe on the 
skin covering the tumor. The femoral artery 
and vein were cannulated with silastic tubing 
(0.012 inch inner diameter, 0.025 inch outer 
diameter; 0.025 inch inner diameter, 0.047 
inch outer diameter respectively, Dow Corning). 
Collaterals were occluded by a groin tourniquet 
and isolation time started when the tourniquet 
was tightened. An oxygenation reservoir and a 
roller pump were included into the circuit. The 
perfusion solution was 5 ml Haemaccel (Beh-
ring Pharma). Melphalan with or without TNF 
were added as boluses to the oxygenation res-
ervoir. A roller pump (Watson Marlow type 505 
U) recirculated the perfusate at a flow rate of 
2.4 ml/min for 30 min. A washout with 5 ml 
oxygenated Haemaccel was performed at the 
end of the perfusion.
Assessment of tumor response. Tumor 
growth was daily recorded by caliper measure-
ment. Tumor volume was calculated as 0.4 x 
(A2 x B), where B represents the longest diame-
ter and A the diameter perpendicular to B. The 
classification of tumor response was: progres-
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sive disease (PD) = increase of tumor volume 
(>25%) within 8 days; no change (NC) = tu-
mor volume equal to initial volume (in a range 
of -25% and + 25%); partial remission (PR) = 
decrease of tumor volume (-25% and -90%); 
complete remission (CR) = tumor volume less 
than 10% of initial volume. The animals with 
partial remission and complete remission were 
considered responders to the therapy.
Measurement of melphalan in tissue. At 
the end of the perfusion directly after the 
washout the tumor and part of the hind limb 
muscle were excised. The tissues were immedi-
ately frozen in liquid nitrogen to stop metabo-
lism of melphalan and stored at -80(C. Tumor 
and muscle tissues were homogenized in 2 ml 
acetonitrile (Pro 200 homogenizer, Pro Scien-
tific) and centrifuged at 2500 g. Melphalan 
was measured in the supernatant by gas chro-
matography-mass spectrometry. p-[Bis(2-chlo-
roethyl)amino]-phenyl-acetic methyl ester was 
used as an internal standard. Samples were 
extracted over trifunctional C18 silica columns. 
After elution with methanol and evaporation, 
the compounds were derived with trifluoroa-
cetic anhydride and diazomethane in ether. The 
stable derivates were separated on a methyl 
phenyl siloxane GC capillary column and mea-
sured selectively by single-ion monitoring GC-
MS in the positive EI mode described earlier by 
Tjaden and de Bruijn [14].
Measurement of interstitial fluid pressure 
(IFP). IFP was measured in tumor and muscle 
during ILP with the Wick-in-Needle technique 
[15]. A 23-gauge needle (Venisystems) with a 
2-3 mm side hole 5 mm from the tip was filled 
with five surgical sutures 6/0 (Braun Medical 
B.V.) and connected to a pressure transducer 
(DTXTM Plus Transducer, Becton Dickinson). 
Pressure was recorded on an analog-digital 
converter (AS/3 DATEX). After cannulating the 
femoral artery and vein, but before applying 
the tourniquet, the needle was inserted in the 
tumor and in the muscle of the same leg. The 
IFP was recorded until the end of the perfu-
sion.
pH measurements. A calibrated pH electrode 
in a 20 Gauge Needle (Harvard Apparatus Inc) 
was inserted in the tumor just before the roller 
pomp was started. The pH of the perfusate was 
measured by inserting a portable pH meter (pH 
meter HI 8424, Hanna Instruments Inc) in the 
oxygenation reservoir.
Hematoxylin-eosin staining. Directly or 6 
hours after perfusion tumors were excised and 
cut in two equal parts. Both parts were divided 
into a peripheral part and a central part. The 
tissues were stored in formalin and embedded 
in paraffin. 4 µm sections were stained with 
hematoxylin-eosin solution (Sigma) using stan-
dard procedures. Three or 4 different tumors 
in each experimental group were subjected to 
blind evaluation. At least 6 slides were exam-
ined from each tumor. All slides were examined 
on a Leica DM-RXA and photographed using a 
Sony 3CCD DXC 950 camera.
TUNEL/CD31PE double staining. Apoptotic 
cell death was detected using the technique 
of 3’hydroxy end labeling (In Situ Cell Death 
detection Kit, Fluorescein labeled, Roche Di-
agnostics). Tumor tissues were also stained 
for endothelial cells to differentiate between 
apoptosis of the endothelium and of tumor 
cells. After ILP the tumors were excised and 
immediately frozen in liquid nitrogen. Staining 
was performed on acetone-fixed 7 µm cryostat 
sections. The tumor sections were fixed in 4% 
paraformaldehyde for 30 min and incubated 
for 1 hour with mouse anti rat CD31PE (1:50; 
Becton Dickinson). After washing with PBS the 
sections were again fixed in 4% paraformalde-
hyde for 10 min and incubated in 0.1% Triton 
X-100 in 0.1% sodium citrate for 2 min on 
ice to allow permeabilization. The slides were 
incubated with the TUNEL mixture for 1 hour 
at 37°C and after that the slides were rinsed 
3 times in PBS and mounted with mounting 
medium containing polyvinyl alcohol (Mowiol 
4-88, Fluka). Endothelial cells were identified 
by red fluorescence and apoptosis by green 
fluorescence. Apoptotic endothelial cells were 
detected by co-localization of red and green 
(displayed as yellow) fluorescence.
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Immunohistochemistry. Directly or 6 hours 
after ILP tumors were excised and frozen in 
liquid nitrogen. Immunohistochemical stain-
ing was performed on acetone-fixed 7 µm cry-
ostat sections. The tumor sections were fixed 
for 30 min with 4% formaldehyde and after 
rinsing with PBS the endogenous peroxidase 
activity was blocked by incubation for 5 min 
in methanol/3% H2O2. The slides were incu-
bated for 1 hour with mouse anti rat CD31, 
-CD4, -CD8, -granulocytes (1:50; Becton Dick-
inson) and -ED-1 for macrophages (1:50; Se-
rotec). Thereafter, sections were washed with 
PBS and incubated for 1 hour with goat anti 
mouse peroxidase-labeled antibody (1:100; ITK 
Diagnostics BV). After rinsing with PBS, posi-
tive cells were revealed by immunoperoxidase 
reaction with DAB solution (ITK Diagnostics 
BV) and counterstained lightly with hematoxy-
lin (Sigma). For quantification of infiltration and 
microvessel density two independent persons 
performed blinded analysis. Six representative 
fields (magnification 16x) in each section and 3 
tumors per treatment were evaluated. The sec-
tions were examined on a Leica DM-RXA and 
photographed using a Sony DXC950 camera. 
For T cell, granulocyte and macrophage infil-
tration the total amount of positive cells were 
counted per field of interest. For the microves-
sel quantification, the number of tumor blood 
vessels (microvessel density, MVD) and the area 
of vessels per field of interest were measured 
in calibrated digital images (Research Assistant 
3.0, RVC). The average size of a vessel was cal-
culated by dividing the number of vessels with 
the area of vessels per field of interest.
Semi-quantitative RT-PCR. Total RNA was 
extracted from frozen tumor tissue using TRI-
zol reagent as suggested by the manufacturer 
(Invitrogen). cDNA synthesis was carried out by 
incubating 1.0 µg RNA with Omniscript Reverse 
Transcriptase (Qiagen) and oligo d(T)16 (Invitro-
gen) for 1 hour at 42°C following heating for 
5 min at 93°C to terminate the reaction. PCR 
reaction was performed with a Biometra T-gra-
dient PCR machine on a reaction mix of 1.5 µl 
cDNA, 200 nM dNTP, 1,5 mM MgCl2, 50 pM of 
the sense and antisense primers and 0.5 U Tita-
nium Taq DNA polymerase (Becton Dickinson) 
in PCR buffer to 50 µl final volume. The prim-
ers were purchased from Invitrogen and primer 
sequences are shown in table 1. ß-actin was 
used as an internal standard. For PCR we used 
the following parameters: initial denaturation 
at 94˚C for 5 min followed by a maximum of 40 
cycles of 94˚C for 45 sec, annealing for 45 sec 
(temperatures see Table 1) and extension 72˚C 
for 1 min. To obtain results from the exponen-
tial phase of the reaction every 2 cycles, 5 µl 
of PCR product was collected and the samples 
were separated on a 1.5% agarose gel, stained 
with ethidium bromide and photographed un-
der ultraviolet light box. A 100-bp ladder was 
used as the standard. The threshold cycle was 
determined as the cycle where the visible band 
of a specific PCR product first appeared on the 
gel. The results were expressed as the cycle of 
first appearance of the band normalized with 
the cycle of first appearance of ß-actin.
Statistical analysis. Results were evaluated for 
statistical significance with the Mann Whitney 
U test. P-values below 0.05 were considered 
statistically significant. Calculations were per-
formed on a personal computer using Graph-
Pad Prism v3.0 and SPSS v11.0 for Windows 
2000.
RESULTS
The combination TNF and melphalan re-
sults in increased antitumor response. 
Combination of TNF and melphalan resulted 
in an increased antitumor activity with a re-
sponse rate (PR and CR) of 80% compared to 
perfusion with melphalan alone (P < 0.001). 
Progressive disease was found in all animals 
treated with sham or TNF alone. Perfusion with 
melphalan alone showed some inhibition of 
tumor growth compared to sham and TNF, re-
sulting in 17% response. This tumor response 
increased to 80% when TNF was added (Table 
2). Another important observation made was 
the softening of the tumor, during the 30 min 
of perfusion, when treated with TNF in combi-
nation with melphalan. A characteristic we did 
not observed in the other treatments.
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Table 1. RT-PCR primers for the immune related genes.
Gene Primers Annealing temp. Product size (bp)
ß-actin f: 5’-ATGGATGACGATATCGCTG-3’
r: 5’-ATGAGGTAGTCTGTCAGGT-3’
60ºC 569
IL-6 f: 5’-GACTTCACAGAGGATACC-3’
r: 5’-TAAGTTGTTCTTCACAAACTCC-3’
55ºC 294
GRO/CINC-A f: 5’-GAAGATAGATTGCACCGATG-3’
r: 5’-CATAGCCTCTCACACATTTC-3’
57ºC 367
IL-10 f: 5’-TGACAATAACTGCACCCACTT-3’
r: 5’-TCATTCATGGCCTTGTAGACA-3’
60ºC 402
IL-12 f: 5’-TCATCAGGGACATCATCAAACC-3’
r: 5’-CGAGGAACGCACCTTTCTG-3’
65ºC 210
TNF f: 5’-TACTGAACTTCGGGGTGATCGGTCC-3’
r: 5’-CAGCCTTGTCCCTTGAAGAGAACC-3’
60ºC 295
IFN f: 5’-GCCTCCTCTTGGATATCTGG-3’
r: 5’-GTGCTGGATCTGTGGGTTG-3’
60ºC 239
MCP-1 f: 5’-ATGCAGGTCTCTCTGTCACG-3’
r: 5’-CTAGTTCTCTGTCATACT-3’
57ºC 446
MIP-2 f: 5’-GGCACAATCGGTACGATCCAG-3’
r: 5’-ACCCTGCCAAGGGTTGACTTC-3’
55ºC 287
TGF-ß1 f: 5’-TGGAAGTGGATCCACGAGCCCAAG-3’
r: 5’-GCAGGAGCGCACGATCATGTTGGAC-3’
55ºC 240
Note: ß-actin, was used as a housekeeping gene. f, forward primer; r, reverse primer; IL, interleukin; GRO/CINC-A, 
growth regulated gene product/cytokine-induced neutrophil chemo attractant (rat analog for IL-8); TNF, tumor necrosis 
factor-alpha; IFN, interferon-gamma; MCP-1, monocyte chemoattractant protein-1; MIP-2, macrophage inflammatory 
protein-2; TGF-ß1, transforming growth factor-ß1.
Table 2. Tumor response and drug accumulation after TNF-based ILP with melphalan.
Treatment
Tumor volume 
(mm3)a
Response rate
(% of animals)b
Melphalan in tu-
mor
(ng/g tissue)c
Melphalan in skin/
muscle (ng/g tis-
sue)cPD SD PR CR
Sham > 5000 100
TNF 4570 ± 511 100
Melphalan 1918 ± 293 33 42 25 136 ± 24 316 ± 91
TNF+melphalan 491 ± 245* 13 7 40 40 831 ± 293* 290 ± 125
Note: Animals were treated with ILP with sham, TNF, melphalan and melphalan plus TNF.
a Tumor volume was measured 8 days after ILP. Data represent tumor volume ± SD of at least 7 animals; *, P < 0.01 
versus treatment with melphalan.
b Tumor response is classified as described in the experimental procedures. PD, progressive disease; SD, stable disease; 
PR, partial response; CR, complete response.
c Intratumoral and muscular melphalan concentration were measured at the end of perfusion as described in the ex-
perimental procedures. Data represents ng melphalan per gram tissue ± SD of at least 3 animals; *, P < 0.01 versus 
treatment with melphalan.
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Addition of TNF increases intratumoral 
melphalan concentration. Immediately af-
ter perfusion with melphalan or melphalan in 
combination with TNF tumor and muscle were 
excised and melphalan concentration was mea-
sured. In tumor tissue perfused with melphalan 
and TNF, we measured a 6-fold increased mel-
phalan uptake compared to tumor tissue treat-
ed with melphalan alone (P < 0.01). That an in-
creased uptake of melphalan by TNF is specific 
for the tumor is demonstrated by the fact that 
in skin and muscle no effect of TNF was found 
on the uptake of melphalan (Table 2). The mel-
phalan concentration increased from 136 ng/g 
tissue to 831 ng/g tissue when TNF was co-
administered. The IC50 of melphalan on BN175 
cells is 250 ng/ml [16], demonstrating that the 
addition of TNF to the ILP shift the intratumoral 
drug concentration in to an active range. Ad-
dition of TNF does not change the sensitivity of 
BN175 cells in vitro, indicating that only mel-
phalan has a cytotoxic effect on the tumor cells. 
This indicates that the increased intratumoral 
melphalan concentration is responsible for the 
cytotoxic effect on the tumor cells leading to 
tumor regression. Important to mention is that 
the IC50 of melphalan on endothelial cells is 
must higher (40,000 ng/ml), which implies that 
endothelial cells are most likely not affected by 
melphalan in the ILP setting [17].
Addition of TNF results in destruction of the 
vasculature, extravasation of erythrocytes 
and increase apoptosis of endothelial cells. 
Previously, we demonstrated vascular damage, 
extravasation of erythrocytes and necrosis, 
causing drastic alterations in permeability and 
integrity of the vasculature 24 hours after ILP 
with melphalan in combination with TNF [7]. In 
HE stainings directly after perfusion with TNF 
plus melphalan, an increase in the number and 
size of necrotic areas was observed accompa-
nied by scattered extravasation of erythrocytes 
(Fig. 1). In some areas we detected destruction 
of the vasculature and from these vessels infil-
tration of erythrocytes into the surrounding tu-
mor tissue occurred. In tumors treated with TNF 
alone, we also observed destruction of the vas-
culature and erythrocyte infiltration from these 
vessels. After melphalan or sham treatment, 
no extravasation of erythrocytes, necrotic areas 
and loss in endothelial integrity was observed. 
Strikingly, no clear differences between central 
and peripheral part of the tumors were seen 
directly or 6 hours after ILP, with the exception 
that after 6 hours slightly more necrotic areas 
were detected (data not shown). For the de-
N
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TNF + melphalan TNF Melphalan Sham
Figure 1. Effect of TNF on the histopathology of tumor tissue after ILP. HE staining directly after perfusion with 
melphalan in combination with TNF showed necrotic areas, destruction of the vascular lining and extravasation of erythro-
cytes (arrow). Perfusion with TNF alone also induced vascular damage and erythrocyte infiltration. In sham or melphalan-
treated tumors the vessel lining was still intact. Dotted line denotes the boundary between normal tumor tissue (T) and 
necrotic tissue (N). Scale bar apply for all images, 100 µm. (See color section for a full-color version.)
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tection of apoptotic endothelial cells we per-
formed a tunnel/CD-31 double staining (Fig. 
2). In all four treatments apoptotic tumor cells 
were observed sporadically. In the TNF and TNF 
plus melphalan treated tumors an increased 
number of apoptotic endothelial cells were de-
tected directly after perfusion.
Addition of TNF has no effect on the in-
terstitial fluid pressure. As TNF has been 
shown to reduce interstitial fluid pressure (IFP) 
in tumor tissue in a systemic treatment [18]. IFP 
measurements were performed in both tumor 
and muscle tissue during ILP to investigate if 
TNF-induced lowering of the IFP could be an 
explanation for the enhanced drug accumula-
tion and softening of the tumor. Under normal 
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Figure 2. Effect of TNF on apoptosis of endothelial cells in tumor directly after ILP. Photographs demonstrating 
apoptotic tumor cells (green, arrowhead), endothelial cells (CD31, red) and apoptotic endothelial cells (yellow, arrow). 
Perfusion with melphalan in combination with TNF or with TNF alone induces apoptosis of endothelial cells whereas in the 
staining of tumor tissue after sham or melphalan perfusion no apoptotic endothelial cells were observed. Scale bar apply 
for all images, 100 µm. (See color section for a full-color version.)
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conditions the IFP of tumor tissue is much high-
er than that of muscle tissue (Fig. 3a). Tighten-
ing of the tourniquet resulted in an increased 
IFP in both tissues and start of the perfusion 
pump did not further increase the IFP. None of 
the treatments had an effect on the IFP in the 
tumor and the only increase we could see was 
in the muscle of the melphalan treated group 
after 20 and 30 min (P < 0.05). We speculated 
that the pressure inflicted by the pump in the 
extracorporal circuit might have a major im-
pact on the IFP. Indeed, when we increased the 
pump rate in our animal model, tumor IFP in-
creased and decreased again when the pump 
rate was reduced (data not shown). Although 
only one test was performed clearly the effect 
of the pump rate on the IFP was confirmed in 
de clinical setting in which comparable results 
were obtained (Fig. 3b).
The pH in tumor and perfusate is not in-
fluenced by the treatments. Tumor acidity 
can increase the antitumor activities of weak 
acid chemotherapeutics like melphalan [19]. 
Although acidosis is already a known fact in 
the microenvironment of solid tumors and is 
found in hypoxic areas we tested the hypoth-
esis whether treatment with TNF could cause a 
lowering of pH in tumor tissue. The pH of the 
tumor at the beginning of the perfusion was 
slightly acidic (6.9 ± 0.1) and lowered during 
perfusion until 6.6 ± 0.3. The pH of the per-
fusate was 6.9 ± 0.1. Adding the drugs had no 
effect whereas oxygenation lowered the pH to 
6.2 ± 0.1. Directly after start of the perfusion 
the pH of the perfusate increased to 6.5 ± 0.3 
and was 6.9 ± 0.1 at the end of perfusion. None 
of the treatments had an effect on the pH of 
the tumor or the perfusate indicating that TNF 
does not induce acidosis in this setting.
Addition of TNF has no effect on the num-
ber of vessels shortly after perfusion. The 
increased uptake of melphalan might be cor-
related with the functionality of the tumor-
associated vasculature. Quantification of the 
microvessel density and functionality was per-
formed by immunohistochemical staining of 
endothelial cells. The number of vessels as well 
as vessel area was measured. The area per ves-
sel was computed by dividing the total area of 
vessels by the number of vessels. Although we 
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Figure 3. TNF has no effect on interstitial fluid pressure during ILP. (a) Representative graph of the IFP recorded dur-
ing perfusion as described in the experimental procedure tumor (continuous line) and muscle (dotted line) and no effect of 
TNF was measured. (b) Representative graph of the IFP measured in a patient during ILP. Decreasing perfusion pump rate 
during ILP resulted in a lower IFP and vice versa indicating that in an ILP the IFP is dictated by the pump pressure.
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observed endothelial damage in the HE stain-
ing, addition of TNF had no effect on the num-
ber and size of the vessels directly after perfu-
sion (Table 3). The vessel area in the center or 
periphery part of the tumor was significantly 
decreased six hours after ILP compared to the 
area measured directly after perfusion with 
sham, TNF or melphalan (P < 0.05), however 
no change was observed after perfusion with 
TNF in combination with melphalan.
Tumor infiltration is not affected by the ad-
dition of TNF. In a previous study of ILP with 
IL-2 in combination with melphalan we ob-
served an redistribution of macrophages which 
was not observed in a sham perfusion [20]. In 
vitro data showed that TNF has only an effect 
on endothelial cells when combined with IFN 
and pheripheral blood mononuclear cells [17]. 
Therefore we also examined the possible sec-
ondary effects of TNF in the ILP. Performing ILP 
with TNF, directly or 6 hours after perfusion, we 
found no evident alterations in number (Table 
4) of localization (Fig. 4) of the examined tu-
mor infiltrating cells in all 4 treatments groups.
Addition of TNF did not change the cy-
tokine profile shortly after perfusion. As 
the number of tumor infiltrating cells was not 
affected by TNF, we hypothesized that TNF 
could probably activate macrophages and T 
lymphocytes resulting in the production of 
non-specific effector molecules. However, from 
the 9 cytokines examined we found no change 
in expression profile between the treatments 
groups (Table 5).
DISCUSSION
Clinical studies showed impressive improve-
ment of the antitumor activity of melphalan 
in local treatment of different tumor types 
when TNF was co-administered [1,2]. In this 
paper and in previous studies, we demonstrate 
Table 3. Microvessel density and area of the tumor vessels after ILP with sham, TNF, melphalan or TNF plus 
melphalan.
Sham TNF Melphalan TNF + melphalan
Number of vesselsa
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
19 ± 6
43 ±12
46 ± 31
36 ± 15
21 ± 7
32 ± 9
34 ± 13
29 ± 5
22 ± 2
34 ± 6
32 ± 14
38 ± 26
34 ± 25
19 ± 5
18 ± 7
25 ± 6
Total vessel areab
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
7.6 ± 0.7
7.6 ±0.3
4.0 ± 1.1*
3.8 ± 0.5*
10.7 ± 2.7
7.2 ± 0.4
4.0 ± 0.7*
3.5 ± 0.4*
5.9 ± 0.9
7.2 ± 0.1
6.1 ± 1.4
3.9 ± 1.5*
5.7 ± 1.0
5.0 ± 1.1
7.2 ± 2.4
3.6 ± 0.5
Vessel sizec
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
0.44 ± 0.09
0.22 ± 0.08
0.16 ± 0.05*
0.14 ± 0.04
0.59 ± 0.25
0.28 ± 0.10
0.14 ± 0.0*
0.13 ± 0.02
0.27 ± 0.03
0.23 ± 0.03
0.22 ± 0.03
0.18 ± 0.08
0.41 ± 0.17
0.30 ± 0.08
0.48 ± 0.16
0.18 ± 0.07
Note: Animals were treated with ILP with sham, TNF, melphalan and melphalan plus TNF and directly or 6 hours after ILP 
the tumors were excised and sections of the center or periphery were stained for CD31 positive cells.
a Number of vessels per field of interest at magnification 16x. Data represent total number ± SEM of 6 sections of 3 
individual tumors.
b Percentage of total vessel are per field of interest at magnification 16x. Data represent percentage of total area ± SEM 
of 6 sections of 3 individual tumors; *, P < 0.05 versus 0 hours of the same tumor region.
c Size of one vessel per field of interest at magnification 16x. Data represent percentage endothelium per vessel ± SEM 
of 6 sections of 3 individual tumors;*, P < 0.05 versus 0 hours of the same tumor region.
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Table 4. Tumor infiltration after ILP with sham, TNF, melphalan or TNF plus melphalan.
Sham TNF Melphalan TNF + melphalan
CD4a
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
0.3 ±0.1
1.0 ± 0.5
1.0 ± 0.5
0.5 ± 0.3
0.5 ± 0.3
1.4 ± 0.4
0.9 ± 0.4
0.6 ± 0.2
0.2 ± 0.1
0.7 ± 0.5
1.2 ± 0.4
0.8 ± 0.3
13.5 ± 13.0
0.5 ± 0.3
0.4 ± 0.1
1.6 ± 0.4
CD8a
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
34 ± 21
64 ± 26
22 ± 12
62 ± 20
27 ± 21
35 ± 7
51 ± 16
33 ± 3*
67 ± 47
75 ± 27
41 ± 13
51 ± 7
56 ± 55
139 ± 25
48 ± 29
42 ± 8#
Granulocytesa
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
60 ± 4
74 ± 19
69 ± 10
109 ± 39
89 ± 18
81 ± 25
72 ± 18
71 ± 12
48 ± 3*
62 ± 10
79 ± 14
50 ± 13
88 ± 12
37 ± 5
47 ± 6*#
81 ± 12#
Macrophagesa
center
periphery
center
periphery
0 hours
0 hours
6 hours
6 hours
189 ± 5
221 ± 42
171 ± 34
246 ± 39
192 ± 33
165 ± 11
174 ± 18
214 ± 34
201 ± 20
207 ± 23
230 ± 29
180 ± 16
172 ± 34
239 ± 11
147 ± 10
189 ± 2#
Note: Animals were treated with ILP with sham, TNF, melphalan and melphalan plus TNF and directly or 6 hours after 
ILP the tumors were excised and sections of the center or periphery were stained for CD4, CD8, granulocytes and mac-
rophages.
a Number of positive cells per field of interest at magnification 16x. Data represent total number ± SEM of 6 sections of 3 
individual tumors;*, P < 0.05 versus sham treatment of the same time point and region of the tumor; #, P < 0.05 versus 
0 hours of the same tumor region.
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Figure 4. TNF has no effect on redistribution of granulocytes and macrophages. Directly after treatment tumors 
were excised and stained for granulocytes and macrophages. There was no change in the number or redistribution of the 
tumor infiltrating cells between the treatments. Scale bar apply for all images, 100 µm. (See color section for a full-color 
version.)
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that isolated limb perfusion with melphalan in 
combination with TNF in soft tissue sarcoma-
bearing rats results in high response rates. This 
combination therapy is also very effective for 
the rat osteosarcoma and with another che-
motherapeutical agent, namely doxorubicin 
[21,22]. We demonstrated that the basis for 
the synergy is a significant enhancement of 
tumor drug accumulation. Subsequent events 
were selective destruction of the tumor-asso-
ciated vasculature leaving the normal vessel of 
the targeted area intact. This impaired blood 
flow leads to edema and necrosis. Although we 
observed these features already in rodent tu-
mor models with TNF alone, no significant tu-
mor regression occurred in these animals. Also 
these effects were observed at least 24 hours 
after perfusion whereas the tumor specific up-
take of the chemotherapeutic drug occurred 
within the 30 min of perfusion. Melphalan is 
an alkylating agent and has a cytotoxic effect 
on dividing tumor cells whereas TNF works se-
lectively on tumor-associated vasculature. We 
therefore hypothesis that ILP with melphalan 
and TNF follows a two-way mechanism. First, 
TNF targets the tumor vasculature therefore fa-
cilitating access of melphalan in the tumor tis-
sue followed by destruction of the tumor cells 
by melphalan.
Here we focus on the direct effects of TNF 
on the tumor microenvironment and second-
ary immunological effects during and shortly 
after perfusion. Already during perfusion with 
TNF and melphalan softening of the tumor was 
observed, a feature also observed in the clini-
cal setting [23], which could be an indication 
of hemorrhage or inflammation. Histological 
analysis of these tumors revealed some areas 
with complete destruction of the vasculature. 
The size and number of tumor vessels were 
not affected by the treatments this shortly af-
ter perfusion. We hypothesize that the slightly 
increased apoptotic cell number found directly 
after ILP, only partly explain the vascular dam-
age caused by TNF in combination with mel-
phalan. Ruegg et al. showed that inhibition of 
the αVβ3-mediated endothelial cell adhesion 
results in apoptosis and finally disruption of the 
tumor vasculature induced by TNF and IFNγ, 
but in this study tumor biopsies were examined 
24 hours after ILP [24], which might therefore 
be a secondary effect.
After perfusion with TNF in combination 
with melphalan or with TNF alone we observed 
scattered extravasation of erythrocytes in the 
surrounding tissue. This is not seen in sham or 
melphalan treated tumors. It is reported that 
erythrocytes can play an important role in the 
transport of certain drugs [25,26]. However, 
little is known about the contribution of eryth-
rocytes in the transport of melphalan. Wildiers 
et al. showed that 1 hour after i.p. adminis-
tration of melphalan 25% of the melphalan 
in the blood was transported via erythrocytes. 
Table 5. Cytokine expression after ILP with sham, TNF, melphalan or TNF plus melphalan.
Gene Shama TNFa Melphalana TNF + melphalana
0 hours 6 hours 0 hours 6 hours 0 hours 6 hours 0 hours 6 hours
IL-6 10 ± 1 8 ± 2 9 ± 0 6 ± 2 9 ± 0 9 ± 0 10 ± 1 7 ± 2
GRO/CINC-A 10 ± 1 5 ± 2* 7 ± 1 5 ± 3 10 ± 0 5 ± 1* 10 ± 2 4 ± 2*
IL-10 13 ± 1 13 ± 1 15 ± 4 13 ± 1 15 ± 1 13 ± 1 15 ± 1 12 ± 2
IL-12 15 ± 1 17 ± 3 14 ± 0 15 ± 3 13 ± 1 17 ± 1* 14 ± 0 16 ± 2
TNF 19 ± 1 13 ± 1* 17 ± 1 13 ± 2* 18 ± 2 14 ± 0* 17 ± 1 13 ± 1*
IFN 15 ± 1 11 ± 2 15 ± 1 13 ± 2 15 ± 1 13 ± 1 14 ± 0 13 ± 1
MCP-1 6 ± 1 5 ± 2 6 ± 1 6 ± 2 5 ± 0 6 ± 1 7 ± 0 6 ± 1
MIP-2 11 ± 1 8 ± 3 10 ± 3 7 ± 2 12 ± 1 9 ± 0* 12 ± 1 9 ± 2
TGF-ß1 3 ± 1 6 ± 2 4 ± 0 4 ± 2 3 ± 1 6 ± 0* 3 ± 1 5 ± 1
Note: Animals were treated with ILP with sham, TNF, melphalan and melphalan plus TNF and directly or 6 hours after ILP 
the tumors were excised and semiquantitative RT-PCR performed.
a Numbers are the cycles where the first band of each cytokine appeared corrected for the first band of ß-actin of the 
same sample. Data represent average ± SD of 3 individual tumors; *, P < 0.05 versus 0 hours
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He also showed that although the transport of 
melphalan via erythrocytes was less than that 
in plasma it correlated well with melphalan 
availability in embryonic stem cell-derived tu-
mors [27]. An increased extravasation of mel-
phalan-encapsulated erythrocytes by TNF could 
be a plausible explanation for the augmented 
concentration of melphalan in the tumor envi-
ronment and further experiments on the role 
of erythrocytes are currently performed in our 
laboratory.
Tumors are characterized by dilated hyper-
permeable and irregular shaped blood vessels, 
a lack of functional lymphatics and an abnormal 
turnover of extracellulair matrix components. 
Fluid and serum proteins leak from the vessels 
and accumulate in the interstitium increasing 
the interstitial fluid pressure. This chaotic vas-
cular structure and diminished buffering capac-
ity of the interstitial fluid pressure contributes 
to an acidic microenvironment of the tumor. 
Poor uptake of drugs into tumor interstitium 
is thought to, at least in part, be responsible 
for the low efficiency in pharmacological treat-
ment of solid malignancies [28,29]. Kristensen 
et al. showed that TNF caused a reduction in 
the IFP in human melanoma xenografts, what 
could lead to enhanced uptake of large mol-
ecules [18]. It has been demonstrated that low-
ering pH condition potentates the melphalan 
toxicity towards several tumor cell lines [19,30]. 
In our experiments we did not see an effect of 
TNF on the IFP during perfusion. Moreover, the 
pressure measured was solely ascribed to the 
design of this model. In our study we found 
that the pH in the BN175 tumor is slightly acid-
ic and none of the treatments had an effect on 
the pH in the tumor during ILP.
TNF is able to up regulate expression of sev-
eral cytokines (IL-1, IL-6, IL-8, IFNγ) in cancer 
and inflammatory responses. Up-regulation of 
these cytokines in the tumor microenvironment 
can account as a secondary effect of TNF. Tu-
mor infiltrating lymphocytes that express these 
cytokine are equally important. In vitro studies 
showed that TNF alone has hardly a direct ef-
fect on endothelial cells, only in combination 
with IFNγ and peripheral blood mononuclear 
cells we observed morphological changes of 
the endothelial layer leading to increased per-
meability [17]. Mocellin et al. found 24 hours 
after ILP with TNF and doxorubicin an increase 
in CD4 mRNA expression in the tumor microen-
vironment compared with tumor tissue before 
treatment [31]. An increased TIA-1 gene ex-
pression in tumor biopsies 24 hours after TNF-
based ILP compared to the patients treated with 
doxorubicin alone was found. They observed 
no change in tumor infiltrating lymphocytes 
as well as some other relevant cytokines, like 
IFNγ, IL-10 and TGF-ß. After in vitro stimulation 
with TNF of the different cell types that repre-
sent the tumor environment, TIA-1 expression 
is significantly increased in endothelial cells and 
NK cells. These experiments indicate that TNF-
induced TIA-1 over-expression might sensitize 
endothelial cells to pro-apoptotic stimuli pres-
ent in the tumor microenvironment and en-
hance NK cell cytotoxic activity against cancer 
cells [32]. Directly or 6 hours after ILP, we also 
found no effect on the expression profile of 
the panel of cytokines we tested and observed 
no variations in number or re-localization of 
tumor infiltrating lymphocytes between the 
treatments. A limitation of using the complete 
tumor for gene profiling is that we cannot link 
gene expression with a specific subset of cells. 
Further experiments are currently performed 
to investigate the gene expression in the dif-
ferent cell sources of the tumor and the im-
portance of a local up- or down regulation of 
cytokines. The imbalance in the cytokine profile 
within the tumor microenvironment more than 
the absolute level of an individual cytokine may 
be responsible for an effective versus ineffec-
tive immune response and needs to be further 
exploited.
In conclusion, application of TNF in com-
bination with melphalan in an isolated limb 
perfusion strongly improves response rates, 
which is due to an augmented melphalan ac-
cumulation in the tumor during ILP. We have 
recently reported a similar and crucial activity 
of histamine and interleukin-2 in this setting 
[16,20]. This increased drug accumulation by 
TNF is not explained by a lowering of the IFP. 
However, the tumor endothelial lining is dam-
aged in TNF-based ILP, rendering the vessels lo-
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cally more permeable to small molecules but 
also to erythrocytes that could function as car-
riers for melphalan. The exact mechanism of 
TNF-induced damage to the endothelial lining 
could not be explained by changes in cytokine 
expression or a redistribution of infiltrating 
lymphocytes around the vessels as we did ob-
served after interleukin-2 based ILP although a 
local imbalance of cytokines around these ves-
sels could be contribute to permeability chang-
es and will be further investigated.
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ABSTRACT
Successful treatment of solid tumors with chemotherapeutics re-
quires that adequate levels reach the tumor cells. Tumor vascular 
normalization has been proposed to enhance drug delivery and 
improve tumor response to chemotherapy. Differently, augment-
ing leakage of the tumor-associated vasculature, and as such en-
hance vascular abnormality, may improve tumor response as well. 
In the present study we show that addition of low-dose tumor 
necrosis factor-alpha (TNF) to systemic injections with pegylated 
long circulating liposomes, augmented the tumor accumulation 
of these liposomes 5 to 6-fold which strongly correlated with 
enhanced tumor response. Using intravital microscopy we could 
study the liposomal distribution inside the tumor in more detail. 
Especially 100 nm liposomes effectively extravasate in the sur-
rounding tumor tissue in the presence of TNF and this occurred 
without any effect on tumor vascular density, branching and di-
ameter. Next to that, we observed in living animals that tumor 
cells take up the liposomes intact, followed by intracellular deg-
radation. To our knowledge this is an unprecedented observa-
tion. Taken together, TNF renders more tumor vessels permeable, 
leading to a more homogeneous distribution of the liposomes 
throughout the tumor, which is crucial for an optimal tumor re-
sponse. We conclude that delivery of nano-particulate drug for-
mulations to solid tumor benefits from augmenting the vascular 
leakage through vascular manipulation with vasoactive drugs like 
TNF.
INTRODUCTION
Delivery of drugs in solid tumors is still a ma-
jor problem faced in chemotherapy and fre-
quently responsible for failure of initially prom-
ising agents. It is well recognized that the 
pathophysiology of the tumor vasculature and 
stromal compartment presents a important ob-
stacle [1]. This inadequate drug delivery leads 
to poor responses and regrowth of tumors. 
Several studies have shown that encapsulation 
of anticancer agents in pegylated long circu-
lating liposomes can reduce systemic toxicity 
while retaining or even improving in vivo ef-
ficacy [2-4]. Because of their small size, long 
circulation time, and reduced interaction with 
serum proteins, these liposomes tend to accu-
mulate in tumors, presumably due to leakage 
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through the often-compromised tumor vascu-
lature [5,6].
Recently, a combination of tumor vascular 
therapy with chemotherapy gained interest. Ad-
ministration of the anti-VEGF compound beva-
cizumab improved tumor response and survival 
in patients with metastatic colorectal cancer 
when used in combination with 5-fluorouracil/
leucovorin [7,8]. While anti-VEGF therapy is 
thought to have its effect through inhibition of 
angiogenesis, the tumor vascular normalization 
inflicted by bevacizumab has been proposed as 
a major contribution to the observed clinical 
outcome [9,10]. Also, tumor vascular manipu-
lation, next to destruction or inhibition, may be 
a useful approach in solid tumor chemothera-
py. We propose that apposed to tumor vascu-
lar normalization, further abnormalization, in 
particular vascular leakage, as well may benefit 
chemotherapy [11]. Indeed, administration of 
TNF, histamine or interleukin-2 improved lo-
cal drug delivery and tumor response [12-14]. 
An augmented vascular permeability and dis-
ruption of the vascular lining was the crucial 
observation in all these settings. With respect 
to TNF, we showed in previous studies that co-
administration of liposomal doxorubicin (Doxil) 
and TNF resulted in a drug accumulation ac-
companied by pronounced tumor response in 
both rat and murine tumor models [15,16]. 
Also in the isolated limb perfusion (ILP), in 
which TNF is co-administered with a chemo-
therapeutic agent for the treatment of patients 
with limb threatening tumors, addition of TNF 
results in increased accumulation of drug inside 
the tumor accompanied by improved response 
rates [14,17]. TNF is likely to augment the leaki-
ness of the vasculature by increasing the gaps 
in the endothelial lining, leading to improved 
extravasation of chemotherapeutic drugs into 
the tumor interstitium [18].
The goal of this present investigation was to 
dissect the effect of tumor vascular manipula-
tion by TNF on intratumoral distribution of pe-
gylated long circulating liposomes. For this we 
used labeled liposomes from different sizes and 
performed intravital microscopy in the mouse 
dorsal skin-fold chamber for a detailed insight 
in the intratumoral localization of the admin-
istered liposomes. Here we show that TNF not 
only increases the leakiness of some tumor ves-
sels but also renders more vessels permeable to 
liposomes while leaving the vascular function 
(e.g. flow) intact. As a result a more homoge-
neous drug distribution in the tumor is reached 
explaining an improved tumor response.
EXPERIMENTAL PROCEDURES
Agents. Recombinant murine tumor necrosis 
factor-alpha (mTNF), with a specific activity of 3 
x 107 U/mg and endotoxin levels below 1 units 
(EU) per mg protein [19] was kindly provide by 
Boehringer Ingelheim GmbH. Doxorubicin hy-
drochloride (Adriblastina) was purchased from 
Pharmachemie and pegylated long circulating 
liposomal doxorubicin (Doxil/Caleyx) was pur-
chased from Schering-Plough.
Preparation of long circulating lipo-
somes. For the preparation of liposomes fol-
lowing chemicals were used; partially hydro-
genated egg phosphatidyl choline (PHEPC; 
lipoid GMbH), cholesterol (Sigma) and dis-
tearoyl phosphatidylethanolamine poly-
(ethyleneglycol) (PEG-DSPE; ALZA Corporation) 
in a molar ratio of 1.85:1:0.15. Liposomes of 
100 nm were prepared by sonication as de-
scribed before [20]. Liposomes of 400 nm and 
800 nm were obtained by multiple extrusions 
through polycabonate membranes (Nuclepore) 
with corresponding pore size. Liposomes were 
labeled with Gallium67 citrate (Nordian) accord-
ing to Gabizon et al. [21]. Long circulating rho-
damine liposomes (Rho-PEG-L) were composed 
of PHEPC, cholesterol and PEG-DSPE in a molar 
ratio of 1.85:1:0.15 and labeled with 0.1 mol% 
of the fluorescent bilayer marker lissamine-rho-
damine-phosphatidyl-ethanolamine (Molecular 
Probes). The exact size was measured by dy-
namic light scattering (DLS, Malvern 4700 sys-
tem, Malvern) and the amount of lipid was de-
termined according to Bartlett [22]. Doxil-DiO 
liposomes were produced by incubating Doxil 
with 0.2 mol% of the lipophilic tracer diocta-
decyloxacarbocyanine perchlorate (DiO-C18(3)) 
(Molecular Probes) during 10 min at room tem-
perature and sonicated for 20 sec.
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Animals and tumor model. Specific patho-
gen-free female C57BL/6 mice were purchased 
from Harlan-CPB, weighing about 20 grams, 
and were fed a standard laboratory diet ad 
libitum (Hope Farms). The B16BL6 melanoma 
tumor model was used for this study. All ani-
mal studies were done in accordance with pro-
tocols approved by the committee on Animal 
Research of the Erasmus MC, Rotterdam, the 
Netherlands.
Treatment protocol. Experiments were started 
when the subcutaneous transplanted B16BL6 
tumors reached a diameter of 8-10 mm. For 
tumor response, mice were randomized into 
the following 4 groups: saline, mTNF, Doxil 
and Doxil immediately followed by injection of 
mTNF. Mice were injected five times in the tail 
vein with an interval of 4 days between the in-
jections; first dose of 4.5 mg/kg Doxil and 1.0 
mg/kg for consecutive doses. Murine TNF in a 
dose of 1 µg/mouse, which is well tolerated in 
mice without any side effects, was given for all 
five treatments. Tumor growth was recorded by 
caliper measurement and volumes calculated 
using the formula 0.4 x (A2 x B) where B repre-
sents the largest diameter and A the diameter 
perpendicular to B). The tumor size is expressed 
as tumor size index, i.e. the tumor volume in 
relation to initial tumor volume. For biodistribu-
tion studies and determination of doxorubicin 
levels in serum, mice were injected via the tail 
vein with 48 µmol/kg 67Ga-labeled liposomes 
or 1 mg/kg Doxil in combination with saline or 
mTNF (1 µg/mouse). After sacrifice, tumor and 
tissues were collected, weighed, and counted 
in a Beckmann 8000 gamma counter and data 
are expressed as percentage of injected dose 
per gram tissue. Serum samples were collected 
by cardiac puncture before sacrifice. A Hitachi 
F4500 fluorescence spectrometer (excitation 
472 nm and emission 590 nm) was used for 
measurement of the samples as previously de-
scribed [16,23].
Biodistribution using the dorsal skin-fold 
chamber. Preparation of the dorsal skin-fold 
chamber is an adaptation from previously de-
scribed procedures [24-26]. Briefly, mice were 
anesthetized (100 µl of a 2:1:1 (v:v:v) mixture 
of saline, ketamine and xylazine) and hair was 
removed from the back of the animal. After dis-
secting the skin, leaving the fascia and oppos-
ing skin, the skin-fold of the mouse was sand-
wiched between two frames, fixed with two 
light metal bolds and sutures. A small piece of 
tumor (0.1 mm3) was transplanted in the fascia 
and on both sides the window was closed with 
a 12 mm diameter microscopic cover glass of 
0.13-0.16 mm thick. The mice were housed in 
an incubation room with an ambient tempera-
ture of 32°C and a humidity of 70%. Experi-
ments started 10 to 14 days after implantation 
of the dorsal skin-fold chamber. Mice were in-
jected via the tail vein with 4.5 mg/kg doxoru-
bicin, 4.5 mg/kg Doxil-DiO or 48 µmol/kg Rho-
PEG-L immediately followed by injection with 
saline or mTNF (1 µg/mouse).
Fluorescent imaging. At given time points, 
mice were anesthetized and fixed to the heat-
ed microscope stage of a Zeiss LSM 510 META 
confocal microscope. Injection of 50 µl FITC-
BSA (1 mg/ml, Sigma) allowed visualization of 
functional vessels. Randomly selected tumor 
regions were examined with 20x (NA 0.5) long 
working distance objective lens and detailed 
examination was performed using 40x water 
emersion objective lens (NA 0.8). Scans were 
made with a 488 argon laser for DiO and FITC-
BSA (505-550 nm band pass filter) and a 543 
nm Helium-Neon laser for doxorubicin/Doxil 
and rhodamine (560-615 nm band pass filter). 
Vessel morphology such as vessel density (the 
area of vessels as percentage of the total field 
of interest), vessel segments (the number of 
vessels connected to each other at the branch-
ing point) and diameters were analyzed using 
the Zeiss LSM Image Browser 4.0 software. Im-
ages were analyzed using Image Tool (Don Wil-
cox, University of Texas Health Science Center). 
The RGB color images of 512 x 512 pixels were 
converted to grayscale in Image Tool. The fluo-
rescence intensity ranged form 0 to 255 and 
we distinguished specific staining from back-
ground using a threshold of 45. The proportion 
of pixels with fluorescence intensity above the 
threshold was calculated. To determine extrava-
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sation of liposomes a gridline overlay was ap-
plied of 64x64 pixels using Adobe Photoshop 
6.0. Extravasation of liposomes was scored by 
counting the number of times the gridlines in-
tersected with intra- or extravascular presence 
of liposomes. Second, using a look-up table 
the fluorescence intensity of the representative 
grayscale images were converted to a pseudo 
color spectrum from 0 to 255 and transformed 
to a surface plot. The heights of the peaks cor-
respond to the fluorescence intensity.
In vitro uptake. B16BL6 melanoma cells were 
maintained in DMEM supplemented with 10% 
heat inactivated FCS. Tumor cells were cultured 
on a cover glass and grown till confluence. 
The cells were washed and Doxil or doxorubi-
cin was added at a concentration of 5 µg/ml. 
The cells were placed under a Zeiss LSM 510 
META confocal microscope equipped with an 
incubation chamber, which is maintained at 
37°C with controlled CO2-flow. Every 5 min-
utes scans were made using the 543 nm laser 
and 560-615 nm band pass filter.
Statistical analysis. Results were evaluated 
for statistical significance with the Kruskal Wal-
lis and Mann Whitney U test. All statistical tests 
were two-sided and P-values below 0.05 were 
considered statistically significant. Calculations 
were performed on a personal computer using 
GraphPad Prism v3.0 and SPSS v11.0 for Win-
dows 2000.
RESULTS
Addition of TNF improves response to 
Doxil. To evaluate the antitumor activity of 
Doxil in combination with low-dose mTNF, 
B16BL6-bearing mice were treated with sa-
line, mTNF, Doxil and Doxil in combination with 
mTNF (Table 1). Combination of Doxil with 
mTNF resulted in a tumor growth arrest and 
all mice were still in the treatment at the end 
of the experiment. Control and mTNF treated 
mice showed progressive disease and had to 
be sacrificed between day 8 and 12. Treatment 
with Doxil alone showed some tumor response 
and at the end of treatment 33% of the mice 
had a tumor size index smaller than 4.
Addition of TNF increases accumulation of 
liposomes in the tumor. We speculated that 
the observed improved tumor response was 
not due to a direct effect of mTNF on the tu-
mor cells. First, mTNF by itself has no effect on 
tumor progression. Second, the concentration 
of mTNF, which can theoretically be reached in 
the tumor, is too low to have a direct effect on 
these tumor cells (data not shown). Therefore 
we studied whether mTNF augmented lipo-
somal delivery in the tumor. The results show 
a 6.3-fold increased accumulation of 100 nm 
liposomes in the tumor 12 hours after co-ad-
ministration with mTNF compared to liposomes 
alone (P < 0.05), and a 5.5-fold increase after 24 
hours (P < 0.05) (Fig. 1a). Co-administration of 
mTNF and 400 nm liposomes resulted in a 5.1-
fold enhanced accumulation at 12 hours (P < 
0.05) and 9.2-fold at 24 hours (P < 0.01) com-
pared to liposomes alone. In case of 800 nm 
Table 1. Tumor response after systemic treatment of B16BL6-bearing mice.
Treatment Response of B16BL6 melanoma (tumor size index) % mice with TSI < 4
Day 4 Day 8 Day 12 Day 16 Day 16
Saline 2.4 ± 0.3 2.8 ± 0.8 - - 0
mTNF 2.3 ± 0.8 3.2 ± 0.1 - - 0
Doxil 2.1 ± 0.8 3.0 ± 1.0 4.0 ± 1.5 3.8 ± 0.4 33
Doxil + mTNF 1.3 ± 0.4# 1.4 ± 0.3*# 1.5 ± 0.3* 2.0 ± 0.8* 100
Note: Mice were injected 5 times via tail vein with an interval of 4 days with saline, mTNF, Doxil and Doxil in combination 
with mTNF and tumor size index (TSI, the tumor volume in relation to the tumor volume at the start of treatment) was 
calculated.
Data represent tumor size index ± SD of at least 4 individual animals; *, P < 0.05 versus injection with Doxil alone at the 
same time point; #, P < 0.05 versus injection with mTNF alone at the same time point.
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liposomes, addition of mTNF did not cause an 
increased accumulation of these liposomes (4.1 
± 3.7% without mTNF, 3.8 ± 0.9% with mTNF, 
data not shown). Accumulation of 400 and 
800 nm liposomes in tumor was significantly 
lower compared to 100 nm liposomes, even in 
the presence of mTNF, indicating the beneficial 
properties of small liposomes. Besides localiza-
tion in tumor, liposomal distribution to other 
organs was investigated. In the spleen, mTNF 
did not increase uptake of all three liposome 
sizes. Only in hart and liver we observed a slight 
increase op liposomal uptake with the addition 
of mTNF with could potentially give an increase 
in cardiotoxicity (data not shown). Twelve hours 
after injection 51 ± 25% of the liposomes were 
still present in the blood circulation whereas 
free doxorubicin was hardly measurable (2.7 ± 
0.9%, data not shown). Even after 72 hours 
still 15 ± 2% of the liposomes were measured 
in the circulation. With the addition of mTNF 
a lower liposomal percentage (P < 0.05) was 
found in the blood circulation (25 ± 18% for 
12 hours and 6 ± 4% for 72 hours) (Fig. 1b). 
Liposome accumulation is selectively augment-
ed in the tumor by the addition of mTNF and is 
the main cause of the increased clearance from 
the circulation.
Addition of TNF improves extravasation 
and homogenous distribution of 100 nm 
long circulating liposomes. Ten days after tu-
mor implantation in the dorsal skin-fold cham-
ber a tumor size of 4 to 5 mm was reached. 
Few supplying vessels could be observed. Un-
like the normal blood vessels around the tu-
mor, the newly formed vessels are not well 
organized. They display tortuous structure, 
frequent branching and irregular diameters 
(Supplementary Fig. 1). Clearly, addition of a 
tolerable dose of mTNF resulted in augmented 
liposome accumulation in tumor. However, it is 
still unclear how TNF affects the tumor vascu-
lar lining. Moreover, insight in the intratumoral 
localization of the liposomes is lacking. There-
fore we studied the effect of mTNF on intra-
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Figure 1. Addition of TNF increases uptake of long circulating liposomes in tumor tissue. (a) The effect of mTNF 
on 67Ga-labeled liposome distribution of different sizes was analyzed 12 or 24 hours after systemic injection. Addition of 
mTNF increased tumor localization of liposomes significantly. Columns represent percentage liposomes per gram tumor 
tissue ± SEM of at least 3 individual animals; #, P < 0.01; *, P < 0.05 versus no mTNF of the same time point. (b) Analysis 
of Doxil in the blood circulation after systemic injection in combination with saline or mTNF. Twelve hours after injection 
significantly less liposomes were found in the blood circulation. Data points represents percentage liposomes in the blood 
circulation ± SD of at least 3 individual animals; *, P < 0.05 versus no TNF of the same time point.
Homogenous distribution of liposomes is mediated by TNF128
tumoral distribution of liposomes with the use 
of intravital microscopy. We first investigated 
extravasation of Rho-PEG-L with a size of 100 
nm. We observed hardly any extravasation 
when only Rho-PEG-L was administered. In-
terestingly, when liposomes were found, these 
appeared accumulated in tumor vessels. Addi-
tion of mTNF resulted in abundant extravasa-
tion of liposomes into the tumor interstitium 
(Supplementary Fig. 2). Only in a few areas li-
posomes were still present inside blood vessels. 
Twenty-four hours after injection of liposomes 
and mTNF, 50 µl FITC-BSA was administered 
intravenously to visualize functionality and per-
meability of blood vessels. With the addition 
of mTNF, FITC-BSA extravasated at the same 
spot as the liposomes indicating that these 
vessels were still leaky. At higher magnifica-
tion we observed that FITC-BSA positive vessels 
were quite permeable for 100 nm liposomes. 
This indicates that liposomes extravasated from 
blood vessels that remained functional in spite 
of their increased leakiness (Fig. 2a). Surface 
plots of the liposomal fluorescence showed 
fluorescence peaks representing intravascu-
lar liposomes. Addition of mTNF resulted in 
broad areas with high fluorescence intensity 
representative of massive liposome extravasa-
tion (Fig 2b). Without mTNF the incidence that 
a liposome was found intravascular was 70 ± 
16% and 74 ± 12% after 12 and 24 hours re-
spectively. With the addition of mTNF hardly 
any liposomes could be found inside the ves-
sels anymore (2 ± 2% after 12 hours and 1 ± 
a
b c
Supplementary Figure 1. Intravital microscopy reveals profound intratumoral vascularization in the B16BL6 
model. Ten days after tumor implantation in the dorsal skin-fold chamber the tumor growth and vasculature were visual-
ized. (a) While some newly formed blood vessels originating from the surrounding normal vasculature feed the B16BL6 
tumor, abundant intratumoral branches were observed (magnification, arrow). (b) For a better visualization in the B16BL6 
tumor, FITC-BSA was injected and a chaotic, branched tumor vasculature is observed in the tumor. (c) The pattern of the 
normal vasculature displayed minimal branching, even vessel diameter and a definable direction. Scale bar apply to all 
images, 250 µm. (See color section for a full-color version.)
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1% after 24 hours) (Fig. 2c). Microvascular pa-
rameters were determined by intravital micros-
copy when the tumors were treated. Addition 
of mTNF had no effect on vessel density, num-
ber of segments and diameter, indicating that 
accumulation of liposomes was not the result 
of a change in vessel number or size (Supple-
mentary Table. 1). Summarizing, the addition 
of mTNF caused an increased extravasation of 
100 nm liposomes into the tumor interstitium 
in a more homogeneous way. Less liposomes 
were trapped inside blood vessels when mTNF 
was co-administered. These results indicate 
that administration of mTNF results in an in-
crease in the number of leaky vessels.
Addition of TNF did not alter the intratu-
moral distribution of 400 nm long circulat-
ing liposomes. It has been shown previously 
that tumor vessel are permeable for transport 
of macromolecules with a maximum size of 400 
nm, suggesting a cutoff size of the pores some-
where between 400 to 600 nm [27]. Strikingly, 
as shown above, most tumor vessels of the 
B16BL6 melanoma did not allow extravasation 
of the 100 nm liposomes, whereas addition of 
mTNF clearly affected the gap size. To investi-
gate if mTNF has a comparable effect on intra-
tumoral distribution of larger liposomes, Rho-
PEG-L of 400 nm were injected. Without mTNF 
liposomes became mostly trapped inside blood 
vessels, rendering these vessels non-functional 
as no intravascular presence of FITC-BSA could 
be observed. Addition of mTNF enhanced the 
extravasation of liposomes only slightly, most-
ly at the periphery of the tumor (Fig. 3a and 
Supplementary Fig. 3). Analysis of the fluo-
rescence intensity showed a 2-fold increase of 
intratumoral localization of liposomes due to 
the addition of mTNF (Fig. 3b). However, less 
then 10% of the liposomes were present in 
the surrounding tumor tissue even when co-
administered with mTNF (Fig. 3c and Fig.3d). 
These results indicate a diminished usefulness 
of the 400 nm liposomes as compared to li-
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Supplementary Figure 2. Addition of TNF leads to an increased accumulation of long circulating liposomes 
(Rho-PEG-L) in the tumor tissue. Intravital microscopy scans of the B16BL6 melanoma were compared to illustrate 
the effect of mTNF on the liposomal uptake after systemic administration. (a) Hardly any liposomes were observed in the 
tumor tissue. Only in a few regions liposomes were seen intravascular (insert, arrow). Addition of mTNF clearly inflicted a 
homogenous intratumoral accumulation of liposomes. Scale bar apply to all images, 500 µm. (b) The increase in height of 
the fluorescence intensity peaks of the surface plots illustrates increased accumulation of liposomes when combined with 
mTNF. (See color section for a full-color version.)
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Figure 2. Addition of TNF promotes liposomal extravasation through hyperpermeable vessels. The effect of 
mTNF on tumor distribution of systemically injected long circulating liposomes (Rho-PEG-L) was studied by intravital 
microscopy. Twelve or 24 hours later mice were injected with FITC-BSA to visualize functional vessels. (a) In mice injected 
with Rho-PEG-L alone, some liposomes were seen in the surrounding tumor tissue (asterix), but predominantly in the 
blood vessels. In blood vessels filled with liposomes no green FITC-BSA fluorescence could be seen (arrow), indicating 
that these intravascular liposomes were obstructing the blood flow. When mTNF was added, liposomal extravasation was 
observed at sites were also FITC-BSA leaked out (asterix), indicating that mTNF rendered the vessels hyperpermeable for 
liposomes. FITC-BSA was seen in the tumor vessels (arrowhead) indicating intact functionality. These blood vessels seemed 
deprived of liposomes suggesting that all liposomes had extravasated into the surrounding tumor tissue. Scale bar ap-
ply to all images, 200 µm. (b) Surface plots show high intensity peaks in the tumor vessels when liposomes alone were 
given. Consistent with the confocal pictures, surface plot of images from mice injected with liposomes combined with 
mTNF show high fluorescence intensity at hyperpermeable sites in the tumor. (c) After calculation of the incidence that 
a liposome was found inside a vessel, a strong reduction in intravascular presence was found when mice were injected 
in combination with mTNF. Columns represent percentage liposomes found intravascular ± SEM of at least 6 scans of 5 
individual animals; #, P < 0.01 versus no mTNF of the same time point. (See color section for a full-color version.)
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Supplementary Table 1. Vessel morphology after treatment with saline or mTNF.
12 hours 24 hours
Saline mTNF Saline mTNF
Density a 13.0 ± 3.1 22.4 ± 5.0 22.0 ± 1.6 20.1 ± 2.0
Segments b 76 ± 9 96 ± 11 139 ± 20* 122 ± 26
Diameter c 16.8 ± 1.1 18.5 ± 0.6 17.8 ± 0.8 18.9 ± 1.0
Note: After the B16BL6 melanoma, implanted in the dorsal skin-fold chamber, established its own blood supply, mice 
were injected with saline or mTNF (1 µg/mouse). Twelve or 24 hours later vessel morphology was examined. Data 
represent the mean ± SEM of at least 6 scans in at least 3 individual animals; *, P < 0.05 versus 12 hours of the same 
treatment.
a Percentage of total vessel area per field of interest at magnification 20x.
b Number of vessels per mm2.
C Vessel diameter (µm).
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Figure 3. Addition of TNF does not render the tumor blood vessels permeable for 400 nm liposomes. Tumor 
distribution of systemic injection with long circulating liposomes (Rho-PEG-L) of 400 nm in combination with saline or 
mTNF using intravital microscopy was studied. Twelve or 24 hours later mice were injected with FITC-BSA to visualize 
functional vessels. (a) In mice injected with liposomes, even with the addition of mTNF, hardly any extravasation into the 
surrounding tumor tissue could be seen. Only at the rim of the tumor (dotted line) accumulation of liposomes could be 
observed (asterix). In some vessels liposomes were found to remain inside a FITC-BSA permeable tumor vessel (arrow-
head). When vessels were filled with liposomes these vessel became non-functional (arrow). Scale bar apply to all images, 
200 µm. (b) Although more 400 nm liposomes were found in the tumor with the addition of mTNF, levels were much 
lower compared to 100 nm liposomes. Columns represent percentage fluorescent area density ± SEM of at least 6 scans 
of 3 to 4 individual animals. (c) After calculation of the extravascular fluorescent intensity hardly any liposome could be 
measured outside the vessels, indicating that even with the addition of mTNF 400 nm liposomes remained trapped in the 
tumor vessels Columns represent percentage extravascular fluorescent area density ± SEM of at least 6 scans of 3 to 4 
individual animals. (d) The incidence that a liposome was found inside the vessel no difference was found between the 
two treatment groups. Also when mTNF was co-administered liposomes were predominantly found inside the tumor ves-
sels. Columns represent percentage liposomes found intravascular ± SEM of at least 6 scans of 3 individual animals. (See 
color section for a full-color version.)
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posomes of 100 nm for the treatment of solid 
tumors, also in combination with mTNF.
Addition of TNF improves uptake of lipo-
somal doxorubicin but not of free doxoru-
bicin. It is known from previous studies that 
total drug accumulation of free doxorubicin in 
tumor tissue is rather low compared to Doxil 
[15]. In the present study we examined the in-
tratumoral distribution of free doxorubicin and 
Doxil. Doxil is labeled with DiO to distinguish 
between localization of the liposome and dox-
orubicin, which is red fluorescent. When free 
doxorubicin was administered, either with or 
without mTNF, hardly any drug was detectable 
in the tumor and if any extravasation could be 
observed it occurred at the highly vascularized 
rim of the tumor (Fig. 4a). Limited, focal and 
heterogeneous extravasation of Doxil was ob-
served especially at the tumor periphery when 
injected alone. Addition of mTNF dramatically 
enhanced extravasation of Doxil (Fig. 4b). Sig-
nificantly more liposomes (7.1-fold increase af-
ter 12 hours, P < 0.01 and 3.1-fold increase 24 
hours after injection, P < 0.05) were present 
extravascular in the tumor tissue when mTNF 
was co-administered (Fig. 4c). Administration 
of mTNF augmented total liposomal accumu-
lation 4.7-fold only at 12 hours after injection 
(P < 0.01) (Supplementary Fig. 4). Although 
liposomes did not penetrate far into the tumor 
tissue, abundant extravasation could be ob-
served already at 12 and 24 hours after injec-
tion (Fig. 4d).
Doxil is taken up intact by the tumor cell 
and degraded intracellular. Insight in the in-
tratumoral fate of liposomal doxorubicin is lim-
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Supplementary Figure 3. Addition of TNF does not render the tumor blood vessels permeable for 400 nm lipo-
somes. Tumor distribution of systemic injection with long circulating liposomes (Rho-PEG-L) of 400 nm in combination 
with saline or mTNF using intravital microscopy was studied. In mice injected with liposomes hardly any extravasation into 
the surrounding tumor tissue could be seen even with the addition of mTNF. The image overlay shows that obstruction 
of the 400 nm liposomes is found in the chaotic tumor related vessels. Scale bar apply to all images, 200 µm. (See color 
section for a full-color version.)
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Figure 4. Addition of TNF provokes extravasation of long circulating liposomes. Tumor distribution of doxorubicin 
and Doxil was studied using intravital microscopy. Twelve hours after administration of doxorubicin, mice were injected 
with FITC-BSA to visualize functional vessels. In the case of Doxil, the liposomal component was labeled with a fluorescent 
marker DiO. B16BL6 melanoma-bearing mice were injected with doxorubicin or Doxil-DiO in combination with saline or 
mTNF. (a) In mice treated with doxorubicin, 12 hours later hardly any drug could be observed in the tumor tissue (dotted 
line = rim of the tumor) even in the presence of mTNF, although the vessels were functional. (b) When Doxil-DiO alone 
was administered, liposomes were observed in the vessels (arrows) and surrounding tissue. However, when Doxil-DiO was 
combined with mTNF massive extravasation of Doxil from the blood vessels (dotted line) into the tumor interstitium was 
observed (arrowheads). (c) After calculation of the extravascular fluorescent intensity a significant increase was found 12 
hours and 24 hours after injection in combination with mTNF. Columns represent percentage extravascular fluorescent 
area density ± SEM of at least 6 scans of 5 individual animals; #, P < 0.01; *, P < 0.05 versus no mTNF at the same time 
point. (d) Twelve and 24 hours after administration of Doxil in combination with mTNF empty vessels (dotted line) were 
observed surrounded by extravasated liposomes (arrowheads). Scale bar apply to all images: 200 µm. (See color section 
for a full-color version.)
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Supplementary Figure 4. Addition of TNF provokes extravasation of long circulating liposomes. Tumor distribu-
tion of doxorubicin and Doxil 12 hours after administration was studied using intravital microscopy. After calculation of 
the fluorescence area density of these pictures hardly any free doxorubicin in the tumor could be detected, even with 
the addition of mTNF. Murine TNF significantly increased Doxil accumulation 12 hours after injection. Columns represent 
percentage fluorescent area density ± SEM of at least 6 scans of 5 individual animals; #, P < 0.01 versus no mTNF of the 
same time point.
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ited. Doxorubicin containing liposomes, such as 
Doxil, are relatively rigid and only slowly release 
their content resulting in a prolonged exposure 
of the tumor cells to the drug. However, this 
also means that low or moderate peak levels of 
free drug are reached. Elucidation of the lipo-
somal fate and release of contents is useful for 
drug delivery strategies, certainly if controlled 
degradation of these carriers is applied [28]. 
Here, we observed in vivo that after extrava-
sation of Doxil-DiO into the interstitial space, 
the liposomes were taken up as such by the 
tumor cells. Thirty-six hours after injection of 
Doxil-DiO in combination with mTNF a sepa-
ration of the two dyes (DiO and doxorubicin) 
was observed and transport of doxorubicin 
to the nucleus of the tumor cells could be de-
tected, while the lipid marker remained in the 
cytoplasm (Fig. 5a). These results indicate that 
presumably most liposomes are taken up intact 
by the cells and broken down in the cytoplasm. 
Also in vitro uptake of doxorubicin or Doxil by 
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Figure 5. The complete liposome is taken up by the tumor cell and broken down in the cytoplasm. Using in-
travital microscopy the cellular uptake of Doxil was observed. (a) Thirty-six hours after systemic injection of Doxil-DiO, 
the liposomes (yellow) were seen in the cytoplasm of the tumor cell, whereas only doxorubicin (red) could be observed 
in the nucleus (arrow). At higher magnification, doxorubicin (red, arrow) was seen in the nucleus while the liposome 
(green, arrow) was only found in the cytoplasm. Also 72 hours after systemic injection the red fluorescent of doxorubicin 
in the nucleus of the tumor cell and the yellow fluorescent of the complete liposome inside the cytoplasm could still be 
observed. (b) For better understanding of the uptake of doxorubicin in the B16BL6 melanoma cell, cells were incubated 
with doxorubicin or Doxil and time-lapse microscopy was performed. Doxorubicin was immediately taken up by the cell 
and transported to the nucleus. On the other hand, Doxil took much longer to occur in the cytoplasm. Scale bar apply to 
all images; 200 µm. (c) The percentage B16BL6 cells positive for doxorubicin in the cytoplasm (■) and nucleus (▲) after 
incubation with free doxorubicin or in the cytoplasm (□) and nucleus (∆) after incubation with Doxil were calculated. Very 
rapidly all cells had taken up the doxorubicin and stained positive for nuclear doxorubicin. In case of cells incubation with 
Doxil, doxorubicin was observed in the cytoplasm much later compared to the administration of free drug. Transport 
from the cytoplasm to the nucleus also took much longer. Data points represent the percentage cells that are positive for 
doxorubicin. (See color section for a full-color version.)
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tumor cells was studied. Free doxorubicin was 
immediately taken up by the cells and directly 
transported to the nucleus. Twenty minutes 
after incubation all cell stained positive for 
nuclear doxorubicin. When B16BL6 cells were 
exposed to Doxil, accumulation of this drug in 
the cytoplasm was observed after 15 min. A 
marginal intracellular transport of doxorubicin 
to the nucleus was observed in a period of 2 
hours (Fig. 5b and Fig. 5c). Uptake by cells as 
well as intracellular transport of doxorubicin 
was not affected by mTNF (data not shown). 
These results confirm our observations in vivo 
and indicate that Doxil is taken up intact by 
the tumor cells and remains predominantly in 
the cytoplasm, while intracellular breakdown is 
slow.
DISCUSSION
Here we demonstrate that addition of low-
dose TNF to systemic administration of pegy-
lated long circulating liposomes facilitates ex-
travasation of these liposomes in solid tumor. 
Strikingly, this is in particular observed when 
liposomes of 100 nm are used, while larger 
liposomes, e.g. 400 and 800 nm, hardly ex-
travasate, even in the presence of TNF. Our 
data shows that the permeability of the tumor 
vasculature is not only very heterogeneous but 
also does not allow passage of liposomes with 
a diameter of 400 nm or larger. Intratumoral 
distribution studies reveal that administration 
of TNF results in a strongly enhanced and more 
homogeneous distribution of the co-injected 
liposomes. These results indicate that more 
vessels become permeable with the adminis-
tration of TNF. Next to this we show, and to 
our knowledge for the first time, by intravital 
microscopy that liposomes are taken up com-
pletely by tumor cells, followed by intracellu-
lar degradation of the liposomes upon which 
released doxorubicin enters the nucleus. These 
findings are confirmed by in vitro experiments. 
These results are in contradiction to the believe 
that the liposomes are degraded in the intersti-
tial space followed by uptake of the released 
chemotherapeutic compound by the tumor 
cells [29].
In spite of promising results in vitro or even 
in animal studies chemotherapeutic agents ap-
peared often disappointing in the treatment 
of patients. The major prerequisite for a good 
tumor response is an effective delivery of the 
systemically injected drug to its target, the tu-
mor cell. However, when injected in the blood-
stream many obstacles have to be overcome 
[30]. Some of these impediments can be obvi-
ated with the use of pegylated long circulating 
liposomes. Unlike free administered drug their 
liposomal encapsulated counterpart has limited 
toxicity and gives the drug prolonged circula-
tion half-live, thereby enhancing the efficacy of 
targeted drug delivery [31,32]. Second, blood 
flow in a tumor is very heterogeneous due to 
the abnormal vascular organization. This irreg-
ular blood flow leads to well vascularized parts 
and necrotic/hypoxic parts obstructing the ho-
mogenous delivery of a drug [1]. Thirdly, the 
drug has to leave the circulation and cross the 
endothelial lining to reach its target, the tumor 
cell. In general, the endothelial lining of blood 
vessels forms a tight, uniform and continuous 
monolayer of cells. However, the endothelial 
cells in tumor blood vessels do not comply with 
this phenotype and can best be described as 
disorganized [33,34]. They appear to be per-
meable to macromolecules and particles, with 
a determined cut off of 400 nm [27,35]. The 
tumor-associated vasculature has become an 
important target for tumor treatment and 
several strategies have been reported. (I) The 
antiangiogenesis approach interferes with the 
formation of new tumor blood vessels and nor-
malize the existing blood vessels to improve 
a more effective delivery [36,37]. (II) Vascular 
disrupting agents inflicts direct damage to the 
endothelial cells that will initially leads to vascu-
lar shutdown [38,39]. (III) Manipulation of the 
tumor vasculature with vasoactive drugs, like 
TNF or histamine, causes a better delivery of 
the co-administered chemotherapeutic drug 
that act on the tumor cells [14,40].
The main focus of our study is the use of 
tumor vascular manipulation as an effective 
way to improve solid tumor treatment. Previ-
ously, we demonstrated that addition of TNF to 
an isolated perfusion with melphalan or doxo-
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rubicin dramatically improves tumor response 
[14,41]. Moreover, also in a systemic setting 
addition of TNF to liposomal chemotherapy 
improves tumor response [15,16]. This synergy 
is not, or at least not solely, due to a direct ac-
tivity of TNF on the tumor cells and does not 
result from a direct destruction of the tumor-
associated vasculature [17]. More importantly, 
addition of TNF, both in the perfusion setting 
as well as in the systemic setting, augmented 
the accumulation of the co-administered drug 
in the tumors. Other investigators showed 
that TNF also enhanced tumor accumulation 
of liposome-encapsulated adriamycin [42] and 
radio-labeled antibodies [43]. These findings 
led to our search for alternative agents with 
known vascular permeability increasing activity, 
such as histamine and interleukin-2. We have 
shown that these agents also enhance drug 
accumulation in the tumor resulting in syner-
gistic antitumor activity in an isolated setting 
[13,44]. Apparently this dual approach consist-
ing of a combination of tumor cell and tumor 
vasculature directed therapy is an important 
concept for a good tumor response. Although 
it is known that TNF is capable of increasing 
the permeability of an endothelial lining, the 
effect of TNF on tumor vessels in the tumor is 
largely unknown. Ruegg et al. showed that TNF 
in conjunction with interferon-gamma induced 
functional down-modulation of the αvβ3 in-
tegrin, resulting in detachment and anoikis of 
the endothelial cells [45]. This possibly explains 
why tumor vessels, in which αvβ3 exposure is 
increased, are more responsive to TNF than en-
dothelial cells from healthy vessels, which are 
quiescent. It has also been shown that TNF in 
combination with interferon-gamma and pe-
ripheral blood mononuclear cells stimulates 
elongation and gap-formation between en-
dothelial cells, increasing permeability of the 
endothelial lining [46].
In present study, we demonstrate that low-
dose TNF does indeed augment extravasation 
of liposomes while the endothelial lining is not 
destroyed and the vessels remain functional. 
Further investigation is required to determine 
which type of tumor vessels are affected by 
TNF and if other components of the vascula-
ture, like pericytes and basal membrane, play 
a role in this dual regimen. In conclusion, we 
show that systemically administered low-dose 
TNF improves drug accumulation in solid tumor 
by making more vessels permeable to 100 nm 
liposomes. This results in a more homogeneous 
drug distribution within the tumor exposing 
more tumor cells to the drug and causing in-
creased antitumor efficacy. Additionally, we 
show that the liposomes are taken up intact by 
tumor cells and are degraded intracellular, re-
leasing the cytotoxic drug. Our results indicate 
that the dual approach, tumor vascular manip-
ulation, with TNF combined with chemothera-
py, has strong potential for solid tumor therapy 
and necessitates the further development of 
clinical applicable formulations.
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ABSTRACT
Several strategies targeting the tumor-associated vasculature 
(TAV) have been developed to improve cancer therapy; the anti-
angiogenesis and vascular destruction strategy. However combi-
nation therapy, in which induction of vascular hyperpermeability 
improves tumor response to chemotherapy, has become increas-
ingly important in the treatment of solid tumors. Addition of the 
vasoactive cytokine tumor necrosis factor-alpha (TNF) to systemic 
treatment with liposomal encapsulated doxorubicin (Doxil) im-
proves tumor response in mice bearing the B16BL6 melanoma 
or the human melanoma BLM correlating with an increased per-
meability of the TAV and extravasation of Doxil into the tumor 
intersitium. However, addition of TNF has no effect in the Lewis 
Lung Carcinoma (LLC) or the human melanoma 1F6. TNF-induced 
permeability acts predominantly through the stimulation of TNF-
receptor 1 (TNFR1, p55) and we observe that TNFR1 in the TAV is 
primarily expressed by pericytes. Furthermore, we demonstrate a 
higher pericyte coverage in B16BL6 and BLM relatively to the LLC 
and 1F6, which suggests that the ubiquitous TNFR1-expressing 
pericytes are responsible for the TNF-induced vessel permeability 
leading to an augmented drug accumulation and ultimately to an 
improved tumor response. These results indicate pericytes as an 
alternative target for tumor vascular therapy.
INTRODUCTION
In contrast to the structured and organized 
blood vessels of basic organs, the tumor-associ-
ated vasculature (TAV) can best be described as 
“abnormal”. The TAV displays a lack of hierar-
chical branching in which the recognizable fea-
tures of arterioles, capillaries and venules are 
lost. Vessels are tortuous, leaky and unevenly 
dilated and this results in a chaotic blood flow 
[1]. Due to a better understanding of the in-
volvement of the TAV in tumor progression, 
a prospective anticancer target is provided by 
inhibiting or destroying these tumor vessels 
[2-3]. Next to that, altered tumor physiology as 
a result of tumor vascular manipulation can be 
used to improve chemotherapy. Recently, anti-
angiogenic therapy with Avestin was shown to 
improve clinical outcome that was suggested to 
result from tumor vascular normalization [4-6]. 
However, further manipulating the abnormal-
ity of the TAV, by vasoactive agents, can be 
used as well to improve the delivery of classical 
antitumor drugs, the cytotoxic agents that di-
rectly kill tumor cells. We showed that systemic 
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co-administration of such a vasoactive agent, 
tumor necrosis factor-alpha (TNF) in combina-
tion with liposomal encapsulated doxorubicin 
(Doxil), results in increased drug accumulation 
and improved tumor response [7,8] without a 
direct cytotoxic effect on the endothelial lin-
ing [9]. The majority of TNF biologic effects are 
mediated by TNF-receptor 1 (TNFR1, p55) and 
stimulation of TNFR1 is known to increase vas-
cular permeability in vitro and in vivo [10] that 
could explain the intratumoral drug accumula-
tion.
Blood vessels are composed of two major 
associating cell types. The endothelial cells that 
form the luminal layer of the vessel wall and 
the pericytes, also referred to as Rouget-cells 
or mural cells, surrounding and stabilizing the 
vascular tube. Until recently, pericytes were 
believed to be absent in the TAV but studies 
showed their significant contribution in tumor 
angiogenesis. As a result, pericytes gained new 
interest as a potential target in antiangiogenic 
therapies [11,12].
In the current study, using tumors with di-
verse tumor vasculature characteristics, we ex-
amined the efficacy of systemic treatment with 
low-dose TNF and Doxil and showed tumor 
dependent responsiveness to TNF-based com-
bination treatment. In addition, we explored 
the initial status of endothelial cells and asso-
ciated pericytes. We hypothesize that TNF-R1 
positive pericytes play a determining role and 
likely explains the mechanism of TNF-induced 
permeability.
EXPERIMENTAL PROCEDURES
Agents. Recombinant murine tumor necrosis 
factor-alpha (mTNF) and recombinant human 
tumor necrosis factor-alpha (HuTNF) were kind-
ly provided by Boehringer Ingelheim GmbH. 
Murine TNF had a specific activity of 3 x 107 U/
mg and endotoxin levels were < 1 U/mg pro-
tein. HuTNF had a specific activity of 5.8 x 107 
U/mg and endotoxin levels were < 1.25 U/mg 
protein. Pegylated long circulating liposomal 
doxorubicin (Doxil/Caleyx) was purchased from 
Schering-Plough.
Animals and tumor model. Specific patho-
gen-free male C57BL/6 mice (Harlan-CPB) and 
NMRI Nu/Nu mice (Charles River) were kept 
in a control environment with 12 hours light/
dark cycles and fed a standard laboratory diet 
ad libitum (Hope Farms). Four tumors were 
used in these experiments: B16BL6 melanoma, 
Lewis Lung Carcinoma (LLC), the highly meta-
static human melanoma cell line BLM and the 
non-metastatic human melanoma cell line 1F6 
[13]. The mice were anesthetized by isoflurane 
(Pharmachemie) inhalation and a small tumor 
fragment of 3 mm3 was implanted subcutane-
ously in the flank of the mice. When the tu-
mor reached a diameter of 10 mm, tumor tis-
sue was dissected under sterile conditions, cut 
in small identical pieces, and directly used for 
implantation in the dorsal skin-fold chamber 
(0.1 mm3 tumor pieces) or subcutaneously (3 
mm3 tumor pieces) for the efficacy study, mea-
surements of liposomal drug accumulation and 
immunohistochemistry as described below. All 
animal studies were done in accordance with 
protocols approved by the committee on Ani-
mal Research of the Erasmus MC, Rotterdam, 
the Netherlands.
Tumor treatment and monitoring. Treat-
ment was started when tumors reached an av-
erage diameter of 8 to 10 mm. The mice were 
randomized into the following 4 groups: saline, 
mTNF, Doxil and Doxil plus mTNF. Mice were in-
jected 5 times in the tail vein with an interval of 
4 days between injections; first dose of 4.5 mg/
kg Doxil and 1.0 mg/kg for consecutive doses. 
mTNF in a dose of 1 µg/mouse, which is well 
tolerated in the mice without any side effects, 
was given for all 5 treatments. When mice 
were treated with Doxil plus TNF, these agents 
were injected separately, Doxil directly followed 
by TNF. Tumor growth was recorded by caliper 
measurement and volumes calculated using 
the formula 0.4 x (A2 x B) where B represents 
the largest diameter and A the diameter per-
pendicular to B. The tumor size was expressed 
as tumor size index i.e. the tumor volume in 
relation to initial tumor volume. Mice were sac-
rificed if the tumor weight exceeded 10% of 
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the body mass, the mice lost 10% body weight 
or at the end of the experiment.
Determination of doxorubicin levels in tu-
mor tissue. Mice received a single dose of sa-
line, 4.5 mg/kg Doxil or 4.5 mg/kg Doxil plus 1 
µg/mouse mTNF via i.v. injection. Tumors were 
excised 12 hours after injection, immediately 
snap-frozen in liquid nitrogen and stored at 
–70°C until further analysis. Tissues were ana-
lyzed for doxorubicin and its fluorescent me-
tabolites as previously described [14]. Briefly, 
tumors were weighted upon thawing, 5 ml 
of acidified isopropanol (0.075 N HCl in 90% 
isopropanol) was added and the tumors were 
homogenized. After incubation for 24 hours at 
4°C the samples were centrifuged for 30 min 
at 2500 rpm and doxorubicin content in the su-
pernatant was measured using a Hitachi F4500 
fluorescence spectrometer (excitation 472 nm 
and emission 590 nm). A standard curve was 
prepared with known concentrations of dox-
orubicin diluted in acidified isopropanol. All 
measurements were repeated after addition of 
an internal doxorubicin standard. The amount 
of doxorubicin in the tumor was corrected for 
background and expressed as µg doxorubicin 
per gram tumor tissue.
Biodistribution using the dorsal skin-fold 
chamber. Preparation of the dorsal skin-fold 
chamber is an adaptation from previously de-
scribed procedures [15-17]. Briefly, mice were 
anesthetized as described above and hair was 
removed from the back of the animal. After 
dissecting the skin, leaving the fascia and op-
posing skin intact, the skin-fold of the mouse 
was sandwiched between two frames, fixed 
with 2 light metal bolds and sutures. A small 
piece of tumor (0.1 mm3) was transplanted be-
tween the fascia and on both sides the window 
was closed with a 12 mm diameter microscopic 
cover glass. The mice were housed in an incu-
bation room with an ambient temperature of 
29°C and a humidity of 70%. Experiments 
started when the tumor reached a size of 4 
to 5 mm. Mice were injected i.v. with 4.5 mg/
kg Doxil or 4.5 mg/kg Doxil plus 1 µg/mouse 
mTNF. The mice were anesthetized and fixed 
to the heated microscope stage of a Zeiss LSM 
510 META confocal microscope. Randomly se-
lected tumor regions were examined with 20x 
(NA 0.5) long working distance objective lens 
and detailed examination was performed us-
ing 40x (NA 0.8) water emersion objective lens. 
Scans were made with a 543 nm Helium-Neon 
laser with 560-615 band pass filter for Doxil 
and stored as digital files. For measurements 
of fluorescence intensity, images were ana-
lyzed using Image Toolv2 (Don Wilcox, Univer-
sity of Texas Health Science Center) and ImageJ 
1.37v (Wayne Rasband, National Institute of 
Health). The RGB color images of 512 x 512 
pixels were converted to grayscale. The fluo-
rescence intensity ranged form 0 to 255 and 
we distinguished specific staining from back-
ground using a threshold of 45. The proportion 
of pixels with fluorescence intensity above the 
threshold was calculated. Using a look-up table 
the fluorescence intensity of the representative 
grayscale images were converted to a pseudo 
color spectrum from 0 to 255 and transformed 
to a surface plot. The heights of the peaks cor-
respond to the fluorescence intensity.
Tissue samples and immunohistochemis-
try. For quantification of the vascular morphol-
ogy, untreated tumors with a diameter of 8 to 
10 mm were excised, immediately snap-frozen 
in liquid nitrogen and stored at –70°C until 
further analysis. Second, 10 min before tumor 
excision mice were intravenously injected with 
50 µl Griffonia simplicifolia lectin I (1 mg/ml, 
Sigma) for visualization of functional vessels. 
Tumor material standardized taken pre-ILP from 
patients scheduled for TNF-based melphalan 
ILP at the Erasmus MC-Daniel de Hoed Cancer 
Centre was included in this study. Endothelial 
cells and vessel functionality were evaluated by 
immunohistochemistry using following primary 
antibodies: rat anti mouse monoclonal CD31 
(1:100; BD Pharmingen), goat anti lectin I 
(1:400; Vector Laboratories), sheep anti human 
CD31 (1:100; R&D systems). Pericytes were 
stained with rabbit anti polyclonal NG2 Chon-
droitin Sulfate Proteoglycan (1:200; Chemi-
con). TNF receptor 1 was stained with goat anti 
mouse TNFR1 (1:10; R&D systems) and mouse 
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anti human TNFR1 (1:100; Alexis). Secondary 
antibodies used were green (488), red (555 or 
594) and far red (645) Alexa Fluor (1:400; Mo-
lecular Probes). Cryostat sections of 5 or 30 µm 
were air dried and fixed with acetone for 10 
or 30 min. Sections of 30 µm were permeabi-
lized with PBS/0.5% TritonX-100 for 30 min. 
After the blocking step with PBS/1%BSA for 30 
min sections were incubated overnight at 4°C 
with primary antibodies diluted in PBS/1%BSA. 
Sections were incubated for 1 hour at room 
temperature with corresponding secondary 
Alexa Fluor antibodies diluted in PBS/1%BSA. 
Thereafter the sections were mounted with 
mounting medium containing polyvinyl alcohol 
(MoWiol-488; Fluka).
Quantifications of the vascular morphol-
ogy. Observations of the tumor vasculature in 
tumor sections were made with a Zeiss LSM 
510 META confocal microscope. Randomly 
selected tumor regions were examined with 
Plan-Neofluar 40x or 63x oil lenses. Scans were 
made with a 488 nm Argon, 543 nm and 633 
nm Helium-Neon laser. RGB color images of 
512 x 512 pixels were made of at least 3 tu-
mors. Six random fields of interest were taken 
of each tumor section and 3 sections per tu-
mor. Vessel size and number were analyzed 
using the Zeiss LSM Image Browser 4.0 soft-
ware. The microvessel size (MVS), microvessel 
density (MVD, the number of vessels per mm2) 
and the percentage endothelial cells per vessel 
(the area of vessels per field of interest) were 
calculated. Vessels that stained positive for 
lectin were considered functional vessels. The 
microvessel pericytes coverage index (MPI) was 
analyzed with ImageJ. The RGB images of the 
endothelial cells and pericytes were both bina-
rized. The area of the binarized endothelial cells 
was dilated with 4 µm from the original edges 
using an ImageJ macro, an overlap of the di-
lated endothelial cells with pericytes was made 
as described before [18]. The MPI was calcu-
lated using the formula: MPI = (pixel density 
of the endothelial cells/pixel density overlap) x 
100 percent.
In vitro cytotoxicity assay. B16BL6, LLC, 
BLM and 1F6 cells were maintained in DMEM 
(Lonza) supplemented with 10% heat inacti-
vated fetal calf serum (Lonza). The tumor cells 
were added to 96 well-plate (Costar BV) at a 
final concentration of 6x103 cells per well and 
allowed to grow for 24 hours at 37ºC in 5% 
CO2. Thereafter, tumor cells were incubated for 
72 hours in the presence of various concentra-
tions Doxil and mTNF for B16BL6 and LLC or 
HuTNF for BLM and 1F6. The range of final 
drug concentrations was 0.01 - 10 µg/ml TNF 
and 0.001 - 10 µg/ml Doxil. Cell viability was 
assessed using the MTT staining [19]. Briefly, 
3 hours before the end of the incubation 50 
µl MTT reagent (3 mg/ml, Sigma) was added 
to the medium. After incubation the medium 
was removed and the formazan crystals were 
dissolved in 100 µl DMSO (Sigma) and optical 
density (O.D.) was read at 540 nm in a micro-
titer plate reader. Tumor cell growth was cal-
culated using the formula: cell growth = (O.D. 
test well/O.D. control) x 100 percent.
Human umbilical vein endothelial cells (HU-
VEC) were isolated by collagenase digestion us-
ing the method described by Jaffe et al. [20]. 
Each isolate was derived from an individual 
umbilical vein and used for experiments at pas-
sage 5. HUVEC were cultured in HUVEC me-
dium containing human endothelial-serum free 
medium (Invitrogen), 20% newborn calf serum 
(Lonza) 10% human serum (Lonza), 20 ng/ml 
bFGF (Peprotech EC Ltd), 100 ng/ml EGF (Pep-
rotech EC Ltd) in fibronectin (Roche) coated 
flasks. HUVEC had the characteristic cobble-
stone morphology and tested positive for CD31. 
Human umbilical vein smooth muscle cells (HU-
VSMC) were cultured in modified MCDB-107 
medium supplemented with FCS, EGF and 
bFGF (CellMade). HUVSMCs were added to a 
12 well-plate (Costar) at a final concentration 
of 9x104 cells per well and allowed to grow for 
24 hours at 37ºC in 5% CO2. Thereafter, the 
cells were incubated with 1 µg/ml TNF for 72 
hours in HUVSMC-medium and supernatant 
was collected. As a control, HUVSMCs were 
incubated with medium alone. Also, as nega-
tive controls TNF and HUVSMC-medium was 
added to an empty well for the indicated time 
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period and collected. HUVEC were added to 
a 48 well-plate (Costar), coated with fitronec-
tin, at a final concentration of 2x104 cells per 
well and allowed to grow for 24 hours. HUVEC 
were incubated with the HUVSMC conditioned 
medium and control medium for 72 hours. 
Morphological changes of the HUVEC were ex-
amined with a 10x (NA 0.30) Plan-Neofluoar 
objective lens using an inverted Zeiss Axiovert 
100M microscope equipped with an Axiocam 
digital camera (Carl Zeiss). Cell elongation 
was measured and expressed as the ratio of 
the length of the major cell axis to the width 
perpendicular to the length. Ten cells and at 
least four independent incubations were deter-
mined. Al measurements were done using the 
AxioVision 3.0 software. Growth of endothe-
lial cells was measured using the sulphorho-
damine B (SRB) protein stain assay, according 
to the method of Skehan [21]. Briefly, cells 
were washed with PBS, incubated with 10% 
trichloric acetic acid (1 hour, 4ºC) and washed 
in distilled water. Cells were then stained for 15 
minutes with SRB, washed with 1% acetic acid 
and allowed to dry. Protein bound SRB was dis-
solved in 10 mM Tris buffer and optical density 
(O.D.) was measured at 545 nm in a microtiter 
plate reader. Cell growth was calculated using 
the formula: percentage cell growth = (O.D. 
test well/O.D control well) x 100 percent.
Statistical analysis. Results were evaluated 
for statistical significance with the Mann Whit-
ney U test. The correlation between MVS and 
MPI was calculated with the two-tailed Pearson 
Correlation. P-values below 0.05 were consid-
ered statistically significant. Calculations were 
performed using GraphPad Prism v3.0 and 
SPSS v11.0 for Windows 2000.
RESULTS
Addition of low-dose mTNF increases an-
titumor activity and intratumoral distribu-
tion of Doxil in B16BL6 and BLM tumors. 
To evaluate the antitumor activity of Doxil in 
combination with low-dose mTNF, tumor-bear-
ing mice were treated at 4 days intervals with 
a total of 5 injections of saline, mTNF, Doxil or 
Doxil in combination with mTNF. In B16BL6-
bearing mice combination of low-dose mTNF 
and Doxil proved to be more effective than 
Doxil alone, with a prolonged tumor growth 
delay. However, in LLC-bearing mice the addi-
tion of low-dose mTNF to Doxil treatment did 
not improve tumor response and all animals 
showed progressive disease (Fig. 1a). Treat-
ment of BLM melanoma with Doxil in combi-
nation with mTNF resulted in profound growth 
inhibition as compared to treatment with Doxil 
alone. No difference in tumor response was 
found between Doxil alone and Doxil in com-
bination with mTNF in 1F6-bearing mice (Fig. 
1b). Sham treatment or mTNF alone resulted in 
progressive disease in all 4 tumors and at the 
end of the treatment all tumors had a tumor 
size index more than 4 times the original size 
(Table 1). Summarizing, addition of low-dose 
mTNF to the Doxil regimen had a significant an-
titumor effect in the B16BL6 and BLM tumor. 
However, this synergistic effect was not found 
in the treatment of LLC and 1F6. In vitro ex-
periments were performed to define whether 
direct cytotoxicity contributed to the improved 
tumor response of Doxil in combination with 
TNF. Exposure of B16BL6 or LLC cells showed 
a strong cytotoxic effect for Doxil and resulted 
in a response curve with an IC50 of 0.07 and 
0.05 µg/ml respectively. Although both cell 
lines showed reduced cell viability after expo-
sure to 10 µg/ml mTNF, addition of TNF did not 
significantly alter the IC50 of Doxil. Also when 
incubating the human melanomas BLM and 
1F6 with Doxil and HuTNF we observed only 
a cytotoxic effect of Doxil with an IC50 of 0.1 
µg/ml for both cell lines. Both cell lines were 
moderate sensitive for 10 µg/ml HuTNF but 
addition of HuTNF hardly changed the IC50 for 
Doxil. These data indicates that TNF in vitro did 
not influence the sensitivity of the tumor cells 
to Doxil (Fig. 1c). In previous experiments, us-
ing several animal models, we found that TNF 
in combination with a chemotherapeutic drug, 
like melphalan, doxorubicin or Doxil resulted 
in an improved antitumor response which 
most likely results from of the augmented in-
tratumoral drug accumulation [7-9,22,23]. To 
investigate if intratumoral drug uptake corre-
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Figure 1. Addition of TNF improves tumor response and augments intratumoral drug uptake in B16BL6 and 
BLM. (a,b) Graphs show the tumor size index of subcutaneous implanted B16BL6 and LLC (a) and BLM and 1F6 (b) dur-
ing systemic treatment with Doxil and low-dose mTNF. Mice were injected 5 times i.v. with an interval of 4 days (arrows). 
Addition of mTNF resulted in synergistic tumor response of the B16BL6 and BLM, but no effect of mTNF was observed in 
the LLC and 1F6. Data points represents tumor size index ± SD of 6 individual animals. (c) In vitro growth of tumor cells 
(B16BL6, LLC: upper graph; BLM, 1F6: lower graph) 72 hours following incubation with different concentration Doxil and 
10 µg/ml TNF (mTNF for B16BL6, LLC and HuTNF for BLM and 1F6). Addition of TNF had no synergistic effect with Doxil 
on the tumor cells. Data points represent percentage cell growth of incubated cells compared to control treated cells at 0 
hour ± SEM of 3 individual experiments in duplicate. (d) Doxil uptake in the tumors (B16BL6, LLC: upper graph; BLM, 1F6: 
lower graph) with or without addition of mTNF. Tumors were excised 24 hours following a single injection and the amount 
of doxorubicin was measured. Addition of mTNF to Doxil treatment enhanced drug accumulation in the B16BL6 and 
BLM tumors in contrast to LLC and 1F6. Columns represent µg doxorubicin per g tumor tissue ± SD of 3 to 5 individual 
animals; *, P < 0.05 TNF versus no TNF. (e) Representative immunofluorescent photographs of CD31 expression and Doxil 
accumulation in B16BL6 and LLC 12 hours following treatment with Doxil and TNF. In accordance with the Doxil uptake, 
accumulation of Doxil into the tumor intersititium was observed in the B16BL6 and hardly any Doxil was seen in the LLC. 
Scale bar apply to all images, 100 µm. (See color section for a full-color version.)
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lates with tumor response, the concentration 
of doxorubicin in tumor tissue was measured. 
Doxorubicin levels in B16BL6 and BLM were 
higher with the addition of mTNF (2.5-fold in 
B16BL6, 2-fold in BLM). In contrast, mTNF did 
not increase doxorubicin concentrations in LLC 
and 1F6 (Fig. 1d and Fig. 1e). These data indi-
cate a strong correlation between intratumoral 
drug uptake and tumor response.
Differential extravasation of Doxil induced 
by low-dose mTNF. Clearly, addition of a tol-
erable dose mTNF resulted in augmented lipo-
some accumulation in B16BL6 and BLM tumors 
whereas no increase was observed in LLC and 
1F6. Intravital microscopy was used to obtain a 
better insight in the effect of mTNF on the in-
tratumoral localization of liposomes. When the 
tumor in the dorsal skin-fold chamber reached 
a size of approximately 4 to 5 mm it established 
its own blood supply and hardly any accumu-
lation of liposomes was found when the tu-
mors were treated with Doxil alone (data not 
shown). With the addition of mTNF abundant 
extravasation of liposomes into the tumor in-
terstitium of B16BL6 and BLM was observed. 
This effect was not apparent in LLC and 1F6 
(Fig. 2a). Surface plots show increased fluores-
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Figure 2. Addition of TNF strongly improves liposomal distribution in the tumor interstitium of the B16BL6 
and BLM. (a) Representative intravital microscopy scans of the tumors were compared to illustrate the effect of mTNF on 
liposomal uptake following systemic administration. Addition of mTNF clearly inflicted an intratumoral accumulation of 
Doxil in the B16BL6 and BLM 24 hours after treatment. Scale bar apply to all images, 200 µm. (b) Increase in height of 
the fluorescence intensity peaks of the surface plots illustrates increased accumulation of liposomes when combined with 
mTNF in the B16BL6 and BLM. (c) After calculation of the extravascular fluorescent intensity a significant increase was 
found in the B16BL6 (left graph) and in BLM (right graph) 24 hours following injection of Doxil in combination with mTNF. 
Columns represent fluorescent area density ± SEM of at least 4 scans of 3 individual animals; *, P < 0.05 B16BL6 or BLM 
versus LLC or 1F6. (See color section for a full-color version.)
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cent peaks representing the intratumoral lipo-
somes in the B16BL6 and BLM tumor (Fig. 2b). 
Analysis of the fluorescence intensity shows a 
3.2-fold increase of intratumoral liposomes in 
B16BL6 compared to LLC and a 2.4-fold in-
crease comparing BLM with 1F6 following addi-
tion with mTNF (Fig. 2c). These results indicate 
that administration of TNF causes an increased 
extravasation of Doxil into the tumor stroma, 
which is most likely caused by a difference in 
the vascular bed of the TNF-sensitive tumors, 
B16BL6 and BLM, versus the non-sensitive tu-
mors LLC and 1F6.
B16BL6 and BLM tumors have fewer but 
larger vessels compared to LLC and 1F6. 
Immunohistochemical analysis revealed that 
B16BL6 contained predominantly large func-
tional blood vessels with a mean vascular size 
(MVS) of 3097 ± 250 µm2. In the LLC tumor 
the MVS was 572 ± 77 µm2; 5.4-times smaller 
compared to the B16BL6 (Fig. 3a and Fig. 3b). 
The tumor vasculature of the BLM consists of 
a more heterogeneous vascular architecture. 
Around 34% of the vessels were small capil-
lary size blood vessels (<300 µm2), 35% had an 
intermediate size (between 300 and 1500 µm2) 
and 31% were large vessels (>1500 µm2) (Fig. 
3a and Supplementary Table 1). The MVS 
in the BLM was 1150 ± 26 µm2, significantly 
larger than the MVS of 448 ± 120 µm2 in the 
1F6 (Fig. 3b). Furthermore, the mean vascu-
lar density (MVD) of the LLC (123 ± 16) and 
the 1F6 (101 ± 32) yielded significant higher 
values than the MVD of the B16BL6 (26 ± 2) 
and BLM (64 ± 4) (Fig. 3c). Although a high 
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Figure 3. Structural differences in vasculature between TNF-sensitive and TNF-insensitive tumors. (a) Tumor-
bearing mice were injected i.v. with lectin, 10 min later tumors were excised and histological sections were stained for 
endothelial cells (CD31, green) and functional blood vessels with an antibody against lectin (red). Scale bar apply to all 
images, 50 µm. (b) After measuring the microvessel size (MVS) significant larger blood vessels were found in the B16BL6 
and BLM. (c) The microvessel density (MVD) was determined by counting the number of vessels per mm2 and was found 
significant higher in the LLC and 1F6 (d) The percentage functional vessels was calculated and in spite of a significant 
difference in size and density, most of the tumor vessels were functional. Columns represent mean ± SEM of at least 6 
scans from 3 sections of 3 individual tumors; *, P < 0.05 B16BL6 or BLM versus LLC or 1F6. (See color section for a full-
color version.)
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degree of vessels were functional in the 1F6 
this was significant less than the amount of 
functional vessels found in the BLM. However, 
the majority of the vessels were functional in all 
tumors (Fig. 3d). Still, the variation in the ves-
sel structure could not explain the difference in 
TNF-response between these two tumor types. 
The observed response and accompanied per-
meability change is more likely a result of an 
increase in the number of leaky vessels in the 
vascular bed of the B16BL6 and BLM.
Pericytes, but not endothelial cells, express 
TNFR1. TNF-induced vascular permeability is 
found to be regulated by stimulation of TNFR1 
[24]. To identify TNFR1-expressing cells we co-
stained tumor sections for endothelial cells or 
pericytes and TNFR1 in human melanoma bi-
opsies and mice tumors before treatment. In 
previous experiments using human biopsies 
TNFR1 expression was found in cells in close 
proximity to the vessels but not on endothelial 
cells [25]. Here, in accordance to these experi-
ments, endothelial cells hardly expressed TNFR1 
(Fig. 4a). However, the TNFR1-expressing cells 
closely associated with the endothelial cells and 
were found to be pericytes (Fig. 4b). Therefore, 
pericytes rather then endothelial cells are likely 
involved in the TNF-induced permeability in this 
model.
Pericyte coverage correlates with induc-
tion of leakage in response to TNF. Pericytes 
were considered present in the tumor section if 
NG2 positive cells were observed surrounding 
the vessel as demonstrated in figure 5. Pericytes 
loosely associated with endothelial cells had a 
distinct morphology with multiple cytoplasmic 
extensions into the tumor parenchyma (Fig. 5a 
and Fig. 5b). It seemed that pericytes are mov-
ing away from the vessel wall occasionally con-
necting an adjacent blood vessel (Fig. 5c). Also 
CD31-positive endothelial sprouts migrating 
into the tumor tissue were associated with a 
pericyte sleeve (Fig. 5d). Secondly, LLC and 1F6 
contained multiple cells that stained positive 
for NG2 without association with endothelial 
cells (Fig. 5e). These cells are usually defined 
as myofibroblasts and were rarely found in the 
B16BL6 and BLM. To explain the difference in 
TNF response, we examined the interaction be-
tween endothelial cells and TNFR1 expressing 
pericytes in the tumor-associated vasculature. 
The confocal images already showed a more 
extensive interaction of pericytes and endothe-
lial cells in blood vessels of the B16BL6 and BLM 
(Fig. 6a). These images were analyzed using an 
ImageJ macro in which the endothelial lining is 
dilated (green) and the overlap with pericytes 
(red) is shown in black as illustrated (Fig. 6b) 
and calculated as microvessel pericytes cover-
age index (MPI). In accordance with the ves-
sels size, significant more endothelial cells were 
found in the vasculature of B16BL6 and BLM 
compared to LLC and 1F6 (Fig. 6c). The MPI 
was significant higher in B16BL6 (70 ± 8%) 
and BLM (60 ± 1%) compared to LLC (46 ± 
1%) and 1F6 (37 ± 4%) (Fig. 6d). This indicates 
that high TNFR1-expressing perciytes coverage 
is responsible for the TNF effects making the 
vessels more leaky for macromolecules. In ad-
dition, we found no correlation between MPI 
and MVS in all 4 tumors indicating that even 
small vessels in these tumors had a mature 
Supplementary table 1: Distribution of the microvessel size
Tumor Microvessel size (% vessels)a
< 300 µm2 > 300 / <1500 µm2 > 1500 µm2
B16BL6 6.2 ± 3.4 22.0 ± 8.7 71.8 ± 9.2
LLC 54.5 ± 4.0 37.4 ± 3.0 8.1 ± 2.0
BLM 33.8 ± 1.9 35.0 ± 0.9 31.2 ± 1.9
1F6 49.2 ± 12.9 43.7 ± 9.0 7.1 ± 4.5
Note: Tumor sections stained for endothelial cells with an antibody against CD31 were analysed and the microvessel size 
(MVS) was measured.
a The vessels are subdivided into 3 categories: small (< 300 µm2), intermediate (between 300 and 1500 µm2) and large (> 
1500 µm2) vessels. Data represent percentage vessels ± SEM of at least 6 scans from 3 sections of 3 individual tumors. 
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Figure 4. TNFR1 is expressed by pericytes of the tumor-associated vasculature. (a) Immunofluorescent staining 
for endothelial cells (CD31, red) and TNFR1 (green) in human (upper panels) and mouse (lower panels) tumor sections 
showed no co-localization (arrow). (b) Staining for pericytes (NG2, purple) and TNFR1 (green) showed TNFR1 expression 
by pericytes (arrowhead) of the tumor-associated vasculature of human (upper panels) and mouse (lower panels) tumor 
biopsies. Scale bar apply to all images, 20 µm. (See color section for a full-color version.)
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Figure 5. Morphology of the tumor-associated endothelial cells (CD31, green) and pericytes (NG2, red). (a, b) 
NG2 staining of pericytes show close association with endothelial cells, however multiple protrusions (arrows) into the 
tumor stroma were observed. (c) Some pericytes projected away from a vessel and connected neighboring vessels. (d) 
Endothelial cells migrating into the tumor parenchyma were found to be associated with pericytes at several occasions 
(arrowhead). (e) NG2 positive cells that were not associated with endothelial cells (asterix), designated as myofibroblasts, 
were found in the LLC. Scale bar applied to all images, 20 µm. (See color section for a full-color version.)
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phenotype. However, there was a significant 
correlation between the MVS and functionality 
indicating that larger vessels are functional ves-
sels (Supplemental Fig.1).
TNF-stimulated smooth muscle cells have 
an effect on endothelial cells in vitro. Fur-
thermore we examined the interaction be-
tween endothelial cells and smooth muscle 
cells in vitro. TNF has hardly any effect on HU-
VSMC (data not shown). We observed that HU-
VEC incubated with TNF-conditioned HUVSMC 
medium became elongated and gaps between 
the cells were observed. HUVEC incubated 
with TNF showed also some cell elongation but 
not as severe as the incubation with TNF-con-
ditioned HUVSMC medium. Incubating HUVEC 
with control-conditioned HUVSMC medium 
from had identical morphological features as 
the control (Fig. 7a). We also observed that en-
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dothelial cells incubated with TNF-conditioned 
HUVSMC medium went into growth arrest and 
induced stronger cell elongation compared to 
control-conditioned HUVSMC medium (Fig. 
7b). This indicates that indeed mural cells are 
the target of TNF producing a factor that there-
after has an effect on the endothelial cells.
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DISCUSSION
In the present study we show that addition of 
low-dose mTNF to systemic Doxil treatment re-
sulted in an enhanced antitumor response in 
B16BL6 and BLM, but not in LLC and 1F6-bear-
ing mice. Tumor response correlates with an 
increased intratumoral Doxil concentration in 
B16BL6 and BLM, which was not found in LLC 
and 1F6. These results were confirmed in more 
detail by intravital microscopy, which showed 
that mTNF facilitates extravasation of lipo-
somes into the tumor tissue in the B16BL6 and 
BLM tumor. Importantly, we show a correlation 
between augmented TNF-induced leakage and 
presence of TNFR1 expressing pericytes around 
tumor vessels in B16BL6 and BLM. These results 
indicate pericytes as primary target for TNF and 
likely responsible for the observed endothelial 
leakage.
Several studies report on the increased per-
meability of the tumor-associated vasculature 
due to their disorganized phenotype. Tumor 
endothelial cells are irregular shaped, some-
times even overlapping each other or display 
fenestrae [26]. These openings make the vessel 
highly permeable and allow passage of macro-
molecules, with an average cut off of 400 nm 
across the vasculature [27,28]. Commonly, en-
dothelial cells form the inner lining of the vessel 
wall, while pericytes and other mural cells wrap 
around the vascular tube to form a stable blood 
vessel. The mature phenotype of the quiescent 
vasculature in organs is usually characterized by 
an extensive coverage with pericytes. Similarly 
to endothelial cells, pericytes have well-defined 
features in healthy blood vessels but exhibit bi-
zarre properties in the TAV [29]. Also, the MPI 
varies greatly among tumor types. Eberhard et 
al. quantified maturation in glioblastoma and 5 
different carcinoma’s and found that MPI rang-
es from 10 to 20% in glioblastoma and renal 
cell carcinoma to approximately 65% in mam-
mary and colon carcinomas [30]. Although, 
pericytes coverage is not a well-reliable param-
eter for tumor-angiogenesis and maturation, 
as pericytes can be associated well beyond the 
end of an endothelial sprout [29], these cells 
may present an useful target for therapy as we 
show here.
In 1971 Folkman proposed the hypothesis 
that prohibiting the development of newly 
formed tumor blood vessels would be an at-
tractive new approach in cancer treatment [31] 
and several strategies for targeting the tumor-
associated vasculature have been reported. 
First, antiangiogenic drugs prevent the forma-
tion of new blood vessels and normalize the 
existing blood vessels to improve a more effi-
cient drug delivery [6,32]. Second, vascular dis-
rupting agents directly kill the endothelial cells, 
leading to vascular shutdown [33,34] and, 
third the disorganized structure of the tumor 
vasculature can be further enhanced with va-
soactive agents that increase intratumoral drug 
uptake [9,35-37]. In all these settings both en-
dothelial cells but also other cells comprising 
the vasculature, such as pericytes, can be used 
as a target.
The main focus of our study is the use of 
the vasoactive agent TNF as an effective way 
to improve solid tumor treatment. TNF is a 17-
kDa multicytokine involved in cell apoptosis 
as well as cell survival and signals via two dis-
tinct receptors, TNFR1 and TNFR2 from which 
TNFR1 initiates the majority of TNF’s biological 
effects. TNFR1 has an intracellular Death Do-
main, which is absent in TNFR2, and signals to 
apoptosis via several caspases. Alternatively, 
binding of TNF to TNFR1 can also leads to the 
transcription of c-Jun and NF-kB that are impor-
tant for cell proliferation and survival [38,39]. 
Previously, we demonstrate that low-dose TNF 
indeed enhances extravasation of liposomes 
in B16BL6 melanoma and BN-175 soft-tissue 
sarcoma while the endothelial lining is not de-
stroyed and the vessels remain functional [7,9]. 
Ferrero et al. showed that stimulation of TNFR1 
is sufficient to increase endothelial permeabil-
ity in vitro. They found that neutralizing TNFR1 
decreased TNF-induced permeability changes 
in the liver. However, detailed analysis to the 
TNF-sensitive cell type in the vasculature was 
lacking [24].
In this study, we show that the effectiveness 
of a dual targeting approach with the vasoac-
tive agent TNF, in combination with Doxil, is 
dependent on the architecture of the tumor 
vessels. We have analyzed microvessel density, 
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microvessel size, functionality and pericyte cov-
erage of the vascular bed and found distinctive 
differences correlating with the TNF-response. 
B16BL6 and BLM tumors contained large ves-
sels with a low MVD. By comparison, a high 
degree of small vessels were present in the 
non-responding tumors LLC and 1F6. Despite 
the differences in vessel architecture the ma-
jority of the vessels in all four tumors were 
functional, but we observed only extravasation 
of liposomes in B16BL6 and BLM. Therefore, 
we concluded that direct endothelial targeting 
was not responsible for the TNF-induced per-
meability changes. Comparably, we observed 
in vitro hardly any passage of macromolecules 
through an endothelial cell layer when only ex-
posed to TNF. Gap formation and permeability 
were increased when endothelial cells were co-
incubated with TNF and IFN [40]. These results 
indicate that at least endothelial permeability 
is affected indirectly by TNF or that endothelial 
cells do not express TNFR1. Staining of human 
and mouse tumor tissue confirmed this as we 
observed that tumor-associated pericytes rath-
er than endothelial cells expressed TNFR1. Cor-
respondingly, B16BL6 and BLM showed a high 
pericyte coverage, which explains their respon-
siveness to TNF. In addition, LLC and 1F6 had 
a low pericyte coverage and this is consistent 
with the insensitivity to TNF and the absence of 
permeability changes.
From this study we conclude that high cov-
erage of tumor vessels with TNFR1-expressing 
pericytes correlates with responsiveness to TNF. 
Based on these observations we hypothesize 
that pericytes rather then endothelial cells are 
the primary target for TNF, implying that bene-
ficial activity of TNF in a combination treatment 
protocol could be predicted by the presence of 
pericytes in the tumor vasculature.
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ABSTRACT
Growth of solid tumors depends largely on the development of 
a functional vasculature, which has been the focus in antitumor 
therapy since Folkman in 1971 proposed that prohibiting the for-
mation of new vessels could inhibit tumor growth. The recogni-
tion of the tumor vascular bed as an important target led to the 
development of 3 vascular-targeted strategies. I) The antiangio-
genesis strategy that prevents the formation of new blood ves-
sels and normalizes the remaining vessels. II) Applying vasculo-
destructive agents to induce apoptosis in the endothelium of the 
tumor-associated vasculature that results in vascular collapse and 
tumor necrosis. III) Promoting further abnormalization of the al-
ready abnormal features of the tumor-associated vasculature with 
vasoactive agents to enhance vessel permeability. Tumor necrosis 
factor-alpha (TNF) is a very promising vasoactive agent because 
of its antitumor effects but its severe systemic toxicity is a major 
drawback. Therefore a new setting, in which the optimal thera-
peutic benefit of TNF could be exploited, needed to be found. 
Through an isolated perfusion high dose of TNF can be admin-
istered in the blood circulation of the tumor-bearing extremity 
or organ. Alternatively, systemically low doses can be safely ad-
ministered for several times. Importantly, TNF has no antitumor 
effect by itself and the combination with a conventional chemo-
therapeutic drug that targets the tumor cell is a prerequisite for a 
good tumor response. In this dual approach, TNF enhances intra-
tumoral accumulation of the chemotherapeutic drug resulting in 
an impressive tumor response.
INTRODUCTION
At the end of the 19th century Dr. William Coley, a surgeon from New York, observed spontaneous 
tumor regression in patients suffering from a bacterial infection. Later, he developed a vaccine 
from two dead bacteria stains Streptococcus pyogenes and Serratia marcescens, the so-called 
Coley’s Toxin, to successfully treat sarcoma patients. This toxin was also used for carcinomas, 
melanomas, lymphomas and myelomas and inducing a fever seemed the essential requirement 
for a good tumor response [1]. It was not until 1975 that Dr. Carswell isolated tumor necrosis 
factor (TNF) in serum form mice treated with bacterial endotoxin and found it to induce identical 
haemorrhagic necrosis of methylcholanthrene A fibrosarcoma (Meth A) tumors as the endotoxin 
itself [2]. With the development of new recombinant DNA techniques, human TNF became avail-
able for pre-clinical and clinical application [3,4]. However, TNF appeared to exert cytotoxic activ-
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ity only towards some animal and human tumor cell lines [5] while the majority of malignant cells 
and most normal cells, including fibroblasts and endothelial cells are relative insensitive to TNF 
in vitro [6-9]. Also, systemic and intramuscular TNF therapy proved less successful than originally 
anticipated with ineffective tumor response and severe toxic effects including fever, fatigue, hy-
potension, shock and cachexia [10,11].
The development of chemotherapeutic agents, that would kill cancer cells, has long been the 
focus for the treatment of solid tumors. Agents may seem promising in a culture disk but when 
administered as a single agent in patients the results are often disappointing. Insufficient delivery 
at the target site, the tumor cell, results often in failure of the therapy and development of alter-
native strategies to increase chemotherapeutic agents at the tumor site proved to be a major suc-
cess in treatment of solid tumors. TNF induces a better delivery of these agents at the tumor site 
by manipulating the tumor-associated vasculature. The models used and the mechanism behind 
this effect will be further discussed.
THE FORMATION OF NEW VESSELS
Vessel development. Angiogenesis, the process in which new blood vessels are formed form 
pre-existing blood vessels, is required for further growth and development of most tissues. Once 
the vasculature has been established, it remains mostly quiescent except in the ovary, uterus and 
the placenta during pregnancy. All other activation of the endothelium is found in processes dur-
ing wound healing and inflammation and several other pathological conditions, like cancer, arth-
erosclerosis, diabetic retinopathy and arthritis. There is a delicate balance between pro-angiogenic 
and antiangiogenic molecules and in many pathological conditions the balance changes in favor 
of angiogenesis, the so-called angiogenic switch [12]. Vascular endothelial growth factor (VEGF) 
and fibroblast growth factor (FGF) are among the initial factors involved in the angiogenic vessel 
growth. Mature blood vessels consist of endothelial cells (ECs), that form the luminal lining of the 
vessel wall, and perivascular cells (pericytes in capillaries and smooth muscle cells in larger ves-
sels), which remain in close association with the ECs. These perivascular cells are responsible for 
vasoconstriction and dilation and prevent rupture due to blood flow pressure [13]. Blood vessels 
are embedded in the extracellular matrix (ECM), existing of several proteins including fibronectin, 
vitronectine, collagen and laminin [14].
One of the initial steps in the formation of a new blood vessel is weakening of contact be-
tween neighboring ECs, between ECs and underlying basal membrane (BM), detachment of 
pericytes and production of proteases that degrade the components of the ECM. The molecular 
mechanism involved in capillary sprouting has been extensively studied [15,16]. Pericytes have 
been shown to restrict the proliferation and migration of ECs so loss of pericytes from the ves-
sels is required in the initiation of ECs sprouting [17-20]. In the presence of VEGF, angiopoietin-2 
(Ang2) binds to the Tie receptor tyrosine kinase, Tie-2, which is upregulated in angiogenic vessels 
and results in the loss of interaction between endothelial cells, pericytes and ECM [21]. Next, for 
an EC to migrate and subsequently form a new blood vessel, the BM and the ECM have to be 
demodulated. Additionally, the ECM is a reservoir of several growth factors like VEGF, bFGF and 
transforming growth factor (TGF), which are released during angiogenesis contributing to further 
migration, proliferation and survival of the cells. The rearrangement of the ECM is facilitated by 
matrix metalloproteinases (MMPs), zinc-dependent endopeptidases capable of degrading and 
reorganizing the matrix proteins to suit better migration [22,23].
The leading EC in the angiogenic sprout is a non-proliferating cell with long protrusions scan-
ning the microenvironment and migrating towards the angiogenic stimulus. Second, the VEGF-A 
gradient also stimulates proliferation of the stalk cells forming a bipolar (basal-luminal) cord [24]. 
After an endothelial sprout is formed, perivascular cells are needed to stabilize the tubular struc-
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ture. Platelet-derived growth factor B (PDGFB) is secreted by endothelial cells in the presence of 
VEGF and signals though the PDGF-β receptor, which is expressed on perivascular cells. Also, 
angiopoetin-1 (Ang1) is produced by perivascular cells and binds to the Tie-2 receptor at the EC 
membrane. The Ang1/Tie-2 association promotes interaction between ECs and perivascular cells 
and is therefore important in stabilization of newly formed vessels [25,26]. Maturation of the 
sprout is initiated by transforming growth factor-beta (TGF-ß), secreted by ECs and perivascular 
cells. In a dose-dependent manner, TGF-ß can promote proliferation in ECs but also maintains 
EC quiescence to induce maturation of the vessel by stimulating the migration and recruitment 
of perivascular cells to the endothelial tube [19,27]. Furthermore, TGF-ß stimulates synthesis and 
deposition of ECM proteins and prevents their degradation by inducing plasminogen activator 
inhibitor 1 in ECs [28,29].
The tumor-associated vasculature. The presence of blood vessels is essential for growth and 
survival of a tumor. Tumors start as avascular masses that depend on diffusion of oxygen from 
pre-existing nearby vessels. When tumor cells starts to proliferate further growth will rely on the 
formation of blood vessels. In areas localized beyond the diffusion distance of 200 µm hypoxia 
will arise and will stimulate tumor cells to produce several pro-angiogenic factors, like VEGF-A 
and bFGF shifting the angiogenic balance in favor of angiogenesis [30]. In contrast to the struc-
turally precise organization of the vascular bed of the basic organs, the tumor-associated vascula-
ture (TAV) is “abnormal”. They display a lack of hierarchical branching organization in which the 
recognizable features of arterioles, capillaries and venules is lost. They are tortuous and unevenly 
dilated. As a result, tumor blood flow is chaotic, might be stationary and can even change direc-
tion. This leads to hypoxia and acidosis in solid tumors [31].
Tumor ECs are disorganized with irregular shape, sometime even overlapping each other or 
displaying fenestrae [32]. These intracellular openings make the vessel highly permeable and 
allow passage of molecules across the vasculature. Dvorak et al. demonstrated that the leaky 
vessels are predominantly mature veins and venules lined by a continuous endothelium and that 
immature interface vessels and tumor penetrating vessels do not leak macromolecules [33]. This 
leakage subsequently results in an increased interstitial pressure that is maintained by the ab-
sence of functional lymphatics. Tumor-associated pericytes also display phenotypic differences 
not found in normal conditions. They are loosely associated with the ECs, display long extensions 
into the tumor stroma and are irregularly scattered [34]. Also, ECs and pericytes are loosely associ-
ated with the basal membrane which is irregular in thickness, matrix composition, assembly and 
structure [35]. The TAV varies greatly among tumor types. Eberhard et al. quantified maturation 
in glioblastoma and 5 different carcinoma’s and found that microvessel pericyte coverage ranges 
form 10 to 20 % in glioblastoma and renal cell carcinoma to approximately 65 % in mammary 
and colon carcinomas [36]. Therefore, it seems logically that tumors that are less dependable on 
their vessel structure are less likely to react to tumor vessel therapy. In the K1735 murine mela-
noma tumors angiogenic sprouts lacking pericytes are evolving into functional endothelial tubes. 
Coverage of pericytes comes later and these vessels are larger in size and lack proliferating ECs 
[37]. In contradiction, in Lewis lung carcinoma and MCa-IV pericytes are present in practically 
all vessels undependably of size. Moreover, the endothelial sprouts were closely associated with 
pericytes and these even extended the endothelial tip cell [34].
TREATMENT OF SOLID TUMORS BY USING THE TUMOR-ASSOCIATED 
VASCULATURE
In 1971 Folkman proposed the hypothesis that prohibiting the development of newly formed 
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tumor blood vessels would be an attractive new approach in cancer treatment [38]. Starving the 
tumor to death through withdrawal of the inflow of nutrients using vascular targeting agents was 
in theory a strait forward approach. However, putting the theory in practice proved not so simple, 
but this idea led to several strategies focusing on the TAV. First, the antiangiogenesis strategy 
interferes with the formation of new tumor blood vessel and deprives the tumor of oxygen and 
nutrients required for tumor development. Several growth factors are important in this process 
and VEGF is believed to be the most important. VEGF is an important mitogen for vascular en-
dothelial cells, mediates secretion and activation of MMPs and increases vascular permeability 
[38-42]. All these actions promote tumor vessel formation and it is not surprising that develop-
ment of VEGF antagonists became the major focus in antiangiogenic therapy. Besides preventing 
the development of new blood vessels, the antiangiogenic therapy also normalizes the existing 
TAV. These normalized tumor vessels are believed to be more susceptible to conventional chemo-
therapy [43,44].
A second approach is the direct damage of the established tumor vasculature by vascular dis-
rupting agents (VDAs) that will initiate vascular collapse, shutdown of tumor blood flow depriving 
the tumor of oxygen and nutrients leading to tumor necrosis [45]. VDAs exploit the difference in 
tumor ECs, because these cells have a the higher proliferating status and dependence on a tubu-
lin cytoskeleton to maintain their shape then ECs in normal vessel [46,47].
A third approach consists of further enhancing the abnormal features of the TAV to improve a 
more homogenous drug delivery. A chemotherapeutic agent may show promising antitumor ef-
fects in vitro, but in vivo the antitumor effect will be limited if insufficient amounts of the agents 
reach its target, the tumor cell. This inadequate drug delivery has always been a major problem 
in the treatment of solid tumors. After systemic injection the drug dilutes massively in the blood 
stream and is rapidly cleared by liver and kidney. Because of the severe side effects of most che-
motherapeutic drugs simply increasing the injected dose is not an option. When reaching the 
tumor site, a homogeneous drug distribution is difficult to accomplice due to the irregular blood 
flow and inhomogeneous perfusion of tumors. Also, the drug has to leave the blood circulation 
across the endothelial lining into the tumor interstitial space. Although ECs in tumor vessels 
display fenestrae and mature veins appear to be permeable for macromolecules with a cut off 
around 400 nm [32,33,48,49], extravasation of drug is often limited to the rim of the tumor. The 
dense tumor microenvironment, rich in a variety of matrix components (i.e. collagen, laminins, 
trombospondin, fibronectin, hyaluronate) and multiple types of stromal cells (fibroblasts, myofi-
broblasts, inflammatory cells) accompanied with a high interstitial fluid pressure, provide a solid 
barrier. Therefore, a dual approach is required combining an agent with vasoactive properties 
with a conventional chemotherapeutic agent that target the tumor cell.
MANIPULATION OF THE TUMOR-ASSOCIATED VASCULATURE
The isolated limb perfusion. The technique of the isolated limb perfusion (ILP) was first de-
scribed in 1958 by Creech et al. and was used for the treatment of a patient with multiple in 
transit melanoma who refused amputation. With this technique, isolation of the blood circulation 
is achieved by clamping the major vein and artery, ligating the collateral vessels and application 
of a tourniquet around the basis of the limb to compress the remaining minor vessels. The main 
artery and vein is cannulated and connected to an oxygenated extracorporeal circuit. After isola-
tion, chemotherapeutic agents can be injected into the circuit and regional concentrations 15 
to 25 times higher can be reached compared to systemic administration [50]. After the proce-
dure a washout is performed to ensure minimal systemic exposure to the drug. Also, ILP can be 
performed with mild hyperthermia (38.5 – 40°C) that improves local drug uptake whereas true 
hyperthermia (>41°C) is associated with increased toxicity. The main advantage of this method 
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is that locally very high concentrations of cytotoxic drugs can be accomplished with minimal 
systemic leakage and side effects. To use the antitumor properties of TNF, while limiting the side 
effects, Lejeune introduced TNF in the ILP [51,52]. The combination of TNF with the chemothera-
peutic drug melphalan is now primarily used for the treatment of soft tissue sarcoma (STS) and 
melanoma in transit metastasis (IT-mets) of the extremities. STS are fast growing tumors and IT-
mets exist of several large ulcerating lesions providing much painful discomfort for the patients 
and amputation was often the only option available. However, with the development of the ILP 
limb salvage and tumor control has replaced amputation in managing STS and IT-mets [53-55]. 
The excellent response rates and limb salvage of the TNF-based ILP with melphalan led to the ap-
proval of TNF by the European Medicine Evaluation Agency [56,57]. Angiograms taken from pa-
tients before perfusion show a well-developed tumor vasculature, which is selectively destroyed 
after TNF-based ILP while leaving the normal vessels intact [58-60].
For pre-clinical studies a rat ILP is developed that resembles the clinical setting to further inves-
tigate the role of TNF in this model [61]. Two different sarcomas are used: the rapidly growing and 
metastasizing high grade soft tissue sarcoma BN175 and the rapidly growing and metastasizing 
intermediated grade osteosarcoma ROS-1. A perfusion of BN175-bearing rats with TNF alone has 
no effect on the tumor growth and treatment with only melphalan resulted in a stable disease. 
However, complete remission in 75% of the animals is found with the combination of TNF and 
melphalan [62]. Also, in the ROS-1 tumor, the combination TNF and melphalan results in an sig-
nificant increased tumor response [63]. In vitro, TNF has no direct cytotoxic effects in these cell 
lines and, more importantly, no synergistic effects between TNF and melphalan could be observed 
[63,64]. These observations indicate that the activity of TNF is most likely not directed towards the 
tumor cells but to the stromal compartment of the tumor. Histopathology of the tumors revealed 
that TNF induces edema, extravasation of erythrocytes and haemorrhagic necrosis suggestive of 
radical alteration in permeability and integrity of the tumor vasculature [65]. Indeed, directly after 
perfusion with TNF plus melphalan, taking 30 minutes, vascular destruction was detected and 
erythrocyte extravasated into the surrounding tumor tissue from these damaged vessels [66]. This 
endothelial damage, however, is not directly responsible for the tumor response since these ef-
fects are also observed with TNF alone and the combination with melphalan is necessary to obtain 
an efficient tumor response. Further studies revealed that immediately after TNF-based perfusion 
a six-fold increase of intratumoral melphalan concentration has been demonstrated compared to 
a perfusion with melphalan alone. This event is specific for the tumor environment as no increase 
was found in the skin and muscle [66,67]. Bauer et al. performed ILP on nude rats bearing a 
human melanoma xenograph and also reported high response rates with TNF and melphalan. 
Although they found no TNF-induced increase in intratumoral melphalan concentration, they 
observed extensive erythrostasis in the tumor vasculature [68].
After the success with the TNF-based ILP other chemotherapeutic drugs, like actinomycin D 
and doxorubicin were investigated. Actinomycin D is an anticancer antibiotic that has been used 
in patients with osteogenic sarcoma in combination with bleomycin and cyclophosphamide but 
this treatment is associated with severe nausea and anorexia [69]. Martijn et al. showed that 
melphalan-based ILP with actinomycin D in patients with IT-mets offer no improved response 
rates compared to melphalan alone [70]. However, actinomycin D increase the TNF sensitivity of 
tumor cells in vitro [71] and local administration of TNF in combination with actinomycin D in 
mice delays the growth of several tumors [72,73]. In the rat ILP model synergy between TNF and 
actinomycin D is observed but is accompanied with severe idiosyncratic locoregional toxicity to 
the normal tissue and therefore abandoned for further studies in this setting [74]. However, the 
TNF-based ILP with doxorubicin is more promising. Doxorubicin is the agent of choice for the 
treatment of sarcoma but is also accompanied with rigorous toxicity [75-77] and could therefore 
be a suitable agent for ILP. TNF-based ILP with doxorubicin results in an impressive tumor response 
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compared to ILP with doxorubicin alone in both tumor models (54 % versus 0% for the BN175 
and 100% versus 0% in the ROS-1) without any side effects. In accordance with the melphalan 
treatment this tumor effect was also accompanied with enhanced intratumoral doxorubicin con-
centrations [78].
Systemic liposomal treatment. Another strategy to increase the amount of chemotherapy at 
the site of the tumor is the systemic use of liposomal-encapsulated drug. Liposomes are vesicular 
structures that exist of one or more phospholipid bilayers and have been developed to improve 
drug delivery at the tumor site and decrease toxicity normally associated with the conventional 
drug. However, development of liposomal chemotherapeutic agents has been hindered primarily 
by their rapid uptake by the mononuclear phagocyte system. Coating the liposomes with polyeth-
ylene glycol (PEG) increases the hydrophilic properties of the liposomal surface, thereby avoiding 
phagocytosis and prolonging blood circulation with a reserved or even improved tumor response 
[79-83]. As a result several of these sterically stabilized liposomes are developed for clinical use 
and two pegylated liposomal antracyclines are commercially available: pegylated liposomal doxo-
rubicin (Doxil in the US, Caelyx in Europe) and liposomal daunorubicin (DaunoXome). Doxil, en-
capsulated doxorubicin in small (100 nm) unilamellar liposomes, shows a decrease in toxic effect, 
as alopecia, nausea, vomiting and cardiotoxicity, associated with the use of free doxorubicin 
[84-86]. Systemic treatment with low-dose TNF in combination with Doxil of BN175-bearing rats 
and B16BL6 or Meth A-bearing mice results in improved tumor response compared to treatment 
with Doxil alone [87-89]. In agreement with the ILP, TNF-induced enhanced accumulation of the 
liposomes in the tumor appears to be crucial for the observed response. Also in vitro, no direct 
cytotoxic effect of TNF, or synergism with Doxil was observed indicating a TNF host-mediated ef-
fect.
The use of intravital microscopy allows a better insight in the intratumoral location of the 
liposomes and enables longitudinal studies on the kinetics of intratumoral events. We used this 
technique to understand the effect of low-dose TNF on intratumoral fate of liposomes. Mice, 
implanted with the B16BL6 melanoma tumor in a dorsal skin-fold chamber were injected i.v. with 
liposomes together with a low well-tolerated dose of TNF. Liposomes, without the addition of 
TNF, remain predominantly in the vessels and hardly any accumulation in the tumor tissue could 
be observed. In contradiction, co-administration of TNF and liposomes resulted in abundant ex-
travasation of liposomes from the blood stream into the surrounding tissue. Even 24 hours later, a 
fluorescent marker extravasated at the same spot indicating that these tumor vessels remain leaky 
and functional. Additionally, we observed no effect of this low-dose TNF on several microvessel 
parameters, like branching, density and diameter, indicating that the observed effect is not the 
result of vascular destruction but rather results from further enhancement of the already leaky 
properties if the tumor vasculature to allow passage of molecules with a certain size [90]. Appar-
ently to achieve vascular destruction higher levels of TNF, like those administered in the ILP, are 
needed. Further investigation into the exact mechanism of this TNF effect is ongoing.
Also, encapsulating TNF into long circulating liposomes reduce the TNF associated side effects, 
shows similar biological activity and results in an increased localization of the cytokine in the 
tumor [91-93]. Systemic injection with long circulating liposomal TNF in combination with Doxil 
resulted in an improved tumor response in soft tissue sarcoma-bearing rats [94] and enhanced 
the effects of radiation against human colon cancer xenographs due to increased lymphocyte 
infiltration [95,96].
Sensitizers for TNF. Intravenous administration of a low dose TNF (3 – 5 µg) in Meth A-bearing 
mice results in thrombosis, increased vessel permeability, leukostasis, and hemorrhage in the 
tumor vessels leading to necrosis and regression of the tumor. In vitro, Meth A cells are relative 
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insensitive to TNF, further indicating a host-mediated effect [2]. From the supernatant of Meth A 
culture medium several factors were isolated that modulate the endothelial properties; vascular 
permeability factor, nowadays known as VEGF, and endothelial monocyte activating polypeptides 
I and II (EMAP) [97-99]. EMAP has the ability to induce tissue factor procoagulant activity in ECs 
and it was speculated that over-expression of EMAP-II might predispose the tumor vasculature to 
the procoagulant effects of TNF and increase sensitivity to the cytokine. B16BL6 melanoma and 
HT-1080 human fibrosarcoma-bearing mice underwent hemorrhage after intratumoral EMAP-II 
administration followed by systemic injection of TNF [100]. Also upregulation of EMAP-II using 
retroviral gene transfer shows that initially TNF-resistant tumors become sensitive to systemic 
TNF therapy [101] and therefore EMAP-II could be of additional benefit in the ILP. To investigate 
the role of EMAP-II in the ILP retroviral gene transfer was used to generate EMAP-II expressing 
BN175 and secondly wild-type tumor-bearing rats were pre-treated intravenously with recombi-
nant EMAP-II. The results form these studies showed that EMAP II renders the otherwise resistant 
tumor responsive to TNF [102,103].
Tumor biopsies taken from patients with IT-mets revealed that the upregulation of EMAP-II 
strongly correlates with complete response. No correlation was found in the STS patients due to 
an overall low expression of proEMAP and EMAP-II in this type of tumor [104]. Therefore EMAP-II 
could potentially be a prognostic factor for TNF-treatment of patients with IT-mets. In vitro experi-
ments show that EMAP-II facilitates TNFR1 apoptotic signaling in the ECs [105,106]. However, 
little is known about the TNFR1 expression profile within tumor tissue before and after ILP but 
co-staining for ECs and TNFR1 shows that TNFR1 is mainly expressed by cells closely associated 
with ECs but not by ECs themselves. In contradiction to EMAP-II that co-localizes with ECs [104]. 
This is very surprising and suggests that another cell type beside the ECs in the tumor vasculature 
is responsible for the TNF-induced antitumor effects. This might be a first indication that ECs are 
indirectly involved in the TNF-induced effect and could explain why ECs in vitro are resistant to 
TNF alone and need other cytokines like interferon-gamma (IFN), EMAP-II, interleukine-1beta 
(IL-1ß) or blood cells to induce changes in macromolecule permeability, morphological changes 
and apoptosis [6,107]. Apparently, the underlying mechanism of TNF-based therapy is more com-
plicated then a simple binding of TNF to TNFR1 expressing ECs and is currently under investiga-
tion.
Transformation of TNF. Besides local treatment or drug encapsulation to reduce the toxicity or 
improve delivery, the chemical structure of the compound can be altered. Corti et al. coupled TNF 
with a cyclic CNGRC peptide, a CD13 ligand, to better target the tumor vasculature (NGR-TNF). 
Mice bearing B16F3 melanoma or RMA-T lymphoma were pretreated with NGR-TNF intraperito-
neal followed 2 hours later by interperitoneal injection of doxorubicin or melphalan. Although 
the LD50 values of mTNF and NGR-mTNF are similar, mTNF was inactive at doses lower than 100 
to 1,000 ng while NGR-mTNF inflicted antitumor effects with doses as low as 0.001 – 0.1 ng 
without any toxic side effects [108]. This low dose is sufficient to improve the antitumor effects 
of doxorubicin or melphalan in lymphoma and B16F1-bearing mice as a result of a better pen-
etration of the chemotherapeutic drug in the tumor tissue [108,109]. Second, coupling TNF with 
RGD, also induced a delay in tumor growth without toxic effects [110].
Mayumi and colleagues chemically modified TNF with water-soluble polymers like PEG or poly-
vinylpyrollidone (PVP). This increase of the steric hindrance and protection from proteolytic deg-
radation resulted in an increased drug stability and circulation time. However, the increase in size 
limits the distribution from blood to target tissue and steric hindrance can inhibit binding to the 
receptor. Therefore an optimal modification was designed to find the balance between clearance, 
toxicity and antitumoral activity [111-113], which proved to be effective in treatment of S-180 
tumor-bearing mice [114]. Shibata et al. designed a pegylated lysine-deficient mutant TNF (sp-
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PEG-mTNF-K90R) with higher affinity for both TNF-receptors with an antitumor activity 60-fold 
higher than native TNF in the Meth A mouse model [115]. Also binding of TNF at the surface of 
gold nanoparticles (cAu-TNF) improved the safety of TNF while retaining the antitumor efficacy 
by selectively altering the permeability of the tumor vasculature [116].
Another mutant, TNF-SAM2, with increased N-terminal basicity has a higher biological activity 
and milder toxicity than conventional TNF [117,118] and has similar antitumor activity in the mel-
phalan- or doxorubicin-based ILP in BN175-rats [119] . It is being tested in the clinical ILP because 
of its potential decreased toxicity and is potentially applicable in regional perfusions that are not 
leakage free.
Alternatives for TNF. As mentioned, TNF targets the tumor-associated vasculature and improves 
intratumoral drug delivery. So agents with identical vasoactive properties could potentially be 
an alternative for TNF-based therapy. Histamine is found to be a excellent candidate. It is an 
inflammatory modulator that is predominantly formed and stored in the granules of mast cells 
and basophils and causes edema by promoting gaps between ECs and in so doing increases the 
permeability in venules [120-122]. Replacing TNF with histamine in the ILP in combination with 
either melphalan or doxorubicin results in a tumor response comparable to TNF-based ILP. Histo-
pathology of the tumor showed vasodilatation of the tumor vasculature, damage to the ECs and 
extravasation of erythrocytes into the tumor interstitium. As a consequence edema and massive 
hemorrhage occurred. Similar to TNF-based ILP, the major antitumor effect could be explained by 
an indirect effect through a histamine-mediated accumulation of chemotherapeutic drug in the 
tumor tissue [64,123]. Although, histamine is only slight cytotoxic to ECs in vitro, within 15 min-
utes after histamine exposure gap-formation between the cells resulted in increased permeability 
[64]. These histamine-induced changes are also found by others and are believed to act through 
changes in VE-cadherin expression [124-126].
Second, interleukine-2 (IL-2) is a cytokine produced by activated T-cells to maintain their growth 
and cytotoxic response [127] and has been widely used in the treatment of solid tumors [128-130]. 
High doses of IL-2 causes serious side effects, like hypotension and vascular leakage syndrome 
causing intravascular liquid entering the organ interstitial space [131]. Because of its ability to 
induce vascular permeability this cytokine was speculated to be a good candidate for ILP. Indeed, 
we found a synergistic antitumor response in BN175-bearing rats after perfusion with IL-2 and 
melphalan correlating with an increased melphalan concentration in the tumor [132]. However, in 
contradiction to TNF and histamine no apparent vascular damage is seen after ILP although scat-
tered erythrocytes are observed between the tumor cells indicating an increased vascular leakage. 
Interestingly, no increased extravasation of macrophages was found in the tumor tissue after ILP 
but there was a clear difference in distribution of these cells. In control and melphalan-treated 
animals an even distribution of macrophages throughout the tumor tissue was observed, while a 
clear clustering of these cells was found in the IL-2 plus melphalan group [132].
As histamine and IL-2 are tested in combination for the treatment of melanoma [133], we fur-
ther investigated the triple combination histamine, IL-2 and melphalan. Histamine or IL-2-based 
melphalan perfusion resulted in an overall response of respectively 66% and 67%. Surprisingly, 
histamine and IL-2 together with melphalan led to on overall response of only 29%. Immunohis-
tology revealed that the histamine-induced hemorrhage and vascular destruction was abolished 
by the addition of IL-2. Because of these poor results investigation on the triple combination 
therapy was discontinued [134].
Interaction and adhesion of sprouting endothelial cells with the ECM is mediated by endothe-
lial transmembrane receptors or integrins like αVß3 and αVß5. Quiescent cells shown no luminal 
expression of these receptors while enhanced exposure of these integrins is found on tumor ECs 
making these integrins an potential target for antitumor therapy [135,136]. In preventing interac-
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tion between the integrins αVβ3 and αVβ5 and their ECM ligands apoptosis of ECs take place. 
Cilengitide (EMD 121974) is a cyclic RGD containing peptide with high affinity for αV-integrins. 
Intraperitoneal injection with Cilengitide resulted in tumor growth arrest of glioblastoma, a highly 
vascularized invasive tumor, in mice [137] and improved, in combination with radioimmunother-
apy, the treatment of breast cancer xenographs [138]. The potential contribution of Cilengitide in 
the melphalan-based ILP to improve solid tumor response is currently under investigation in our 
laboratory.
GENERAL CONCLUSION
Although antiangiogenic or vascular disrupting strategies are more generally known, manipula-
tion of existing tumor vasculature, strategies to enhance vascular leakage and fluid flow into the 
tumor, also have been demonstrated to be useful. So, next to vascular normalization, as is shown 
with for instance anti-VEGF-based therapy, we would like to propose vascular abnormalization 
as a powerful alternative in solid tumor combination chemotherapy. We and other demonstrated 
that vasoactive agents like TNF or histamine further enhance these abnormal features in the 
tumor-associated vessels and as such augments the accumulating of conventional chemotherapy 
into the tumor tissue, ultimately resulting in an enhanced tumor response.
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ABSTRACT
Solid tumor therapy with chemotherapeutics greatly depends 
on the efficiency with which drugs are delivered to tumor cells. 
The typical characteristics of the tumor physiology both promote 
but also appose accumulation of blood borne agents. The leaky 
tumor vasculature allows easy passage of drugs. However, the 
disorganized vasculature causes heterogeneous blood flow and 
together with the often elevated interstitial fluid pressure this re-
sults in poor intratumoral drug levels and failure of treatment. 
Manipulation of the tumor vasculature could overcome these 
barriers and promote drug delivery. Targeting the vasculature has 
several advantages. The endothelial lining is readily accessible and 
the first to be encountered after systemic injection. Second, en-
dothelial cells tend to be more stable than tumor cells and thus 
less likely to develop resistance to therapy. Third, targeting the 
tumor vasculature can have dual effects: 1) Manipulation of the 
vasculature can enhance concomitant chemotherapy, and 2) sub-
sequent destruction of the vasculature will add to kill the tumor. 
In particular tumor necrosis factor-alpha is studied. Its action on 
solid tumors, both directly through tumor cell kill and destruction 
of the tumor vasculature, and indirectly through manipulation 
of the tumor physiology, appears complex. Understanding the 
mechanism of TNF and agents with comparable action on solid 
tumors is an important focus to further develop combination im-
munotherapy strategies.
INTRODUCTION
One of the main problems of chemotherapy is getting the active drug to the tumor site. There are 
a number of factors related to characteristics of the drug, such as binding to blood components, 
circulation time, toxicity, stability and solubility, which determine efficacy of the chemotherapy and 
therefore simply increasing the dose is not the answer. Also typical features of the tumor affect 
intratumoral accumulation of agents. Solid tumors tend to exhibit a leaky vasculature with gaps 
between endothelial cells of around 400 nm but ranging as far as more than a micrometer [1-4]. 
This feature enables passive accumulation of blood borne elements such as antibodies or lipo-
somes in the tumor interstitial space. On the other hand a number of factors are identified which 
negatively influence drug delivery to solid tumors. The rapid angiogenesis typically associated 
with solid tumor growth results in an immature and disorganized vasculature, which is tortuous 
and curved, and chaotic in its hierarchy [5-7]. The presence of shunts and uncontrolled branching 
results in irregular or even absent blood flow that results in an inadequate heterogeneous delivery 
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of drugs. In addition, tumors tend to exhibit an elevated interstitial fluid pressure [8-10], which 
works against the drug accumulation. Moreover, lymphatic vessels may be compressed impairing 
the flow of lymph [11-13] and thus the inflow of antitumor agents. Lastly, the blood volume of a 
tumor is generally quite low compared to the total body volume. So, massive dilution occurs after 
systemic administration while only a limited fraction distributes to the tumor.
It is our believe that if enough of a chemotherapeutic agent could be delivered, i.e. the con-
centration reached in the tumor cell is above the level needed to kill the cell, the desired tumor 
response is achieved. In other words, we do not need to improve the killing capacity of the drug 
per se, but we need to improve the delivery of the administered agent to the tumor. There are a 
number of techniques that can be used to augment intratumor drug concentrations. For instance 
loco-regional treatment strategies are used such as intratumoral injection, infusion or perfusion, 
which impairs the volume of distribution and raises local drug levels. Delivery may be improved by 
targeting or encapsulation in liposomes. Here we will discus the use of vasoactive agents, in par-
ticular TNF and agents with comparable activity, to manipulate the tumor physiology to enhance 
drug accumulation.
The use of vasoactive drugs and especially understanding their mechanism of action is crucial 
in further development of better or new combination therapies. Although ample knowledge 
on TNF exists detailed insight in its precise actions is missing. It appears that rather complex 
and multifactorial immunological pathways are involved. While direct triggering of apoptosis 
in tumor cells has long been thought to be a main route of action it became clear that indirect 
pathways through cells of the immune system and their cytokines are probably more likely to be 
of importance. To unravel the pathways and key factors involved in TNF-based combination im-
munotherapy is key in our research and key to the success of combination immunotherapy with 
tumor manipulating agents.
TUMOR MANIPULATION – COMBINATION CHEMOTHERAPY
The use of vascular manipulating agents. A major step forward in the treatment of solid 
tumors is the recognition of the tumor-associated vasculature as an important target for therapy. 
There are several ways at which the tumor-associated vasculature can be approached in solid tu-
mor therapy (Fig. 1). First, as advocated by Folkman in 1971, inhibition of the tumor vascular de-
velopment, also known as antiangiogenic therapy, has a direct effect on growth and progression 
of the tumor [14,15]. As typically further growth of the tumor is inhibited this type of approach 
is particularly of value in early disease stages. However, O’Reilly et al. as well as others demon-
strated tumor regression with the single use of antiangiogenic agents in mouse tumor models 
[16-18]. Second, already established tumors can be treated with so-called vascular disrupting 
agents (VDAs) by destruction of the existing tumor-associated vasculature [19-21]. The lack of 
oxygen and nutrient supply results in serious damage to the tumor cells and consequently tumor 
regression. Last, the tumor vascular bed can be manipulated to improve intratumoral drug deliv-
ery by facilitating enhanced permissiveness of the tumor for co-administered chemotherapeutics. 
Here two approaches can be identified: vascular normalization [5,22] and vascular abnormaliza-
tion [23,24].
The use of VEGFR-antibodies, results in inhibition of tumor growth or tumor regression, 
through inhibition of angiogenesis [25-28]. VEGF, initially also referred to as vascular permeability 
factor (VPF), is considered the central factor both in physiological angiogenesis as well as in an-
giogenesis involved in pathological processes [29,30]. VEGF is a mitogen and survival factor for 
endothelial cells but has also vasoactive properties, as the name VPF indicates. Together with the 
angiopoietins (Ang1 and 2) VEGF regulates interaction of endothelial cells with other endothelial 
cells, pericytes and basal membrane, in which VEGF triggers dissociation of the endothelial cells 
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resulting in leakage and formation of edema [31-33]. It was observed that inhibition of VEGF 
decreased vascular leakage, but also normalized the tumor-associated vasculature [5,22,25]. The 
highly irregular and abundant branching, immature vascular status and chaotic structure was 
reversed to a more normal, healthy and mature looking vascular bed. As a result of this normal-
ization the interstitial fluid pressure drops and a better and more homogeneous blood flow is 
observed which potentially brings more chemotherapeutic to the tumor and thus inflicts a better 
tumor response.
An alternative approach, and quite the opposite of the mechanism described above, is the 
induction of further abnormalization of the tumor vasculature by vasoactive agents. The already 
leaky vasculature of solid tumor permits preferential accumulation of blood borne elements, 
which is also referred to as natural fate. Whenever material in the blood circulates long enough 
it will eventually accumulate in leaky tissue, such as exists in the tumor [34-36]. However, not all 
tumor-associated vessels of solid tumors exhibit an increased permeability. Dvorak et al. demon-
strated that the leaky vessels are predominantly mature veins and venules lined by a continuous 
endothelium and immature interface vessels while tumor-penetrating vessels do not leak macro-
molecules [4]. By certain vasoactive agents, known for their capacity to induce edema, the per-
meability of the tumor-associated vasculature can be (further) enhanced. As discussed below the 
augmented permeability, which is inflicted by these agents, results firstly from a further widening 
of the already existing gaps [37]. For instance high dose TNF or histamine treatment in an iso-
lated perfusion setting inflicts massive extravasation of erythrocytes [38,39]. Moreover, vascular 
abnormalization may also affect tumor-associated vessel previously impermeable and showing 
characteristics of mature vessels, relatively straight with a continuous endothelial lining, enabling 
leakage of particulate matter up to a size of 100 nm as we showed for low dose TNF [40]. Es-
pecially this latter effect of TNF results in a more homogeneous distribution of the concomitant 
administered chemotherapeutic drug in the tumor.
The capacity of vasoactive drugs to change the tumor pathophysiology, and by doing so fa-
cilitate a better chemotherapeutic delivery, is our main focus. Here the use of vasoactive agents, 
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Figure 1. Different approaches can be used to utilize the tumor vascular bed as target in solid tumor therapy. 
Firstly, antiangiogenic therapy, initially intended to have a direct antitumor activity, may possibly facilitate improved tumor 
response to concomitant chemo- or radiotherapy. Secondly, direct disruption of the tumor vasculature may induce a tu-
mor response. But more importantly, this type of approach appears to render favorable response particularly when used 
in combination with chemotherapy. Thirdly, manipulation for the tumor physiology may facilitate better accumulation of 
concomitant chemotherapy. Here, two opposing concepts apply. The possibility of tumor vascular normalization has been 
advocated recently as an important facilitator of chemotherapeutic drug accumulation. Normalization results in a more 
clear-cut structure of the vasculature with improved blood flow and lower interstitial fluid pressure in the tumor. Contrary 
to this principal, we coined the concept of tumor vascular abnormalisation. It has been shown that the tumor vascular 
properties, in particular the elevated permeability, allow preferential accumulation of blood borne elements. As not all 
vessels in tumors are leaky, further abnormalisation results in higher and more homogeneous extravasation of drugs into 
the tumor.
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such as tumor necrosis factor-alpha (TNF), IL-2 and Histamine in local and systemic therapy in 
conjunction with chemotherapy for the treatment of solid tumors, will be discussed. In these set-
tings these vasoactive drugs demonstrate potent and selective activity on the tumor vascular bed, 
which strongly improves tumor response.
Biochemotherapy with vasoactive agents. Biochemotherapy is based on a dual approach: first 
a chemotherapeutic drug is needed to target to tumor cells. Second, a vasoactive agent is admin-
istered. For successful treatment with a combination therapy of solid tumors a chemotherapeutic 
drug is indeed crucial as the tumor vascular manipulation is not principally intended to have an 
effect by itself but initially serves as a facilitator for the co-administered chemotherapeutic drug. 
Next to that, we believe and it is our observation that in order to obtain a beneficial and espe-
cially lasting tumor response, solely targeting the tumor-associated vasculature is not enough. 
The choice of the cytotoxic drug may largely depend on the type of tumor under treatment but is 
also determined by the treatment approach. Irrespective of its action the chemotherapeutic drug 
should have pharmacological properties that are compatible with combination immunotherapy 
with vasoactive agents.
To achieve an effective concentration of a chemotherapeutic drug in tumor it is desirable to 
minimize distribution of the active compound and to increase local exposure. One such method is 
regional application of the therapeutic agent. Depending on the type of local therapy, for instance 
isolated perfusion or single pass infusion, augmented drug concentrations can be prolonged or 
respectively initially reached. Secondly, inhibition of distribution of the chemotherapeutic agent 
throughout the body not only impairs clearance and dilution of the applied agent but also mini-
malizes systemic toxicity, allowing therefore higher dosages to be applied [41]. Another method 
is to formulate the chemotherapeutic agent in such way that its circulation time is prolonged. 
Typically this can be achieved by inhibiting binding to elements in the blood, preventing clearance 
and diminishing extravasation at unwanted sites. In our systemic treatment setting we use for this 
purpose liposomal encapsulation, providing completely different pharmacokinetics and toxicity 
profile to the chemotherapeutic drug [34,42]. For instance the circulation half time of doxoru-
bicin is prolonged from minutes to three days in humans when encapsulated in long circulating 
pegylated liposomes such as Doxil. At the same time the potential cardiotoxicity is reduced while 
a new dose limiting toxicity is observed to hands and feet.
The prolonged and elevated concentration in blood is of crucial importance in biochemother-
apy with vasoactive drugs. In order to enable the chemotherapeutic drug to reach the tumor and 
benefit from the induced leakage the agent has to pass preferably the vascular bed of the solid 
tumor indefinitely. In that setting all drug will eventually end up in the tumor because of its leaky 
vasculature. It has been shown that increased circulation time of liposomes directly correlates with 
better accumulation in the solid tumor [43,44]. To optimally utilize the permeabilizing properties 
of the vasoactive agents the enhanced leakiness should be maintained at long as possible while at 
the same time this change in property of the vessel should not negatively influence functionality 
of these vessels. Therefore it is imperative that the blood flow through the vessels is maintained, 
or even better increased, as shutdown of course only impairs intratumoral drug accumulation 
and distribution. An excellent example of a vasoactive agent with these properties is the cytokine 
tumor necrosis factor-alpha.
VASCULAR MANIPULATION AGENTS
The history of TNF started at the end of the 19th century when Dr. William Coley, a surgeon from 
New York, observed that cancer patients with a bacterial infection sometime showed spontane-
ous tumor regression [45]. He developed a vaccine from two dead bacteria strains Streptococcus 
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pyogenes and Serratia marcescens, the so-called Coley’s Toxin, that could mimicked the tumor 
regression. It was also found that inducing fever was a prerequisite for a good tumor response 
[46]. This led to the further investigation to identify the active compound in the toxin and the 
host factors produced after toxin challenge. However, this appeared not an easy task, as the 
immune response induced by the toxin is a successive cascade stimulating other cascades and 
cellular responses, so the single cytokine that initiated this cascade was difficult to identify. Bacte-
rial lipopolysaccharide (LPS) was found to induce hemorrhagic necrosis in mouse tumors and a 
serum factor, induced by LPS appeared responsible for this effect [47]. In 1975 Dr. Carswell iso-
lated a factor, that he named tumor necrosis factor, from the serum of bacillus Calmette-Guerin 
(BCG)-infected mouse treated with LPS and TNF induced identical hemorrhagic necrosis of meth-
ylcholantherene A fibrosarcoma (Meth A) tumors as the LPS itself [48]. With the development 
of new recombinant DNA techniques, human TNF became available for pre-clinical and clinical 
application [49,50].
Phase I trails designed to determine the maximal tolerated doses and toxicity demonstrated 
severe side effects as vasoplegia, multiorgan failure, shock and cachexia. Moreover, in phase II 
trial the maximal tolerated dose of 200-400 µg/m2 proved insufficient to cause an antitumor ef-
fect [51-55]. Given the poor responses and severe toxicities, clinical application of TNF was largely 
abandoned. Until, in 1998 Lejeune et al. introduced TNF in the isolated limb perfusion, taking 
advantage of this system to achieve loco-regional doses up to 30 times higher than the maximal 
tolerated dose [56,57] and is further discussed in this paper.
Monocytes and macrophages are the main source of TNF, but many other cells of the immune 
system, smooth muscle cells, endothelial cells and tumor cells also produce TNF [58]. TNF binds 
as a trimer of 17 kDa subunits and exerts its effects by binding to high-affinity receptors, which 
are present on the plasma membrane. Thus far two receptors, a TNF receptor of 55 kDa (TNFR1), 
which is expressed on a majority of cell types and a TNF receptor of 75 kDa (TNFR2), which is 
predominantly expressed by immune cells have been identified. Although the affinity for TNFR2 
is 5 times higher compared to TNFR1, the latter initiates the majority of biological activities of 
TNF. Binding of TNF to TNFR1 can initiates two opposite pathways; cell survival or apoptosis. TNF 
binding to TNFR1 leads to the binding of TNFR-associated death domain (TRADD) to the death 
domain of the receptor and recruits receptor interacting protein (RIP), FAS-associated death do-
main (FADD) and TNFR-associated factor 2 (TRAF-2). These proteins are responsible for further 
signaling. FADD binds to pro-caspase 8 leading to the activation of caspase 8. This activation 
initiates a protease cascade leading to apoptosis also involving the release of cytochrome C from 
mitochondria. Alternatively, the complex can recruit TRAF-2 leading to the nuclear factor kappa 
B transcription factor (NF-kB) activation. This results in the phosphorylation of the inhibitor of kB 
(IkB) that is normally bound to NF-kB retaining the transcription factor in the cytoplasm. Upon 
release the NF-kB is translocated to the nucleus activating several proliferating genes [59,60].
Selective sensitivity of the tumor-associated vasculature to TNF. A large number of studies 
focused on the ability of TNF to kill cancer cells. However, soon after the identification of TNF as 
a major mediator of tumor necrosis, the attention has been shifted to an indirect TNF-induced 
antitumor effect rather than a TNF-cytotoxic effect. This was based on experiments with the same 
Meth A, as these cells were resistant to TNF in vitro. Also, systemic administration of TNF cause 
necrosis in well established subcutenous tumors whereas small early tumors and intraperitoneal 
tumors did not respond to TNF therapy [61]. Furthermore, TNF only affected tumor-associated vas-
culature as the vascularization of normal tissue implants remained intact [62]. Stoeckler claim that 
TNF-R1 expression on the tumor vasculature and presumably on the surface of tumor endothelial 
cells is likely to be the most important target of TNF antitumor activity. They observed that TNF 
antitumor effect remained in TNFR2-/- mice and was absent in TNFR1-/- mice. TNF induced tumor 
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necrosis in TNFR1-/- tumors in WT mice still occurred, indicating a host mediated effect [63]. 
Ferrero et al. showed that stimulation of TNFR1 is sufficient to increase endothelial permeability 
in vitro. She found that neutralizing TNFR1 decreased TNF-induced permeability changes in the 
liver. However, detailed analysis to the TNF-sensitive cell type in the vasculature was lacking [64]. 
When we stained for TNFR1 in human melanoma biopsies we found that endothelial cells express 
hardily any TNFR1, but TNFR1 expressing cells were found in close proximity with the endothelial 
cells, suggesting another cell-member of the TAV as possible target for TNF [65].
ISOLATED LIMB PEFUSION; GATEWAY TO UNDERSTANDING ACTIONS 
AND SUCCESFUL APPLICATION OF TNF
Probably one of the most favorable examples of regional cancer therapy is the isolated limb 
perfusion. Both ease of the technique and superior control over drug distribution contributes to 
the success of this method in the treatment of locally advanced sarcoma and multiple or bulky 
melanoma of the extremity. The isolated limb perfusion (ILP) procedure was first described by 
Creech et al. in 1958 and further improved in the following years [66,67]. Basically it consists of 
temporary isolating the circulation of the limb from the rest of the body, by cannulating the main 
limb vessels, connecting them to a heart-lung machine via a pumping role and a primer perfusate. 
The collateral vessels are ligated and a tourniquet placed in the root of the limb assuring a safe 
isolation to allow local administration of high doses of chemotherapeutic agents, up to 15 to 
30 times higher than the maximal tolerated dose, without systemic side effects as exposure of 
the rest of the body is kept to a minimum. This procedure is typically combined with mild hyper-
thermia (39-40°C).
ILP with the alkylating cytotoxic agent melphalan (L-phenyl-alanine-mustard) has been used for 
the treatment of patients with advanced extremity melanoma while achieving complete respons-
es of about 50%. Other chemotherapeutic agents have been tried as alternatives to, or combined 
with melphalan, such as doxorubicin, cisplatin, fotemustine, but none provided better tumor 
responses as compared to melphalan alone [68]. In spite of the good results seen for melanoma, 
mainly for small lesions, the responses for of bulky tumors and sarcomas were as poor as 20% 
overall response rates [67,69,70]. The combination of TNF to this treatment positively changed 
this scenario, increasing the overall response rate to the range of 80% and a limb salvage index 
of 70%. Based on these data TNF-melphalan ILP was recognized as the best treatment option for 
limb threatening soft tissue sarcomas and licensed for this use in 1998 by the European Agency 
for the Evaluation of Medical Products (EMEA) [71]. Currently we and others demonstrated that 
application of melphalan together with TNF in ILP renders inoperable tumors resectable (sarcoma 
or bulky melanoma) with an 70-100% limb salvage rate [56,72-74].
Improvement and understanding TNF-based ILP. Acknowledging the possible importance of 
understanding underlying mechanisms involved in TNF-based ILP in combination with melphalan 
or doxorubicin we developed several animal models. Especially the rat models, and to lesser 
extent mouse models, are instrumental in elucidating mechanisms and to study these combina-
tions. Larger animals, such as pigs, have been used to practice new technique and gain insight in 
pharmacokinetics.
Initially the rat sarcoma ILP model was utilized to improve the established TNF-based ILP and 
further fine-tune certain aspects that cannot be tested in humans. This model closely mimics 
the clinical setting, not only qua technique but also with respect to response rate [75,76]. We 
tested a number of requisites such as optimal temperature and duration of perfusion, impact of 
local oxygenation and minimally needed TNF concentration in the perfusate. Normally the ILP is 
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conducted under mild hyperthermia (around 38-39°C), which appeared the optimal temperature 
as the response rate dropped severely with lower temperature. At a temperature above 40°C, in 
spite of slightly increased response rate, local toxicity appeared uncontrollable. In the rat model a 
perfusion-duration of 30 minutes seems adequate as longer duration did not improve response, 
and most importantly, no melphalan could be detected anymore in the perfusate. If ILP duration is 
shortened the response rate rapidly drops. Strikingly we observed that during the ILP the concen-
tration of TNF in the perfusate hardly declines over time, indicating that only a fraction of the TNF 
binds to the available receptors and is consumed [77]. From this one would conclude that a much 
lower concentration of TNF would be sufficient. Indeed the concentration of TNF can be lowered 
5-fold, which is however much less than anticipated. It is well established that the sensitivity of 
tumor cells and endothelial cells to certain cytotoxic agents is affected by hypoxic conditions [78]. 
The ILP currently conducted on patients is oxygenated. We observed that hypoxia did not improve 
response in ILP, but also performing the ILP under anoxic conditions did not affect local toxicity 
[77]. Skipping the oxygenation during ILP makes it more practical and less expensive to perform.
Like hypoxia, also certain agents are known to enhance the cytotoxicity of TNF. Therefore next 
to TNF also IFNγ (IFN) was used in the clinical ILP [56,73,79-82]. It is believed and shown in vitro 
that IFN and TNF synergistically induce apoptosis in certain tumor cell lines [83,84]. Importantly, 
we showed that addition of IFN by pre-ILP injections only marginally adds to the tumor response 
and can be omitted [85]. Comparable to IFN, actinomycin D is well known for its capacity to 
dramatically increase TNF-induced cell death in vitro. However, addition of actinomycin D also 
drastically enhances local toxicity of TNF to such an extent that its use is not to be considered 
in patients [86]. We speculated that inhibition of NO production could possibly promote tumor 
response in a TNF-based ILP. During the TNF-based ILP triggering of the NO production may oc-
cur which could both have a negative effect on the tumor through direct cytotoxicity. However, 
elevated levels of NO may also affect angiogenesis and thus potential regrowth of the tumor. 
Indeed, addition of L-NAME, a known NO inhibitor, further improved tumor response in a TNF-
based ILP with melphalan [87].
With the aid of our ILP models we could not only optimize the clinical protocol but also inves-
tigate the working mechanism of TNF. It was generally believed that while the chemotherapeutic 
drug, melphalan mostly but also doxorubicin is used in ILP, targets the tumor cells, both tumor 
cells and endothelial cells are killed by TNF. Angiograms made before and after ILP in patients 
demonstrate specific disappearance of the tumor vascular bed while healthy vessels remain visible 
[88,89]. Importantly, we and others demonstrated that ILP with TNF alone has no or marginal ef-
fect on tumor progression [77,90], indicating that irrespective of the nature of the tumor vascular 
effects TNF is not able to inflict serious damage to the tumor. More so, if a tumor response is ob-
served with TNF alone this could be directly related to a sensitivity of the tumor cell itself [76,91]. 
From this we concluded that ILP with TNF alone is not useful. Next to that, based on these 
observations we formulated the hypothesis that TNF rather influenced the effectiveness of the 
co-administered chemotherapeutic drug. In particular we found that addition of TNF augmented 
intratumoral drug accumulation irrespective of the chemotherapeutic drug used. We showed that 
TNF changes the pathophysiology of the tumor in an ILP setting resulting in an augmented accu-
mulation of the co-administered drug melphalan or doxorubicin [91,92]. This was also observed 
in isolated hepatic perfusion (IHP) model, and systemic setting in which lower local levels of TNF 
are reached as discussed below [40,93-97].
TOXICITY REDUCTION OF TNF TO BROADEN ITS USEFULNESS
As TNF has high intrinsic toxicity several attempts were made to lower toxicity while at the same 
time maintain or increase bioactivity [94,98-105]. We tested in our ILP model the TNF mutant 
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SAM2. TNF-SAM2, developed by Soma et al., has increased N-terminal basicity and has been 
shown to have both a two-fold higher cytotoxic activity in vitro and up to 20-fold lower acute tox-
icity in a murine model, compared to conventional TNF [98,103,106]. Reduced systemic toxicity 
was demonstrated in a canine model [107]. Moreover, an increase in tumor cytotoxicity on several 
different tumors in vitro was demonstrated when compared to conventional TNF [108]. In spite of 
these favorable results ILP with TNF-SAM2 combined with melphalan resulted in comparable syn-
ergistic tumor response [109]. Increased antitumor activity and lowered toxicity has been reported 
for other TNF mutants, in which specific amino acids has been altered. Besides affecting the toxic-
ity of the molecule directly, attempts to modify the usefulness of TNF has been made by improv-
ing delivery. Corti et al. coupled TNF with a cyclic CNGRC peptide, an aminopeptidase N (CD13) 
ligand, to better target the tumor vasculature (NGR-TNF) [110]. This fusion product showed 12-15 
times more antitumor activity than TNF. The binding appears quite specific for tumor vessels as it 
binds to CD13 isoforms expressed by the tumor blood vessels and not to CD13 expressed on kid-
ney tissue of myeloid cells. Mice bearing B16F3 melanoma or RMA-T lymphoma were pretreated 
with NGR-TNF intraperitoneally followed 2 hours later by interperitoneal injection of doxorubicin 
or melphalan. Although the LD50 values of mTNF and NGR-mTNF are similar, mTNF was inactive at 
doses lower than 100 to 1,000 ng but NGR-mTNF has an antitumor effects with doses as low as 
0.001 – 0.1 ng without any toxic side effects. This low dose is sufficient to improve the antitumor 
effects in lymphoma and B16F1 bearing mice with doxorubicin or melphalan as a result of a bet-
ter penetration of the chemotherapeutic drug in the tumor tissue [110,111]. Modification of the 
NGR peptide demonstrated that both the cyclic CNGRC and the linear GNGRG target tumor ves-
sels, but the cyclic form has 10-fold more antitumor activity [112]. These results direct also atten-
tion to targeting of chemotherapeutics to tumor vessels by coupling of NGR ligands [113]. More-
over, as TNF increases drug delivery to solid tumors combination of NGR-TNF with chemotherapy 
seems obvious. Indeed, pretreatment of tumor-bearing mice with NGR-TNF enhanced response to 
a number of chemotherapeutics (doxorubicin, melphalan, cisplatin, paclitaxel and gemcitabine) 
[114]. As was shown with TNF by us [37] also NGR-TNF has no direct effect on cytotoxicity of the 
used chemotherapeutics in vitro. So, NGR-TNF most likely works indirectly through an action of 
the stroma. An indication is the observation that NGR-TNF lacks activity in the absence of IFNγ 
[115]. No synergy was observed when NGR-TNF was used in combination with doxorubicin in 
IFN knockout mice or mice treated with anti-IFN antibodies. Moreover, administration of IFN to 
the knockout mice restored the NGR-TNF activity. Typically it was observed that NGR-TNF in the 
presence of IFN doubled the accumulation of doxorubicin in the tumor. These observations are 
in correlation with MRI studies showing increased leakage of contrast agent into the tumor in 
mice treated with NGR-TNF [116]. Targeting of TNF can also be improved by coupling antibod-
ies directed towards tumor vessel specific ligands. A possible target found is the extra-domain B 
(ED-B) of fibronectin, which is found around neovasculature of growing tumors. The antibody L19 
has a high affinity for ED-B and localizes to tumor vessels after injection in tumor-bearing mice 
[117,118], and its pharmaceutical properties can be adjusted by tailoring the antibody moiety 
[119]. When coupled to IL-2 L19 strongly enhances the antitumor activity of IL-2 [120]. Moreover, 
L19-12 and L19-TNF both showed good antitumor activity and when combined led to eradication 
of tumors in mice [121,122]. Treatment with L19-TNF in combination with melphalan induced 
strong tumor response [123]. This treatment resulted in rejection of challenges with tumors from 
syngeneic and different origin, indicating profound immune activation. Mayumi et al. chemically 
modified TNF with water-soluble polymers like polyethyleneglycol or polyvinylpyrollidone. This in-
crease of the steric hindrance and protection from proteolytic degradation results in an increased 
drug stability and circulation time. However, the increase in size limits the distribution from blood 
to target tissue and steric hindrance can inhibit binding to the receptor. Therefore an optimal 
modification was designed to find the balance between clearance, toxicity and antitumoral activ-
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ity [124-126] and proved to be effective in treatment of S-180 tumor-bearing mice [127]. Shibata 
et al. designed a pegylated lysine-deficient mutant TNF (sp-PEG-mTNF-K90R) with higher affinity 
for both TNF-receptors with an antitumor activity 60-fold higher than native TNF in the meth A 
mouse model [128]. Also binding of TNF at the surface of gold nanoparticles (cAu-TNF) improved 
the safety of TNF while retaining the antitumor efficacy by selectively altering the permeability of 
the tumor vasculature [129].
SYSTEMIC APPLICATION OF TNF
The success of TNF in the ILP setting reinitiated interest in systemic application. Initially TNF was 
used as a single drug and failed as such. However, recognition of the activity of TNF towards the 
tumor-associated vasculature presented new possibilities for this drug. We hypothesized that 
like in the ILP setting TNF could possibly improve tumor response to chemotherapy in a systemic 
treatment protocol. However, it is far from easy to establish a local TNF concentration, when 
systemically injected, in the tumor as can be reached in the ILP. To improve tumor delivery we 
encapsulated TNF in stealth liposomes and showed improved tumor localization [130]. More so, 
addition of liposomal TNF to chemotherapy with Doxil (liposomal doxorubicin) resulted in strongly 
improved tumor response in a rat soft tissue sarcoma model [131]. We observed in this setting 
that a small fraction of the TNF was released from the liposomes shortly after injection, while the 
main fraction remained liposome associated. The fraction released appeared to be responsible for 
the improved outcome. Addition of low dose free TNF (15 µg/kg) to treatment with Doxil inflicted 
dramatic tumor response (partial or complete remission) in 75% of the rats, while all other treat-
ments at the best resulted in a delay of tumor outgrowth [94,132]. Comparable to observations in 
the ILP, repeated systemic injection with a non-toxic low dose TNF augmented the accumulation 
of doxorubicin in the tumor. This could be confirmed in a mouse B16BL6 melanoma model show-
ing strong responses in the TNF plus Doxil treatment groups accompanied by augmented intratu-
moral drug accumulation [97]. Addition of TNF also improved treatment with cisplatin containing 
liposomes indicating that the interaction was not drug dependent [133]. Using intravital micros-
copy we demonstrated that TNF induced permeability of the tumor vasculature and rendered 
more vessel leaky [40]. Strikingly, increased vascular permeability did not affect tumor vascular 
function, as we demonstrated that vessels remained functional even when turned leaky to the 
liposomes for at least 2 days. We proposed that the beneficial effect of TNF in the systemic treat-
ment protocol with Doxil is due to a higher accumulation of the drug in the tumor but especially 
results from a more homogeneous distribution. It is possible that a vasoactive agent like TNF could 
be used in a plethora of chemotherapies to improved local delivery and thus tumor response. It 
is important to note that in this setting TNF is used to facilitate a better functionality of the used 
chemotherapeutic drug while TNF itself has no or hardly a direct effect on the tumor.
ALTERNATIVE VASOACTIVE AGENTS IL-2 AND HISTAMINE
Interleukin-2. Since its identification by Morgan et al. in 1976, T cell growth factor or interleu-
kin-2 (IL-2) remains the major cytokine used in long-term culture of T lymphocytes [134]. IL-2 is a 
15 kDa glycoprotein and primarily expressed by activated CD4+ T lymphocytes, although produc-
tion by naïve CD8+ T lymphocytes, dendritic cells and thymic cells has been reported. It activates 
immune cells by binding to the IL-2 receptor, which is found on all classes of lymphocytes. IL-2R 
consists of three subunits: the α- (CD25), β- (CD122) and the common γ-chain (CD132) and all 
three subunits are required for high affinity binding.
In different animal models interleukin-2 (IL-2), as a single agent, has been shown to have 
antitumor activity [135,136]. Clinical studies have been carried out mainly in patients with renal 
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cell cancer and melanomas [137,138]. High doses and multiple dosing are needed, which is as-
sociated with serious systemic toxicity with hypotension, massive vascular leakage syndrome and 
multiple organ failure leading to death [139-141].
IL-2 as a vasoactive agent. We hypothesized that IL-2 could be a good candidate to be used 
in an isolated limb perfusion. IL-2 is known not to have direct antitumor activity, but we specu-
lated that IL-2 could well impact on the tumor pathophysiology in a similar way as TNF. Indeed, 
we found a synergistic antitumor response in our rat ILP model after perfusion with IL-2 and 
melphalan correlating with an increased melphalan uptake in the tumor tissue [142]. However, 
although an influx of erythrocytes into the tumor tissue and obstruction in the blood vessels was 
observed, the damage to the vasculature and the hemorrhagic necrosis was not so dramatic as 
compared to TNF-perfusion. Directly after ILP no clear difference was seen in the number of infil-
trating T lymphocytes, granulocytes and macrophages. Macrophages were present in larger num-
ber than the other cells, without difference between the treatments. Yet, there was a profound 
distinction in the cell distribution, showing an even distribution in the control treated animals and 
a clustering of these cells after IL-2 plus melphalan ILP. IL-2 is known to activate macrophages to 
produce several cytokines, like TNF and free radicals that could contribute to the further cytotoxic 
effect on the tumor cells. Endogenous produced TNF was found to be upregulated in tumors after 
ILP with IL-2. From this study we concluded that IL-2 could be a good candidate for improved 
tumor response, as an alternative for TNF.
Histamine. Histamine was first isolated in early 1900 but at that time point there was no knowl-
edge of its physiological activity or potential interest. In 1910 Barger and Dale isolated it from a 
particular ergot extract, the Ergotinum dialysatum [143,144]. Although Ackermann and Kutscher 
also succeeded in isolating of histamine independently, particularly the almost complete descrip-
tion of its pharmacological actions by Dale receives credits. Dale was particularly interested in the 
capillary dilator effect of histamine and considered the possibility that, either its release or the 
release of a histamine-like substance might contribute to the regulation of capillary blood flow. 
According to him, this liberation would be the result of metabolic activity, and could provide fine 
adjustment of the capillary circulation to the needs of the tissues. He also described its role in the 
anaphylactic shock and showed that histamine could be extracted from tissues [145].
Histamine is a primary amine synthesized and stored within secretory granules of human mast 
cells and basophils; but also in cells of the epidermis, gastric mucosa, neurons of the central 
nervous system, as well as in cells in regenerating or rapidly growing tissues. It is one of the 
most important mediators involved in various physiological and pathological conditions, includ-
ing neurotransmission, numerous brain functions, secretion of pituitary hormones, regulation of 
gastrointestinal and circulatory functions and inflammatory reactions [146,147]. Histamine has 
also been shown to potently influence the immune response, being the principal mediator of the 
immediate hypersensitivity reaction that follows interaction of antigen with specific IgE molecules 
on the surface of mast cells and/or basophiles, and vascular endothelial cells are major targets for 
the biological actions of histamine. Interestingly, pending on the timing of exposure, histamine 
limits TNF responses through a direct effect on TNF receptor shedding, characterizing its regula-
tory effect [148].
Histamine as vasoactive agent. Histamine’s classical effect on fine vessels is the formation of 
edema by an increase in the flow of lymph and its protein content to the extracellular space and 
also the formation of gaps between endothelial cells, increasing transcapillary vesicular transport 
[149]. Inflammatory edema facilitates the transfer of immunologically active molecules and cells 
from the vascular space to the tissues. In spite of the beneficial effects, excessive loss of molecules 
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and water from the vascular space can also impair organ physiology; therefore, the importance 
of rapidly restoring normal barrier properties. Histamine is accredited as meeting these proper-
ties, rapidly and transiently increasing endothelial permeability in post capillary venules [150,151]. 
The exact mechanism responsible for the formation of endothelial gaps and recovery in these 
vessels has been explored in the past decades, revealing a multiple step process. Histamine binds 
to H1 receptors, activating the inositol phosphate second messenger system and consequently 
increasing the intracellular calcium concentration [152,153]. These events may in the end lead to 
endothelial contraction, the mechanism claimed responsible for gap formation [151,154,155].
There is a consensus that histamine-induced increased permeability is a transient event and 
that recovery happens, even in the presence of histamine. This permeability recovery phenom-
enon, mediated by increased intracellular cAMP level, also involves negative feedback inhibition, 
resulting in reversible modulation of the dimension of junctional gaps [156]. This pathway is 
shared by a number of so-called “endothelial stabilizers” preventing permeability increase by in-
flammatory mediators. Prostaglandin (PGI2), a member of postanoid family, acts as one of these 
“endothelial stabilizers” to prevent the histamine induced permeability increase in venules and 
to decrease permeability of endothelial monolayers by activating the cAMP second messenger 
system. The increase in intracellular cAMP concentration in endothelial cells, linked to the gap 
reclosure phenomenon, is associated with an increase in the amount of F-actin in these cells. 
Probably the stabilization of the machinery involved in endothelial contraction occurs by increased 
polymerisation of actin filaments and prevention of the actin-myosin contraction [157]. PGI2 is 
mainly produced by endothelial cells and histamine stimulates its production after very short 
time incubation periods of 1 to 2 minutes [158]. In agreement with this, Wu and Baldwin used 
the PGI2 synthetase inhibitor tranylcypromine and showed that permeability recovery was totally 
abolished in some vessels, but still existed in others. Nevertheless, the extent of recovery for the 
latter ones was decreased [150].
Examining the temporal changes in the permeability coefficient over a 2 hour period Ehringer 
et al. showed that there are dynamic alterations in the time course of changes in HUVEC perme-
ability, which are different for different vasoactive mediators of inflammation, namely thrombin, 
histamine and bradykinin [159]. For histamine, permeability coefficients in vitro reached a maxi-
mum at 0-30 minutes and remained at this peak value for the entire 120 minutes studied. Since 
HUVEC cells were constantly exposed to histamine during the whole duration of the experiment, 
the authors speculated that it could have led to a deleterious effect on vascular integrity. Contrary 
to his observation we showed by a FACS apoptosis/necrosis assay that HUVEC were still viable, 
even when histamine remained present, while permeability continued to rise for the whole 60 
minutes evaluated. Although our evaluation period ran for half the time, the concentrations of 
histamine used by us were 200-times higher (circa 2x10-3 M against 10-5 M) [38].
In line with the endothelium heterogeneity, barrier integrity differs not only between organs 
but also between different vascular segments of the same organ. Moreover, endothelial cells de-
rived from conduit vessels and microvessels are phenotypically distinct and thus, present site spe-
cific vascular responses to inflammation [160]. Discriminating between key events that regulate 
these responses and the signaling events activated to coordinate these processes shall provide a 
better understanding of the microvascular biology process and open new possibilities of treat-
ment in sepsis, but also in oncology for a better drug delivery to tumor cells.
Based on the properties of histamine, we hypothesized that histamine could be a good alter-
native to TNF in the isolated perfusion setting. Indeed, histamine dramatically improved tumor 
response when co-administered with melphalan in an ILP [38]. Like TNF addition of histamine 
caused severe hemorrhage and even more dramatic disruption of the endothelial lining of the 
tumor vascular bed. Also we showed that histamine augmented intratumor melphalan or doxo-
rubicin concentration and established a more homogeneous distribution [161] and could be a 
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excellent alternative to TNF in an isolated hepatic perfusion due to absence of noticeable toxicity 
in this setting [162].
INFLAMMATORY ASPECTS OF TNF THERAPY IN CANCER
Vascular leakage and destruction. Infection or tissue injury induces an inflammatory response, 
a cascade of molecular and cellular events that provides protection by containing the tissue dam-
age at the site of infection or injury. The acute inflammatory reaction is initiated after activation 
of tissue macrophages and the release of several cytokines, such as TNFα, IL-1 and IL-6. The cytok-
ines act on fibroblast and endothelial cells inducing coagulation and permeability increase by loss 
of intracellular adhesion. TNF and IL-1 stimulate the upregulation of specific cell surface receptors, 
like selectins, intercellular adhesion molecules (ICAM) and vascular adhesion molecules (VCAM) 
[163-166]. Cells in the blood circulation recognize these specific adhesion molecules and adhere 
to the endothelium followed by transmigration into the tissue space. This results in a massive 
influx of immune cells into the damage tissue participating in eradication of the pathogen and 
stimulation of the healing process. In turn, TNF affects the function of macrophages and endothe-
lial cells that leads to the secretion of other cytokines like IL-1, IL-8 and IFN further promoting the 
phagocytic activity [167]. Also several colony-stimulating factors are secreted that increase the 
production of leukocytes. Triggered by TNF, IL-1 and IL-6, the local inflammatory response is ac-
companied by the acute-phase response that induces several acute-phase proteins [168]. Each of 
these cytokines has an effect on the hypothalamus to induce fever. Increase in body temperature 
inhibits the growth of pathogens and enhance the immune response.
TNF was first identified as the most potent anticancer cytokine in serum from cancer patients, 
treated with bacterial extract or endotoxins [48]. The induction of a fever after the bacterial infec-
tion was crucial for a good antitumor response. In Meth A tumor-bearing mice, TNF was found to 
induce hemorrhagic necrosis as a result of massive extravasation of erythrocytes into the tissue. 
Already during TNF-based melphalan ILP softening of the tumor was observed, a feature also ob-
served in the clinical setting [169], which could be an indication of hemorrhage or inflammation. 
Indeed, histological analysis of these tumors showed destruction of the vasculature, extravasation 
of erythrocytes in parts of the tumor and hemorrhagic necrosis [170]. However, also TNF alone 
induced edema, vascular congestion, extravasation of erythrocytes and hemorrhagic necrosis but 
this hardly influences tumor response, as a combination with melphalan is necessary to obtain 
good tumor activity. Reports have been made about the important role of erythrocytes in the 
transport of certain drug [171,172]. Wildiers et al. showed that 1 hour after i.p. administration of 
melphalan 25% of the melphalan in the blood was transported via the erythrocytes [173].
Vascular bed activation. Factors expressed at the luminal side of endothelial cells play a central 
role in the clotting system by regulating the expression of binding sites for anticoagulant or pro-
coagulant factors. Blood flow, in a normal functional vasculature is maintained in the quiescent 
endothelial cells by the expression of several anticoagulant pathways. TNF shift the haemostatic 
properties of the endothelium to favor clot formation by increasing the expression of the proco-
agulant tissue factor and plasminogen activator inhibitor-1 and suppressing of the cofactor activity 
of procoagulant protein C and the anticoagulant cofactor thrombomodulin [174-176]. Adhesion 
of leukocytes to the endothelium also induce procoagulant tissue factor by endothelial cells [177]. 
When tissue factor is inhibited, the TNF-induced fibrin deposition is decreased and blood flow 
restored [178]. TNF also mediates the release of von Willebrand factor (vWF) from endothelial 
cells. vWF supports thrombus formation by maintaining platelet adhesion (platelet-endothelium) 
but also by forming platelet aggregates (platelet-platelet) [179]. vWF which is restricted to the 
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endothelial layer prior to perfusion was redistribute to the perivascular and subepidermal pattern 
in patients biopsies 3 hours after TNF-based melphalan perfusion. Within a period of 24 hours, 
intravascular thrombocyte aggregation and erythrostasis was observed without tissue factor and 
fibrin deposits, indicating that the thrombocyte aggregation was no a result of local procoagu-
lant activity, but rather a result of endothelium damage. This could indicate that TNF induced 
endothelial damage leads to expression of vWF and adhesion of thrombocytes that eventually 
impairs the blood flow leading to obstruction and edema [180]. During the first hours after per-
fusion the endothelial cells appeared swollen and the vessels were progressively destroyed [181]. 
These observations were also made in the TNF-based melphalan ILP in the rat model. Blood ves-
sels were loaded with erythrocytes, showed platelet aggregation and the endothelial cells were 
round with swollen mitochondria [39].
Delayed-type reaction. We also studied the delayed-type reaction in slowly regressing melano-
ma biopsies because tumor remission without massive hemorrhagic necrosis frequently requires 
a period of weeks or even months following ILP. Around 60% of the lesions in the melanoma 
patients with a delayed-time response were less that 0.5 cm in diameter at the time of ILP and 
the immediate effect of TNF is known to relate with tumor size, because of the prerequisite of an 
established vasculature. In these delayed-type lesions, degenerated tumor cells were in close as-
sociated with melanin-loaded macrophages and an increased amount of eosinophils were found 
in the dermis near the tumor but not in the tumor itself. Melphalan synergizes with TNF to yield 
better response rates then melphalan alone. However histopathology findings in the delayed-
time response with TNF-based melphalan showed an identical pattern suggesting the long term 
effect of melphalan [182].
Involvement of leukocytes. Recruitment of polymorphonuclear cells (PMN) was observed 3 
hours after perfusion followed by intratumoral localization within 3 days. T lymphocytes and 
macrophages were detected during the first 7 days and B lymphocytes during the second week. 
Tumors that were treated with melphalan alone did not show significant necrosis and PMN infil-
tration [181]. The angiograms taken from patients after 7 to 10 days after TNF-based melphalan 
ILP showed a complete destruction of the tumor-associated vasculature while normal tissue ves-
sels were spared [72,183]. However, these were long-term effects whereas the increased accumu-
lation of chemotherapeutic drug was observed directly after perfusion. When we investigated the 
presence of tumor-infiltrating immune cells we observed no evident change between the treat-
ments in the infiltration or tumor localization of CD4 and CD8-positive cells, granulocytes and 
macrophages in rat tumors taken immediately or 6 hours after perfusion [170]. In that time period 
also no effect on the expression profile of several important cytokines (IL-6, IL-8, IL-10, IL-12 and 
IFN) was observed. A limitation of using the complete tumor for gene profiling is that we cannot 
link gene expression with the specific subset of cells. This indicates that the tumor-infiltrating im-
mune cells are not a prerequisite for the induction for the permeability changes of the endothelial 
cells during perfusion. However, they are required for the further eradication of the tumor. A 
schematic overview of the different tumor-associated cells is depicted in figure 2 (Fig. 2).
Although there is no difference in distribution of leukocytes directly after perfusion, the TNF-
induced effects as hemorrhage were lost in leukopenic rats after TNF-based melphalan ILP, result-
ing in impaired tumor response, indicating an important role of leucocytes in the outcome [184]. 
In vitro studies revealed that TNF had negligible effect on tumor cells and even endothelial cells. 
However TNF in combination with IFN induced morphological changes of endothelial cells; the 
cells became elongated and gap formation between the cells occurred [37,185]. Importantly, 
these morphologic changes were much more pronounced when peripheral blood mononuclear 
cells (PBMC) were added. Cells became further elongated, therefore intensifying gap formation 
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that contributed to an increased permeability. PBMC-derived interleukin-1beta (IL-1ß) was re-
sponsible for this effect [37]. IL-1ß mediated the production of several matrix metalloproteinases 
participating in degradation of the extracellular matrix leading to detachment of the endothelial 
cells. Furthermore, IL-1ß is also known to decrease the endothelial integrity by affecting adherens 
junctions proteins, like VE-cadherin and ß-catenin. These effects were observed in a long term in 
vitro experiments. On the other hand TNF-activated PMN are able to increase the permeability of 
this monolayer for small molecules, with minimal damage to the endothelial monolayer, within 30 
minutes. These observations led us to the conclusion that TNF-induced vascular damage partially 
mediated by the activated PMN already localized in the tumor increased the extravasation of the 
chemotherapeutic drug and erythrocytes into the tumor tissue. A simplified scheme is depicted in 
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Figure 2. Schematic overview. Involvement of the different tumor compartments after TNF- based melphalan perfusion. 
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leukocyte members: PMN and cells present in the PBMC pool. In particular cells producing IL-1ß and IFN are involved. 
TNF triggers the release of these cytokines and affects the endothelial cells directly. When interacting together TNF, IL-1ß 
and IFN resort endothelial gap formation, which is absent or less apparent when one of these cytokines is missing. We 
speculate that activated immune cells already present in the tumor contribute to the cytokine production as well. (See 
color section for a full-color version.)
Chapter 11 195
figure 3 (Fig. 3). Once located in the tumor tissue the chemotherapeutic drug kills the tumor cells. 
Infiltration of other leucocytes contributes in the further eradication of the tumor tissue.
LESSONS TO BE LEARNED FROM TNF-BASED COMBINATION THERAPY
The results obtained with TNF are exemplary for the current increasing interest in combination 
therapy. The use of antiangiogenic agents in combination with chemotherapy already indicated 
that tumor cell-targeted therapy benefits also directly from this antiangiogenic approach through 
alterations in the tumor physiology. The application of TNF shows excellently that manipulation 
of the tumor physiology in such way that additional chemotherapy is improved is a powerful tool 
in solid tumor therapy. Moreover, the central lesson to be learned here is that such a vasoactive 
agent not necessarily has to have a direct antitumoral activity. It changes the way we should look 
at combination therapy. Next to that, recognition of the essential effect of TNF allowed us to 
identify new and potentially better drugs, such as histamine, which could be of particular useful-
ness in settings that do not permit the use of TNF. We have now a better understanding of the 
pathways triggered by the vasoactive agents leading to the alterations in the tumor vascular bed 
and how these alterations affect intratumoral drug distribution. We anticipate that eventually 
tumor-manipulating agents will earn a central role in chemotherapy solid tumor therapy.
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General discussion: “Aiming for both tumor cells and 
stroma”
GENERAL DISCUSSION OF THIS THESIS
The primary aim of the research, described in this thesis was to improve the efficacy of conven-
tional chemotherapy by increasing accessibility of the agent to the tumor cell. Achieving ad-
equate drug concentrations at the site of its target, the tumor cell, remains a major challenge in 
systemic therapy. Pathophysiologic conditions at the tumor site hamper drug uptake because of 
heterogenous and chaotic blood flow patterns with hypoperfusion in multiple areas of the tumor, 
non-functional vessels and shunting of blood, high interstitial pressure zones due to a lack of 
lymphatic vessels, stasis and reversed blood flow (Fig. 1). In addition, the abnormal features and 
composition of the endothelial cells, pericytes, basal membrane and extracellular matrix hinders 
passage of the drug.
Improving drug uptake at the tumor site. Achieving better intratumoral drug levels by manip-
ulating the TAV with vasoactive agents or using drug formulations that will utilize the physiologic 
particularities, are important approaches to improve antitumor efficacy. Liposomal formulations, 
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Figure 1. The difference in tumor-associated vasculature and normal vasculature. (a) Blood vessels deliver nutri-
ents, oxygen and other molecules in the tissues it passes and removes toxins. This system is arranged in arteries, veins and 
capillaries with their own specific characteristics and phenotype. (b) In contrast to the structural organized blood vessels of 
the basic organs, the tumor-associated vasculature is “abnormal”. It display a lack of hierarchical branching and organiza-
tion in which the recognizable features of arterioles, capillaries and venules is lost. The vessels are tortuous and unevenly 
dilated. As a result, tumor blood flow is chaotic, might be stationary and can even change direction. This leads to hypoxia 
and acidosis in solid tumors. Due to these properties of the tumor-associated vasculature the intratumoral drug accumula-
tion is very heterogeneous. (c) The complete overview of the dorsal skin-fold window with a lewis lung carcinoma (arrow) 
6 days after tumor implantation. (See color section for a full-color version.)
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especially long circulating liposomes, lead to improved intratumoral drug levels because of capi-
talization on the leakiness of the TAV in comparison to normal vessels. Encapsulated doxorubicin 
(Doxil/Caelyx) is such an example and is used for AIDS-related Kaposi’s sarcoma, recurrent ovarian 
cancer and has recently also been approved by the FDA for multiple myeloma [1]. Alternatively, 
the chemical structure of a drug can be altered to reduce its toxicity. This has been done for TNF. 
TNF-SAM2, developed by Soma et al. has an increased N-terminal basicity with milder side ef-
fects compared to conventional TNF [2]. TNF coupled to cyclic CNGRC peptide (a CD13 ligand, 
expressed specifically on tumor vasculature) or to the antibody L19 (against the extra-domain 
B of fibronectin) has the tendency to home and bind more specifically to the tumor-associated 
vasculature making these TNF-mutants more active in significant lower dose [3,4]. Also binding 
of TNF at the surface of gold nanoparticles (cAu-TNF) improved the safety of TNF while retain-
ing the antitumor efficacy by selectively altering the permeability of the tumor vasculature [5]. 
Locoregional administration of drugs is another strategy to increase intratumoral drug levels. 
One of such methods is utilized in our experiments; the isolated limb perfusion (ILP). This method 
allows the administration of very high doses of chemotherapeutic drugs and other agents (e.g. 
cytokines) and achieves drug levels 15 to 50 times higher than can be achieved using the systemic 
administration that is limited by the maximal tolerated dose. This leads to very high response rates 
and tumor control [6].
Targeting both the stromal compartment and the tumor cells. A tumor does not solely ex-
ist of tumor cells and the stromal compartment is equally important in tumor development and 
growth. The TAV provides thereafter an interesting target in anticancer therapy. Endothelial cells 
are easily targeted and are believed to have more genetic stability then tumor cells, hence drug 
resistance is not likely to appear [7]. In 1971 Folkman proposed the hypothesis that prohibiting 
the development of newly formed tumor blood vessels would be an attractive new approach in 
cancer treatment [8]. The antiangiogenesis strategy inhibits the function of growth factors that 
are needed for the development and growth of new vessels. A second approach is the direct 
damage of the established tumor vasculature by vascular disrupting agents (VDAs) that will initi-
ate vascular collapse, shutdown of tumor blood flow, depriving the tumor of oxygen and nutri-
ents, leading to tumor necrosis [9]. It was demonstrated that these antiangiogenic and vascular 
disruptive strategies are not sufficiently effective and that the combination with chemotherapy is 
required for optimal antitumor responses.
Improving tumor response by dual targeting. Besides the antiangiogenic and vascular de-
structive approaches we propose a third strategy, “tumor vessel abnormalization” in which the 
tumor-associated vasculature is manipulated with vasoactive agents like TNF or Cilengitide to im-
prove the delivery of the chemotherapeutic compound at the site of the tumor cells. As the other 
strategies both attack the vasculature this is a counter intuitive approach in which an adequate 
vasculature is a prerequisite for a good antitumor response.
Two animal models were used to better investigate the underlying mechanisms. First, the iso-
lated limb perfusion with high-dose TNF or Cilengitide in combination with the chemotherapeutic 
drug melphalan in a short exposure setting. Second, the systemic treatment with multiple injec-
tions of low-dose TNF and Doxil. The choice of a chemotherapeutic agent depends on its efficacy 
in killing the tumor cells. However, for successful treatment the bioavailability of the chemothera-
peutic drug has to be facilitated by an agent with vasoactive/modulating properties. Low-levels of 
TNF in the systemic setting and short exposure to Cilengitide in the ILP are sufficient to give a sig-
nificant tumor response. In the ILP with high-dose TNF damage of the endothelial cells is already 
observed immediately after perfusion [10]. De Wilt et al. found that the TNF concentration could 
be reduced 5-fold while retaining synergy, but that below a certain threshold synergy between 
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TNF and melphalan or doxorubicin was completely lost [11]. Observations made in the dorsal 
skin-fold chamber show that a single injection of low-dose TNF suffices to increase the perme-
ability of the vessels without affecting the functionality of the vessel [12]. Systemic low-dose TNF 
therapy synergizes with Doxil in the treatment of both the soft tissue sarcoma BN175 [13] and the 
less vascularized osteosarcoma ROS-1 [14]. Drug accumulation was measured 24 hours after the 
third injection. A significant increase in intratumoral drug concentration was observed (1 µg/g for 
Doxil versus 2.3 µg/g for Doxil + TNF) in the BN175 soft tissue sarcoma model. In contrast, TNF 
had no effect on drug accumulation in the ROS-1 osteosarcoma model. We speculate that the 
vessels of this tumor are already quite leaky, which is supported by the higher drug concentration 
(4 µg/g) in this tumor without the presence of TNF. In vitro we observed that TNF had no direct 
effect BN175 cells while a 40% reduction in cell growth was observed when TNF was added to 
ROS-1 cells. These results indicate that TNF can have a direct effect on tumor cells (if sensitive) or 
an effect on the intratumoral drug delivery through manipulation of the vasculature.
About the liposomal fate we gained more insight using the dorsal skin-fold chamber. We ob-
served that after leaving the vasculature a perivascular rim of cells take up the complete liposome. 
The liposome is intracellularly degraded and releases its content (doxorubicin) which then enters 
the nucleus. Also in vitro we observed that free doxorubicin almost immediately transports into 
the nucleus. In contrast, when we incubated cells with liposomal doxorubicin (Doxil) this remains 
for days inside the cytoplasm and the doxorubicin content is released very slowly after which it 
can be observed in the nucleus (Fig. 2) [12]. This is in contradiction to previous publications that 
believe that doxorubicin is released in the interstitial space.
Also in the ILP, an increased uptake of the chemotherapeutic melphalan is found with the 
addition of TNF within the time frame of the perfusion and already during perfusion softening 
of the tumor occurs [10,15]. Histological analysis reveals that directly after perfusion some ar-
eas with destruction of the endothelial lining and erythrocytes infiltration can be seen. Because 
erythrocytes are know to be the main carrier for melphalan this is most likely the route by which 
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Figure 2. Intratumoral and intracellular fate of Doxil. Using the dorsal skin-fold chamber we observed that, with the 
addition of TNF, Doxil labeled with a green fluorescent marker extravasates from the tumor blood vessels into the tumor 
intersitium between 12 to 24 hours. (a) Seventy-two hours after systemic injection, the liposomes (green fluorescent) re-
mained in the cytoplasm of the cell, while doxorubicin (red fluorescent) was found in the nucleus. No indications of Doxil 
or liposomes outside the cells in the interstitial space were found. This suggest that the liposome is taken up completely 
by the cells and is thereafter broken down. (b) Tumor cells were incubated with doxorubicin in a migration ring and the 
fate of the free drug was followed for several hours. Almost immediately after adding the drug, doxorubicin was taken up 
by the cells and transported to the nucleus. (c) In contrary to the free drug, when cells were incubated with Doxil hardly 
any drug was observed in the nucleus and most remained in the cytoplasm. Scale bar apply for all images, 20 µm. (See 
color section for a full-color version.)
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melphalan enters the tumor tissue [16]. In previous studies, we already noted the infiltration of 
immune cells several days after perfusion [17,18]. However, within a time-frame of 6 hours we 
did not observe significant differences in infiltration of these cells and cytokines, indicating that 
they are not required for the initiation of vessel changes but play rather a role in the eradication 
of the tumor [10]. Besides TNF, we investigated other vasoactive compounds like histamine, IL-2 
and Cilengitide [19,20]. Cilengitide is an integrin inhibitor capable of disrupting the endothelial 
layer of angiogenic vessels. As for TNF, Cilengitide alone is not sufficient to trigger an antitumor 
response and needs to be accompanied by a chemotherapeutic agent.
The exact target of TNF: endothelial cells or pericytes? The prevailing hypothesis until re-
cently has been that the chemotherapeutic drug targets the tumor cells whereas the tumor-asso-
ciated endothelial cells are targeted by TNF. Immediately after TNF-based perfusion we observed 
in histological analysis some areas with complete destruction of the vasculature, but this is not 
enough to cause significant regression of the tumor [10]. Using the dorsal skin-fold chamber we 
observed that a combination with a chemotherapeutic compound is a prerequisite because TNF 
augment the intratumoral concentration of the co-administered chemotherapy [12]. TNF induces 
permeability of the tumor vasculature and increases the leakiness of vessels for macromolecules 
resulting in a better and more homogenous drug distribution. This increased permeability did 
not affect the functionality and size of the vessels for at least 2 days after treatment. However, 
we also found that TNF-induced vascular permeability is not a general phenomenon, as there is 
no increased accumulation of Doxil in the lewis lung carcinoma (LLC) and the 1F6 human mela-
noma resulting in a poor antitumor response. Obviously the properties of the tumor-associated 
vasculature are very important in TNF-response. The TNF-responding tumor, the B16BL6 mouse 
melanoma and the highly aggressive human melanoma BLM, contain large vessels in low-density 
whereas the non-responding tumors, LLC and 1F6, have a high degree of small vessels. Despite 
the difference in vessel architecture, the majority of the vessels are functional. This observation 
suggests that endothelial cells may not be the primary target of TNF. The lack of TNF-effect was 
already observed in vitro as hardly any passage of macromolecules through the endothelial layer 
was observed. Gap formation and permeability changes were only eminent when TNF was co-
incubated with IFN [21]. Also, in an earlier study we reported that when human biopsies were 
stained for TNFR1, the receptor was located at cells that were not endothelial cells but cells 
closely associated with the endothelial cells [22]. Further histological survey of human and mouse 
tumor biopsies revealed that, rather than endothelial cells, the tumor-associated pericytes are 
the TNFR1 expressing cells. This discovery substantiates the observations regarding the tumor 
response. B16BL6 and BLM have a higher pericyte coverage compared to LLC and 1F6, making 
the latter less responsive to the addition of TNF. Based on these observations we hypothesize that 
pericytes rather then endothelial cells are the primary target for TNF, implying that beneficial activ-
ity of TNF in a combination treatment protocol could be predicted by the presence of pericytes in 
the tumor vasculature. Most likely in the presence of TNF the pericytes produce a factor that in 
turn stimulated permeability increase of the endothelial cells. Further investigation is required to 
uncover the factor responsible for these changes.
GENERAL CONCLUSION
In the past multiple studies have demonstrated spectacular antitumor effects obtained with 
high-dose TNF and chemotherapy in the ILP model. Here we show that also a low doses of TNF 
can be effective. Further research has shown that the TNF-effect depends on the cellular make-up 
of the vascular bed and that not the endothelial cells but the pericytes are the primary target for 
TNF (Fig. 3). Aiming at multiple targets improves efficacy of therapeutic approaches. Manipulat-
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ing the tumor-associated vasculature with vasoactive agents increases the bioavailability of the 
chemotherapeutic compound in the tumor and is a prerequisite for a good tumor response. Ma-
nipulating and exploiting the pathophysiologic properties of the tumor vasculature, a process that 
we have called “tumor vessel abnormalization”, is different from the regular antiangiogenic and 
vascular destruction strategies. Results in this thesis show that this strategy improves the efficacy 
of chemotherapeutics. Isolated limb perfusion using TNF is already an approved treatment and 
other vasoactive agents have become available to be used in this system. We have demonstrated 
that low-dose TNF can mediate a good antitumor response in combination with liposomal che-
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Figure 3. Abnormalization of the tumor-associated vasculature. In the vasculature of basic organs the endothelial 
cells forms a quiescent and tightly packed lining separating the blood and blood-born elements from the rest of the body. 
Mural cells (smooth muscle cells and pericytes) form the muscle of the blood vessel and have specific properties according 
to the type of blood vessel they can be found at. The tumor-associated vasculature has endothelial cells that are morpho-
logical different from these in the normal vessels. Because of the fast growing properties of most tumors they are highly 
active and have irregular shapes with openings between the cells making the vessel highly permeable. Also the pericytes 
are different, forming a loose association with the endothelial cells and displaying extensions into the intersitium. The 
basal membrane is irregular in size with a different protein composition and structure. After TNF-based therapy, TNF binds 
to the TNFR1 located on the pericytes. These cells produce to further elucidate endogenous factors that has its effect on 
endothelial cells. The permeability of the endothelial lining is further increased for the co-administered drug, melphalan 
(in free form this will have micromolecular properties however absorbed in erythrocytes melphalan will act as a macro-
molecule) or long-circulating liposomes Doxil. MMPs produced by the endothelial cells will degrade the underlying matrix 
providing a better entrance for the chemotherapeutic compound. The liposomal drug enters as a whole the tumor cell 
were it is slowly degraded releasing the active drug intracellulary that eventually kills the tumor cell. (See color section for 
a full-color version.)
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motherapeutic drug formulations. Partially based on these results a clinical trial will start using 
nano(gold)particle TNF with enhanced tumor uptake kinetics and in the near future in melanoma 
patients.
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SUMMARY
In this thesis a third strategy in tumor vessel targeted anticancer therapy is investigated. This pro-
vascular approach, which we have called “tumor vessel abnormalization”, enhances the already 
abnormal features of the tumor-associated vasculature and further improves the permeability of 
these vessels. This results in an increased extravasation of cytotoxic agents from the blood circula-
tion into the tumor tissue ultimately leading to improved tumor response. This is rather a coun-
terintuitive approach as the other two concepts; antiangiogenesis and vascular destruction are 
antivascular strategies in which tumor vessel formation is respectively prohibited or destroyed.
In chapter 1 an introduction on the tumor-associated vasculature and previous results is giv-
en.
In chapter 2 we investigate the efficacy of the systemic treatment with free doxorubicin or 
liposomal encapsulated doxorubicin (Doxil) in osteosarcoma-bearing rats, and the effect of tu-
mor necrosis factor-alpha (TNF) on this approach. We observed an improved antitumor effect 
when using Doxil compared to doxorubicin, correlating with a higher intratumoral drug con-
centration. Addition of TNF further increased the tumor response to Doxil although no further 
increase in intratumoral concentration was measured. We also observed that this osteosarcoom 
was less vascularized compared to the previous investigated soft tissue sarcoma (BN175) in which 
TNF does increase intratumoral drug concentration. However, the intratumoral concentration of 
Doxil, without the addition of TNF, was 4-times higher in the ROS-1 osteosarcoma compared to 
BN175 indicating that these vessels are already quite permeable or become permeable earlier in 
the treatment. Compared to the BN175, ROS-1 is 10-times less sensitive to Doxil. However, in 
contradiction to BN175, TNF has a direct toxic effect on the ROS-1. From this we conclude that 
TNF affects the tumor cells directly and due to presence of already permeable vessels massive 
extravazation of Doxil occurs.
Chapter 3 describes the efficacy of the integrin inhibitor Cilengitide in the melphalan-based 
isolated limb perfusion (ILP) in soft tissue sarcoma-bearing rats. The results show that addition 
of Cilengitide improved the antitumoral activity of melphalan accompanied with an augmented 
intratumoral concentration. These results also corroborate a critical role of the integrins αVβ3 and 
αVβ5 for the integrity and survival of angiogenic tumor vessels. In vitro we observed that Cilen-
gitide prevents cell adhesion and promotes detachment of endothelial cells. In vivo no damage of 
the endothelial cells was observed after treatment with Cilengitide alone, most likely due to the 
short exposure time. However, in contradiction to TNF, Cilengitide renders the tumor cells, as well 
as the endothelial cells, more sensitive to melphalan, which may very well explain the observed 
antitumor response. From this data we conclude that when using the integrin inhibitor Cilengit-
ide, endothelial cells become more sensitive to melphalan leading to apoptosis of the endothelial 
cells. This results in an increased melphalan accumulation and erythrocytes extravasation in the 
tumor microenvironment, leading to tumor necrosis and hemorrhage.
As becomes clear from the data presented in chapter 4, TNF as a single agent has little effect 
on endothelial cells in vitro. Only when TNF is combined with interferon-gamma we observed 
significant structural changes in the endothelial layer, which were further enhanced by the ad-
dition of peripheral blood mononuclear cells (PBMC). Additionally, we found that TNF-primed 
PBMC produce endogenous interleukin-1beta (IL-1ß), which is at least partly responsible for the 
observed effect. These changes in monolayer morphology, such as cell elongation and gap forma-
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tion, changed the dense cobblestone-like endothelial monolayer into a more fibroblast-like phe-
notype accountable for the observed permeability increase of the endothelial layer. Translating 
this to the in vivo situation, we speculate that although there is a rapid damage to the endothelial 
cells when using TNF in the ILP, these damages are not a result of a direct cytotoxic effect of TNF 
on the endothelial cells and a interaction with other, locally produced factors is required.
Chapter 5 addresses the role of matrix metalloproteinases (MMPs) in cell detachment and gap 
formation of endothelial cells. We investigated the production of MMPs after TNF-stimulation of 
PBMC and endothelial cells. It seemed that the production of MMP-9 is in part responsible for 
the induced morphological changes and increased permeability. Also in these experiments we 
observed that endogenously produced IL-1ß is accountable for these changes in cell to matrix 
contact. Again a rather counterintuitive approach as elevated levels of MMPs are often correlated 
with tumor aggressiveness and bad prognosis. From these experiments we conclude that the 
production of MMPs is required to induce changes in the endothelial lining that lead to increased 
permeability and extravasation of the chemotherapeutic drug.
Besides the effect on cell to matrix degradation, the effect of TNF-primed PBMC on endothelial 
cells was also investigated on the cell to cell adhesion in chapter 6. We looked primarily at VE-
cadherin, the transmembrane protein of the adherens junctions. Using immunohistology staining, 
western blotting and PCR we found that increased permeability and morphological changes in 
the endothelial cells are rather accompanied with degradation of VE-cadherin at the cell mem-
brane, while the overall expression is not changed.
In chapter 7 we demonstrate the TNF effect on the tumor microenvironment directly after 
ILP and conclude that TNF rapidly damages the tumor endothelial lining. This damage turns the 
vessels more permeable for small molecules like melphalan but also for erythrocytes, inducing 
hemorrhage. Erythrocytes have been reported as carriers for melphalan and may account for the 
increased drug delivery in the tumor. No tumor response was observed in animals treated with 
TNF alone, indicating that a chemotherapeutic drug is mandatory to obtain a tumor response. 
We also measured no change in interstitial fluid pressure during the procedure. In addition, early 
in the treatment we observed no change in gene profile in the set of cytokines we have tested. 
However, as the immune profile was measured in the complete tumor, this is still open for debate. 
Most likely the expression profiles of the individual cells in the tumor microenvironment rather 
than the overall levels may be responsible for the immune response. Nevertheless, based on the 
results mentioned in this chapter we conclude that TNF in the ILP-setting has no effect on the 
interstitial fluid pressure and the augmented melphalan accumulation is most likely the result of 
an increased permeability of the tumor vasculature.
More detailed information about the TNF effect on the vasculature is given in chapter 8 us-
ing the systemic approach instead of the locoregional treatment. In accordance with previous 
experiments, we found increased intratumoral drug concentration in tumors treated systemically 
with low-dose TNF in combination with a conventional chemotherapy, in this case liposomal en-
capsulated doxorubicin (Doxil). Using the dorsal skin-fold chamber we observed that liposomes 
present in the tumors were primarily located in the vessels. However, in combination with TNF a 
more homogenous intratumoral distribution was accomplished and Doxil extravasated out of the 
vessels into the tumor tissue. With this technique, we studied the intracellular location of Doxil. 
To our knowledge for the first time, it was observed in vivo that liposomes are completely taken 
up by a cell and are broken down in the cytoplasm. These results indicate that TNF, in a non-toxic 
dose, renders the tumor vessels more permeable contributing to a better extravasation of Doxil 
resulting in an improved tumor response.
The efficiency of TNF in this setting is further elucidated in chapter 9. Four tumors types, with 
different vessel characteristics, were investigated regarding their sensitivity towards TNF in com-
bination with Doxil. We found that in tumors with large vessels the addition of TNF increased the 
Chapter 13 219
tumor response compared to the treatment with Doxil alone. However, in tumors with small ves-
sels addition of TNF to Doxil had no effect on tumor growth. More detailed investigation revealed 
that the receptor for TNF (TNFR1) was not located on the tumor-associated endothelial cells but 
on the pericytes and these TNFR1 expressing pericytes were present in a higher degree in the TNF-
responding tumors. From this study we conclude that high coverage of tumor vessels with TNFR1-
expressing pericytes correlates with responsiveness to TNF. This is a first indication that pericytes 
and not endothelial cells may be the primary target of TNF. Our results imply that benefit of TNF 
could be predicted by the presence of pericytes in the tumor vasculature.
SAMENVATTING
In deze thesis wordt een derde strategie onderzocht op het gebied van kankertherapie, die 
zich richt op de tumorvasculatuur. In een tumor hebben de bloedvaten reeds abnormale eigen-
schappen die zich over het algemeen niet bevinden in bloedvaten van andere organen. Door de 
“abnormalisatie”-methode toe te passen worden deze kenmerken versterkt. Bij deze methode 
neemt voornamelijk de doorlaatbaarheid van de vaten toe. Dit resulteert in een verhoogde uit-
treding van een chemotherapeuticum vanuit de bloedstroom in het tumorweefsel en resulteert 
uiteindelijk in een verbeterde tumorrespons.
Deze provasculaire benadering is controversieel vergeleken met de twee andere vasculaire 
strategieën. Deze behandelwijzen; de antiangiogene en vasculair destructieve strategieën zijn 
antivasculaire methodes waarbij de vorming van nieuwe tumorbloedvaten wordt voorkomen of 
waarbij de reeds bestaande bloedvaten worden vernietigd.
In hoofdstuk 1 wordt een introductie gegeven over het tumorvaatbed en de resultaten voor-
afgaande aan deze thesis.
In hoofdstuk 2 wordt onderzoek beschreven naar de werkzaamheid van een systemische 
behandeling met vrij doxorubicine of liposomaal doxorubicine (Doxil) in combinatie met tumor 
necrosis factor-alpha (TNF) in ratten met een osteosarcoom, de ROS-1 tumor. We zien een beter 
antitumor effect met Doxil dan met doxorubicine en dit correleert met de mate van aanwezigheid 
van het chemotherapeuticum in het tumorweefsel. Er wordt meer Doxil in de tumor gevonden 
dan doxorubicine. Door het chemotherapeuticum te combineren met TNF wordt een nog betere 
tumorrespons verkregen. We merkten echter ook op dat TNF niet bijdraagt aan een verhoogde 
concentratie van Doxil of doxorubicine in de tumor. De ROS-1 heeft minder vaten vergeleken met 
een andere tumor, het weke delen sarcoom BN175, die we in eerdere experimenten uitvoerig 
hebben bestudeerd. In de BN175 zorgt TNF namelijk wel voor een verhoogde concentratie van 
Doxil in de tumor. De tumorconcentratie van Doxil is echter in de ROS-1 viermaal hoger dan in de 
BN175. Dit impliceert mogelijk dat de bloedvaten in de ROS-1 reeds een verhoogde doorlaatbaar-
heid hebben. Het is ook denkbaar dat de verhoogde doorlaatbaarheid bij de ROS-1 vroeger in de 
behandeling ontstaat. Vergeleken met BN175 zijn ROS-1 tumorcellen tienmaal minder gevoelig 
voor Doxil maar zijn wel gevoelig voor TNF, terwijl de BN175 tumorcellen dat niet zijn. Uit de re-
sultaten concluderen wij dat TNF een direct toxisch effect op deze tumor heeft. Daarnaast komt, 
door de reeds aanwezige doorlaatbaarheid van de bloedvaten, een grote concentratie van het 
Doxil in de tumor terecht. Deze factoren dragen daardoor bij aan de goede tumorrespons wan-
neer Doxil in combinatie met TNF wordt toegediend.
Hoofdstuk 3 beschrijft de werking van de integrine inhibitor Cilengitide in een geïsoleerde 
ledemaat perfusie (ILP) in ratten met een weke delen sarcoom. De resultaten laten zien dat Cilen-
gitide de werking van het chemotherapeuticum melphalan versterkt. Ook in deze setting is een 
verhoogde concentratie van melphalan in de tumor waar te nemen. Deze resultaten bevestigen 
eveneens de belangrijke rol van de integrines, αVβ3 en αVβ5, in de integriteit en overleving van 
Summary/Samenvatting220
tumorvaten. In vitro observaties toonden aan dat Cilengitide de aanhechting van cellen verhindert 
en daarnaast het loslaten van cellen bevordert. In vivo werd geen beschadiging van endotheelcel-
len waargenomen wat hoogst waarschijnlijk te wijten is aan de korte blootstelling van de cellen 
aan Cilengitide. Echter, in tegenstelling tot TNF worden tumor- en endotheelcellen die zijn bloot-
gesteld aan Cilengitide gevoeliger voor melphalan. Vermoedelijk is dit een belangrijke verklaring 
voor de waargenomen verbeterde tumorrespons. Uit deze data kunnen we concluderen dat door 
het gebruik van de inhibitor Cilengitide endotheelcellen gevoeliger worden voor melphalan, wat 
leidt tot apoptose van deze cellen. Vervolgens resulteert dit in een verhoogde melphalan accumu-
latie en extravasatie van rode bloedcellen in het tumorweefsel. Deze uittreding is verantwoorde-
lijk voor tumornecrose en bloedingen en levert uiteindelijk een goede tumorrespons op.
De data verkregen in hoofdstuk 4 maakt duidelijk dat TNF als een alleenstaande behandeling 
weinig effect heeft op endotheelcellen in vitro. Significante structurele veranderingen in de endo-
theellaag werden waargenomen wanneer de cellen aan TNF in combinatie met interferon- gamma 
(IFN) worden blootgesteld. Deze veranderingen werden nog sterker door verdere toevoeging van 
mononucleaire bloedcellen (PBMC). Eveneens vonden we dat TNF-behandelde PBMC endogeen 
interleukine-1beta (IL-1ß) produceren, dat gedeeltelijk verantwoordelijk is voor de veranderingen 
in de endotheellaag. Deze morfologische veranderingen, zoals celverlenging en het ontstaan van 
gaten, geven de hechte kobbelsteenachtige laag cellen een meer fibroblastachtig uiterlijk en zijn 
verantwoordelijk voor de verhoogde doorlaatbaarheid van de cellaag. Aan de hand van deze 
resultaten speculeren we dat de schade aan de endotheelcellen, die wordt waargenomen in de 
ILP, niet rechtstreeks door TNF worden veroorzaakt, maar met name door IFN en IL-1ß en dat de 
interactie met andere endogeen geproduceerde elementen een belangrijke rol spelen.
Hoofdstuk 5 behandelt de rol van matrix metalloproteinases (MMP’s) bij de aanhechting van 
endotheelcellen en het ontstaan van gaten in de endotheellaag. We onderzochten de aanmaak 
van MMP’s na TNF stimulatie van PBMC en endotheelcellen. Het lijkt erop dat de productie van 
MMP-9 gedeeltelijk verantwoordelijk is voor de morfologische veranderingen en de toegeno-
men doorlaatbaarheid van de endotheelcellen. In deze experimenten werd ook waargenomen 
dat endogeen IL-1ß belangrijk is voor de veranderingen in de aanhechting van cellen aan de 
onderliggende matrix. Dit is opnieuw een controversiële bevinding aangezien verhoogde MMP 
waarden worden gecorreleerd met agressiviteit van de tumor en een slechte prognose. Uit deze 
experimenten concluderen wij dat de MMP productie verantwoordelijk is voor de veranderingen 
in de endotheellaag, wat vervolgens voor een betere doorlaatbaarheid en extravasatie van het 
chemotherapeuticum zorgt
Naast cel-matrix contact wordt in hoofdstuk 6 ook gekeken naar het effect van TNF-gesti-
muleerde PBMC op de aanhechting van endotheelcellen onderling. Dit onderzoek focust zich 
voornamelijk op VE-cadherine, het transmembraan eiwit van de adherens junctions. Door ge-
bruik te maken van technieken als immunohistologie, western blot en PCR vonden we dat de 
toegenomen doorlaatbaarheid en morfologische veranderingen in de endotheellaag samengaan 
met de afbraak van VE-cadherine aan het celmembraan en niet te wijten is aan een verminderde 
aanmaak.
In hoofdstuk 7 wordt het effect van TNF in de tumor na het uitvoeren van de ILP bespro-
ken. Na de perfusie is al meteen een flinke schade aan de tumor vasculatuur waar te nemen. 
Door deze beschadigingen wordt de doorlaatbaarheid van de bloedvaten verhoogd voor zowel 
kleine moleculen als melphalan. We zagen ook een toename in extravasatie van rode bloedcel-
len die bloedingen in het tumorweefsel veroorzaken. Uit eerder onderzoek is gebleken dat rode 
bloedcellen melphalan kunnen opnemen en dit fenomeen zal zeker bijdragen aan de verhoogde 
melphalan concentratie in de tumor. Bij dieren die enkel met TNF behandeld zijn werd geen bete-
re tumorrespons waargenomen wat impliceert dat een chemotherapeuticum noodzakelijk is voor 
een goede respons. Er werd ook geen verandering in de intersitiële drug gemeten tijdens de ILP.
Chapter 13 221
Bovendien zagen we geen veranderingen in het genetische profiel van een aantal geteste cy-
tokinen in de tumor, alhoewel dit nog steeds ter discussie staat aangezien dit werd gemeten in 
de volledige tumor. Hoogstwaarschijnlijk is het expressiepatroon van de individuele cel en niet die 
van de volledige tumor belangrijker in een immuunreactie. Desondanks kunnen we concluderen 
dan TNF in de ILP geen effect heeft op de interstitiële druk en dat de verhoogde melphalan ac-
cumulatie in de tumor een resultaat is van een toegenomen doorlaatbaarheid van de tumorvas-
culatuur.
Meer gedetailleerde informatie over het TNF-effect op de bloedvaten wordt gegeven in hoofd-
stuk 8 waar we gebruik maken van een systemische behandeling. In samenspraak met de voor-
gaande resultaten vonden we hier ook toegenomen concentraties van het chemotherapeuticum 
in tumoren van dieren die systemisch behandeld zijn met een lage dosis TNF in combinatie met 
Doxil. Door gebruik te maken van het huidflapmodel kunnen we zien dat de liposomen hoofd-
zakelijk in de bloedvaten te vinden zijn wanneer geen TNF werd gegeven. Door Doxil echter te 
combineren met TNF ontstaat een homogenere verspreiding van de liposomen in de tumor en 
treedt ook meer Doxil uit de bloedvaten in het omliggende tumorweefsel. Met deze techniek 
kunnen we ook de intracellulaire aanwezigheid van Doxil bestuderen in een in vivo situatie. Naar 
onze mening werd hier voor het eerst aangetoond dat liposomen volledig door een tumorcel 
worden opgenomen en in het cytoplasma worden afgebroken. De resultaten in dit hoofdstuk 
wijzen er op dat een lage niet-toxische dosis TNF zorgt voor een verhoogde doorlaatbaarheid van 
de bloedvaten dat bijdraagt aan een betere uittreding van Doxil naar het omliggende weefsel en 
uiteindelijk resulteert in een verbeterde tumorrespons.
De efficiëntie van TNF is verder bestudeerd in hoofdstuk 9. Vier tumortypes met verschil-
lende vasculaire eigenschappen werden onderzocht op hun gevoeligheid voor TNF in combinatie 
met Doxil. We vonden dat in tumoren met grote vaten de toevoeging van TNF bijdraagt aan 
een verhoogde tumorrespons vergeleken met de respons op enkel Doxil. Dit in tegenstelling tot 
de tumoren met kleine vaten waar TNF geen effect op de repons heeft. Uit meer gedetailleerd 
onderzoek blijkt dat de receptor voor TNF (TNFR1) niet op de tumor endotheelcellen zit maar op 
de pericyten. Ook blijkt dat deze TNFR1 tot expressie brengende pericyten in grotere aantallen 
aanwezig zijn in de tumoren die reageren op TNF. Uit deze studie concluderen we dat de aan-
wezigheid van deze pericyten correleert met de gevoeligheid van de tumor voor TNF. Voor het 
eerst werd waargenomen dat TNF werkt op de tumor geassocieerde pericyten en niet per se op 
de endotheelcellen. Deze resultaten houden in dat de TNF-respons kan worden voorspeld aan de 
hand van de aanwezigheid van pericyten in de tumor vasculatuur.
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
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
        


     
     
  
       

      





      
     

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
 
    
     
 
     
     
     
   

     
     
    
    
    


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Color Section 231
        
             


          
    




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
        

        

       
 
      
       


      
        
       
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Figure 2. Massive necrosis is observed after Doxil treatment. Paraffin sections of the osteosarcoma after systemic 
treatment were stained with haematoxylin-eosin. Sham and TNF-treated tumors hardly showed any necrosis when the 
tumors reached a size of 17 mm. Necrosis was observed in Doxil treated tumors that was further enhanced with the ad-
dition of TNF. Scale bar apply for upper pictures, 500 µm. Scale bar apply for lower pictures, 100 µm.
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Perfusate sample melphalan measurment
End of experiment
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Figure 1. Time-line of Cilengitide treatment and sample collection.
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Figure 3. Histopathology of BN175 tumor after Cilengitide treatment in combination with a melphalan-based 
ILP. (a) Tumors were excised immediately after treatment for histological evaluation. Left panel, H&E staining was per-
formed on tumors of all groups and showed no effect on tumor cells and tumor vasculature (open arrow) when animals 
were treated with sham, melphalan or TNF alone. Confirming previous results, ILP with melphalan plus TNF resulted in 
marked vascular damage (arrow head), which was accompanied by hemorrhage and edema (asterisk). Right panel, ad-
ministration of Cilengitide alone had no noticeable effect on tumor histology or on tumor-associated vasculature (open 
arrow). However, when Cilengitide was combined with melphalan, TNF or melphalan plus TNF massive vascular destruc-
tion (open arrow) and hemorrhage (asterik) were observed. (b) Damage to the tumor-associated vasculature is visualized 
by CD31 staining. Tumors were removed at the end of the treatment, frozen and processed for immunohistochemistry as 
described in the experimental procedures. Perfusion with Cilengitide alone had marginal effect on tumor vessel integrity 
or diameter (closed arrow), while treatment with a combination of Cilengitide with melphalan, TNF or melphalan plus TNF 
resulted in profound loss of vascular integrity (open arrow) and widening of the vascular lumen (arrow head). Endothelial 
cell apoptosis is shown after treatment with Cilengitide plus melphalan and TNF by TUNEL staining. The photograph 
(lower right panel) demonstrates apoptotic tumor cells (green), endothelial cells (red) and apoptotic endothelial cells (yel-
low, arrow). Scale bar apply for all images, 100 µm.
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Medium TNF + IFN TNF + IFN + PBMC
Figure 2. The cytoskeleton changes after incubation of primed PBMC. Staining for F-actin (red) and DAPI (blue) 
after incubation of HUVEC as described in the experimental procedures. Untreated cells revealed actin mainly localized 
at the periphery of the cell and clustering to form actin rich points (arrow). Cells treated with TNF (10 µg/ml) in combina-
tion with IFN (0.001 µg/ml) showed a decrease in peripheral actin and actin fibers oriented in the long axis of the cell. 
Cells treated with a combination of TNF, IFN and PBMC showed further elongation of actin fibers. Scale bar apply for all 
images, 50 µm.
PBMC
IFN
IL-1beta
Tumor tissue
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Figure 7. Proposed mechanism of TNF-mediated changes in tumor vascular permeability leading to augmented 
local drug accumulation in high-dose TNF combination therapy. Here we show that TNF, added in combination with 
cytotoxic agents, activate PBMC to produce IL-1ß and IFN. Mainly IFN and IL-1ß are responsible for the induction of mor-
phological changes of the endothelial lining of the tumor-associated vasculature, thereby increasing vascular permeability. 
This enhances infiltration of blood cells and improves drug accumulation in the surrounding tumor tissue.
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Figure 3. VE-cadherin is degraded at the cell membrane. (a) Staining for VE-cadherin and DAPI of HUVEC after in-
cubation for 72 hours as described in the experimental procedures. Control treated cells show that VE-cadherin localized 
at cell-cell junctions between two cells. Incubating the cells with TNF and IFN resulted in a more speckled pattern of VE-
cadherin. Addition of PBMC and IL-1ß further reduced VE-cadherin expression at the cell junctions. Scale bar apply for all 
images, 50 µm. (b) Western blotting show a significant decrease in the expression of VE-cadherin in the membrane frac-
tion of HUVEC after incubation of TNF in combination with IFN and PBMC. Replacing PBMC with IL-1ß also significantly 
decreased the amount of VE-cadherin. Columns represent percentage pixel density compared to control ± SD of at least 
4 individual experiments; *, P < 0.05 versus control treated cells.
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Figure 1. Effect of TNF on the histopathology of tumor tissue after ILP. HE staining directly after perfusion with 
melphalan in combination with TNF showed necrotic areas, destruction of the vascular lining and extravasation of erythro-
cytes (arrow). Perfusion with TNF alone also induced vascular damage and erythrocyte infiltration. In sham or melphalan-
treated tumors the vessel lining was still intact. Dotted line denotes the boundary between normal tumor tissue (T) and 
necrotic tissue (N). Scale bar apply for all images, 100 µm.
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Figure 2. Effect of TNF on apoptosis of endothelial cells in tumor directly after ILP. Photographs demonstrating 
apoptotic tumor cells (green, arrowhead), endothelial cells (CD31, red) and apoptotic endothelial cells (yellow, arrow). 
Perfusion with melphalan in combination with TNF or with TNF alone induces apoptosis of endothelial cells whereas in 
the staining of tumor tissue after sham or melphalan perfusion no apoptotic endothelial cells were observed. Scale bar 
apply for all images, 100 µm.
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Figure 4. TNF has no effect on redistribution of granulocytes and macrophages. Directly after treatment tumors 
were excised and stained for granulocytes and macrophages. There was no change in the number or redistribution of the 
tumor infiltrating cells between the treatments. Scale bar apply for all images, 100 µm.
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Supplementary Figure 1. Intravital microscopy reveals profound intratumoral vascularization in the B16BL6 
model. Ten days after tumor implantation in the dorsal skin-fold chamber the tumor growth and vasculature were visual-
ized. (a) While some newly formed blood vessels originating from the surrounding normal vasculature feed the B16BL6 
tumor, abundant intratumoral branches were observed (magnification, arrow). (b) For a better visualization in the B16BL6 
tumor, FITC-BSA was injected and a chaotic, branched tumor vasculature is observed in the tumor. (c) The pattern of the 
normal vasculature displayed minimal branching, even vessel diameter and a definable direction. Scale bar apply to all 
images, 250 µm.
240
Rho-PEG-L Bright field Merge
N
o
T
N
F
T
N
F
a b
F
lu
o
re
s
c
e
n
c
e
in
te
n
s
it
y
255
0
TNF
255
0
No TNF
Supplementary Figure 2. Addition of TNF leads to an increased accumulation of long circulating liposomes 
(Rho-PEG-L) in the tumor tissue. Intravital microscopy scans of the B16BL6 melanoma were compared to illustrate 
the effect of mTNF on the liposomal uptake after systemic administration. (a) Hardly any liposomes were observed in the 
tumor tissue. Only in a few regions liposomes were seen intravascular (insert, arrow). Addition of mTNF clearly inflicted a 
homogenous intratumoral accumulation of liposomes. Scale bar apply to all images, 500 µm. (b) The increase in height 
of the fluorescence intensity peaks of the surface plots illustrates increased accumulation of liposomes when combined 
with mTNF.
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Supplementary Figure 3. Addition of TNF does not render the tumor blood vessels permeable for 400 nm lipo-
somes. Tumor distribution of systemic injection with long circulating liposomes (Rho-PEG-L) of 400 nm in combination 
with saline or mTNF using intravital microscopy was studied. In mice injected with liposomes hardly any extravasation into 
the surrounding tumor tissue could be seen even with the addition of mTNF. The image overlay shows that obstruction of 
the 400 nm liposomes is found in the chaotic tumor related vessels. Scale bar apply to all images, 200 µm.
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Figure 2. Addition of TNF promotes liposomal extravasation through hyperpermeable vessels. The effect of 
mTNF on tumor distribution of systemically injected long circulating liposomes (Rho-PEG-L) was studied by intravital 
microscopy. Twelve or 24 hours later mice were injected with FITC-BSA to visualize functional vessels. (a) In mice injected 
with Rho-PEG-L alone, some liposomes were seen in the surrounding tumor tissue (asterix), but predominantly in the 
blood vessels. In blood vessels filled with liposomes no green FITC-BSA fluorescence could be seen (arrow), indicating 
that these intravascular liposomes were obstructing the blood flow. When mTNF was added, liposomal extravasation was 
observed at sites were also FITC-BSA leaked out (asterix), indicating that mTNF rendered the vessels hyperpermeable for 
liposomes. FITC-BSA was seen in the tumor vessels (arrowhead) indicating intact functionality. These blood vessels seemed 
deprived of liposomes suggesting that all liposomes had extravasated into the surrounding tumor tissue. Scale bar ap-
ply to all images, 200 µm. (b) Surface plots show high intensity peaks in the tumor vessels when liposomes alone were 
given. Consistent with the confocal pictures, surface plot of images from mice injected with liposomes combined with 
mTNF show high fluorescence intensity at hyperpermeable sites in the tumor. (c) After calculation of the incidence that 
a liposome was found inside a vessel, a strong reduction in intravascular presence was found when mice were injected 
in combination with mTNF. Columns represent percentage liposomes found intravascular ± SEM of at least 6 scans of 5 
individual animals; #, P < 0.01 versus no mTNF of the same time point.
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Figure 3. Addition of TNF does not render the tumor blood vessels permeable for 400 nm liposomes. Tumor dis-
tribution of systemic injection with long circulating liposomes (Rho-PEG-L) of 400 nm in combination with saline or mTNF 
using intravital microscopy was studied. Twelve or 24 hours later mice were injected with FITC-BSA to visualize functional 
vessels. (a) In mice injected with liposomes, even with the addition of mTNF, hardly any extravasation into the surround-
ing tumor tissue could be seen. Only at the rim of the tumor (dotted line) accumulation of liposomes could be observed 
(asterix). In some vessels liposomes were found to remain inside a FITC-BSA permeable tumor vessel (arrowhead). When 
vessels were filled with liposomes these vessel became non-functional (arrow). Scale bar apply to all images, 200 µm. (b) 
Although more 400 nm liposomes were found in the tumor with the addition of mTNF, levels were much lower compared 
to 100 nm liposomes. Columns represent percentage fluorescent area density ± SEM of at least 6 scans of 3 to 4 individual 
animals. (c) After calculation of the extravascular fluorescent intensity hardly any liposome could be measured outside the 
vessels, indicating that even with the addition of mTNF 400 nm liposomes remained trapped in the tumor vessels Columns 
represent percentage extravascular fluorescent area density ± SEM of at least 6 scans of 3 to 4 individual animals. (d) 
The incidence that a liposome was found inside the vessel no difference was found between the two treatment groups. 
Also when mTNF was co-administered liposomes were predominantly found inside the tumor vessels. Columns represent 
percentage liposomes found intravascular ± SEM of at least 6 scans of 3 individual animals.
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Figure 4. Addition of TNF provokes extravasation of long circulating liposomes. Tumor distribution of doxorubicin 
and Doxil was studied using intravital microscopy. Twelve hours after administration of doxorubicin, mice were injected 
with FITC-BSA to visualize functional vessels. In the case of Doxil, the liposomal component was labeled with a fluorescent 
marker DiO. B16BL6 melanoma-bearing mice were injected with doxorubicin or Doxil-DiO in combination with saline or 
mTNF. (a) In mice treated with doxorubicin, 12 hours later hardly any drug could be observed in the tumor tissue (dotted 
line = rim of the tumor) even in the presence of mTNF, although the vessels were functional. (b) When Doxil-DiO alone 
was administered, liposomes were observed in the vessels (arrows) and surrounding tissue. However, when Doxil-DiO was 
combined with mTNF massive extravasation of Doxil from the blood vessels (dotted line) into the tumor interstitium was 
observed (arrowheads). (c) After calculation of the extravascular fluorescent intensity a significant increase was found 12 
hours and 24 hours after injection in combination with mTNF. Columns represent percentage extravascular fluorescent 
area density ± SEM of at least 6 scans of 5 individual animals; #, P < 0.01; *, P < 0.05 versus no mTNF at the same time 
point. (d) Twelve and 24 hours after administration of Doxil in combination with mTNF empty vessels (dotted line) were 
observed surrounded by extravasated liposomes (arrowheads). Scale bar apply to all images: 200 µm.
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Figure 5. The complete liposome is taken up by the tumor cell and broken down in the cytoplasm. Using in-
travital microscopy the cellular uptake of Doxil was observed. (a) Thirty-six hours after systemic injection of Doxil-DiO, 
the liposomes (yellow) were seen in the cytoplasm of the tumor cell, whereas only doxorubicin (red) could be observed 
in the nucleus (arrow). At higher magnification, doxorubicin (red, arrow) was seen in the nucleus while the liposome 
(green, arrow) was only found in the cytoplasm. Also 72 hours after systemic injection the red fluorescent of doxorubicin 
in the nucleus of the tumor cell and the yellow fluorescent of the complete liposome inside the cytoplasm could still be 
observed. (b) For better understanding of the uptake of doxorubicin in the B16BL6 melanoma cell, cells were incubated 
with doxorubicin or Doxil and time-lapse microscopy was performed. Doxorubicin was immediately taken up by the cell 
and transported to the nucleus. On the other hand, Doxil took much longer to occur in the cytoplasm. Scale bar apply to 
all images; 200 µm. (c) The percentage B16BL6 cells positive for doxorubicin in the cytoplasm (■) and nucleus (▲) after 
incubation with free doxorubicin or in the cytoplasm (□) and nucleus (∆) after incubation with Doxil were calculated. Very 
rapidly all cells had taken up the doxorubicin and stained positive for nuclear doxorubicin. In case of cells incubation with 
Doxil, doxorubicin was observed in the cytoplasm much later compared to the administration of free drug. Transport 
from the cytoplasm to the nucleus also took much longer. Data points represent the percentage cells that are positive for 
doxorubicin.
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Figure 1. Addition of TNF improves tumor response and augments intratumoral drug uptake in B16BL6 and 
BLM. (a,b) Graphs show the tumor size index of subcutaneous implanted B16BL6 and LLC (a) and BLM and 1F6 (b) dur-
ing systemic treatment with Doxil and low-dose mTNF. Mice were injected 5 times i.v. with an interval of 4 days (arrows). 
Addition of mTNF resulted in synergistic tumor response of the B16BL6 and BLM, but no effect of mTNF was observed in 
the LLC and 1F6. Data points represents tumor size index ± SD of 6 individual animals. (c) In vitro growth of tumor cells 
(B16BL6, LLC: upper graph; BLM, 1F6: lower graph) 72 hours following incubation with different concentration Doxil and 
10 µg/ml TNF (mTNF for B16BL6, LLC and HuTNF for BLM and 1F6). Addition of TNF had no synergistic effect with Doxil 
on the tumor cells. Data points represent percentage cell growth of incubated cells compared to control treated cells at 0 
hour ± SEM of 3 individual experiments in duplicate. (d) Doxil uptake in the tumors (B16BL6, LLC: upper graph; BLM, 1F6: 
lower graph) with or without addition of mTNF. Tumors were excised 24 hours following a single injection and the amount 
of doxorubicin was measured. Addition of mTNF to Doxil treatment enhanced drug accumulation in the B16BL6 and 
BLM tumors in contrast to LLC and 1F6. Columns represent µg doxorubicin per g tumor tissue ± SD of 3 to 5 individual 
animals; *, P < 0.05 TNF versus no TNF. (e) Representative immunofluorescent photographs of CD31 expression and Doxil 
accumulation in B16BL6 and LLC 12 hours following treatment with Doxil and TNF. In accordance with the Doxil uptake, 
accumulation of Doxil into the tumor intersititium was observed in the B16BL6 and hardly any Doxil was seen in the LLC. 
Scale bar apply to all images, 100 µm.
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Figure 2. Addition of TNF strongly improves liposomal distribution in the tumor interstitium of the B16BL6 
and BLM. (a) Representative intravital microscopy scans of the tumors were compared to illustrate the effect of mTNF 
on liposomal uptake following systemic administration. Addition of mTNF clearly inflicted an intratumoral accumulation 
of Doxil in the B16BL6 and BLM 24 hours after treatment. Scale bar apply to all images, 200 µm. (b) Increase in height 
of the fluorescence intensity peaks of the surface plots illustrates increased accumulation of liposomes when combined 
with mTNF in the B16BL6 and BLM. (c) After calculation of the extravascular fluorescent intensity a significant increase 
was found in the B16BL6 (left graph) and in BLM (right graph) 24 hours following injection of Doxil in combination with 
mTNF. Columns represent fluorescent area density ± SEM of at least 4 scans of 3 individual animals; *, P < 0.05 B16BL6 
or BLM versus LLC or 1F6.
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Figure 3. Structural differences in vasculature between TNF-sensitive and TNF-insensitive tumors. (a) Tumor-
bearing mice were injected i.v. with lectin, 10 min later tumors were excised and histological sections were stained for 
endothelial cells (CD31, green) and functional blood vessels with an antibody against lectin (red). Scale bar apply to all 
images, 50 µm. (b) After measuring the microvessel size (MVS) significant larger blood vessels were found in the B16BL6 
and BLM. (c) The microvessel density (MVD) was determined by counting the number of vessels per mm2 and was found 
significant higher in the LLC and 1F6 (d) The percentage functional vessels was calculated and in spite of a significant dif-
ference in size and density, most of the tumor vessels were functional. Columns represent mean ± SEM of at least 6 scans 
from 3 sections of 3 individual tumors; *, P < 0.05 B16BL6 or BLM versus LLC or 1F6.
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Figure 5. Morphology of the tumor-associated endothelial cells (CD31, green) and pericytes (NG2, red). (a, b) 
NG2 staining of pericytes show close association with endothelial cells, however multiple protrusions (arrows) into the 
tumor stroma were observed. (c) Some pericytes projected away from a vessel and connected neighboring vessels. (d) 
Endothelial cells migrating into the tumor parenchyma were found to be associated with pericytes at several occasions 
(arrowhead). (e) NG2 positive cells that were not associated with endothelial cells (asterix), designated as myofibroblasts, 
were found in the LLC. Scale bar applied to all images, 20 µm.
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Figure 4. TNFR1 is expressed by pericytes of the tumor-associated vasculature. (a) Immunofluorescent staining 
for endothelial cells (CD31, red) and TNFR1 (green) in human (upper panels) and mouse (lower panels) tumor sections 
showed no co-localization (arrow). (b) Staining for pericytes (NG2, purple) and TNFR1 (green) showed TNFR1 expression 
by pericytes (arrowhead) of the tumor-associated vasculature of human (upper panels) and mouse (lower panels) tumor 
biopsies. Scale bar apply to all images, 20 µm.
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Figure 6. Difference in pericyte coverage is found between TNF-sensitive tumors and TNF-insensitive tumors. 
(a) Tumor sections were stained for endothelial cells (CD31, green) and pericytes (NG2, red). In the merge picture an in-
tense association between endothelial cells and pericytes was seen in the B16BL6 and BLM. Scale bar apply to all images, 
50 µm. (b) Analysis of the endothelial-pericyte association. Images of the endothelial cells (green) and pericytes (red) were 
binarized and the diameter of endothelial cells was dilated. The overlap of both cells is shown in black. (c) The percentage 
endothelial cells per vessel were calculated for B16BL6, LLC (left graph), BLM and 1F6 (right graph). In accordance with 
the MVS, B16BL6 and BLM contained significantly more endothelial cells per vessel then respectively the LLC and 1F6. 
Columns represent percentage area endothelium per vessel per field of interest ± SEM of at least 6 scans from 3 sections 
of 3 individual tumors; *, P < 0.05 B16BL6 or BLM versus LLC or 1F6. (d) Using the overlap images, microvessel pericyte 
coverage index (MPI) was measured in the B16BL6, LLC (left graph) and BLM, 1F6 (right graph). The MPI in tumor vessels 
of B16BL6 and BLM was significant higher compared to the MPI in LLC and 1F6. Columns represent percentage MPI of at 
least 6 scans from 3 sections of 3 individual tumors; *, P < 0.05 B16BL6 or BLM versus LLC or 1F6.
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Figure 2. Schematic overview. Involvement of the different tumor compartments after TNF- based melphalan perfu-
sion.
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Figure 3. Action of TNF on the vascuar bed. The action of TNF on the tumor vascular bed involves at least two key 
leukocyte members: PMN and cells present in the PBMC pool. In particular cells producing IL-1ß and IFN are involved. TNF 
triggers the release of these cytokines and affects the endothelial cells directly. When interacting together TNF, IL-1ß and 
IFN resort endothelial gap formation, which is absent or less apparent when one of these cytokines is missing. We specu-
late that activated immune cells already present in the tumor contribute to the cytokine production as well.
251
a
b
c
Figure 1. The difference in tumor-associated vasculature and normal vasculature. (a) Blood vessels deliver nutri-
ents, oxygen and other molecules in the tissues it passes and removes toxins. This system is arranged in arteries, veins and 
capillaries with their own specific characteristics and phenotype. (b) In contrast to the structural organized blood vessels of 
the basic organs, the tumor-associated vasculature is “abnormal”. It display a lack of hierarchical branching and organiza-
tion in which the recognizable features of arterioles, capillaries and venules is lost. The vessels are tortuous and unevenly 
dilated. As a result, tumor blood flow is chaotic, might be stationary and can even change direction. This leads to hypoxia 
and acidosis in solid tumors. Due to these properties of the tumor-associated vasculature the intratumoral drug accumula-
tion is very heterogeneous. (c) The complete overview of the dorsal skin-fold window with a lewis lung carcinoma (arrow) 
6 days after tumor implantation.
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Figure 2. Intratumoral and intracellular fate of Doxil. Using the dorsal skin-fold chamber we observed that, with the 
addition of TNF, Doxil labeled with a green fluorescent marker extravasates from the tumor blood vessels into the tumor 
intersitium between 12 to 24 hours. (a) Seventy-two hours after systemic injection, the liposomes (green fluorescent) re-
mained in the cytoplasm of the cell, while doxorubicin (red fluorescent) was found in the nucleus. No indications of Doxil 
or liposomes outside the cells in the interstitial space were found. This suggest that the liposome is taken up completely by 
the cells and is thereafter broken down. (b) Tumor cells were incubated with doxorubicin in a migration ring and the fate 
of the free drug was followed for several hours. Almost immediately after adding the drug, doxorubicin was taken up by 
the cells and transported to the nucleus. (c) In contrary to the free drug, when cells were incubated with Doxil hardly any 
drug was observed in the nucleus and most remained in the cytoplasm. Scale bar apply for all images, 20 µm.
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Figure 3. Abnormalization of the tumor-associated vasculature. In the vasculature of basic organs the endothelial 
cells forms a quiescent and tightly packed lining separating the blood and blood-born elements from the rest of the body. 
Mural cells (smooth muscle cells and pericytes) form the muscle of the blood vessel and have specific properties according 
to the type of blood vessel they can be found at. The tumor-associated vasculature has endothelial cells that are morpho-
logical different from these in the normal vessels. Because of the fast growing properties of most tumors they are highly 
active and have irregular shapes with openings between the cells making the vessel highly permeable. Also the pericytes 
are different, forming a loose association with the endothelial cells and displaying extensions into the intersitium. The 
basal membrane is irregular in size with a different protein composition and structure. After TNF-based therapy, TNF binds 
to the TNFR1 located on the pericytes. These cells produce to further elucidate endogenous factors that has its effect on 
endothelial cells. The permeability of the endothelial lining is further increased for the co-administered drug, melphalan 
(in free form this will have micromolecular properties however absorbed in erythrocytes melphalan will act as a macro-
molecule) or long-circulating liposomes Doxil. MMPs produced by the endothelial cells will degrade the underlying matrix 
providing a better entrance for the chemotherapeutic compound. The liposomal drug enters as a whole the tumor cell 
were it is slowly degraded releasing the active drug intracellulary that eventually kills the tumor cell.
